

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01H 1/00, C07H 21/04, C07K 14/00, C12N 5/04, 5/10, C12P 19/34, C12Q 1/68	A1	(11) International Publication Number: WO 98/30083 (43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US98/00615 (22) International Filing Date: 9 January 1998 (09.01.98) (30) Priority Data: 08/781,734 10 January 1997 (10.01.97) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US). (72) Inventors: SHEN, Kathy; 44228 Country Club Drive, El Macero, CA 95618 (US). MEYERS, Blake; 904 Drake Drive, Davis, CA 95616 (US). MICHELMORE, Richard, W.; 36757 Russel Boulevard, Davis, CA 95616 (US). (74) Agents: EINHORN, Gregory, P. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS (57) Abstract The present invention provides RG nucleic acids and proteins which confer disease resistance to plants. The nucleic acids can be used to produce transgenic plants resistant to pests. Antibodies to proteins of the invention are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

5

The present application is a continuation-in-part application ("CIP") of U.S. Patent Application Serial No. ("USSN") 08/781,734, filed January 10, 1997. The
10 aforementioned application is explicitly incorporated herein by reference in its entirety and
for all purposes.

This invention was made with Government support under Grant Nos. 92-37300-7547 and 95-37300-1571, awarded by the United States Department of Agriculture.
15 The Government has certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates generally to plant molecular biology. In particular, it relates to nucleic acids and methods for conferring pest resistance in plants.
20 particularly lettuce.

BACKGROUND OF THE INVENTION

Recently, several resistance genes have been cloned by several groups from several plants. Many of these genes are sequence related. The derived amino acid
25 sequences of the most common class, *RPS2*, *RPM1* (bacterial resistances in *Arabidopsis* (Mindrinos *et al.* *Cell* 78:1089-1099 (1994)); Bent *et al.* *Science* 265:1856-1860 (1994); Grant *et al.*, *Science* 269:843-846 (1995)), *L6* (fungal resistance in flax; Lawrence, *et al.*, *The Plant Cell* 7:1195-1206 (1995)), and *N*, (virus resistance in tobacco; Whitham, *et al.*, *Cell* 78:1101-1115 (1994); and U.S. Patent No. 5,571,706), all contain leucine-rich
30 repeats (LRR) and nucleotide binding sites (NBS).

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

LRR domains can mediate protein-protein interactions and are found in a variety of proteins involved in signal transduction, cell adhesion and various other functions. LRRs are leucine rich regions often comprising 20-30 amino acid repeats where leucine and other aliphatic residues occur periodically. LRRs can function extracellularly or intracellularly.

Since the onset of civilization, plant diseases have had catastrophic effects on crops and the well-being of the human population. Plant diseases continue to effect enormous human and economic costs. An increasing human population and decreasing amounts of arable land make all approaches to preventing and treating plant pathogen destruction critical. The ability to control and enhance a plant's protective responses against pathogens would be of enormous benefit. Tissue-specific and temporal control of mechanisms responsible for plant cell death would also be of great practical and economic value. The present invention fulfills these and other needs.

What is needed in the art are plant disease resistance genes and means to create transgenic disease resistance plants, particularly in lettuce. Further, what is needed in the art is a means to DNA fingerprint cultivars and germplasm with respect to their disease resistance haplotypes for use in plant breeding programs. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid constructs. These constructs comprise an RG (resistance gene) polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and an RG4 polypeptide. RG1, RG2, RG3, RG4, and the like, represent individual "RG families." Each "RG family," as defined herein, is a group of polypeptide sequences that have at least 60% amino acid sequence identity. Individual members of an RG family, *i.e.*, individual species of the genus, typically map to the same genomic locus. The invention provides for constructs comprising nucleotides encoding the RG families of the

invention, which can include sequences encoding a leucine rich region (LRR), and/or a nucleotide binding site (NBS), or both.

The invention provides for an isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence
5 identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide. In alternative embodiments, the nucleic acid construct comprises an RG polynucleotide which encodes an RG polypeptide comprising an leucine rich region (LRR), or, an RG polypeptide comprising a nucleotide binding site
10 (NBS). The nucleic acid construct can comprise a polynucleotide which is a full length gene. In another embodiment, the nucleic acid construct encodes a fusion protein.

In one embodiment, the nucleic acid construct comprises a sequence encoding an RG1 polypeptide. The RG1 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 and
15 SEQ ID NO:137 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

In another embodiment, the nucleic acid construct comprises a sequence encoding an RG2 polypeptide. The RG2 polypeptide can be encoded by a polynucleotide
20 sequence selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87
25 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N);
30 SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In other embodiments, the nucleic acid construct comprises a RG3 sequence (SEQ ID NO:68) encoding an RG3 polypeptide (SEQ ID NO:138) (RG3). In other embodiments, the nucleic acid construct comprises an RG4 sequence (SEQ ID NO:69) encoding an RG4 polypeptide (SEQ ID NO:139) (RG4).

5 In other embodiments, the nucleic acid construct comprises a RG5 sequence (SEQ ID NO:134) encoding an RG5 polypeptide (SEQ ID NO:135). The RG5 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

The invention also provides for a nucleic acid construct which comprises an RG7 sequence encoding an RG7 polypeptide. The RG7 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

10 In further embodiments, the nucleic acid construct can further comprise a promoter operably linked to the RG polynucleotide. In alternative embodiments, the promoter can be a plant promoter; a disease resistance promoter; a lettuce promoter; a constitutive promoter; an inducible promoter; or, a tissue-specific promoter. The nucleic acid construct can comprise a promoter sequence from an RG gene linked to a heterologous polynucleotide.

The invention also provides for a transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide. The expression cassette can comprise a plant promoter or a viral promoter; the plant promoter can be a heterologous promoter. In one embodiment, the transgenic plant is lettuce. In alternative embodiments, the transgenic plant comprises an expression cassette which includes an RG polynucleotide selected from the group consisting of SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J); SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104

(RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W); SEQ ID NO:68 (RG3); SEQ ID NO:69 (RG4); SEQ ID NO:134 (RG5); or SEQ ID NO:136 (RG7).

The invention provide for a transgenic plant comprising an expression cassette comprising an RG polynucleotide which can encode an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W); an RG4 polypeptide as set forth by SEQ ID NO:72; an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135; or, an RG7 polypeptide.

The invention also provides for a method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence. In this method, the plant can be a lettuce plant; and, the RG polynucleotide can encode an RG polypeptide selected from the group consisting of an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID

NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:72; SEQ ID NO:74; SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W). In this method, the promoter can be a plant disease resistance promoter, a tissue-specific promoter, a constitutive promoter, or an inducible promoter.

The invention also provides for a method of detecting RG resistance genes in a nucleic acid sample, the method comprising: contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and, wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample. In this method, the RG polynucleotide can be an RG1 polynucleotide, an RG2 polynucleotide, an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide. In this method, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide, and, the RG resistance gene can be amplified by the polymerase chain reaction. In one embodiment, the RG polynucleotide is labeled.

The invention further provides for an RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification, the figures and claims.

All publications, patents and patent applications cited herein are hereby
5 expressly incorporated by reference for all purposes.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to families of RG genes, particularly from *Lactuca sativa*. Nucleic acid sequences of the present invention can be used to confer resistance in
10 plants to a variety of pests including viruses, fungi, nematodes, insects, and bacteria. Sequences from within the RG genes can be used to fingerprint cultivars or germplasm for the presence of desired resistance genes. Promoters of RG genes can be used to drive heterologous gene expression under conditions in which RG genes are expressed. Further, the present invention provides RG proteins and antibodies specifically reactive to RG
15 proteins. Antibodies to RG proteins can be used to detect the type and amount of RG protein expressed in a plant sample.

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*,
20 *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*,
25 *Triticum*, and, *Sorghum*. In particularly preferred embodiments, species from the family *Compositae* and in particular the genus *Lactuca* are employed such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

The nucleic acids of the present invention can be used in marker-aided selection. Marker-aided selection does not require the complete sequence of the gene or
30 precise knowledge of which sequence confers which specificity. Instead, partial sequences can be used as hybridization probes or as the basis for oligonucleotide primers to amplify nucleic acid, e.g., by PCR. Partial sequences can be used in other methods, such as to

follow the segregation of chromosome segments containing resistance genes in plants. Because the RG marker is the gene itself, there can be negligible recombination between the marker and the resistance phenotype. Thus, RG polynucleotides of the present invention provide an optimal means to DNA fingerprint cultivars and wild germplasm with respect to their disease resistance haplotypes. This can be used to indicate which germplasm accessions and cultivars carry the same resistance genes. At present, selection of plants (e.g., lettuce) for resistance to some diseases is slow and difficult. But linked markers allow indirect selection for such resistance genes. Moreover, RG markers also allow resistance genes to be identified and combined in a manner that would not otherwise be possible. Numerous accessions have been identified that provide resistance to all isolates of downy mildew (*Bremia lactucae*). However, without molecular markers it is impossible to combine such resistances from different sources. The nucleic acid sequences of the invention provide for a fast and convenient means to identify and combine resistances from different sources. The RG markers of the invention can also be used to identify recombinants that have new combinations of resistance genes in *cis* on the same chromosome.

In addition, RG markers may allow the identification of the Mendelian factors determining traits, such as field resistance to downy mildew. Once such markers have been identified, they will greatly increase the ease with which field resistance can be transferred between lines and combined with other resistances.

In another application, primers to RG sequences can be also designed to amplify sequences that are conserved in multiple RG family members. This gives genetic information on multiple RG family members. Alternatively, one or more primers can be made to sequences unique to a single resistance gene genus or a single RG specie. This allows an analysis of individual family groups (an RG genus) or an individual family member (a specie). Primers made to individual RGs at the edge of each cluster can be used to select for recombinants within the cluster. This minimizes the amount of linkage drag during introgression. Classical and molecular genetics has shown that pest resistance genes tend to be clustered in the genome. Pest resistance loci comprise arrays of genes and exhibit a variety of complex haplotypes rather than being simple alternate allelic forms. Pest resistance is conferred by families, or genuses, of related RG sequences, individual members, or species, of which have evolved to have a different specificity.

Oligonucleotide primers can be designed that amplify members from multiple haplotypes, or genuses, or amplify only members of one genus, or only amplify an individual specie. This will provide codominant information and allow heterozygotes to be distinguished from homozygotes.

5 Further, comparison of RG sequences will allow a determination of which sequences are critical for resistance and will ultimately lead to engineering resistance genes with new specificities. Resistance gene sequences were not previously available for lettuce. Marker-aided selection will greatly increase the precision and speed of breeding for disease resistance. Transgenic approaches will allow pyramiding of resistance genes
10 into a single Mendelian unit, transfer between sexually-incompatible species, substitute for conventional backcrossing procedures, and allow expression of other genes in parallel with resistance genes.

 The RG polynucleotides also have utility in the construction of disease resistant transgenic plants. This avoids lengthy and sometimes difficult backcrossing
15 programs currently necessary for introgression of resistance. It is also possible to transfer resistance polynucleotides between sexually-incompatible species, thereby greatly increasing the germplasm pool that can be used as a source of resistance genes. Cloning of multiple RG sequences in a single cassette will allow pyramiding of genes for resistance against multiple isolates of a single pathogen such as downy mildew or against multiple
20 pathogens. Once introduced, such a cassette can be manipulated by classical breeding methods as a single Mendelian unit.

 Transgenic plants of the present invention can also be constructed using an RG promoter. The promoter sequences from RG sequences of the invention can be used with RG genes or heterologous genes. Thus, RG promoters can be used to express a
25 variety of genes in the same temporal and spatial patterns and at similar levels to resistance genes.

Nucleic acids of the Invention and Their Preparation

RG Polynucleotide Families

30 The present invention provides isolated nucleic acid constructs which comprise an RG polynucleotide. In alternative embodiments, the RG polynucleotide is at least 18 nucleotides in length, typically at least 20, 25, or 30 nucleotides in length, more

typically at least 100 nucleotides in length, generally at least 200 nucleotides in length, preferably at least 300 nucleotides in length, more preferably at least 400 nucleotides in length, and most preferably at least 500 nucleotides in length.

In particularly preferred embodiments, the RG polynucleotide encodes a RG protein which confers resistance to plant pests. This RG protein can be longer, equivalent, or shorter than the RG protein encoded by an RG gene. In various embodiments, an RG polynucleotide can hybridize under stringent conditions to members of an RG family (an RG genus); *e.g.*, it can hybridize to a member of the RG1 RG family, such as an RG1 polynucleotide selected from the group consisting of: SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO: 3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J).

In other embodiments, the polynucleotide can also hybridize under stringent conditions to a member of the RG2 family; such as an RG2 polynucleotide selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In alternative embodiments, each RG2 gene can also include an AC15 sequence which hybridizes under stringent conditions to a polynucleotide selected from the group consisting of: SEQ ID NO:56 (AC15-2A); SEQ ID NO:57 (AC15-2B); SEQ ID NO:58 (AC15-2C); SEQ ID NO:59 (AC15-2D); SEQ ID NO:60 (AC15-2E); SEQ ID NO:61 (AC15-2G); SEQ ID NO:62 (AC15-2H); SEQ ID NO:63 (AC15-2I); SEQ ID

NO:64 (AC15-2J); SEQ ID NO:65 (AC15-2L); SEQ ID NO:66 (AC15-2N); SEQ ID NO:67 (AC15-2O).

In other embodiments, an RG polynucleotide can hybridize under stringent conditions to an RG3 (SEQ ID NO:68), an RG4 (SEQ ID NO:69), and RG5 (SEQ ID NO:135), and an RG7 (SEQ ID NO:137), RG family member.

The present invention further provides nucleic acid constructs which comprise an RG polynucleotide which encodes RG polypeptides from various RG families; such as an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and RG4 polypeptide, and RG5 polypeptide, and an RG7 polypeptide.

Exemplary RG1 polypeptides have the sequences shown in SEQ ID NO:2 (RG1A), SEQ ID NO:4 (RG1B), SEQ ID NO:6 (RG1C), SEQ ID NO:8 (RG1D), SEQ ID NO:10 (RG1E), SEQ ID NO:12 (RG1F), SEQ ID NO:14 (RG1G), SEQ ID NO:16 (RG1H), SEQ ID NO:20 (RG1I). Exemplary RG2 polypeptides have the sequences shown in SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

An exemplary RG3 polypeptide has the sequence shown in SEQ ID NO:138. An exemplary RG4 polypeptide has the sequence shown in SEQ ID NO:139. RG polynucleotides will have at least 60% identity, more typically at least 65% identity, generally at least 70% identity, and preferably at least 75% identity, more preferably at least 80% identity, and most preferably at least 85%, 90%, or 95% identity at the deduced amino acid level. The regions where substantial identity is assessed can be inclusive or exclusive of the nucleotide binding site or the leucine rich region.

Vectors and Transcriptional Control Elements

The invention, providing methods and reagents for making novel species and genres of RG nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic plants and animals, using constitutive and inducible transcriptional and translational *cis*- (e.g., promoters and enhancers) and *trans*-acting control elements.

The expression of natural, recombinant or synthetic plant disease resistance polypeptide-encoding or other (*i.e.*, antisense, ribozyme) nucleic acids can be achieved by operably linking the coding region a promoter (that can be plant-specific or not, constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an *in vitro* reaction system or a suitable host cell or organism. Synthetic procedures may also be used. Typical expression systems contain, in addition to coding or antisense sequence, transcription and translation terminators, polyadenylation sequences, transcription and translation initiation sequences, and promoters useful for transcribing DNA into RNA. The expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette *in vivo*, e.g., plants, eukaryotes, or prokaryotes, or a combination thereof, (e.g., shuttle vectors) and selection markers for the selected expression system, e.g., plant, prokaryotic or eukaryotic systems. To ensure proper polypeptide expression under varying conditions, a polyadenylation region at the 3'-end of the coding region can be included (see Li (1997) *Plant Physiol.* 115:321-325, for a review of the polyadenylation of RNA in plants). The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA (e.g., using *Agrobacterium tumefaciens* T-DNA replacement vectors, see e.g., Thykjaer (1997) *Plant Mol Biol.* 35:523-530; using a plasmid containing a gene of interest flanked by *Agrobacterium* T-DNA border repeat sequences; Hansen (1997) "T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes," *Proc. Natl. Acad. Sci. USA* 94:11726-11730.

To identify the promoters, the 5' portions of the clones described here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further

upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G (see, *e.g.*, Messing, in *Genetic Engineering in Plants*, pp. 221-227, Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the RG coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from viral genes, such as T-DNA.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, for example, episomal expression systems (*e.g.*, cauliflower mosaic virus (CaMV) viral RNA is generated in the nucleus by transcription of an episomal minichromosome containing supercoiled DNA, Covey (1990) *Proc. Natl. Acad. Sci. USA* 87:1633-1637). Alternatively, coding sequences can be inserted into the host cell genome becoming an integral part of the host chromosomal DNA.

Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode biocide resistance, such as antibiotic resistance, particularly resistance to chloramphenicol, kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997. Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*. See also, Mengiste (1997) "High-efficiency transformation of *Arabidopsis thaliana* with a selectable marker gene regulated by the T-DNA 1' promoter," *Plant J.* 12:945-948, showing that the 1' promoter is an attractive alternative to the cauliflower mosaic virus (CaMV) 35S promoter for the generation of T-DNA insertion lines, the 1' promoter may be especially beneficial for the secondary transformation of transgenic strains containing the 35S promoter to exclude homology-mediated gene silencing.

The endogenous promoters from the RG genes of the present invention can be used to direct expression of the genes. These promoters can also be used to direct expression of heterologous structural genes. The promoters can be used, for example, in recombinant expression cassettes to drive expression of genes conferring resistance to any number of pathogens or pests, including fungi, bacteria, and the like.

Constitutive Promoters

In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired gene in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include those from viruses which infect plants, such as the cauliflower mosaic virus (CaMV) 35S transcription initiation region; the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*; the promoter of the tobacco mosaic virus; and, other transcription initiation regions from various plant genes known to those of skill. See also Holtorf (1995) "Comparison of different constitutive and inducible promoters for the overexpression of transgenes in *Arabidopsis thaliana*," *Plant Mol. Biol.* 29:637-646.

Inducible Promoters

Alternatively, a plant promoter may direct expression of the plant disease resistance nucleic acid of the invention under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include pathogenic attack, anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters. For example, the invention incorporates the drought-inducible promoter of maize (Busk (1997) *supra*); the cold, drought, and high salt inducible promoter from potato (Kirch (1997) *Plant Mol. Biol.* 33:897-909).

Embodiments of the invention also incorporate use of plant promoters which are inducible upon injury or infection to express the invention's plant disease resistance (RG) polypeptides. Various embodiments include use of, *e.g.*, the promoter for a tobacco (*Nicotiana tabacum*) sesquiterpene cyclase gene (EAS4 promoter), which is expressed in wounded leaves, roots, and stem tissues, and upon infection with microbial pathogens (Yin

(1997) *Plant Physiol.* 115(2):437-451); the ORF13 promoter from *Agrobacterium rhizogenes* 8196, which is wound inducible in a limited area adjacent to the wound site (Hansen (1997) *Mol. Gen. Genet.* 254:337-343); the Shpx6b gene promoter, which is a plant peroxidase gene promoter induced by microbial pathogens (demonstrated using a fungal pathogen, see Curtis (1997) *Mol. Plant Microbe Interact.* 10:326-338); the wound-inducible gene promoter wun1, derived from potato (Siebertz (1989) *Plant Cell* 1:961-968); the wound-inducible *Agrobacterium pmas* gene (mannopine synthesis gene) promoter (Guevara-Garcia (1993) *Plant J.* 4:495-505).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the nucleic acids of the invention. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (*Glycine max* L.) (Liu (1997) *Plant Physiol.* 115:397-407); the auxin-responsive Arabidopsis GST6 promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) *Plant J.* 10: 955-966); the auxin-inducible parC promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) *Mol. Plant Microbe Interact.* 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) *Science* 274:1900-1902).

Plant promoters which are inducible upon exposure to chemicals reagents which can be applied to the plant, such as herbicides or antibiotics, are also used to express the nucleic acids of the invention. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) *Plant Cell Physiol.* 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. Coding sequence can be under the control of, *e.g.*, a tetracycline-inducible promoter, *e.g.*, as described with transgenic tobacco plants containing the *Avena sativa* L. (oat) arginine decarboxylase gene (Masgrau (1997) *Plant J.* 11:465-473); or, a salicylic acid-responsive element (Stange (1997) *Plant J.* 11:1315-1324. Using chemically- (*e.g.*, hormone- or pesticide-) induced promoters, harvesting of fruits and plant parts would be greatly facilitated. A chemical which can be applied to the transgenic plant in the field and induce expression of a polypeptide of the invention throughout all or most of the plant would make an environmentally safe defoliant or herbicide. Thus, the invention also provides for transgenic plants containing an inducible gene encoding for the RG

polypeptides of the invention whose host range is limited to target plant species, such as weeds or crops before, during or after harvesting.

Abcission promoters are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. In some embodiments, when a plant disease resistant polypeptide-encoding nucleic acid is under the control of such a promoter, rapid cell death, induced by expression of the invention's polypeptide, can accelerate and/or accentuate abcission, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like. Induction of rapid cell death at this time would accelerate separation of the fruit from the plant, greatly augmenting harvesting procedures. See, *e.g.*, Kalaitzis (1997) *Plant Physiol.* 113:1303-1308, discussing tomato leaf and flower abcission; Payton (1996) *Plant Mol. Biol.* 31:1227-1231, discussing ethylene receptor expression regulation during fruit ripening, flower senescence and abcission; Koehler (1996) *Plant Mol. Biol.* 31:595-606, discussing the gene promoter for a bean abcission cellulase; Kalaitzis (1995) *Plant Mol. Biol.* 28: 647-656, discussing cloning of a tomato polygalacturonase expressed in abcission; del Campillo (1996) *Plant Physiol.* 111:813-820, discussing pedicel breakstrength and cellulase gene expression during tomato flower abcission.

Tissue-Specific Promoters

Tissue specific promoters are transcriptional control elements that are only active in particular cells or tissues. Plant promoters which are active only in specific tissues or at specific times during plant development are used to express the nucleic acids of the invention. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, ovules, pollen, pistils, or flowers. Such promoters are referred to as "tissue specific". The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

For example, a seed-specific promoter directs expression in seed tissues. Such promoters may be, for example, ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed coat-specific, or some combination thereof. A leaf-specific promoter has been identified in maize, Busk (1997) *Plant J.* 11:1285-1295. The ORF13 promoter from *Agrobacterium rhizogenes* exhibits high activity in roots (Hansen (1997) *supra*). A maize pollen-specific promoter has been identified in maize (Guerrero (1990)

Mol. Gen. Genet. 224:161-168). A tomato promoter active during fruit ripening, senescence and abscission of leaves and, to a lesser extent, of flowers can be used (Blume (1997) *Plant J.* 12:731-746). A pistil specific promoter has been identified in the potato (*Solanum tuberosum* L.) SK2 gene, encoding a pistil-specific basic endochitinase (Ficker (1997) *Plant Mol. Biol.* 35:425-431). The Blec4 gene from pea (*Pisum sativum* cv. Alaska) is active in epidermal tissue of vegetative and floral shoot apices of transgenic alfalfa, making it a useful tool to target the expression of foreign genes to the epidermal layer of actively growing shoots. The activity of the Blec4 promoter in the epidermis of the shoot apex makes it particularly suitable for genetically engineering defense against insects and diseases that attack the growing shoot apex (Mandaci (1997) *Plant Mol Biol.* 34:961-965).

The invention also provides for use of tissue-specific plant promoters include a promoter from the ovule-specific *BEL1* gene described in Reiser (1995) *Cell* 83:735-742, GenBank No. U39944. Suitable seed specific promoters are derived from the following genes: *MAC1* from maize, Sheridan (1996) *Genetics* 142:1009-1020; *Cat3* from maize, GenBank No. L05934, Abler (1993) *Plant Mol. Biol.* 22:10131-1038; the gene encoding oleosin 18kD from maize, GenBank No. J05212, Lee (1994) *Plant Mol. Biol.* 26:1981-1987; viviparous-1 from *Arabidopsis*, Genbank No. U93215; the gene encoding oleosin from *Arabidopsis*, Genbank No. Z17657; *Atmyc1* from *Arabidopsis*, Urao (1996) *Plant Mol. Biol.* 32:571-576; the 2s seed storage protein gene family from *Arabidopsis*, Conceicao (1994) *Plant* 5:493-505; the gene encoding oleosin 20kD from *Brassica napus*, GenBank No. M63985; *napA* from *Brassica napus*, GenBank No. J02798, Josefsson (1987) *JBL* 26:12196-1301; the napin gene family from *Brassica napus*, Sjodahl (1995) *Planta* 197:264-271; the gene encoding the 2S storage protein from *Brassica napus*, Dasgupta (1993) *Gene* 133:301-302; the genes encoding oleosin a, Genbank No. U09118, and, oleosin B, Genbank No. U09119, from soybean; and, the gene encoding low molecular weight sulphur rich protein from soybean, Choi (1995) *Mol Gen, Genet.* 246:266-268. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins.

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as

used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

The invention also provides for use of tissue-specific promoters derived from viruses which can include, *e.g.*, the tobamovirus subgenomic promoter (Kumagai
5 (1995) *Proc. Natl. Acad. Sci. USA* 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdaguer (1996) *Plant Mol. Biol.* 31:1129-1139).

10 In some embodiments, the nucleic acid construct will comprise a promoter functional in a specific plant cell, such as in a species of *Lactuca*, operably linked to an RG polynucleotide. Promoters useful in these embodiments include RG promoters. In additional embodiments, the nucleic acid construct will comprise a RG promoter operably linked to a heterologous polynucleotide. The heterologous polynucleotide is chosen to
15 provide a plant with a desired phenotype. For example, the heterologous polynucleotide can be a structural gene which encodes a polypeptide which imparts a desired resistance phenotype. Alternatively, the heterologous polynucleotide may be a regulatory gene which might play a role in transcriptional and/or translational control to suppress, enhance, or otherwise modify the transcription and/or expression of an endogenous gene within the
20 plant. The heterologous polynucleotide of the nucleic acid construct of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics.

Modifying and Inhibiting RG Gene Expression

25 The invention also provides for RG nucleic acid sequences which are complementary to the RG polypeptide-encoding sequences of the invention; *i.e.*, antisense RG nucleic acids. Antisense technology can be conveniently used to modify gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be
30 transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, *e.g.*,

Sheehy (1988) *Proc. Nat. Acad. Sci. USA* 85:8805-8809; Hiatt et al., U.S. Patent No. 4,801,340.

Antisense sequences are capable of inhibiting the transport, splicing or transcription of RG-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA. The transcription or function of targeted nucleic acid can be inhibited, *e.g.*, by hybridization and/or cleavage. One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind RG gene or message, in either case preventing or inhibiting the production or function of RG. The association can be through sequence specific hybridization. Such inhibitory nucleic acid sequences can, for example, be used to completely inhibit a plant disease resistance response. Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of RG message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes. The oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the complementary nucleic acid. One may screen a pool of many different such oligonucleotides for those with the desired activity.

Antisense Oligonucleotides

The invention provides for with antisense oligonucleotides capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such RG oligonucleotides using the novel reagents of the invention. In some situations, naturally occurring nucleic acids used as antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; Antisense Therapeutics, ed. Agrawal (Humana Press, Totowa, N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate,

phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described herein.

Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense RG sequences of the invention (for general background information, see, *e.g.*, Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

Inhibitory Ribozymes

The invention provides for with ribozymes capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing ribozymes and selecting the RG-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such RG ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence, or, preventing transport of the message from the nucleus to the cytoplasm. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of any plant gene. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described, *e.g.*, in Haseioff (1988) *Nature* 334:585-591.

In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid

molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single
5 ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio
10 of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead
15 motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16;
20 the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate
25 binding site which imparts an RNA cleaving activity to the molecule.

Sense Supression

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method
30 to modulate expression of endogenous genes see, Napoli et al., *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

Cloning of RG Polypeptides

Synthesis and/or cloning of RG polynucleotides and isolated nucleic acid constructs of the present invention are provided by methods well known to those of ordinary skill in the art. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of RG genes may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as roots and a cDNA library which contains the RG gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which RG genes or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned RG gene such as the genes disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species.

Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%.

Alternatively, the RG nucleic acids of the invention can be amplified from nucleic acid samples using a variety of amplification techniques, such as polymerase chain reaction (PCR) technology, to amplify the sequences of the RG and related genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.

Oligonucleotides can be used to identify and detect additional RG families and RG family species using a variety of hybridization techniques and conditions. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis)), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560; Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117); transcription amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); and, self-sustained sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA*, 87:1874); Q Beta replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316, Sambrook, and Ausubel, as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202; Arnheim (1990) *C&EN* 36-47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt, *Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995) *Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are described in Wallace, U.S. Pat. No. 5,426,039.

The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium as described earlier.

In some preferred embodiments, members of this class of pest resistance genes can be identified by their ability to be amplified by PCR primers based on the sequences disclosed here. Appropriate primers and probes for identifying RG sequences

from plant tissues are generated from comparisons of the sequences provided herein. See, e.g., Table 1. For a general overview of PCR see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

5 Briefly, the first step of each cycle of the PCR involves the separation of the nucleic acid duplex formed by the primer extension. Once the strands are separated, the next step in PCR involves hybridizing the separated strands with primers that flank the target sequence. The primers are then extended to form complementary copies of the target strands. For successful PCR amplification, the primers are designed so that the
10 position at which each primer hybridizes along a duplex sequence is such that an extension product synthesized from one primer, when separated from the template (complement), serves as a template for the extension of the other primer. The cycle of denaturation, hybridization, and extension is repeated as many times as necessary to obtain the desired amount of amplified nucleic acid.

15 In the preferred embodiment of the PCR process, strand separation is achieved by heating the reaction to a sufficiently high temperature for an sufficient time to cause the denaturation of the duplex but not to cause an irreversible denaturation of the polymerase (see U.S. Patent No. 4,965,188). Template-dependent extension of primers in PCR is catalyzed by a polymerizing agent in the presence of adequate amounts of four
20 deoxyribonucleotide triphosphates (typically dATP, dGTP, dCTP, and dTTP) in a reaction medium comprised of the appropriate salts, metal cations, and pH buffering system. Suitable polymerizing agents are enzymes known to catalyze template-dependent DNA synthesis.

Polynucleotides may also be synthesized by well-known techniques as
25 described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer
30 sequence.

RG Proteins

The present invention further provides isolated RG proteins encoded by the RG polynucleotides disclosed herein. One of skill will recognize that the nucleic acid encoding a functional RG protein need not have a sequence identical to the exemplified genes disclosed here. For example, because of codon degeneracy a large number of nucleic acid sequences can encode the same polypeptide. In addition, the polypeptides encoded by the RG genes, like other proteins, have different domains which perform different functions. Thus, the RG gene sequences need not be full length, so long as the desired functional domain of the protein is expressed.

The resistance proteins are at least 25 amino acid residues in length. Typically, the RG proteins are at least 50 amino acid residues, generally at least 100, preferably at least 150, more preferably at least 200 amino acids in length. In particularly preferred embodiments, the RG proteins are of sufficient length to provide resistance to pests when expressed in the desired plants. Generally then, the RG proteins will be the length encoded by an RG gene of the present invention. However, those of ordinary skill will appreciate that minor deletions, substitutions, or additions to an RG protein will typically yield a protein with pest resistance characteristics similar or identical to that of the full length sequence. Thus, full-length RG proteins modified by 1, 2, 3, 4, or 5 deletions, substitutions, or additions, generally provide an effective degree of pest resistance relative to the full-length protein.

The RG proteins which provide pest resistance will typically comprise at least one of an LRR or an NBS. Preferably, both are present. LRR and/or NBS regions present in the RG proteins of the present invention can be provided by RG genes of the present invention. In some embodiments, the LRR and/or NBS regions are obtained from other pest resistance genes. See, e.g., Yu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11751-11756 (1996); Bent *et al.*, *Science*, 265: 1856-1860 (1994).

Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. Modification can also include swapping domains from the proteins of the invention with related domains from other pest resistance genes.

Pests that can be targeted by RG genes and proteins of the present invention include such bacterial pests as *Erwinia carotovora* and *Pseudomonas marginalis*. Fungal pests which can be targeted by the present invention include *Bremia lactucae*, *Marssonina panattoniana*, *Rhizoctonia solani*, *Olpidium brassicae*, root aphid, *Sclerotinia sclerotiorum* and *S. minor*, and *Botrytis cinerea* which causes gray mold. RG genes also provide resistance to viral diseases such as lettuce and turnip mosaic viruses.

Fusion Proteins

RG polypeptides can also be expressed as recombinant proteins with one or more additional polypeptide domains linked thereto to facilitate protein detection, purification, or other applications. Such detection and purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and plant disease resistant polypeptide may be useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding a plant disease resistant polypeptide of the invention and nucleic acid sequence encoding six histidine residues followed by thioredoxin and an enterokinase cleavage site (*e.g.*, see Williams (1995) *Biochemistry* 34:1787-1797). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described, see *e.g.*, Kroll (1993) *DNA Cell. Biol.*, 12:441-53.

Antibodies Reactive to RG Polypeptides and Immunological Assays

The present invention also provides antibodies which specifically react with RG proteins of the present invention under immunologically reactive conditions. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. "Immunologically reactive conditions" includes reference to conditions which allow an antibody, generated to a particular epitope of an antigen, to bind to that

epitope to a detectably greater degree than the antibody binds to substantially all other epitopes, generally at least two times above background binding, preferably at least five times above background. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols.

"Antibody" includes reference to an immunoglobulin molecule obtained by *in vitro* or *in vivo* generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')₂, Fab, Fv, rIgG, and, inverted IgG). See, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL). An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.* (1989) *Science* 246:1275-1281; and Ward, *et al.* (1989) *Nature* 341:544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14:309-314.

Many methods of making antibodies are known to persons of skill. A number of immunogens are used to produce antibodies specifically reactive to an isolated RG protein of the present invention under immunologically reactive conditions. An isolated recombinant, synthetic, or native RG protein of the present invention is the preferred immunogens (antigen) for the production of monoclonal or polyclonal antibodies.

The RG protein is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the RG protein. Methods of producing monoclonal or polyclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY.

Frequently, the RG proteins and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide

variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The antibodies of the present invention can be used to screen plants for the expression of RG proteins of the present invention. The antibodies of this invention are also used for affinity chromatography in isolating RG protein.

The present invention further provides RG polypeptides that specifically bind, under immunologically reactive conditions, to an antibody generated against a defined immunogen, such as an immunogen consisting of the RG polypeptides of the present invention. Immunogens will generally be at least 10 contiguous amino acids from an RG polypeptide of the present invention. Optionally, immunogens can be from regions exclusive of the NBS and/or LRR regions of the RG polypeptides. Nucleic acids which encode such cross-reactive RG polypeptides are also provided by the present invention. The RG polypeptides can be isolated from any number plants as discussed earlier. Preferred are species from the family *Compositae* and in particular the genus *Lactuca* such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

"Specifically binds" includes reference to the preferential association of a ligand, in whole or part, with a particular target molecule (i.e., "binding partner" or "binding moiety") relative to compositions lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a ligand and a non-target molecule. Nevertheless, specific binding, may be distinguished as mediated through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the ligand and the target molecule than between the ligand and non-target molecule. Specific binding by an antibody to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. The affinity constant of the antibody binding site for its cognate monovalent antigen is at least 10^7 , usually at least 10^8 , preferably at least 10^9 , more preferably at least 10^{10} , and most preferably at least 10^{11} liters/mole. A variety of immunoassay formats are appropriate for selecting antibodies specifically reactive with a particular protein. For

example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically reactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific reactivity. The antibody may be polyclonal but preferably is monoclonal. Generally, antibodies cross-reactive to such proteins as RPS2, RPM1 (bacterial resistances in Arabidopsis, L6 (fungal resistance in flax, PRF (resistance to *Pseudomonas syringae* in tomato), and *N*, (virus resistance in tobacco), are removed by immunoabsorption.

Immunoassays in the competitive binding format are typically used for cross-reactivity determinations. For example, an immunogenic RG polypeptide is immobilized to a solid support. Polypeptides added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above polypeptides to compete with the binding of the antisera to the immobilized RG polypeptide is compared to the immunogenic RG polypeptide. The percent cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with such proteins as RPS2, RPM1, L6, PRF, and *N*, are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with these non-RG resistance proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay to compare a second "target" polypeptide to the immunogenic polypeptide. In order to make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorption is detectable. The fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Production of transgenic plants of the invention

Isolated nucleic acid constructs prepared as described herein can be introduced into plants according techniques known in the art. In some embodiments, the introduced nucleic acid is used to provide RG gene expression and therefore pest resistance in desired plants. In some embodiments, RG promoters are used to drive expression of desired heterologous genes in plants. Finally, in some embodiments, the constructs can be used to suppress expression of a target endogenous gene, including RG genes.

To use isolated RG sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

A DNA sequence coding for the desired RG polypeptide, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant. An expression cassette will typically comprise the RG polynucleotide operably linked to transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the RG gene in the intended tissues of the transformed plant.

Such DNA constructs may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment and microinjection of plant cell protoplasts or embryogenic callus, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Transformation techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.* 3:2717-2722 (1984).

Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

5 *Agrobacterium tumefaciens*-mediated transformation techniques are well described in the scientific literature. See, for example Horsch *et al. Science* 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983). Although *Agrobacterium* is useful primarily in dicots, certain monocots can be transformed by *Agrobacterium*. For instance, *Agrobacterium* transformation of rice is described by Hiei *et al. Plant J.* 6:271-282 (1994). A particularly preferred means of transforming lettuce is
10 described in Michelmores *et al., Plant Cell Reports*, 6:439-442 (1987).

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired RG-controlled phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth
15 medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the RG nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, Macmillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985.
20 Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al. Ann. Rev. of Plant Phys.* 38:467-486 (1987).

The methods of the present invention are particularly useful for incorporating the RG polynucleotides into transformed plants in ways and under
25 circumstances which are not found naturally. In particular, the RG polypeptides may be expressed at times or in quantities which are not characteristic of natural plants.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be
30 used, depending upon the species to be crossed.

Detection of RG Resistance Genes

The present invention further provides methods for detecting RG resistance genes in a nucleic acid sample suspected of comprising an RG resistance gene. The means by which the RG resistance gene is detected is not a critical aspect of the invention. For example, RG resistance genes can be detected by the presence of amplicons using RG resistance gene specific primers. Additionally, RG resistance genes can be detected by assaying for specific hybridization of an RG polynucleotide to an RG resistance gene. In some embodiments, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

In a typical detection method, the nucleic acid sample is contacted with an RG polynucleotide to form a hybridization complex. The hybridization complex may be detected directly (e.g., in Southern or northern blots), or indirectly (e.g., by subsequent primer extension during PCR amplification). The RG polynucleotide hybridizes under stringent conditions to an RG polynucleotide of the invention. Formation of the hybridization complex is directly or indirectly used to indicate the presence of the RG resistance gene in the nucleic acid sample.

Detection of the hybridization complex can be achieved using any number of well known methods. For example, the nucleic acid sample, or a portion thereof, may be assayed by hybridization formats including but not limited to, solution phase, solid phase, mixed phase, or *in situ* hybridization assays. Briefly, in solution (or liquid) phase hybridizations, both the target nucleic acid and the probe or primer are free to interact in the reaction mixture. In solid phase hybridization assays, probes or primers are typically linked to a solid support where they are available for hybridization with target nucleic in solution. In mixed phase, nucleic acid intermediates in solution hybridize to target nucleic acids in solution as well as to a nucleic acid linked to a solid support. In *in situ* hybridization, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the various hybridization assay formats: Singer *et al.*, *Biotechniques* 4(3):230-250 (1986); Haase *et al.*, *Methods in Virology*, Vol. VII, pp. 189-226 (1984); Wilkinson, "The theory and practice of *in situ* hybridization" In: *In situ Hybridization*, Ed. D.G. Wilkinson. IRL Press, Oxford University Press, Oxford; and *Nucleic Acid Hybridization: A Practical Approach*, Ed. Hames, B.D. and Higgins, S.J., IRL Press (1987).

The effect of the modification of RG gene expression can be measured by detection of increases or decreases in mRNA levels using, for instance, Northern blots. In addition, the phenotypic effects of gene expression can be detected by measuring nematode, fungal, bacterial, viral, or other pest resistance in plants. Suitable assays for determining pest resistance are well known. Micheltore and Crute, *Trans. Br. mycol. Soc.*, 79(3): 542-546 (1982).

The means by which hybridization complexes are detected is not a critical aspect of the present invention and can be accomplished by any number of methods currently known or later developed. RG polynucleotides can be labeled by any one of several methods typically used to detect the presence of hybridized nucleic acids. One common method of detection is the use of autoradiography using probes labeled with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P , or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half lives of the selected isotopes. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation. Labeling the RG polynucleotide is readily achieved such as by the use of labeled PCR primers.

The choice of label dictates the manner in which the label is bound to the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by using DNA synthesizers, by nick translation with DNA polymerase I, by tailing radioactive DNA bases to the 3' end of probes with terminal deoxynucleotidyl transferase, by treating single-stranded M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive deoxynucleotides, dNTP, by transcribing from RNA templates using reverse transcriptase in the presence of radioactive deoxynucleotides, dNTP, or by transcribing RNA from vectors containing specific RNA viral promoters (e.g., SP6 promoter) using the corresponding RNA polymerase (e.g., SP6 RNA polymerase) in the presence of radioactive ribonucleotides rNTP.

The probes can be labeled using radioactive nucleotides in which the isotope resides as a part of the nucleotide molecule, or in which the radioactive component is attached to the nucleotide via a terminal hydroxyl group that has been esterified to a radioactive component such as inorganic acids, *e.g.*, ³²P phosphate or ¹⁴C organic acids, or esterified to provide a linking group to the label. Base analogs having nucleophilic linking groups, such as primary amino groups, can also be linked to a label.

Non-radioactive probes are often labeled by indirect means. For example, a ligand molecule is covalently bound to the probe. The ligand then binds to an anti-ligand molecule which is either inherently detectable or covalently bound to a detectable signal system, such as an enzyme, a fluorophore, or a chemiluminescent compound. Enzymes of interest as labels will primarily be hydrolases, such as phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescers include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

Probes can also be labeled by direct conjugation with a label. For example, cloned DNA probes have been coupled directly to horseradish peroxidase or alkaline phosphatase, (Renz, M., and Kurz, K. (1984) A Colorimetric Method for DNA Hybridization. *Nucl. Acids Res.* 12: 3435-3444) and synthetic oligonucleotides have been coupled directly with alkaline phosphatase (Jablonski, E., *et al.* (1986) Preparation of Oligodeoxynucleotide-Alkaline Phosphatase Conjugates and Their Use as Hybridization Probes. *Nuc. Acids. Res.* 14: 6115-6128; and Li P., *et al.* (1987) Enzyme-linked Synthetic Oligonucleotide probes: Non-Radioactive Detection of Enterotoxigenic *Escherichia Coli* in Faeca Specimens. *Nucl. Acids Res.* 15:5275-5287).

Definitions

Units, prefixes, and symbols can be denoted in their SI accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation, respectively. The

headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

5 As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

10 As used herein, "pest" includes, but is not limited to, viruses, fungi, nematodes, insects, and bacteria.

 As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.

15 As used herein, "RG gene," alternatively referred to as "RLG gene," is a gene encoding resistance to plant pests, such as viruses, fungi, nematodes, insects, and bacteria, and which hybridizes under stringent conditions and/or has at least 60% sequence identity at the deduced amino acid level to the exemplified sequences provided herein. RG genes encode "RG polypeptides," alternatively referred to as "RLG polypeptides," which can comprise LRR motifs and/or NBS motifs. The RG polypeptides encoded by RG genes have at least 55% or 60% sequence identity, typically at least 65% sequence identity, preferably at least 70% sequence identity, often at least 75% sequence identity, more preferably at least 80% sequence identity, and most preferably at least 90% sequence identity at the deduced amino acid level relative to the exemplary RG sequences provided herein. The term "RG family" or "RG family genus" or "genus" includes reference to a group of RG polypeptide sequence species that have at least 60% amino acid sequence identity, and, the nucleic acids encoding these polypeptides. The individual species of a genus, i.e., the members of a family, typically are genetically mapped to the same locus.

25 As used herein, "RG polynucleotide" includes reference to a contiguous sequence from an RG gene of at least 18, 20, 25, 30, 40, or 50 nucleotides in length, up to 30

at least about 100 or at least about 200 nucleotides in length. In some embodiments, the polynucleotide is preferably at least 100 nucleotides in length, more preferably at least 200 nucleotides in length, most preferably at least 500 nucleotides in length. Thus, RG polynucleotide may be a RG gene or a subsequence thereof.

5 As used herein, "isolated," when referring to a molecule or composition, such as, for example, an RG polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (*e.g.*, RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, an RG polypeptide or nucleic acid is considered isolated
10 when it has been isolated from any other component with which it is naturally associated, *e.g.*, cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-
15 PAGE) or high performance liquid chromatography (HPLC).

 The term "nucleic acid" or "nucleic acid molecule" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or
20 improved binding properties, for the purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester,
25 sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see *Oligonucleotides and Analogues, a Practical Approach*, edited by F. Eckstein, IRL Press at Oxford University Press (1991); *Antisense Strategies*, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and
30 Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO

97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "exogenous nucleic acid" refers to a nucleic acid that has been isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is found in nature. The term encompasses both nucleic acids originally obtained from a different organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed. invention.

The term "recombinant," when used with reference to a cell, or to the nucleic acid, protein or vector refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new moiety or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise expressed at a different level, typically, under-expressed or not expressed at all. The term "recombinant means" encompasses all means of expressing, *i.e.*, transcription or translation of, an isolated and/or cloned nucleic acid *in vitro* or *in vivo*. For example, the term "recombinant means" encompasses techniques where a recombinant nucleic acid, such as a cDNA encoding a protein, is inserted into an expression vector, the vector is introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from different sources into one vector for expression of a fusion protein, constitutive expression of a protein, or inducible expression of a protein, such as the plant disease resistant, or RG. polypeptides of the invention.

The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe, and can be readily determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and annealing conditions, see, *e.g.*, Sambrook and Ausubel.

The terms "stringent hybridization," "stringent conditions," or "specific hybridization conditions" refers to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as an RG nucleic acid in an expression vector of the invention but not to a non-RG sequence. Stringent conditions are sequence-dependent. Thus, in one set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of RG nucleic acids of the invention. In another set of stringent conditions (less stringent) an oligonucleotide probe will hybridize to all species of the invention's genus but not to non-RG nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5⁰C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30⁰C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60⁰C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45⁰C for 15 minutes (see Sambrook for a description of SSC buffer). An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40⁰C for 15 minutes. a signal to noise ratio of 2x (or higher) than that observed for an unrelated

probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative
5 substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in, *e.g.*, Sambrook, Tijssen (1993) *supra*.

As used herein "operably linked" includes reference to a functional linkage
10 between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

15 In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained herein, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and
20 translated to produce a functional RG polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "RG polynucleotide sequence". In addition, the term specifically includes those full length sequences substantially identical (determined as described herein) with an RG gene sequence which
25 encode proteins that retain the function of the RG protein. Thus, in the case of RG genes disclosed here, the term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring resistance to nematodes, bacteria, viruses, fungi, insects or other pests on a transgenic plant comprising the sequence.

30 Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence, as described below. The term

"complementary to" is used herein to mean that the complementary sequence is identical to all or a specified contiguous portion of a reference polynucleotide sequence.

The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences or the polypeptides of the invention, when optimally aligned, as with, for example, the programs PILEUP, BLAST, GAP, FASTA or BESTFIT (see discussion, *supra*). "Percentage amino acid/nucleic acid sequence identity" refers to a comparison of the sequences of two polypeptides/nucleic acids which, when optimally aligned, have approximately the designated percentage of the same amino acids/nucleic acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two RG nucleic acids or polypeptides which, when optimally aligned, have 60% identity. For example, in one embodiment, nucleic acids encoding RG polypeptides of the invention comprise a sequence with at least 50% nucleic acid sequence identity to SEQ ID NO:1. In other embodiments, the RG polypeptides of the invention are encoded by nucleic acids comprising a sequence with at least 50% sequence identity to SEQ ID NO:1, or, are encoded by nucleic acids comprising SEQ ID NO:1, or, have at least 60% amino acid sequence identity to the polypeptide of SEQ ID NO:2.

"Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 55% or 60% sequence identity, generally at least 65%, preferably at least 70%, often at least 75%, more preferably at least 80% and most preferably at least 90%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding

identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 55% or 60%, preferably at least 70%, more preferably at least 80%, and most preferably at least 95%. Polypeptides having "sequence similarity" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under appropriate conditions. Appropriate conditions can be high or low stringency and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C to about 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50°C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Nucleic acids of the invention can be identified from a cDNA or genomic library prepared according to standard procedures and the nucleic acids disclosed here used as a probe. Thus, for example, stringent hybridization conditions will typically include at least one low stringency wash using 0.3 molar salt (*e.g.*, 2X SSC) at 65°C. The washes

are preferably followed by one or more subsequent washes using 0.03 molar salt (e.g., 0.2X SSC) at 50°C, usually 60°C, or mosre usually 65°C. Nucleic acid probes used to identify the nucleic acids are preferably at least 100 nucleotides in length.

As used herein, "nucleotide binding site" or "nucleotide binding domain" ("NBS") includes reference to highly conserved nucleotide-, *i.e.*, ATP/GTP-, binding domains, typically included in the "kinase domain" of kinase polypeptides, such as a kinase-1a, kinase 2, or a kinase 3a motif, as described herein. For example, the tobacco N and Arabidopsis RPS2 genes, among several recently cloned disease-resistance genes, share highly conserved NBS sequence. Kinase NBS subdomains further consist of three subdomain motifs: the P-loop, kinase-2, and kinase-3a subdomains (Yu (1996) *Proc. Acad. Sci. USA* 93:11751-11756). As discussed in detail herein, examples include the *Arabidopsis* RPP5 gene (Parker (1997) *supra*), the *A. thaliana* RPS2 gene (Mindrinos (1997) *supra*), and the flax L6 rust resistance gene (Lawrence (1995) *supra*) which all encode proteins containing an NBS; and Mindrinos (1994) *Cell* 78:1089-1099; and Shen (1993) *FEBS* 335:380-385. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can identify members having NBS domains, including any of the genus of NBS-containing plant disease resistant polypeptides of the invention.

As used herein, "leucine rich region" ("LRR") includes reference to a region that has a leucine content of at least 20% leucine or isoleucine, or 30% of the aliphatic residues: leucine, isoleucine, methionine, valine, and phenylalanine, and arranged with approximate repeated periodicity. The length of the repeat may vary in length but is generally about 20 to 30 amino acids. An LRR-containing polypeptide typically will have the canonical 24 amino acid leucine-rich repeat (LRR) sequence, which is present in different proteins that mediates molecular recognition and/or interaction processes; as described in Bent (1994) *Science* 265:1856-1860; Parker (1997) *Plant Cell* 9:879-894; Hong (1997) *Plant Physiol.* 113:1203-1212; Schmitz (1997) *Nucleic Acids Res.* 25:756-763; Hipkind (1996) *Mol. Plant Microbe Interact.* 9:819-825; Tornero (1996) *Plant J.* 10:315-330; Dixon (1996) *Cell* 84:451-459; Jones (1994) *Science* 266:789-793; Lawrence (1995) *Plant Cell* 7:1195-1206; Song (1995) *Science* 270:1804-1806; as discussed in further detail *supra*. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can

identify polypeptides having LRR domains, including any member of the genus of LRR-containing RG polypeptides of the invention.

The term "promoter" refers to a region or sequence determinants located upstream or downstream from the start of transcription and which are involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating and/or regulating transcription in plant cells; see also discussion on plant promoters, *supra*.

The term "constitutive promoter" refers to a promoter that initiates and helps control transcription in all tissues. Promoters that drive expression continuously under physiological conditions are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation; see also detailed discussion, *supra*.

The term "inducible promoter" refers to a promoter which directs transcription under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters; see also detailed discussion, *supra*.

The term "abscission-induced promoter" or "abscission promoter" refers to a class of promoters which are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. When the plant disease resistant polypeptide-encoding nucleic acid is under the control of an abscission promoter, rapid cell death, induced by expression of the invention's polypeptide, accelerates and/or accentuates abscission of the plant part, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like; see also detailed discussion, *supra*.

The term "tissue-specific promoter" refers to a class of transcriptional control elements that are only active in particular cells or tissues. Examples of plant promoters under developmental control include promoters that initiate transcription only (or primarily only) in certain tissues, such as roots, leaves, fruit, ovules, seeds, pollen, pistols, or flowers; see also detailed discussion, *supra*.

As used herein "recombinant" includes reference to a cell, or nucleic acid, or vector, that has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

As used herein, a "recombinant expression cassette" or "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter.

As used herein, "transgenic plant" includes reference to a plant modified by introduction of a heterologous polynucleotide. Generally, the heterologous polynucleotide is an RG structural or regulatory gene or subsequences thereof.

As used herein, "hybridization complex" includes reference to a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acids with each other.

As used herein, "amplified" includes reference to an increase in the molarity of a specified sequence. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning methods, host cells, and *in vitro* amplification methodologies are well-known to persons of skill.

As used herein, "nucleic acid sample" includes reference to a specimen suspected of comprising RG resistance genes. Such specimens are generally derived, directly or indirectly, from lettuce tissue.

The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described *supra*.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

5

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1

10 Example 1 describes the use of PCR to amplify RG genes from lettuce.

Multiple primers with low degeneracy, particularly at the 3' end, were designed based on the sequences of two known resistance genes from tobacco and flax.

DNA Templates

15 Lettuce genomic DNA was extracted from cultivar Diana and a mutant line derived from cultivar Diana using a standard CTAB protocol. To generate cDNA templates, RNA was isolated from cultivar Diana and the mutant following standard procedures; first strand cDNA was synthesized using Superscript reverse transcriptase from 1 Φ g total RNA as specified by the manufacturer (Life Technologies). BAC (bacterial artificial chromosome) clones from the *Dm3* region were isolated from a BAC library of
20 over 53,000 clones using marker AC15 that was known to be closely linked to *Dm3*. Bacterial plasmids containing clones of *L6* and *RPS2* were used as positive controls.

PCR with degenerate oligonucleotide primers

25 Oligonucleotide primers were designed based on conserved motifs in the nucleotide binding sites (NBS) of *L6*, *RPS2*, and *N*. Eight primers were made corresponding to the GVGKTT motif in the sense direction; each had 64-fold degeneracy. Six primers were made to the GLPLAL motif in the anti-sense direction; with either 16 or 256-fold degeneracy (Table 1).

30 Oligonucleotides included 14-mer adaptors of (CUA)₄ at the 5' end of the sense primers and (CAU)₄ at the 5' end of the antisense primers to allow rapid cloning of the PCR products into pAMP1 (Life Technologies).

PCR amplification was performed in 50 Φ l reaction volume with 1 Φ M of each of a pair of sense and antisense primers. The templates were denatured by heating to 94EC for 2 min. This was followed by 35 cycles of 30 sec at 94EC, 1 min at 50EC, 2 min at 72EC, with a single final extension of 5 min at 72EC. 25 ng of genomic DNA or cDNA was used. BAC clones as templates required less. The final dNTP concentration was 0.2 mM; MgCl₂ was 1.5 mM.

Forty-eight combinations of sense and antisense primers were tested on a panel of nine templates consisting of two genomic DNA samples, two cDNA preparations, three BAC clones and plasmids containing *L6* and *RPS2* as positive controls.

Amplification from *L6* and *RPS2* resulted in fragments of 516 and 513 respectively. Seven combinations of primers resulted in fragments of approximately this size with multiple templates (Table 2). Primers that gave RLG products were: PLOOPAA, PLOOPAG, PLOOPGA, PLOOPGG, PLOOPAC, GLPL3, GLPL4.

(Intentionally left blank)

Table 1

DEGENERATE PRIMER SEQUENCES for NBS PCR

Sense primers based on GVGKTT amino acid sequence from L6, N and rps2 PLOOP motif:

PLOOPAG 5' GGN GTN GGN AAA ACG AC 3'

PLOOPAA 5' GGN GTN GGN AAA ACA AC 3'

PLOOPAT 5' GGN GTN GGN AAA ACT AC 3'

PLOOPAC 5' GGN GTN GGN AAA ACC AC 3'

PLOOPGG 5' GGN GTN GGN AAG ACG AC 3'

PLOOPGA 5' GGN GTN GGN AAG ACA AC 3'

PLOOPGT 5' GGN GTN GGN AAG ACT AC 3'

PLOOPGC 5' GGN GTN GGN AAG ACC AC 3'

Antisense primers based on GLPLAL amino acid sequence:

GLPL1 5' AGN GCN AGN GGN AGG CC 3'

GLPL2 5' AGN GCN AGN GGN AGA CC 3'

GLPL3 5' AGN GCN AGN GGN AGT CC 3'

GLPL4 5' AGN GCN AGN GGN AGC CC 3'

GLPL5 5' AAN GCC AAN GGC AAA CC 3'

GLPL6 5' AAN GCC AAN GGC AAT CC 3'

TABLE 2. Characteristics of RLGs isolated from lettuce.

	Template	Primers	Number ^a	Size ^b (bp)	Copy number ^c	Dm linkage
RLG1	genomic DNA	PLOOPGA+GLPL6	6/6	522		DM4,
	cDNA	PLOOPGA+GLPL6	1/5			DM13
	genomic DNA	PLOOPAA+GLPL6	5/5			
	cDNA	PLOOPAA+GLPL6	1/1			
RLG2	BACH8	PLOOPGG+GLPL3	3/3	510		DM1, Dm3
RLG3	gemonic DNA	PLOOPGA+GLPL4	3/6	461		Dm5 Dm8
RLG4	genomic DNA	PLOOPGA+GLPL4	1/6	524		

^a Number of RLG sequences out of total number of clones sequenced.

^b Size of fragment amplified from the nucleotide binding domain.

^c Estimated copy number from genomic Southern blot analysis and numbers of clones in the BAC library.

Example 2

Example 2 describes the genetic analysis used to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes.

Bulked segregant analysis was performed to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes. DNA from individuals were pooled for each susceptible and resistant bulk. Amplified products were then mapped by RFLP analysis from our intraspecific mapping population. Resistances from four clusters of resistance genes as well as over six hundred markers have now been mapped on this population. Linkage analysis was done using JIONMAP or MAPMAKER mapping programs. Due to a suppression of recombination in the *Dm3* region, sequences were mapped relative to *Dm3* using a panel of deletion mutants that provided greater genetic resolution than the mapping population (Anderson *et al.* 1996). All blots were washed twice at 63EC in 2x SSC/1% SDS for 20 min, followed by one wash at 63EC in 1x SSC/0.1% SDS for 10 or 30 min.

Most of the RLG sequences were analyzed by bulked segregant analysis (BSA) using pools of resistant and susceptible individuals for each of the four clusters of resistance genes. In genomic Southern analyses, all the RLGs revealed numerous fragments of varying intensity. The numbers of bands was highly dependent of the stringency of hybridization. BSA demonstrated that RLG1 was linked to the *Dm4,7* and *Dm13* clusters. Segregation analysis confirmed this linkage.

RLG2 was derived from BAC H8 that was known to be from the *Dm3* region. BSA with RLG2 demonstrated that the polymorphic bands that distinguished the parents of our mapping population mapped to the *Dm1,Dm3* cluster. Several bands absolutely cosegregated with *Dm1* or *Dm3*. To provide finer genetic resolution, RLG2 was also mapped using a panel of *Dm3* deletion mutants. A number of fragments were missing in largest deletion mutant demonstrating that several RLG2 family members are physically located very close to *Dm3*. No fragment was missing in all deletion mutants; however, this is not unexpected as there is extensive duplication within the region.

15

Example 3

Example 3 describes the screening of a bacterial artificial chromosome library.

Over 53,000 BAC clones containing lettuce genomic DNA were screened with two of the amplified products. High density filters each containing 1536 clones were hybridized to ³²P labelled probes. Filters were washed at 65EC with 40 mM Na₂PO₄/0.1% SDS for 5 min followed by 20 min in the same solution.

To isolate additional RLG sequences we screened our genomic BAC library. Clones were identified that hybridized to RLG1 and RLG2. Nearly all the clones that hybridized to RLG2 also hybridized to marker AC15 that had already been shown by deletion mutant analysis to be clustered around *Dm3*. This provided further evidence for clustering of RLG2 sequences.

Using primers conserved within each family, part of the NBS was amplified from each unique BAC clone and sequenced. This revealed that members within each family varied from 64% identical at the deduced amino acid level. The most divergent members only weakly cross-hybridized to each other. Currently, RLG sequences are

30

considered to be part of the same family of sequences if they are at least 55 % identical at the deduced amino acid level and map to the same region of the chromosome.

Example 4:

5 Example 4 describes the cloning, identification, sequencing and characterization of RG polynucleotide sequences; including use of RG sequences from plasmid and PCR products.

 Doubled stranded plasmid DNA clones and PCR products were sequenced using an ABI377 automated sequencer and fluorescently labelled di-deoxy terminators.
10 Sequences were assembled using Sequencher (Genecodes), DNASTar (DNASTar) and Genetics Computer Group (GCG, Madison, WI) software. Database searches were performed using BLASTX and FASTA (GCG) algorithms.

 Sequences flanking the NBS region for RLG2 and for some of RLG1 were obtained by a series of IPCR and the products sequenced directly. IPCR worked less well
15 for RLG1. Therefore RLG1 was subcloned from a BAC clone into pBSK (Stratagene) and the double stranded plasmid sequenced by long range sequencing.

 Initially, a total of 30 clones were sequenced. Three of these seven primer combinations yielded sequences that comprised continuous open reading frames with sequence identity to the NBS of known resistance genes. Seven out of 10 clones amplified
20 from genomic DNA with the primer pair PLOOPGA/GLP6 were 522 bp long; they were identical to each other and named RLG1. All six clones amplified from genomic DNA or cDNA using the primers PLOOPAA/GLP6 were similar/the same as RLG1. All three clones sequenced from BAC clone H8 were 510 bp long, identical to each other but different from RLG1 and were therefore designated RLG2. The 11 clones sequenced from
25 four other primer combinations had no similarity to any NBS motifs and therefore were not studied further. Therefore, sequencing resulted in the identification of clones containing NBS motifs representing four RLG sequences.

 Comparison of the deduced amino acid sequences of RLG1 and RLG2 to those of known resistance genes revealed that RLG1 and RLG2 are as similar to each other
30 as they are to resistance genes from other species and that this is the same level of identity shown between the known resistance genes (Table 3). The percent identity (upper quadrant) and percent identity (lower quadrant) were determined using the MEGALIGN

routine of the DNASTAR package. Identity refers to the proportion of identical amino acids; identity refers to the proportion of identical and similar amino acids and takes into account substitutions of amino acids with similar chemical characteristics. RG1 and RG2 are as similar to each other and to cloned resistance genes as cloned resistance genes from a variety of species are to each other. L6, resistance to *Melampsora lini* in flax (Lawrence *et al.*, 1995). N, resistance to tobacco mosaic virus in tobacco (Whitham *et al.*, 1994). PRF, required for resistance to *Pseudomonas syringae* in tomato. RPS2, resistance to *Pseudomonas syringae* in *Arabidopsis thaliana* (Bent *et al.*, 1994; Mindrinos *et al.*, 1994). RPM1, resistance to *Pseudomonas syringae* pv. *maculicola* in *A. thaliana* (Grant *et al.*, 1995). The initial RG1 and RG2, sequences were amplified from lettuce using degenerate primers.

Table 3

IDENTITIES OF

RESISTANCE GENE HOMOLOGUES

		RG1	RG2	RG3	RG4	N gene	RPS2
Lettuce	RG1	***	22.7	15.0	29.2	25.4	23.8
Lettuce	RG2		***	32.2	21.6	22.7	33.0
Lettuce	RG3			***	17.2	15.0	32.8
Lettuce	RG4				***	44.3	22.7
Tobacco	N gene					***	21.6
<i>Arabidopsis</i>	RPS2						***

The regions homologous to the primers are included in this analysis as the genomic sequences for RLG1 and RLG2 were determined by IPCR. Interestingly, the genomic sequences for RLG1 exactly matched that of the primers used.

To obtain further evidence that we had amplified resistance genes, we amplified the regions flanking the NBSs of RLG1a and RLG2a by IPCR of BAC clones. These products were then directly sequenced without cloning to minimize the introduction of PCR artifacts. Sequence analysis of the 5' regions failed to detect any homology to known resistance genes. However, the sequence of the 3' region contained leucine-rich

repeats (LRRs). When this sequence was used to search GENBANK using BLASTX, it detected identity to the *Arabidopsis* resistance gene, *RPS2*. This region does not contain as regular LRRs as in some resistance genes; however, the repeat structure seems to be consistent with that of the flax resistance gene, *L6*. Therefore, the presence of an LRR region is further evidence that the sequences we amplified using degenerate oligonucleotide primers are probably resistance genes.

The sequences of the IPCR products also provided the genomic sequences of the regions complementary to the sequences of the degenerate oligonucleotide primers.

The genomic sequences for RLG1 were identical to one of the primers in the mixture.

The RLG sequences are resistance genes as supported by three criteria: the presence of multiple sequence motifs characteristic of resistance genes, genetic cosegregation with known resistance genes, and their existence as clustered multi-gene families. The presence of LRR regions in a similar position relative to the NBS as in cloned resistance genes provides stronger evidence than relying solely sequence similarity between NBS regions.

The clustering of RLG sequences at the same position as the known clusters of resistance genes make them strong candidates for encoding resistance genes. The hybridization patterns and genetic distribution of the RLG sequences are similar to that of cloned resistance genes in other species. Most of these hybridize to small multigene families and preliminary genetic evidence indicates that they are clustered in the genome. Therefore, the degenerate primers that we designed from other resistance genes seemed to have been specific enough to amplify resistance genes rather than P-loop containing proteins in general.

(intentionally left blank)

SEQ ID NO: 1

RLG1A
[Strand]

```
1   ATCGTAACCGTTCGTACGAG ANCGCTGTCCTCCTTCATC TTTGTGCATATGTCATATTC TCATNIRATMTGCCACATNT
81  AATTTTGTGGTATTTTAAA TTAATTTTATTCCACATGT CATTTTATGAGTTTTTCTAT TTTATTGAGTTTCACATAAT
161 ATTTAAATGTAATAACAATA AATGCATATTTATTTTCTT TAAATAAACGCATATAATAT ATAGATTAAAATCATATAAT
241 ACATAGGTTAAACTCATATA ATACATATGTTTCATCCCCAG TTTATTTATATGTTCTCATCC TTAATTTATTTATTTATTTAT
321 TTATTAGAGTAGATGATCTT TGTGATATTAAAAATTTAAT TTGTTCAAAATTTAAATTA TTAATAATCCCAATTTTGA
401 ATAAAAATTAAAAAAATGGN CCCACCATTAGTCCATCACT TTTTCAGCTCATCAATATCG TGAGTATCTCTCTCGTTTC
481 CACCCTAATCAATATTTCCA CGGAATGCAGACTCCTACG GCGTTTCTGAATTTGCGTTC CGACACTGTTCATGGAAGGA
561 GATATTAATCAATGGAGC TGCTCCAATGTTTCATTTGCTG ATGAAAGGTGAATTTGTATGT GAAGANAATGTCAGCGATCN
641 ATCTCCATCCGGAACCCACC ACATTATCAGTGTACCACCA AACCACCTCAAAACGGYGGAA GTAGRRACWRAAAGTCA
721 TGAAGAAATAGATTATTTTG TCCTCATGGGCTGACTGAGG AGCGGGTTTAGTTTCATCATT TTTCTTTGANCAAGAATTA
801 TCGGTCCATCGAATTTTAC ATCGACAAAGAAGTTTCACT TCGCAATGTTTTGTTAAACA ATTTTAAATCTTTTATCTT
881 TTGTTGAACCTCCTCAATT GCAACTTGCACCTTGCACAT TTTGGGCCCAAAATTTGTG GTGGGCGTTAATTTAATCCA
961 CATATTCACGTGAACAATA ATTCAAATCGATCTCTGTTT ATCCAATTCATCAACATCTC TTGATAAATGAAATCATCA
1041 CGCTTCATCCATTTTCATCCA CATCTATACATATATTTCTG CTCTTATCATATTAAACGAT GGCTGAAATCGTTCTTTCTG
1121 CCTTCTTGCAGTGGTGTTC GAAAAGCTGGCATYTGAAGC CTTGAAGAAGATTGTTCCGCT CCAAAGAATTTGAATCTGAG
1201 CTTAAGAAATTTGAAGGAGAC ATTAGACCAAAATCCAAGATC TGCTTAACGATGCTTCCAG AAGGAAGTAACTAATGAAGC
1281 CGTTAAAGATGGCTGAATG ATCTCCAACATTTGGCTTAT GACATAGACGACCTACTTGA TGATTTTGCAACTGAAGCTG
1361 TTCACGTGAGTTGACCGAG GAGGGTGGAGCCTCCTCCAG TATGTTAAGAAAATTAATCC CAAGTTGTTGCACAAGTTTC
1441 TCACAAAGTAATAGGATGCA TGCCAAGTTAGATGATATTG CCACCAGGTTTACAAGAACTG GTAGAGGCAAAAATAATCT
1521 TGGTTAAGTGTGATAACAT ATGAAAAGCCAAAATTGAA AGGTATGAGGCGTCTTTGGT AGATGAAAGCGGTACTGTG
1601 GACGTGAAGATGATAAGAA AAATTCCTGGAGAAGCTGTT GGGGATAAAGATGAATCAG GGAGTCAAACTTCAGCATC
1681 GTCCCCATAGTTGGTATGGG TGGAGTTGGTAAAACAACTC TAGCTAGACTTTTGTATGAT GAAAAGAAATGAAGGATCA
1761 CTTGTAACCTCAGGGCTTGGG TTTGTGTTTCTGATGATTC AGTGTTCCCAATAATAAGCAG AGTTATTTATCAATCTGTGA
1841 CTGGGAAAAGAGGAGTTT GAAGACTTAAATCTGCTTCA AGAAGCTCTTAAAGAGAAAC TTAGGAACCAGCTATTTCTA
1921 ATAGTTTTGGATGATGTGTC GTCTGAAAGCTATGTTGATG GGGAGAAAATAGTGGGCCCA TTCTTTCGGGGTCTCTCTG
2001 AAGTAGAATAATCATGACAA CTGGAAGGAGCAATTTGCTC AGAAAGCTGGGCTTTCTCA TCAAGACCTCTGGAAGGTC
2081 TATCACAAGATGATGCTTTG TCTTTGTTTGTCTCAACACGC ATTTGGTGTACCAAACTTTG ATTACATCCCAACCTAAGG
2161 CCACA-TGGAGA-CTGTTTGT GAAGAAATGTGATGGCTTAC CTCTAGCTTTAAGAACACTT GGAAGGTTATTAAAGGACAAA
2241 AACAGACGAGGAACAATGGA AGGAGCTGTTGGATAGTGGC ATATGGAGGTTAGGAAAGAG CGATGAGATTGTTCCGGCTC
2321 TTAGACTAAGCTACAATGAT CTTTCTGCCCCTTTGAGACT RTTCTTTGCATAYTGCTCCT TGTTCCTCAAGGACTATGAG
2401 TTTGACAAGGAGGAGTTGAT TCTATTGTGGATGGCAGAAG GGTTTTTCGCCAACCAACT AYAAACAAGTCAAGCAACG
2481 KTTGGGCTCTGAATATTTTR AAGAGTTRTTGTCAAGRTCR TTTTTCACATGCTCCTAA TRRCAAACTSTGTTTGTGA
2561 TGCAATGACCTAATGAATGAT TTGGCTACATTTGTTGCTGG AGAATTTTTTTCAAGGTTAG ACATAGAGATGAAGAAGGAA
2641 TTTAGGATGSAATCTTTGGA RAAGCACCGCATATGTCAT TTGTATGTGAGRATTACATA GGTTACAAAARGTTCGAGCC
2721 ATTTAGAGGAGCTAAAAATT TGAGAACATTTTTCAGATTG TCTGTTGGGGTGGTAGAAGA TTGGAAGATGTTTACTTTAT
2801 CAAACAAGGCTTGAATGAC WTACTTTCAGATTACCAATT GTTAAGGTCCTTRAKTTTGA TTRRTCTTAYAATAASYRAG
2881 GTACCAARAATCGTSGGTAG TATGAASCACCTGCGGTATC TTAATCTATCAGRAACTTWA ATCACMCATTTACCGGAAWA
2961 TKTCCTCAATCTTTATAATT TACARACCTGATTTGTCTCT GGCTGTGAMTATTTAGTTAA KTTGCCCAARACCTTCTCAA
3041 ASCTTAAAAATTTGCASCAT TTTGACATGAGGGRATCTCC KAAKTTRAARAACATGCCCT TARGGATTGGTGARTTGAAA
3121 ARTCTACAAACTCTCTTMS TAACATTGGCATAGCAATAA CCGAGCTTAAGAACTTGCAM AAYCTCCATGGGAAARTTTG
3201 TATTGCGGGCTGGGAAAAA TGGAAAAATGCMGTGGGATGC ACGTTAAGCGAATCTGTCTC AAAAAAGGTTWAATGARTTA
3281 NAAACTGGRTTGGGGGTGA TRAATTTAATGTTTTCCGAA ATGGGAACACTTGAAAAAGA AGTCCTCAATGAAGTGATGC
3361 CTCATATGGTACTCTANAA AAAACCCANAATTTATGCTA TAGGGGTATAGAGTTTCCA AATTGGGTTGGTTNCACTAA
3441 GGGTTTCTGAACTAGAGAT GTGTTTCATGGTGTATGAAA AGANTGTTTTACGTAGTTTC ATCAATCACCAGTGGGAAA
3521 TAGATGATATTTTCAGGGCY TACTGATGAGATGTGGAGAG GTATGATAGGGTTCCTTGGG GCGGTAGAAGAAATAAGCAT
3601 CCATCTTGTGAATGAAATAA GATATYTGTTGGGAATCAGAA GCAGAGGCAAGTAAGGTTCT TATGAATTTAAGAAGTTGG
3681 ATTTAGGTGAATGTGAAAAA TTGGTGAGTTTAGGGGAGAA AAAGGAGGATAATCATAATA TTAATAGTGGGAGCAGCTTA
3761 ACATCTTTTAGGAGGTTGAA TGATGGAGATGTAAACAGCT TGGAGCATTCAGGGTGTCCA GATAGCATGGGAATTTGTA
3841 TATGCAATGTGTGATTCAA TACATCCGCTCTCTTCCCA ACAGGAGGAGGACAGAAGAT CAAGTCACTTACCATCACTG
3921 ATTGCAAGAGCTTTCCGAA GAGGAGTTGGGAGGACGAGA GAGGACAAGAGTCTTTATAA ACTCAAAAATGCGAGATGCTT
4001 GAATCAGTAGATATACGTAA TTGGCCAAATCTGAAATCTA TCAGTGAATGAGTTGCTTTC ATTCAAGTGAACAGATTATA
4081 TATATCAACTGTCCGAGTR TGGAGTCTATTCCTGACCAT GAGTTGCCAAATCTCACCTC CTTACAGATCGAAGGAGAG
4161 GACAGCGATTTTCTGACGAA CGGTTACGATTGCACTGGCC GTCGTTTTT
```

SEQ ID NO: 2

RLG1B

[Strand]

```
1  AACCGTTCGT  ACGAGAATCG  CTGTCCTCTC  CTTCCCTGTAA  TATAATGATA  AGAAAAATA  TGATTAAAGG
71  TTTAAATCCA  AAATCCATTA  TTCCACCGGT  GATATGATGC  ACTAGCTGTA  GTATGCAAAA  ACAGTATTAT
141  AAATGCTAAC  CAAAACAGCA  GCTAAGAAAC  AATATAAATA  ATGGTTTGAA  TCGTCCTTTC  TCCGTACAQT
211  CATTTCTTCC  AAATCCCTAT  CATTCAATCA  TACAAGTGCT  CCCATATTAG  GTTTTCACTA  TAAGCAATGG
281  CTGAAATCCT  TGGTTCGCG  TTCTTTGCGG  TGTTCCTTGA  AAAGCTTGCT  TCTGAAGCCT  TGAAGAGGGT
351  TGCTTGCTCC  AAAGTAATTG  ACAAGGAGCT  CGAGAAATTG  AATAGCTCAT  GAATCAATAT  AAAAGCTCTG
421  CTCATATGAT  CTCTCTAGAA  GGAAATAAGT  AAGGAAGCTG  TTRAAGAATG  GTTGAATGCT  CTTCACATT
491  TGCTTACGA  CATAGATGAT  CTACTTGGCG  ATTGGCAAC  CAAAGCTATC  CATCGTAAGT  TCTCTGAGGA
561  ATACGGGGCC  ACCATCAACA  AGGTACGAAA  GTTAATTCCA  TCTTGTTCCT  CTAGTTTGTG  AAGTACTAAG
631  ATGCGCAACA  AGATACATAA  TATTACCAGC  AAGTTACAAG  AACTATTAGA  AGAGAGAAAT  AATCTTGGAT
701  TATGTGAAT  TGGTGAAAGC  CGAAAACCTC  GAAATAGAAA  ATCAGAGACC  TCCTGTCTAG  ATCCATCTAG
771  TATGTGTGGA  CGCACAGATG  ATAAGGAAGC  GTTGCCTTCT  AAGCTATATG  AACCATGTGA  TAGAAACTTT
841  AGCATCTTGC  CNATAGTTGG  TATGGGTGGG  TTAGATAAGA  CCACTTTAGG  TAGACTTTTG  TATGATNAAA
911  TGCAAGTGAA  GGATCACTTC  GAACTCAAGG  CGTGGGTTTG  TGTTCCTGAT  GAGTTTGATA  TCTTCGGTAT
981  AAGCAAAACC  ATTTTCGAAT  CGATAGAGGG  GGGAAACCAA  GAGTTTAAGG  ATTTAAATCT  GCTTCAGGTG
1051  GCTTTAAAGG  AGAAAATCTC  AAAGAAACGA  TTTCTTGTG  TTCTTGATGA  TGTATGGAGC  GAGAGCTATA
1121  CTGATTGGGA  AATTCTAGAA  CGTCCATTTT  TAGCAGGAGC  ACCAGGAAGT  AAAGTAATCA  TCACAACCCG
1191  CAAGTTGTGG  TTGCTAAACC  AATTGGGTCA  TGATCAACCA  TACCAATTGT  CIGATTGTG  ACATGACAAT
1261  GCTCTATCCT  TATTTTGTC  ACACGCATTT  GGTGTAAATA  GCTTTGATTC  ACATCCGATA  CTTAAACAC
1331  ATGGTGAAGG  TATTGTGAA  AAATGTGATG  GTTTGCCATT  GGCTTTGATT  GCCTTGGGA  GGTATTGAG
1401  GACAAAAGA  GATGAGGAAG  AATGGAAGGA  ACTATTGAAT  AGTGAGATAT  GCAGGTTAGG  AAAGAGAGAT
1471  GAGATTATTC  CGGTCTTAG  ACTAAGCTAT  AATGATCTTT  CTGCTCTTT  GAAGCAGTTG  TTTGCATATT
1541  GCTCCTTGTT  CCCCAAAGAC  TATGTGTTCA  ACAAGGAGAA  GTTGATTTTA  TTATGGATGG  CAGAAGGGTT
1611  TTTGCACAAT  GAAAATACAA  ACAAGTCAAT  GGAACGCTTA  GNTCTTGAAT  ATTTTGACGA  CTTGTTGTCA
1681  AGGTCAATTT  TTCAACATGC  ACTCGATGAC  AAATCGTTGT  TTGTGGTGCA  CGACCTCATG  AATGACTTGG
1751  CCACATCTGT  TGCTGGAGAT  TATTTTTTAA  GATTAGACAT  TGAAATGAAA  AAGGAAGCTT  TGGAAAAATA
1821  CCGACATATG  TCATTTGTTT  GTGAGAGTTA  CATGGTTTAC  AAAAGGTTTG  AACCATTTAA  AGGAGCTAAA
1891  AAATTGAGAA  CTTTCTTAGC  AATGCCGTGT  GGGATGATAA  AAAGTTGGAC  AACATTTTAC  TTATCAATA
1961  AGGTCCCTGA  TGACTTACTT  CACGAATTAC  CATGTGTGAG  AGTTCTAAGT  TTGAGTTATC  TTAGCATCAA
2031  GGAGGTACCT  GAAAATAATAG  GCAATTTGAA  AACTTGGCG  TATCTTAATT  TATCACACAC  GAGTATCACA
2101  CATTTACCAG  AAAATGTCTG  CAATCTTTAC  AACTTACAAA  CATTGATCCT  TTGTGGCTGT  TGTTTTATAA
2171  CCAAGTTTCC  CACCAACTTC  TTAAGCTTA  GAAATTTACG  GCATTTGGAC  ATTAGCGATA  CTCCCGGTTT
2241  GAAGAAAGATG  TCCTCGGGGA  TTGGTGAATT  GAAGAACCTA  CACACYCTCT  CCAAGCTCAT  TATTGGAGGT
2311  GAAAAAGAC  TAAAGAGCT  TAAGAACTTA  CAAAATCTCC  ATG
```

RLG1b - Diana
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTTCTGAT GAGTTTGATA TCTTCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAG
211 AGAAGATCTC AAAGAAAAGa TTTCTTCTTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATTNTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGnAGG
491 TATTGTTGAA AAATGTGATG GdTTGCCATT GGCATTGTCTG ACATGATGAT GATG
```

SEQ ID 137

SEQ ID NO: 3

RLG1C

[Strand]

```
1   TCCCGTGCAG CGTNTATCAT TCAGAAGNGC CCAAAGACCA NAGATNTGTT TAANGNTGNT TUTCAGAAGG
71  AAGTAATTGA TGAAGCTGTN AAAAGATGGC TGATTGATNT CCAACAATTG GCTTAGGACA CTGANGACNA
141 ACTTGATGAT NTCGCAACAG AAGCTATTCA TCGTGAGTTG ATCCGTGAAA CTGGAGCTTC CNCCAGCATG
211 GTAAGAAAGC TAATCCCAAG TTGTTGCACA AGTTTCTCAC AAAGTAATAG GATGCATGCC AGGTTAGATG
281 ATATTGCCGC TAAGTNACAA GAACGGTAG AGGCGAAAAA TAATCTTGGT TTAAGTGTGA TAACATACGA
351 AAAACCCCAA ATTGAAAGAG ATGAGGCGTN TTTGGTAGAT GCAAGTGGTA TCATTGGACG TGAAGATGAT
421 AAGAAAAAAT TGCTTCAGAA GCTGTTGGGG GATACCTATG AATCAAGTAG TCAAAACTTC AACATCGTGC
491 CCATAGTTGG TATGGGTGGG GTAGGTAAAA CAACCTTAGC TAGACTTTTG TATGATGAAA AAAAAGTGAA
561 GGATCACTTC GAACTCAGGG TTTGGGTTTG TGTTCCTGAT GAGTTCACTG TTCCCAATAT AAGCAGAGTT
631 ATCTATCAAT CTGTGACTGG TGAACAACAA GAATTTGCAG ATTTAAATCT GCTTCAAGAA GCCCTTAAAG
701 AGAAACTTCA GAACRAACTA TTTCTAATAG TTTTAGATGA TGTATGGTCT GAAAGCTATG GTGATTGGGA
771 GAAATTAGTG GGCCCATTTT ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTIONG GAAGGAGCAA
841 TTACTCAAC AGCTGGGTTT TTCTCATGAA GACCCCTGCG ATAGTATAGA CTCCCTGCAA CGTCTATCAC
911 AAGAAGATGC TTTGCTTTG TTTCTCAAC ACGCATTTGG TGTACCTAAC TTTGATTAC ATCCAACACT
981 AAGGCCATAT GGGGAACAGT TTGTGAAAAA ATGTGGGGGA TTGCCTTTGG CCTTGT
```

SEQ ID NO:4

FLG1D
[Strand]

```
1  CMTACCTTTC TACGAGATCG CTGTCCCTCC TCGATCTGCT TAACGATGCT TCCCAGAAGG AAGTNACTAA
71  TGAAGCGGTT AAAAGATGGC TGAATGATCT CCAACATTTG GCTTATGACA TANACGACCT ACTTGATGAT
141 CTTGCAACAS AAAGCTATTTC NTCSTGAGTT GACCGANGAA GGTGGAGCCT CCACCAGTAT GGTAAGAAAA
211 CTAATCCCAA GTTGTGCAC AAGTTTCTCA CAAAGTTATA GGATGCATGC CAAGTTAGAT GATATTGCCA
281 CCAGGTTACA AGAACTGGTA GAGGCAAAAA ATAATCTTGG TTTAAGTGTG ATAACATATG AAAAGCCCAA
351 AATTGAAGG TATGAGGCAT CTTGGGTAGA CGAAAGTGGT ATTTTGGAC GTTNAGATGA TNAGAAAAAA
421 TTGATGGAGA AGCTGTGGG GGATAAAGAT GAATCCGGAG TCNAACTTC AGCATCCTGC CCATAATTGS
491 TATGGGTGGA GTTGGCNAAA CAACTCTAGC TAGACTCTTG TTTGATGAAA AGACAGTGAA GGATCACTTC
561 GAACCTAGGG CTGGGTTTG TGTTCCTGAT GAATTCAGTA TTCTCAACAT AAGCAAAGTT ATCTATCAAT
631 CTGTGACCGG GGAAAAGAAA GAGTTTGAAG ACTTAAATCT GCTTCAAGAA GCTCTTAGAG GGAAACTACA
701 AAACAAACTA TTCTAATAG TTTTGGATGA TGTATGGTCG GAAAGCTATG GTGATTGGGA GAAATTAGTG
771 GGCCCATTTT ATGCTGGGAC TTCGTGAAGT AGAATAATCA TGACTACTCG GAAGGAGCAA TTACTCAAAC
841 AGTTGGGTTT TTCTCATCAA GACCCCTCTG GTTGTATAGA CTCCCTGCAA CGTCTATCAC AAGATGATGC
911 TTTGTCTTTG TTGTCTCAAC ACGCATTGG TGWCCA
```

RLGLE
[Strand]

```
1  TCTAGCTAGA CTTTGTATG ACGAGATGCA AGAGAAGGAT CACTTCGAAC TCAAGGCGTG GGTTCGTGT  
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAAGAAT  
141 TTAAGGACTT AAATCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTCAAAG AAACGATTTC TACTTGTTC  
211 TGATGATGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT CTGGAACGCC CATTTCCTGC AGGGGCAGCC  
281 GGAAGTAAAA TTATCATGAC GACCCGGAAG CAGTCATTGC TAACCAAACG CGGTACAAAG CAACCTTACA  
351 ACCTTTCCGT TTTGTACAT GACAGTGCTC TCTCTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT  
421 CGATTCCAT CCAACACTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCT
```

SEQ ID NO:5

RLGF
[Strand]

```
1   ATTTTCNGCT CNDAAACAAAN AAAAGCAATG GCTGAAATCT TTCTTTTCNGC ATTCTAGACC AGTATTCTTT
71  GAAAAGNTGG CTTCTGAAGC CTTGAAGAAG ATCGCTCGCT TCCATCGGAT TGATTCTGAG CTCAGAAGAAC
141 TGAAGAGGTC ATTAATCCAG ATCAGATCTG TGCTTAATGA TGCTTCTGAG AAGGAAATAA GTGATGAAQC
211 TGTAAAGAA TGGCTGAATG GTCTCCAACA TTGTCTTAC GACATAGACG ACCTACTTGA TGATTTGGCA
281 ACCGAAACTA TGCATCGTGA GTTGACCCAC GGATCTGGAG CCTCCACCAG CTTGTAAGAA AGATAATCCC
351 AACTTGTTC ACAGATTTCT CACTAAGTAG TAAGATGCGT AACAAAGTAG ATAATATTAC CATCAAGTTA
421 CAAGAAGTGG TAGAGGAAAA AGATAATCTT GGCTTAAGTG TGAAGGTTGA AAGCCCAAAA CATACCAACA
491 GAAGATTACA GACCTCTTTG GTAGATGCAT CTAGCATTAT TGGTCGTGAA GGTGATAAGG ATGCATTGCT
561 CCATAAGCTG CTGGAGGATG AACCAAGTGA TAGAAACTTT AGCATCGTGC CAATAGTTGG TATGGGTGGT
631 GTGGGTAAGA CGACTCTAGC TAGACTTTTG TATGACGAGA TGCAAGAGAA GGATCACTTC GAAGTCAAGG
701 CGTGGGTTTG TGTTCCTGAT GAGTTTGATA TCCTCAATAT AAGCAAAGTT ATCTTCCAAT CGATAGGTGG
771 TGGARACCA GAATTTAAGG ACTTAAATCT CCTTCAAGTA GCTGTAAAAG AGAAGATTTC AAAGAAACGA
841 TTTCTWYTTG TTCTGGATGA TGTTTGGAGT GAAAGCTATA CAGAATGGGA AATTCTAGCA CGTCCATTTC
911 TTGCAGGGGC ACCAGGAAGT AAGATTATCA TGACGACCCG GAAGTTGTGG TTGCTAACCA AACTCGGTTA
981 CAATCAACCT TACAACCTTT CSGTTTTGTC ACATGATAAT GCTTGTCTTT TATTCTGTCA GCAYGCATTG
1051 GGTGAAGATA ACTTCGATTC ACATCCAACA CTTAAACCAC ASGGTGAAG TATTGTGTA AAATGTGACG
1121 GTTTACCATT GGCCTTTRAT GCACTTGGGA GRTTGTGAR GACAAAAACA GATGAGGAAG AATGGAARGA
1191 AGTGTGAAT AGTGAATAT GGGGGTCAGG AAAGGGAGAT GAGATTGTTC CGGCTCTTAA ACTAAGCTAC
1261 AATGATCTCT CTGCTCTTT GAAGAAGTTG TTGCTACT GCTCCTTGT CCAAAGAC TATGTGTTCG
1331 ATAAGGAGGA GTTGATTTTG TTGTGGATGG CAGAAGGTT TTTGCACCA TCAACCACAA GCAAGTCBAT
1401 GGAACGCTTG GGHCAATGAAG GTTTTGATGA ATGTGTGCA AGATCATTIT TTCAACATGC CCTGATGCC
1471 AAATCGATGT TTGTGATGCA TGACCTGATG AATGACTTGG CHACATCTGT TGCTGGAGAT TTTTTTTCAA
1541 GGATGGACAT TGAGATGAAG AARGAATTTA GGAAGGAAGC TTTGSAAAAG YAYCGCCATA TGTCATTTGT
1611 TTGTGAKGAT TACATGGTKI ACAAAGGTT CRAGCCATTS ACAAGGAGCT AG
```

SEQ ID NO: 6

RLGIG
[Strand]

```
1  GTGAAGGATC ACTTCGAACT CAGGGGCTGG GTTTGTGTTT CTGATGAATT TAATATCCTC AATATAAGCA
71  AAGTAATTTA TCAATCTGTA ACCGGGGAAA AAAAGGAGTT TGAAGACTTA AATCTGCTTC AAGAAGCTCT
141 TAAAGAAAAA CTTTGGAATC AGTTATTCTT AATAGTCTG GATGATGTGT GGTCGAAAG CTATCGTGAT
211 TGGGAGAAAT TAGTGGGCCC ATTTTTCG GGGTCCTCTG GAAGTATGAT TATCATGACA ACTCGGAAGG
281 AGCAATTGCC AAGAAAGCTG GGTTCCTC ATCAAGACCC TTTGCAAGGT CTATCACATG ACGATGCTTT
351 GTCTTTGTTT GCTCAACACG CATTGGTGT ACCA
```

SEQ ID NO: 7

RLG1H
[Strand]

```
1  TCTAGCTAGA CTTTGTGATG AGGAAATGCA AGGGAAGGAT CACTTCGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATCTT CAATATAAGC AAAATTATCT TACAAATCGAT AGGTGGTGGA AACCAAGAAT
141 TTACGGAATT AAACCTGCTT CAAGTAGCTT TAAAGAGAGAA GATCTCAAAG AAAAGATTTC TTCTTGTTCT
211 TGATGATGTT TGGAGTGAAA GCTATACCGA TTGGGAAATT CTAGAACGCC CATTTCTTGC AGGGGCACCT
281 GGAAGTAAGA TTATTATCAC CACCCGGAAG CTGTCATTGT TAAACAACT CGGTTACAAT CAACCTTACA
351 ACCTTTCGGT TTTGTCACAT GAGAATGCTT TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CAATTCACAT CCAACACTTA AACCACATGG CGAAGGTATT GTTGAAAAAT GTGAT
```

SEQ ID NO: 8

RLGI
[Strand]

```
1  TCTAGCTAGA CTTGTGTATG ATGAGATGCA AGAGAAGGAT CACTTTGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAGAAT
141 TTAAGGACTT AAACCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTTAAAG AAACGATTTC TTCTTGTTC
211 TGACGACGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT NTGGAACGCC CATTTCCTGC AGGGGCAGCC
281 GGAAATAAAA TTATCATGAC AACCAGAAAG CAGTCATTGC TAACCAAAC TCGTTACAAG CAACCTTACA
351 ACCCTTCCGT TTTGTACAT GACAGTGCTC TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGGTAACCT
421 CGATTACAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCTGGATT GCCATTGGCA
491 TTGTCGACA
```

SEQ ID NO: 9

RLGLJ
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTTCTGAT GAGTTTGATA TCTTCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATCTC AAAGAAAAGa TTTCTTCTTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATTNTAGAA CGCCCAATTIC TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTTGTC ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTAAACCAC ATGGCGaAGG
491 TATTGTGAA AAATGTGATG GaTTGCCATT GGCATTGTCTG ACATGATGAT GATG
```

SEQ ID NO:10

RLGIA aa.

IVTVRTR?LSLLHLLSYVIFS?I?PH?ILWLF.INFYSTCHFMSFSILLSFT.YLNVITINAYLFFFK.THIIYR
LKSynt.VKLI.YICSSPVYLYVSSLIYLLFIY.SR.SL.Y.KFNLFKI.NY..SHNLNKIKKNGPTISP SLFQLINIV
SILLRFHPNQYFQRMDSYGVSEFAFRHCSLKEIINQMELLCQSLLMKGELYVK?MSAI?LHPEPTTSLV
YHQTTONGGSR?T?KS.RIDYFCPHGLTEERV.FIIFL?KNYRSIEFLHRQRSFTSQCFVKQFLIFLSFR.NS
SIATCNLQLLGPQICGGR.FNPHIHCKQ.FKSISVHPIHQHLLIIEIIHASSISSTSIYSLLLSY.TMAEIVLS
AFLTUVFEKLA?EALKKIVRSKRIESELKKLKETLDQIQDLLNDASQKEVTNEAVKRWLNDLQHLAYDID
DLLDD?ATEAV?RELTEEGGASSSMVRKLIPSCCTSFSSQSNRMHAKLDDIATRLQELVEAKNNLGLSVI
TYEKP KIER YEASLVDESGTVGREDDKKKLEKLLGDKDESQSNFSIVPIVGMGGVGKTTLARLLYDEK
KVKDHFELRAWVCVSDSFVSPNISRVYQSVTGEKKEFEDLNLLQEALKEKLRNQLFLIVLDDVWSESY
GDWEKLVGPFLAGSFGSRIMTTRKEQLLRKLGFSHQDPLEGLSQDDALSLFAQHAFGVPNFDSHPTLR
PHGELFVKKCDGLPLALRTLGRLLRTKTDEEQWKELLDSEIWRGLGKSDEIVPALRLSYNDLSA?LKLFA
YCSLFPKDYEFDKELLLWMAEGFLHQPT?NKSQRGLGEYF?ELLSRSFFQHAPN?KSLFVMHDLMD
LATFVAGEFFSRLDIEMKKEFRM?SLEKHRHMSFVCE?YIGYK?FEPFRGAKNLRITFLASVGVVEDWK
MFYLSNKVLND?LQDLPLLRVL?LI?L?I?VP??VGSM?HLRYLNLS?T?ITHLPE??CNLYNLQTLIV
SGC?YLV?LPKTFS?LKNL?HFDNR?TP?LKNMPL?IGELK?LQTLF?NIGIAITELKNL?NLHGK?CIGG
LGKMEHAVGCTLSELVSKKV?..NW??G..ICFPKWEHLKKKSSMK.CLIMVL?KKP?IMSIGGIEFPN
WVGLSRVSETRDVFMVYEK?CFT.FHQSPSGK.MIFSG?TDEMWRGMIG?LGAVEEISIHSCNEIRYLWE
SEAEASKVLMNLKKLDLGEENLVSLGEKKEDNHNINSGSSLTSFRRLNVWRCNSLEHCROPDSMENLY
MHMCDS?TSVSFPTGGGQKIKSLTITDCKKLSEELGGRETRVLINSKMQMLESVDIRNWP NLKSISEL
SCFIHLNRLYISNCP?ESFPDHELPNLTSLTDRRRGQRFSYERLRFDWPSF

SEQ ID NO:11

RLGIB a.a.

NRSYENRCPLLPVI...EKI.LKV.IQNPLFHR.YDALAVCKNSIINANQNSS.ETI.IMV.IVLSPTYTHFFQIPII
HTYKCSHIRFSLAMAEILGSAFFAVFFEKLASEALKRVACSKVIDKELEKLNSS.INIKALLNDASQKEIS
KEAVKEWLNALQHLPYDIDDLGDLATKAIHRKFSEEGATINKVRKLIPSCFSSLSSTKMRNKIHNITS
KLQELLEERNNLGLCEIGESRKLNRKSETS?LDPSSIVGRTDDKEALLKLYEPCDRNFSILPIVGMGGL
DKTTLGRLLYD?MOVKDHFEKAWVCVSDEFDFGISKTFESIEGGNQEFKDLNLLQVALKEKISKKRFL
VLLDDVWSESYTDWEILERPFLAGAPGSKVIITTRKLSLLNQLGHDQPYQLSDLSHDNALSIFCQHAFG
VNSFDSHPILKPHGEGIVEKCDGLPLALIALGRLLRTKRDEEWEKELLNSEIWRGKRDEIIP?LRLSYND
LSASLKQLFAYCSLFPKDYVFNKEKLILLWMAEGFLHNENTNKS MERL?LEYFDDLLSRFFQHALDDKS
LFVVHDL MNDLATS VAGDYFLRLDIEMKKEALEKYRHMSFVCESYMVYKRFEPPFGAKKLRTFLAMPV
GMIKSWTTFFYLSNKVLDLLHELPLLRVLSLSYLSIKEVPEIIGNLKHLRYLNLSHTSITHLPENVCNLYN
LQTLILCGCCFITKFPNNFLKLRNLRHLDISDTPGLKKMSSGIGELKNLHTLSKLIIGGENRLNELKNLQNL
H

SEQ ID NO:12

RLG1c a.a.

SRAT?IIQK?PKT?D?F????QKEVIDEAVKRWLID?QQLAYDT?D?LDD?ATEAIHRELIRETGAS?S
MVRKLIPSCCTSFSQSNRMHARLDDIAAK?QELVEAKNNLGLSVITYEKP KIERDEA?LVDASGIIGRED
DKKKLLQKLLGDTYESSSQNFNIVPIVGMGGVGKTTLARLLYDEKKVKDHFELRWWCVSDEFSVPNIS
RVIYQSVTGENKEFADLNLLQEALKEKLQNKLFIVLDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTR
KEQLLKQLGFSHEDPLHSIDSLQRLSQEDALSLFSQHAFGVPNFDSHPTLRPYGEQFVKKCGGLPLAL

SEQ ID NO:13

RLG ID

?T?LRDRCPSSICLTMLPRRK?LMKPLKDG.MISNIWLMT?TTYLMILQ?KAI??ELT?EGGASTSMVRK
LIPSCCTSFSSQSYRMHAKLDDIATRLQELVEAKNNLGLSVITYEKPkiERYEASLVDESGIFGR?DD?KK
LMEKILLEDKDESGVKLQHLPiIGMGGVG?TTLARLLFDEKTVKDHfELRAWVCVSDEFSILNISKVIYQS
VTGEKKEFEDNLLQEALRGKLQNKLFliVLDDVWSESYGDWEKLVGPfHAGTSGSRIIMTTRKEQLLK
QLGFSHQDPLRCIDSLQRLSQDDALSfAQHAFG?

SEQ ID NO: 14

RLGIE

LARLLYDEM QE KDH FELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKISKKRFLVLD
DVWSESYADWEILERPFLAGAAGSKIIMTTRKQSLTKLGYKOPYNLSVLSHDSALSFCQHALGEDNF
DSHPTLKPHGEGIVEKCA

SEQ ID NO: 15

RLGIF

FSA?NK?KQWLKSFF?HSRPVFFEK?ASEALKKIARFHRIDSELKKLKRSIJQIRSVLNDASEKEISDEA
VKEWLNGLQHLSYDIDDLLDDLATETMHRELTDDLEPPPACKKDNPTCCTDFSLSSKMRNKLNDNITIKL
QELVEEKDNLGLSVKGESPKHTNRRLQTSVLDASSIIGREGDKDALLHKLLEDEPSDRNFSIVPIVGMGG
VGKTTLARLLYDEMQEKFELKAWVCVSDEFDIFNISKVIFQSIGGG?QEFKDLNLLQVAVKEKISKKR
FL?VLDDVWSESYTEWEILARPFLAGAPGSKIIMTTRKLSLLTKLGYNQPYNLSVLSHDNALSLFCQHA
LGEDNFDSHPTLKP?GESIVEKCDGLPLALIALGRLL?TKTDEEEWKEVLNSEIWGSGKGDÈIVPALKLS
YNDLSASLKKLFAYCSLFPKDYVFDKEELJLLWMAEGFLHQSTTSKSMERLGHEGFDELLSRSFQHAPD
AKSMFVMHDLMDLATS VAGDFFSRMDIEMKKEFRKEAL?K?RHMS?VC?DYMV?KRF?P?TRS.

SEQ ID NO: 16

RLG1 G

VKDHFE LRA WCVSDEFN ILNISKVIYQSVTGEKKEFEDLNLLQEALKEKLWNQLFLIVLDDWSESYR
DWEKLVGPFFSGSPGSMIIMTTRKEQLPRKLGFPHQDPLQGLSHDDALSLFAQHAFGVP

SEQ ID NO: 17

RLG 1 H

LARLLYEEMQGKDHFEKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLQVALKEKISKKRFLLVLD
DWSESYTDWEILERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSLFCQHALGEDNFN
SHPTLKPHGEGIVEKCD

SEQ ID NO: 18

RLGI I

LARLVYDEMQEKDHFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKILKKRFLVLD
DVWSESYADWEI?ERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEGNF
DSHPTLKPHGEGIVEKCAGLPLALST

SEQ ID NO: 19

RLG 15

EFGVGKTTLARLLYEEMQGKDHFEKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLRVALKEKISK
KRFLVLDDVWSESYTDWEI?ERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSLFCQH
ALGEDNFNSHPTLKPHG?GIVEKCDGLPLALS

SEQ ID NO: 20

SEQ ID NO: 21
RLG 2A

```
1   TTNACACCAT  AAATTCCTNA  CCTGNNGGGA  CAAAAACCTA  AAAATGGTCC  ATAATGCNCA  AATCAGNAAG
71  GTTGANAAGAG  CTCTAAGTTT  TTNACCTCCA  NCTGATGCNC  NNTCCTCINTA  AAGTTCANAT  CCAAGCTTGC
141 CCTCCAACTC  TANCNCCTTC  AATGGCACCT  CCTCTCTTTC  AAAAGCACAC  AAGAACACTT  TCAAGCTCAA
211 CCACACTCAC  ACAAGCTCTA  GAACNAGGGT  TAGGGCACAT  TTAGGGTTTT  GCTCTCTGGA  AATGGTGTCT
281 AAAAGTGGAG  CCATATGTT  CCTATATATA  GGGCTCACTCC  CACAATTAGG  CTTTCAATCT  GAACGTANTA
351 CGCCCACTGT  ACACATATGG  ACGCCCAACG  TACTCGGTAG  TCTCCGCGTC  AANAATACAC  TCATGAGTAC
421 GCGCAACGTA  CTTTCCCTTA  CGCCCAAGCG  ACTCAAAAGC  CAAACATTCT  TTTCAAGGAC  TAATTTTGAC
491 AACTTGGAGG  AAGAAAAGGA  TCAAGANAT  ATACTTGAAT  TCCGGGATGT  TACAATGAAG  TTGANACCTT
561 GGCTAAAAAA  TTAATTTGGT  TGTGGAAGCC  GTTGGCTGAG  CAAGCAACAA  GGGTAAAAAT  CGTAATCTAC
631 AAATGGTGT  ATTTTCTATT  TCTTCTTATT  ATTTTACTTG  ATTTACGGGT  AGTTTTTTTT  TCTTACAAAA
701 AATATTAAAG  TTGATAAAGT  ATAGCCACTA  AAATTGACTT  TTTCCAAAC  ATAATGTCAA  ATGGTGCCTA
771 TATGTATCAT  GTTGTATTAN  ATAATGAATA  TGATGATNCT  GTTCTATTTA  ANCCGAAAAA  ATTATCTAAT
841 GATTTTATAT  TGGAAAACAA  AGTTGTGATT  TTTNGCATAA  TATAATCAA  TCCNCTTTTG  TMTGGGAGGT
911 GGATAAATGT  GGTAAATTTA  NAACAAGTGT  TTNACNMTG  AAGGGTNTGG  AAAGGTGAA  AAAAGTTAAA
981 ATGATAAAAT  GTTTACACAA  ATGTTGTATC  CGACTGAATA  TNAITGTTAA  GGATNATTGT  ATTAATTTGT
1051 TGATATATAG  TAAGCATAAA  TATTTAGAAT  TGTGACTTAA  ATTTATAAGT  TATNCNAACT  GGATTGAAAC
1121 ATTTTTCGATA  TANATTAGGA  ATGAAAATGA  GCAACCTTAA  CATACTTATC  TTTGGTAGTT  TGGTTATTAT
1191 ATTTTTCATTA  NAATATAGAA  NCATCCCTTT  ATTTTAAACC  CATATTGTGG  ACGGACTTGA  ATAAATGGGA
1261 AAAATGTACC  TTGCTATTTA  GCACAAAAAA  ATTATAAAAA  TGTACATTGC  TATTTAGCAC  AAACAAAAAA
1331 AAAAAACCTA  TCCTTTTTCG  ATTAGTCCAC  AAAGAAATAT  AAAATGGGAA  ATGTGTGTCT  ATTTAATGCA
1401 CTAAGAAAGTA  CTATTTTGCC  TTTATTAAAC  CGGGTAAACC  AATAGAAAAA  TGGAAGTACA  TTGTCATTTA
1471 GCATGAAAAA  AAATAACTTT  CCATTTTTTG  CATCCGGTCA  CAATAATAGA  AAAATGAAAG  TAGCTTCTTA
1541 TTTAGCGAAA  CTAACCTCCT  TTTTCTTTTT  TGGCATCGTA  TCATAAAAAA  TAGACTAAAA  TAGCTTAGTT
1611 TTACATTTTT  AATACATTGA  AATGTCTAAT  CCACATGTTA  TTTCTATAAA  AGGGAATGT  AATTTACTTA
1681 TTCTTTGATT  CTTTGGCTTC  TTTTGTAGTAC  CCAAAACATC  CCTCTATCCA  TCTATTCCAA  CTAAAAATAA
1751 GAAAACTATA  TTCTTCCAT  TGTAGGGATG  TTTATAAATT  TGTAAATGTT  TTTATGCAAA  AAAGTGTITT
1821 TTGTTAATA  GATTAAACGAG  ATTCATTTTT  CAGCATTTTA  GGAGAAGTTC  ATCCATCTTT  TGGATATGAA
1891 GTGCAAGCCA  AGTTCTTTAA  CATGGAATAT  GAGGTCCCTA  TATGCTCAAA  AAATAGCAAA  TGAGAAATTT
1961 TTTAAATGG  ATCCCATATA  AAGAAAATTT  GTTAAATGGT  GTTTTAAAT  TGGTCAATGT  GTCCACCGGA
2031 TGAGCAZAA  ACTAGTTTAT  AAGGGGTAAA  GTTGGGTTTG  GTGGGCCCAT  TTATCTTTAT  TATTTCTAAA
2101 AGTCAGATT  AAGTAAAAAA  AATTATAAGA  TAAATACCAT  AAGGATAAAA  AATCATTTTT  TTTGGACCAA
2171 AGACCAAGT  TGTTAAGGGG  CTGTTTGTGT  TTTTGTGAA  GAGCTGTGCA  ACCACTTTTG  TCTGCGCCGC
2241 ACAGACACG  TGCAGACATA  TGCCTTCGCA  GAGTGTGTGT  TTTTGAAG  TCGCAGACC  AAAAAACGT
2311 CTGCGCGAG  TCATCTGGC  GCATATATGT  TCTACTGTCT  TCAAGGTCT  TCAGACCTCA  TTTTAAACCA
2381 AAAAAAATA  GACCACCGGT  TTTTTTTTTT  TTTTNTTCT  TTCTCTGTA  GCTGAAATG  CATTTTAAAT
2451 CTTTATGACA  TGAATTTAAG  TTTGAAAAAT  TAATTTATTT  CAACAGCTGT  AGACGTAAAA  AACAAACAGT
2521 CTCTTTGTG  CAGACTGTGG  ACATTTGGTC  CACCTCTTCT  ACCGAGAGA  CTGTCAGATG  TGGTCCCGAG
2591 ACTGCAGACA  TTTTGGCTTC  AAATAAACAA  ACATCACCTA  ATTTGACTAC  ACCACACGGA  CCTCCAAATG
2661 AACAAAAAA  AGGTGAAAC  AAAGTTGCCCT  ATTTCTCCAT  ATCCAGGGGC  CATTTATGTA  AGAGTTATCT
2731 AAATTTTAGT  TCGGTAGATC  AGTTCTCACA  TTTTAAACGG  GTAAAGTGT  TGTGTGTACG  CGCGCACCTG
2801 AAAGGTTTGA  ANGTAACCTC  CAAACTGAAN  CAANAATCGA  TATGAAGTAT  CAAGTTAGAG  GTTCAATGG
2871 TGAAGGAATC  AGCTGGAGGT  TGGGGAATCG  AGCTTCCACT  ATTAAGGTAA  AATCCATAAC  CCTAAATGTT
2941 GGTACGCTCA  TATATCAAAT  TCGGTGTTTT  GTTGAATGAA  AAAAGCATGC  TCAAAAAACC  AGTGAAGGC
3011 ACGGTATATG  ACATATTTAT  AGTTACTGAT  AACAAATTAT  GATAATTTTG  GGTTTACGTA  AGTTAGGATT
3081 CGTACTTCAA  CCAAATGTAA  TAGTTTGTGT  GAGTCTATCT  ATGTATTTGG  GGAATCAGAT  TAGCAACGGG
3151 ATTTACTAG  TAATTCGAAA  AAGTCTTTTA  AATAAATTTT  CTGTTTATAA  TTTATGAATA  GTTTTAGCGA
3221 CATCTAATAT  TAAATAGAA  GTATCTGATA  TTGAATTAAT  GTCCCTTAATG  TGAACATAGA  CCTTTTCCAT
3291 TTAATAATGC  CTAATTATTA  GTTCTTAATC  AATAAATTTT  AATTTCGTGT  TTATGCTTCT  AAGACAATAA
3361 AAATCCATGA  TTTACCTTTA  AATATTAACA  AAAATGACCA  TAAATAAATA  AAAAATTAGG  ATACCAAAAC
3431 CCCCCCGCAT  GCGCAATGTC  TAAATATTCT  TGAATGCTTT  GCTTTTCCCT  CTTTTCCTTG  TTAGTCTATT
3501 ATTCTGGAGA  GTTTGAGAGA  GTTTCATACA  AGAAAAATTC  AAGAAGAAAG  CAAAGGTCCA  GGTATTCTCT
3571 TTTCTTAATT  ATGTATTAA  TTACAAGCAT  TTTTACACG  ATCCATGGTT  TTTTGTGTAT  GTTTTTCAAA
3641 TTGAAACTAG  ATTGGGACTT  TTGCCCTTGA  TGATTCATAA  GATATTGCAT  GGAGTTGAGA  TTGTGAAGA
3711 AAAGTGGTGA  ATAGAAAGAG  CAAGTGAATC  CAGATATAGT  ATTTGTAATA  TATGATGATG  AGATAGAGAT
3781 ATGTTAAAC  TGGCTAGAAA  ATTTGTTTAA  TTTGAAATTT  AGGTGTGTGA  ATTTGAAAGA  TACCAAGCTA
3851 ATAACTAATT  AGTTATGCTA  AATAGTTATA  AAGAACAACA  AACTCGTAGT  TTTTTCCTCA  TGATTTTCAA
3921 CCTCTTCGTA  CCAAACTAAA  TTATAACAAA  ATTGAATATC  ATTTCTGTCA  ATCAATTTTA  ACTTTTGTTA
3991 TTATCTCAT  GTCTAAATTT  GCCACAAGTT  TATTTTCATA  GTCATATTGG  ATTATGAAAG  GACTATTTTT
4061 ACCAATTACA  TCTTTACTTT  ATGGCCAAAG  CTAATACAAT  CCGACTAAAC  TAAAGGATTC  TAGGATGCAT
```


SEQ ID NO: 21
RLG 2A cont.

```
4131 ATAGTTTGGCT CCCCGATTAT AGATTTCAT CTAATTTGTC TATTGTACTA ATTTAGGTGC CACCACAAGT
4201 AAATTCCTGA AATGGATGTC GTTAATGCCA TTCTTAAACC AGTTGTCGAG ACTCTCATGG TACCCGTTAA
4271 GAAACACATA GGGTACCTCA TTTCCTGCAG GCAATATATG AGGGAATGG GTATCAAAAT GAGGGGATTG
4341 AATGCTACAA GACTTGGTGT CGAAGAGCAC GTGAACCGGA ACATAAGCAA CCAGCTTGAG GTTCCAGCCC
4411 AAGTCAGGGG TTGGTTTGAA GAAGTAGGAA AGATCAATGC AAAAGTGGAA AATTTCCCTA CGGATGTTGG
4481 CAGTTGTTTC AATCTTAAAG TTAGACACGG GGTCCGAAAG AGAGCCTCCA AGATAATTGA GGACATCGAC
4551 AGTGTCTATG GAGAACACTC TATCATCATT TGGAAATGATC ATTCCATTCCT TTTAGGAAGA ATTGATTTCA
4621 CGAAAGCATC CACCTCAATA CCATCAACCG ATCATCATGA TGAGTTCCAG TCAAGAGAGC AAACCTTCAC
4691 AGAAGCACTA AACGCACCTG ATCCTAACCA CAAATCCCAC ATGATAGCCT TATGGGGAAT GGGCGGAGTG
4761 GGAAGAGCGA CAATGATGCA TCGGCTCAAA AAGGTTGTGA AAGAAAAGAA AATGTTTAAT TTTATAATTG
4831 AGGCGGTTGT AGGGGAAAAA ACAGACCCCA TTGCTATTCA ATCAGCTGTA GCAGATTACC TAGGTATAGA
4901 GCTCAATGAA AAAACTAAAC CAGCAAGAAC TGAGAAGCTT CGGAAATGGT TTGTGGACAA TTCTGGTGGT
4971 AAGAAGATCC TAGTCATACT CGACGATGTA TGGCAGTTTG TGGATCTGAA TGATATTGGT TTAAGTCCCT
5041 TACCAATCA AGTGTGCGAC TTCAAGGTGT TGTTGACATC ACGAGACAAA GATGTTTGCA CTGAGATGGG
5111 AGCTGAAGTT AATTCACCTT TTAATGTGAA AATGTTAATA GAAACAGAA CACAAAGTTT ATTCCACCAA
5181 TTTATAGAAA TTTCCGATGA TGTGTATCCT GAGCTCCATA ATATAGGAGT GAATATTGTA AGGAAGTGTG
5251 GGGGTCTACC CATTGCCATA AAAACCATGG CGTGACTCT TAGAGGAAAA AGCAAGGATG CATGGAAGAA
5321 TGCACCTCTT CGTTTAGAGC ACTATGACAT TGAAAATATT GTTAATGGAG TTTTAAAAAT GAGTTACGAC
5391 AATCTCCAAG ATGAGGAGAC TAAATCCACC TTTTGTCTTT GTGGAATGTA TCCCGAARAC TTTGATATTC
5461 TTACCCGAGG GTTGGTGAGG TATGGATGGG GGTGAAATTT ATTTAAAAAA NIGTATACTA TAGGAGAAGC
5531 AAGAACCAGG CTCACACAT GCATTGAGCG GCTCATTCAT ACAATTTGT TGATGGAAGT TGATGATGTT
5601 AGAGTGATCA AGATGATGTA TCTTGTTCGT GCTTTTGTGT TGGATATGTA TTCTAAAGTC GAGCATGCTT
5671 CCATTGTCAA CCATAGTAAT ACACTAGAGT GGCATGCAGA TAATATGCAC GACTCTTGTA AAAGACTTTC
5741 ATTAACATGC AAGGGTATGT CTAAGTTTCC TACAGACCTG AAGTTTCCAA ACCTCTCCAT TTTGAACTT
5811 ATCCATGAAG ATATATCATT GAGGTTTCCC AAAAATTTT ATGAAGAAAT GGAGAGCTT GAGGTATAT
5881 CCTATGTAAA AATGAAATAT CCATTGCTTC CCTCATCACC TCAATGTTCG GTCAACCTTC GCGTGTTC
5951 TCTACATAAA TGCTCGTTAG TGATGTTTGA CTGCTCTGT ATTGGAATC TGTCGAATCT AGAAGTGCTT
6021 AGCTTTGCTG ATTCGCCAT TGACCGGTTG CCTTCCACAA TCGGAAAGTT GAAGAAGCTA AGGCTACTGG
6091 ATTTGTGCAA GTTGTATGGT GTTCGTATAG ATAATGGTGT CTTAAAAAA TTGGTCAAAC TGGAGGAGCT
6161 CTATATGACA GTGGTTGATC GAGGTGCAAA GCGGATTAGC CTCACAGATG ATAACGCAA GGAGATGCA
6231 GAGCGTTCAA AAGATATTTA TGCAATTAGAA CTGTAGTTCT TTGAAAACGA TGCTCAACCA AAGAATATGT
6301 CATTTGAGAA GCTACAACGA TTCCAGATCT CAGTGGGCG CTATTTATAT GGAGATTCCA TAAAGAGTAG
6371 GCATTTGAT CAATGACAT TGAAGTTGGT TCTTGAAGAA GGTGAATTAT TGGAGCTCG AATGAACGAG
6441 TTGTTTAAAG AAACAGAGGT GTTATGTTTA AGTGTGGGAG ATATGAATGA TCTTGAAGAT ATTGAGGTTA
6511 AGTCATCTTC ACACTTCTT CAATCTTCTT CGTTCACAA TTTAAGAGTC CTGTCTGTTT CAAAGTGTC
6581 AGAGTTGAAA CACTTCTTCA CACCTGCTGT TGCAAACACT TTAAAAAAGC TTGAGCATCT TGAAGTTTAC
6651 AAATGTGATA ATATGGAAGA ACTCATACGT AGCAGGGGTA GTGAAGAAGA GACGATTACA TTCCCAAGC
6721 TGAAGTTTAT ATCTTTGTGT GGGCTACCAA AGCTATCGGG TTTGTGCGAT AATGTCAAAA TAATTGAGCT
6791 ACCACAACCT ATGGAGTTGG AACTTGACGA CATTCAGGT TTCACAAGCA TATATCCCAT GAAAAAGTTT
6861 GAAACATTTA GTTTGTGAA GGAAGAGGTA AATATAAATT TTTAATGCTA ATACATTACA AAGGATCTTT
6931 TCAGTTAAAT CTTTCAAAAT ATATTGTAAT TTGATTGTAT GGGGTATTAT TGTGGATGG GACTATTAA
7001 AAATGATTAT CTGTCAGGTT CTGATTCTTA AGTTAGAGAA ACTGCATGTT AGTAGTATGT GGAATCTGAA
7071 GGAGATATGG CCTTGCGAAT TTAATATGAG TGAGGAAGTT AAGTTCAGAG AGATTAAAGT GAGTAAGTGT
7141 GATAAGCTTG TGAATTTGTT TCCGCACAAG CCCATATCTC TGCTGCATCA TCTTGAAGAG CTTAAAGTCA
7211 AGAATTGTTG TTCCATTGAA TCGTTATTCA ACATCCATTT GGATTTGTGT GGTGCAACTG GAGATGAATA
7281 CAACAACAGT GGTGTAAGAA TTATTAAAGT GATCAGTTGT GATAAGCTTG TGAATCTCTT TCCACACAAT
7351 CCCATGCTTA TACTGCATCA TCTTGAAGAG CTTTGAAGTC AGAATGTGG TTCCAATTGA TCGTTATTCA
7421 ACATTGACTT GGATTTGTCT GGTGCAATTG GCGAAGAAGA CAACAGCATC AGCTTAAGAA ACATCAAAGT
7491 GGAAGATTTA GGAAGCTTAA GANAGGTGT GAGGATAAAA GGTGGAGATA ACTCTCGTCC CTTGTCTCAT
7561 GGTCTTCAAT CTGTTGAAG CATAAGGTT ACNAAATGTN AGAAGTTTAG AAATGTATTC ACACCTACCA
7631 CCACAAAATT TAATCTGGGG GCACCTTTGG AGATTTCAAT AGATGACTGC GGAGAAAAACA GGGGAAATGA
7701 CGAATCGGAA GAGAGTAGCC ATGAGCAAGA GCAGGTAAGG ATTTCAATT CACTGTCTTA ATTAATGATT
7771 AAGCTCTGCG TTTTGAATA AAAAAGGAC AAACCATTTT ATGACTTAAT GTAGCAATAC AAGTCATGTA
7841 TAAGAGTGAC CAACTCTTTT TTATTATATA AATGACTACA AAATATTTT TTTCATTAGA GTCATGTAT
7911 AAATGTGACT AATTTTTCAT CACCTAATCT TAGTTGATAA ATCTTTATAA ATGTCACTAG TACTTTTCA
7981 GTAAATAAAC AAATTTAATA AATTATCAAC AAAAAGCATC AACTAAAAAA ATCCACAAC CCGTAATAAT
8051 TTAAATAAAA AGGATTTAAC ATCTAATACG AACAAATTTT TTTCTAAACA TGATTTGGAC CAAATATCAC
8121 CAGCAACTCA AGTTTGAAT CGATTACGCT TAAACTTGA CCAGCATAA TAGATAGATG AAGTTGAAG
8191 CTAAAGTGCC TATATAAGTT CGTTTCACT TTTTCTTGA TCTTGATAGC AAGTTGAATG ATTTCTTCT
```

RLGZA cont.

8261 TC AAAAATTGA TAAAAATCTA CATTATAAAG AGACTAGCTT GAAAAAAAAT GGTCTAGGTG GGTCTTGGGT
8331 TCTGGTAGAT GAAGATGGAA GGGGAGAGTA TGATTTCAAA GACACAACAC ATCCTTCATT TTATTTATTT
8401 ATTATTATTA TTATTTTTTG ATATCTTGCT CATATTIGTT ACAGATATGT GAGGTCTATT AATCTTTTTA
8471 AATATATATA AAAATAAATA ACATAAATGA GAAATTTAAA TAAAGAATAA ATTAATAAGG GCACAATAGT
8541 CTTTTTAGGT AAGACAAGGA CCAAAACACGC AACAAAAATA AACAGTAGGG ACCATCCGAT TTAACAAAAA
8611 TAATTAGGGA CCAAAAACAT AAATTCCTCC AAACCATAGG GACCATTCAT GTAATTTACT CTTACTTTTC
8681 GTTTTGTCA TATTTGGGTA ACTATTTTTT TTGTACACAT CTAGGTAACG AACTTGTGA AGTGTCCCA
8751 TTTAGGATGT GACCTACTAC AACCGATCAT AATAGTCATA TGTGAACACT TCCAACAAC TTAATTACTTA
8821 GGTGTGTACA AAAAAACAAT AGTTACCATG ATGTGAACAT ACTGAAAAAT TAATTACCTT AGCAAGTTAT
8891 TTTCCCATTT AGGTTGTATG GAAACAGTTC CGTGAGACCG TGACTTGGAT GGTAGATAAA TTTAGTAAAC
8961 TTAACCTTTC AATTAACCTA CCTTTTCTT ATTAACCTAA TTTCAACCTA AATTCCTGATT CTTGTTTGAA
9031 AGTAAGTTGC ATCTTTATTT TTGTATTATC TTGTTGCATA GGATCCTTAG CATCTTTTAA TAATTTATTT
9101 GAAGGTGAAA GATCCAACTA TTTTAAATCT GTTGGCATTT TCCATCATTT GCAACTGTTT CTTGAAAAAA
9171 AAATACCTAA AATCAAAATA ACCATTTTCA AATCCAAAT TATAAGAGAG AATTGTAAAT GGACATGGAA
9241 TCATAAATCA TTAACACAGT TCAGTAAACA AGTTGCTAAT TACATTTCTT GCTGTGCAGA TTGAAATTCT
9311 ATCAGAGAAA GAGACATTAC AAGAAGCCAC TGACAGTATT TCTAATGTTG TATTCCTATC CTGTCTCATG
9381 CACTCTTTTC ATAACCTCCA GAAACTTATA TTGAACAGAG TTAAAGGAGT GGAGGTGGTG TTTGAGATAG
9451 AGAGTGAGAG TCCAACAAGT AGAGAATTGG TAACAACCTA CCATAACCAA CAACAACCTA TTATACTTCC
9521 CAACCTCCAG GAATTGATTC TATGGAATAT GGACAACATG AGTCATGTGT GGAAGTGCAG CAACTGGAAT
9591 AAATCTTCA CTCTTCCAAA ACAACAATCA GAATCCCCAT TCCACAACCT CACAACCATA AAAATTATGT
9661 ATTGCAAAAG CATTAGTAC TTGTTTTGCG CTCATCATGGC AGAACTTCTT TCCAACCTAA AGCATATCAA
9731 GATAAGAGAG TGTGATGGTA TTGGAGAAGT TGTTTCAAAC AGAGATGATG AGGATGAAGA AATGACTACA
9801 TTTACATCTA CCCACACAAC CACCACCTTG TTCCCTAGTC TTGATTCTCT CACTCTAAGT TTCCCTGGAGA
9871 ATCTGAAGTG TATTGGTGGG GGTGGTGCCA AGGATGAAGG GAGCAATGAA ATATCTTTCA ATAATACCAC
9941 TGCAACTACT GCTGTCTTG ATCAATTGGA GGTATGCTTT GTACATATTC AATATTAT TTAATTTCT
10011 TTTTATTTTG CAATATTCTA TAAATAATAC ATTTTATACC CACTATACTA AGATAATAAT TACCTAGAGG
10081 GATGATGCT ATGACACAGC TGCTACACTT CAGAACTCT AGTAAGGGCA GTTATGGAAG TTCAATAAAA
10151 TGATAATGGC ATCTTTTGAT GGGTAATATA GGCAATTTAA GTTTTATTTT TGTAAAGCA GTATTAGCA
10221 AGTACTGGCC AGTAGGAGAG GAGAATATCA CCTTTTGTA AAATCTGGTC ATGTACCCA GAATTTAGTT
10291 AAATGTACA TTTTAGATAT CAGGGTTCAT CAGGTGACAG ATATTGTAGA ATAGAACAAT ATATAATATC
10361 ACCCAAACT ATTTTTTCTA AGGTATTCT GTTAAATATG TGCTTTCTTG TTTTCATNGA ATTTNGCATC
10431 GTATAATTTA GGTGTTAAAG TGATTTTNTC TTCAATAAAT CCGAAATTA ATTAACAAAA AAAAAACAAA
10501 AGTACATTTT TGATGTGGAG AGCACTGGTA TCACITAGTA TATAAAAAAG TTGATTTTGA ATTAACCTTC
10571 TTATACAAAA GTGTGTATA TAGTTTAATT AGTTTACAT CATTTTCCA TGTGGTGTG CAGTTGTCTG
10641 AAGCAGGTGG TGTTCCTGG AGCTTATGCC AATACGCTAG AGAGATGAGA ATAGAATTCT GCAATGCATT
10711 GTCAAGTGTA ATTCCATGTT ATGCAGCAGG ACAAATGCCA AAGCTGAAGG AGAGGACAGC GATTCTCGTA
10781 CGAACGGTTA CGATTGACT GGCCTCGTT TTACA

SEQ ID NO: 21

RLGA a.a.

MDVWNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVNRNISNQLEVPQV
RGWFEEVVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDIDSVMREHSIIWNDHSIPLGRIDSTK
ASTSIPSTDHDEFQSREQTFTALNALDPNHKSHMIALWGMGGVGKTTMMHRLKKVVKEKKMFNFII
EAVVGEKTDPIAQSAVADYLGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLS
PLPNQGVDFKVLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIGVNIVRK
CGGLPIAIKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNLQDEETKSTFLLCGMYPE?FD
ILTEELVRYGWGLKLFKK?YTIGEARTRLNTCIERLIHTNLLMEVDDVRCIKMHDLVRAFVLDMYSKVEH
ASIVNHSNTLEWHADNMHDSCKRSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFKPNFYEEEMKLE
VISYDKMKYPLLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGLKKLR
LLDLTNCYGVRIDNGVLKLVKLEELYMTVVDGRGRKAISLTDDNCKEMAERSKDIYALEFFENDAQPK
NMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVEKGELLEARMNELFKTEVLCLSVGDMNDLEDIE
VKSSSQLLQSSSFNNLRVLVSKCAELKHFFTPGVANTLKKLEHLEVYKCDNMEELJRSRGSEETITTFP
KLKFLSLCGLPKLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLLKEEVLPKLEKLHVSSM
WNLKEIWPCEFNMSSEEVKFREIKVSNCDKLVNLFPHKPISLLHLEELKVKNCGSIESLFNIHLDCVGAT
GDEYNNSGVRIIKVISCDKLVNLFPHNPMSILHLEEELEVENCGSIESLFNIDLDCAGAIGQEDNSISLRNI
KVENLGKLR?VWRIKGGDNSRPLVHGFQSVESIRVTKC?KFRNVFTPTTTNFNLGALLEISIDDCGENR
GNDESEESSHEQEIEILSEKETLQEATDSISNVVFPSCLMHSFHNLOKLILNRVKGVEVFEIESESPTS
RELVTTHHNQQQPILPNLQELILWNMDNMSSHVKCSNWNKFFTLPKQQSES PFHNLTTIKIMYCKSIKY
LFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTFTSTHTTTTLFPSLDSLTSFLENLKCIGGG
GAKDEGSNEISFNNTTATTAVLDQFEVCFVHIQLFI.

SEQ ID NO:22

RLG 2B

SEQ ID NO: 23

1 AGTTTTTTTTT TTCCCAATA TCCATTTATA TGCGATTTAT TTCTGAAATA ATTTTATCAA AACGCAGGAA
71 ACAATGTAGA ATAATACTGG TATAATTAAAT TATATAAAGT TATTAGGCTG AAATCTTGAG GCTACTATAA
141 TTTAATTATC ATAATTGAA AATCATCAA TTGTATTTCCA TGTATATTTA TGTATCAGA TAATTAAATA
211 TATGTGAGCC ACACAAATCC ACATCATCAG ACACCCACC TTATTGTCCG CTACCTCACC ACTTGCATGA
281 TCCCGACATC TTCCCAACCC CACCGACGAC TTGGGGTCTC CTTAATATAT CAATTATTTT CTGTAAGTAT
351 TTATTGTGT AAATGTGTAA TGTCATTTTA CCTTTTTTCT AATATATACA GAAACATAAA TTTTAAATGA
421 AATTCAACTG CGTTTCATTC TTGCATTA AA AAAAAGACT GTACTGTGT CAATATTTTA CTTATAACCT
491 GATTAATTAA TTAAAGCGTA ATTGCATAAT TTGCATTAGG TTGTAATTTT GTGTTTATA GGGAGGGTGA
561 GGGTCACCGG GAATCAAAGC ACTTATGTAA AAGCAGGGGA AATACAAAA ATTTACTCGA AACAAATTTT
631 ATTCATTTTA AGTGAGATAA TAAATGTTCTG ATTAGATTAT GAGAACTAGG AGATTAAAGT GATATATCCC
701 APTTAAAGA AATTGCATTA TTAATTTTGG ATCTCTTGAT GATGACAAAA TTAACCTCGT ACAGGTTATA
771 TATCATATAC AAAATGAGTG GCTATGCTTT CGCTTTCCAA AAAGCAATTA TAGTTATACT ACACCTACAA
841 ATTTTAAAG GGGTTAAACA TATCAAAATA CTGTATAAGT AATTATATA ATATGCATTT AACCTCTAA
911 AGAAAAAGCT ACTAAGCTTG GACCATCTCA GAATTACAAT CATACCCCTC CCCTCAAAAA AGATTCTGAT
981 ATATCATGTC ATTTGGCATT CATTTCTTTT TCACAAATTC TAGTTCTATT CTCAAAAAAT TCGAGTTCTC
1051 GTATTTGTAA GGAAGATCAG AAGAGACIGT TCACACAGGT ACCTCTTTT ATTTATTGAT TCACATTCAT
1121 ATATGTTTAT GTTTTCTTGC TTAATGGTIT CGTCAGTCTA ACTGCGCTTG CTGATTTAAA TTTCTTCACT
1191 TTCTTCCACG GATTTTTTAA ATATTAGTIT TGTGAATGAA CAATTGGTGA AGGAAAGAAA CATGGGAGTC
1261 TTTTCTAAG TAAACCTAGA TACTAGGTT ATAAGGGTAT ATGCTAAAAT GAACATATGCC CATTCACCTT
1331 TGCCCTTTCT TTTACTTTTT AGTTTTTAGA ATCCAAGTTT TCATATGTAT CTCGATGTGT GAGAAGAATA
1401 GGCATTAAGAA AGGTAAAGCA CGTACATAAA ATTGATTAAT TAGTGAATGT TCTTTGATAT CTTATTTTTT
1471 ACTCTCTATA AAAGCATATA GATCAAACAC AAATTGCTAC TTGTTAGTGT AACAACCTCG ACTTAATAAT
1541 GTTAATTAAT AAGATTCTCT TGATTTCAAC TATTTTCTAA CCGAACAAGC TCACTAAAAA CTCATATTGC
1611 TTTGAGTCTG AGTGGTTTAT ATTTGGGGTT TTACATTTAA TTTTGTGTC ATGAATGTGA AAATAGACTG
1681 CTTATTGATT CTTTGTGTTT CATTGAGTTG ATTTTCATTA TTACTACCTT ACAAATGTCT CAGTGATAGA
1751 TTCCAATTAA TTGTCTAATT CGGTGTCTTC TAAATATGTA GGAGCTACTA AAAGCAAAAA TATCGAGCAA
1821 TGTGGGACCC AACGGGGATT GCTGGTGCCA TTATTAACCC AATTGCTCAG ACGGCTTGG TTCCCGTTAC
1891 GGACCATGTA GGCTACATGA TTTCTGCGAG AAAATATGTG AGGGTCAATG AGATGAAAAAT GACAGAGTTG
1961 AATACCTCAA GAATCAGTGT AGAGGAACAC ATTAGCCGGA ACACAAGAAA TCATCTTCAG TTCCATCTCA
2031 AACTAAAGAA TGGTTGGACC AAGTAGAAGG GATCAGAGCA AATGTGGAAA ACTTTCCGAT TGATGTCATC
2101 ACTTGTGTA GTCTCAGGAT CAGGCACAAG CTGTGGACAGA AAGCMTTCAA GATAACTGAG CAGATTGAAA
2171 GTCTAACAGG ACAACTCTCC CTGATCAGTT GGACTGATGA TCCAGTTCTY CTAGGAAGAG TTGGTTCCAT
2241 GAATGCAATCC ACCCTGCAAT CATTAAAGTA TGATTTCCCA TCAAGAGAGA AAACCTTTTAC ACAAGCACTA
2311 ATAGCACTCG AACCCAACCA AAAATTCCAC ATGGTAGCCT TGTGTGGGAT GGGTGGAGTG GGGAGAGCTA
2381 GAATGATGCA AAGGCTGAAG AAGGCTGTG AAGAAAAGAA ATTTGTTAAT TATATTGTTG GGGCAGTTAT
2451 AKGGGAAGAG ACGGACCCCT TTGCCATTCA AGAAGCTATA GCAGATTACC TCGGTATACA ACTCAATGAA
2521 AAAACTAAGC CAGCAAGAGC TGATAAGCTT CGTGAATGGT TCAAAAAGAA TTCAGATGGA GGTAAAGACTA
2591 AGTTCTCTCAT AGTACTTGAC GATGTTTGGC AATTAGTTGA TCTTGAAGAT ATTTGGGTTAA GTCCTTTTCC
2661 AAATCAAGGT GTCGACTTCA AGGTCTTGTG GACATCACGA GACTCACAG TTGTCACTAT GATGGGGGTT
2731 GAAGCTAATT CAATTATTAA CGTGGGCCCT CTAACCTGAAG CAGAAGCTCA AAGTCTGTTT CAACAATTTG
2801 TAGAACTTTC TGAGCCCGAG CTCCAGAAGA TAGGAGAGGA TATCGTAAGG AAGTGTGCG GTCTACCTAT
2871 TGCCATAAAA ACCATGGCAT GTWCTCTTAG AAATAAAGAA AAGGATGCAT GGAAGGATGC ACTTTCCGCG
2941 ATAGAGCACT ATGACATTCA CAATGTTGCG CCCAAAGTCT TTGAAAACGAG CTACCACAAT CTCCAAGAAG
3011 AGGAGACTAA ATCCACTTTT TTAATGTGTG GTTTGTTTCC CGAAGACTTC GATATTCTTA CTGAGGAGTT
3081 GATGAGGTAT GGATGGGGCT TGAAGCTATT TGATAGAGTT TATACGATTA GAGAAGCAAG AACCCAGGCTC
3151 AACACCTGCA TTGAGCGACT GGTGCAGACA AATTGTGTTA TTGAAAGTCA TGATGTTGGG TGTGCAAGA
3221 TGCAATGATCT GGTCCGTGCT TTTGTTTTGG GTATGTTTTT TGAAAGTCAG CATGCTTCTA TTGTCACCCA
3291 TGGTAATATG CCTGGGTGGC CTGATGAAAA TGATATGATC GTGCACTCTT GCAAAAAGAA TTCAATTAACA
3361 TGCAAGGGTA TGATGAGAT TCCAGTAGAC CTCAAGTTTC CTAAACTAAC GATTTTGAAG CTTATGCAATG
3431 GAGATAAGTC GCTAAGGTTT CCTCAAGACT TTTATGAAGG AATGGAAGAG CTCCATGTTA TATCATACGA
3501 TAAAGTGAAG TACCCATTGC TTCTTTTGGC ACCTCGATGC TCCACCAACA TTCCGGTGCT TCATCTCACT
3571 GAATGTTTAT TAAAGATGTT TGATGCTCT TCTATCGGAA ATCTATCGAA TCTGGAAGTG CTGAGCTTTG
3641 CAAATTTTCA CATTGAATGG TTACCTTCCA CAGTCAGAAA TTTAAAGAAG CTAAGGTTAC TTGATCTGAG
3711 ATTTTGTGAT GGTCTCCGTA TAGAACAGGG TGCTTGAAA AGTTTTGTCA AACTTGAAGA ATTTTATATT
3781 GGAGATGATC CTGGGTTTAT AGATGATAAC TGCAATGAGA TGGCAGAGCG TTCTTACAAC CTTTCTGCAAT
3851 TAGAATTCGC GTTCTTTAAT AACAGGCTG AAGTGAAAAA TATGTCATTT GAGAATCTTG AACGATTCAA
3921 GATCTCAATG GATGCTCTT TTGATGAAAA TATCAATATG AGTAGCCACT CATACGAAAA CATGTTGCAA
3991 TTGGTGACCA ACAAAGGTGA TGTATTAGAC TCTAAACTTA ATGGGTTATT TTTGAAAAA GAGGTGCTTT
4061 TTTTAAAGT GCATGGCATG AATGATCTTG AAGATGTTGA GGTGAAGTGC ACACATCTTA CTCAGTCTCT

RLG 2B cont.

SEQ ID NO: 23

4131 TTCAATCTGC AATTTAAAG TTCTTATTAT TTCAAAGTGT GTAGAGTTGA GATACCTTTT CAAACTCAAT
4201 CTTGCAAAACA CTTTGTCAG ACTTGAGCAT CTAGAAGTTT GTGAATGTGA GAATATGGAA GAACTCATAC
4271 ATACTGGAAT TGGGGGTTGT GGAGAAGAGA CAATTAAGCTT CCCTAAGCTG AAGTTTTTAT CTTTGAGTCA
4341 ACTACCGAAG TTATCAAGTT TGTGCCATAA TGTCAACATA ATTGGGCTAC CACATCTCGT AGACTTGATA
4411 CTTAAGGGCA TTCCAGGTTT CACAGTCATT TATCCGCAGA ACAAGTTGCG AACATCTAGT TTGTTGAAGG
4481 AAGGGGTAGA TATATGTTCT TTAATGTTAAT ACAATTTAAA TAATATTTTC AACCAAATTT TCATAATATA
4551 TCTGTAATTT GATTGTATGA TGTGTTATGT TTTATATGTG GCTATTAAGG GATGATTATT TTGTCAGGTTG
4621 TGATTCTTAA GTTGGAGACA CTTCAAATTG ATGACATGGA GAACCTTAGAA GAAATATGGC CTTGTGAAC
4691 TAGTGGAGGT GAGAAAGTTA AGTTGAGAGC GATTAAAGTG AGTAGCTGTG ATAAGCTTGT GAATCTATTT
4761 CCGCGCAATC CCATGTCCTT GTTGCAATCAT CTTGAAGAGC TTACAGTCTG GAAATGCGGT TCCATGAGT
4831 CGTTATTCAA CATTGACTTG GATTGTGTCT GTGCAATTTG AGAAGAAGAC AACCAAGAGCC TCTTAAGAAG
4901 CATCAACGAG GAGAAATTTAG GGAAGCTAAG AGAGGTGTGG AGGATAAAAG GTGCAGATAA CTCTGATCTC
4971 ATCAACGGTT TTCAAGCTGT TGAAAGCATA AAGATTGAAA AATGTAAGAG GTTTAGAAAT ATATTACAC
5041 CTATCACCGC CAATTTTTAT CTGGAGGCAC TTTTGGAGAT TCAGATAGAA GGTGCGGAG GAAATCAGCA
5111 ATCAGAAGAG CAGGTAACGC TTTCAAATTC ACTTCTTAA TTAATTAAGG ACTAAGCTCC TGTTTTGTGA
5181 ATAAATAAGA GGTGGGATGA CTAAACTTGG GCATCACAAT TGCAACAAAA TGTTACAAAC CATGAAACGT
5251 TCAAACCAAT TCTTGAATTA AGGTTTCAAT ACAAGTCATT TAAAAATATG GCTTAAATTT TTTTATATT
5321 TATGTATCAA CATGATTTTT CATTAGAGAT CATTATTATA ATAGTAAGTT TAAAGCAATT TAAATCAGAA
5391 CTAATCTTAA CTTTAGCTAA TAAATCGTTA TAAATGTAAT TAATTACTTT TTAGTGAAAT AAGCAACGGA
5461 TTTAATAAGT TAACAACCTA AATGTCTATT CCTAACAAA AAAACTTTGG TTCAGAAAAA CCGCAATTC
5531 AGATAACTAA AATAAAAAATA TTTGACATTC ACTAAGAGCA TTTTCTTTTC TAAATATGAT TCCAAATGAA
5601 TAAACCTTAA ATTTATACAG AAAATTCCTT TATATATGTT ATACAAAATT TACAAATGTA AATTGGATAT
5671 GTTAATTAA CTTTTATAAT TCTGGTATCA CAAAGGGATA TATAATAAAA TATTATTTTC TGTAGTCATT
5741 TGTAAATGTA CTAGTTTATA ACCCGTGGGA ACCATGAGTT CTAAAAATAG TTAACCTTTC ATAATAAAA
5811 TTTATAATTA TTATTTATTT TAAATAAATT ATTAATTAAG AGATATATCA AAAATTTTAA GTTATTATAA
5881 CTTCAAATTT AACATATAAT TAGAAAAAT ATGATCATAA CTCTGCACT CTCTTTGTAT AAATGCAGAG
5951 AAGCTATTAG TATATTCTA ATCAAGTCCA AACCTAATGA AGCCTATATA ATTTTGTGAA AACTCAATTA
6021 GCATTAGGTT TTAAGAGTCA CCAAAATTCAG AGAATAATCC AATGCTTTCA TTACCCTAT TACGAAAAATA
6091 GTTCTTATAG TTAATAGAAA TGAAACAAA CATTCAAACT AATGTTGCT TATTAAACCA AAGACCCATT
6161 ACTTAGCCAA GAGTTTAAAC AAAAAAAT ACATTTCATGT ATCATTATTC ATGACTAGAT ATATATGAAC
6231 ATGAAGGGAG TTTTATAGA AAATATAATC ATGATATTC AACATAACTT CAGGGAATTC CCAAAATTA
6301 CCAAGTTATT CAAGAAATTA CATCCAAGTC AACCAAGAG AAGTTTAGCC TAGCATGGCT AAACCTAAGA
6371 AACTAAATA AGGATTAGAA GTACCAACA TGTAGTAAGA ATCACAGTAA AAGATGATGT TGTCTGTAT
6441 GTTCTTCTAA GTTCTTCAAG TCTCCAGTTG CTCCTAATAA TGCAAAAGGAG AGCCATTAAA TCTGTATGTA
6511 TTGATCCCTT CAAAAGCTGC ACCAACCTCC CTAAATAAC ACTCAAAGCA AAAATGACAA AATGCCCTGA
6581 AGGACCCCTT GTGGGTGCTT TGCGGGGGTG GAGCTGCATA CGAAAGGTCT TTGGTCTTTG TGAGGGTGAT
6651 GTTGTGCGGG ATAGCTTGTG CATGCTTCC CGCGGGTTCA CGCACATGTG CACAGGTGAT GCATGTGTG
6721 TCGTCTCTTG AGTTTGTAGC CTCCGATGCT TAGTCCACTT GGCCCAATTC GAGTCCAATC AGCTTATAAC
6791 CCATTTTTCT TCAAGTTATC TTCAAGTTAA GCCCAATTTG GCTTCTCCAA ATCATCCATA ACTTCACAGA
6861 ATCGCCCGTT CATCTTAATC CCGGATGCAC AATTATCTC CGTCTTCAT TTTAAGCAAG ATACCACCTT
6931 CTTCTAGCTT CATCCATCAA TAGTACACTT CATGTATCAT CTCTACTAGT TATTAGTCC ACAAATCCTT
7001 GTTGTCTTCC AAATTTAATT ATCTCATTTA GTTCCCGGTT CCGCTACTTT CCTTAAAAAT TGAATTAAG
7071 CTCAGAGAAA TATTAAGTAC CCGAAATGGT CATAAAATTA AAAAAAGGA AAATGCATGA AGATTAACTA
7141 AATGATGAAC GAAATATGCT AAAATAGACT ATAAAATGAA GTAAAATAAA TGAATTTATC GCACCTCGAC
7211 CACCTTATG GCTTGTAGTC CACCCACCTT TCATTCTTGT TACCAATATG GGTAGGAAAC ATCATTAATT
7281 AAGCCAAAAA GCTAACATAT AAGGTTTAG TGACAAAGGT AAGTACTAAA GATGAAAAATA ATCCATTTTT
7351 CTTGTTTTTA CACAACACAC ACATAGGGGC AGACGTAGGA TTTCAAAGTA CAGATTGTTG TTGGCACATA
7421 AGTGTGCTG GTGACATTTT TTTTCTCTTT TTACGTGGTG GCACAACAGT AGGAAAAACG AAAAATTCGA
7491 AATTTTTTAC AATTTGTCTT AAAAAAACA GGGGTTGTTG GTGCCACTAT GGACAACAAA GTTGAAGTGC
7561 CCTACGCGCG CACACACACA CACACACATA GAGAGAGAGA GAGAGAGAGA CAGAGAGAGA AAGAAAAGAA
7631 GAGAGAGAGA GTTTGGGATG TGATACTTCT TTTAGGAAAA TGGAGTTATA TCTTTGATAT TGTATTTTTT
7701 TAATGTAATT TATNTATTTA ATCAATTTAG TTTATAAGTT NTATTTATIN GGNATGAAA AAAAAAGTCT
7771 TTTATACATT GGATTTAACA TAAAAATCCA ACAAATTTAA TCAAAAAGAC CAAACATGTG GCAATTTATG
7841 TATATAATTA ATTCACAATA GTCTTTAGGA ATAGTATTAT ATATATAATT AATTCCTAAT GGTCTTAGGA
7911 ATAGTAAGTT CTTATATTTT AAACTTTTGC CACAATTTCT TGCTTACTTT GACACTTTTC CTCTCTAAT
7981 TTACATATAT ATATATATTA AAGCGCAAAG CACTAGGAA TATAATATTT TCTATATTT TCTGTTTTC
8051 CACAAAGTT TGAACTTTT GCCACTTTTT GTCCCTCTCT AACCTTTTCA ATGTTTTGCG ACAAAGTTTC
8121 CAAAACCTTG CCACTTTGAT CATTCCTCAA CTTTTCACCG CATTAGTTTG TGGAGTTGGC AGTTTTGGTC
8191 CCTCTAACCT CGATATCTC TACTGCTAGC CAAAAGGGT TCCAGAGTTT CACACTTTTG GTCCCTGACA

RLG 23 cont.

8261 GTAACCAAAAT GTGAGATGTC AAAATTTTTC CACATTAGTT TGTGGAGTTG TCCCTTTTGG TCCCCCACA
8331 TTCGATATTC TACTATACGA TCTTATTTT CTCAAATAAC AACACGTATA TTTTCATC: CT AATTGGAAAA
8401 AGAGTTTAA AA: AAAATAAC GACTAGG::: G: GC: GAGTT TTTTTC: ACA AGTTTGTATC AAATCATATC
8471 AAAATTTAAG GTGGAAACGGT GACCACATTA ACCAGAAATG TAATTTATTC TTTGATTTTG ATAATTTTAA
8541 ATATTTTGT GTGATCTATG TATTTAAAAG TAAACAACAA AGAACATAAT CCAAACCCCT AAATTCGAAG
8611 TCTCGCCCAA TTTCTCTATC ACTAGTCCTC ACTTACGATG GCGTTACGTC GCTCTCTCAC TGCTTACAAC
8681 CCTTTGTTGC TACTCATTAC AATAACGAAA AGTTGAATAT CCATATATTT ATTTGGATGT GGAATTGAAC
8751 GAATCTCGTC AAAATTTTGA TTTTGTGAT GGATTTGAGT AGAAGTTTGG GCAGAACGGG AATGATGGTC
8821 TGCAAGTGGT TATAAACITG ATTCTGAGTT ATTACTATAT ATGTAGCCTC TTTACAACGA CCAAGGTTTC
8891 TTCCAGGTAC CATTGTGATCT TTTTAGAACT TAGTTTCTG AAACCCCTG ATTTGGATCA AATATCACC
8961 ACAACTCTTA AAAACTTGAT TAATCAATG TTTCTTCAT CTGATAACA AGTGAATGA TTTTCTACTT
9031 AGATTAACCT GAAAAAAG GTCCATGTGC GTCTGGTGA TCTGGTAAAT GAAGATGGAA GGGAGAGCTG
9101 ACTTTAAAGA CACAAACAGC TCACCATATC TCTTATTTTA TTTTAAATTT GCTTTTGGTG TATTTTCTTT
9171 TTTCCCTATT CTTCTTTCT TGAATCCAG ATGGTATGTG GTGGGATAA TTTACACCTA GAGATTGGGA
9241 ACGATGGGAA GGGGTCTGTG ATTTATGGCT GGCCGAGTTT TACTTATTA CTCAATTTCA ACCTAAATTC
9311 TGATCTTGT TTGAAAAATA GTTGCACTCT TATTTTGTG TATCTTGTG GCATAGGATC CTTAGCATCT
9381 TTTAATAATT TATTTGAAGG TGAAAGATCC AACTATTTTT TAGCTGTGG CATTTTCCAT CATTGCAAC
9451 TGTTCCTTGA AAAAAAATA CCTAAATAA AAATAACCAT TTTCAATCC AAAATTATAA GAGAGAATTG
9521 TAAATGGACA TGAATCATA AATCATTAAC ACAGTTCACT AAACAAGTTG CTAATTACAT TTCTTGCTGT
9591 CGAGATTGAA ATTCTATCAG AGAAAGAGAC ATTACAAGAA GCCACTGGCA GTATTTCAA TCTTGTATTC
9661 CCATCTCTG TCATGCACTC TTTTCATAAC CTCCTGTGTC TTACATTGGA TAATTATGAA GGAGTGGAGG
9731 TGGTATTTGA GATAGAGAGT GAGAGTCCAA CATGTAGAGA ATTGGTAACA ACTCGCAATA ACCAACAACA
9801 GCCTATTATA CTTCCCTACC TCCAGGATTT GTATCTAAGG AATATGGACA ACACGAGTCA TGTGTGGAAG
9871 TGCAGCAACT GGAATAAATT CTTCACTCTT CCAAAACAAC AATCAGAATC CCCATTCCAC AACCTCACAA
9941 CCATAAATAT TCTTAAATGC AAAAGCATT AGTACTTGT TTCGCTCTC ATGGCAGAAC TTCTTTCCAA
10011 CCTAAAGGAT ATCCGGATAA GTGAGTGTGA TGGTATTAAA GAAGTTGTTT CAAACAGAGA TGATGAGGAT
10081 GAAGAAATGA CTACATTAC ATCTACCCAC ACAACCCCA CTTTGTTCCT TAGTCTTGAT TCTCTCACTC
10151 TAAGTTTCTT GGAGAACTG AAGTGTATTG GTGGAAGTGG TGCCAAGGAT GAGGGGAGCA ATGAAATATC
10221 TTTCAATAAT ACCACTGCAA CTACTGCTGT TCTTGATCAA TTTGAAGTAT GCTTTGTACA TATTCATTA
10291 TTTATTTAAT TTCTTTTAT ATTGCAATA TTCTATAAAT AATACATTTT ATACCCACTA TACTAAGATA
10361 ATAATTACCT AGAGGGATGG ATGCTATGAC ACAGCTGCTA CACTTCAGAA ACTCTARTAA GGGCAGTTAT
10431 GGAAGTTCAA TAAATGATA ATGGCATCTT TTGATGGGTA ATATAGGCAA TTTAAGTTT ATTCTGTTA
10501 AAGCAGTATT TAGCAAGTAC TGGCCAGTAG GAGAGGAGAA TATCACCTTT TGTGAAATC TGGTCAATTG
10571 ACCCAGATT TAGTTAAATG TAACATTTTA GATATTAGGG GTTATCAGGT GACAGATATT GTAGAATAGA
10641 ACAATAATGA ATATTACCA AACTATTTT TTCTAAGGTT GCTCTGTAA ATATGTGCTT TCTTGATTTT
10711 ATGAAATTG CATTCCTATA TTTTAGGTGG TAAAGTGATT GTCTCTTCAA TAAATCCCGA AATTTTAA
10781 TTAATAAAAA AAAAAACAAA AGTAAATTTT TGATATGGAG AGCACTGGTA TCATTTAGTA TATAAAAAAC
10851 AGATTTTGA TTAAGTTTCT TATATAAAG CTGTGTATAT AGTTTAAATTA GTTTTACATC ATTTTCCAT
10921 GTGGTGTGC AGTGTCTGA AGCAGGTGGT GTTCTTGGG GCTTATGCCA ATACGCTAGA GAGATAAAAA
10991 TAGGCAACTG CCAATGCATG TCAAGTGTGA TTCCATGTTA TGCAGCAGTA CAAATGCAGA AAGCTT

SEQ ID NO: 23

RLG2B a.u.

MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEEHISRNTRNHLQIP
SQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITEQIESLTRQLSLISWTDOPV?LGRVG
SMNASTSASLSDDFPSREKTFTQALIALEPNQKFHMVALCGMGGVGKTRMMQRLKKA?EEKKLFNYIV
GAVI?EKTDPFAIQEAIADYLG IQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGL
SPFPNQGVDKVLTSRDSQVCTMMGVEANSIINVGLL TEAEQSLFQQFVETSEPELQKIGEDIVRKC
CGLPIAKTMAC?LRNKRKDAWKDALSRIEHYDIHNVPKVFETSYHNLQEEETKSTFLMCGLFPEDFDI
PTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQTNLLIESDDVGCVKMHDLVRAFVLGMFSEVEH
ASIVNHGNMPGWPDENMIVHSCKRISLTCKGMIEIPVDLKF PKLTILKLMHGDKSLRFPQDFYEGMEKL
HVISYDKMKYPLLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVL SFANSHIEWLPSTVRNLKKL
RLDLRFCDGLRIEQGV LKSFVKLEEFYIGDASGFDDNCNEMAERSYNLSALEFAFFNKA EVKNMSFE
NLERFKISVGCSDENINMSSH SYENMLQLVTNKG DVLD SKLNGLF LKTEVLF LSVHGMNDLEDVEVKS
THPTQSSSFCNLKVLIISKVELRYLFKLN LANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLKF
LSLSQLPKLSSLCHNVNIIIGLPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEGVVIPKLETLOIDDMENLEE
IWPCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNIDLDCVGAIGEDN
KSLRSINVENLGKLREVWRIKGADNSDLINGFOAVESIKIEKCKRFRNIFTPTANFYLEALLEIQIEGCG
GNHESEEEQVTL SISLS


































SEQ ID NO: 24

RLG2A
RLG2B
RLG2C
RLG2D
RLG2E
RLG2F
RLG2G
RLG2H
RLG2I
RLG2J
RLG2K
RLG2L
RLG2M

[illegible]

[illegible]

[illegible]

TTCTCGAGAGCTTTGATATCTCTACTGAGAGGTTGATGAGTATCGATATCGATGGGGCTTGAAATTTATTTGATAGAGTTTATTACTATTATGAGAGCGAAGAACAG
 ATCCGAGAGACTTTGATATTTCTACCGAGAGCTTGCTGAGTATGCGATGCGGGGTTCGAAATTTTAAAGAAAGTGATCTATATGAGAGCGAAGAACAG 780
 TTCCGAGAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATATGATGCGGGCTTTAGAGCTTTATTCATAGAGTTTATACGATTATGAGAGCGAAGAACAG 770
 TTCCGAGAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATATGATGCGGGCTTTAGAGCTTTATTCATAGAGTTTATACGATTATGAGAGCGAAGAACAG 770
 TTCCGAGAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATATGATGCGGGCTTTAGAGCTTTATTCATAGAGTTTATACGATTATGAGAGCGAAGAACAG 768
 TTCTCTGAAGAGCTTGATATTTCCGATTCGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 773
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 778
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 778
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 788
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 766
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 780
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 784
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 764
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 777
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 723
 TTCTCTGAAGAGCTTGATATTTCTTACTGAGAGGTTGATGAGGTATGCGATGCGGGCTTTAGAGTATTTAGTATAGAGTTTATTACTATTATGAGAGCGAAGAACAG 752

RLG2A
RLG2B
RLG2C
RLG2D
RLG2E
RLG2F
RLG2G
RLG2H
RLG2I
RLG2J
RLG2K
RLG2L
RLG2M

RLG2A
RLG2B
RLG2C
RLG2D
RLG2E
RLG2F
RLG2G
RLG2H
RLG2I
RLG2J
RLG2K
RLG2L
RLG2M

[illegible]

RLG2A	1210	1220	1230	1240	1250	1260	1270	1280	1290	1300
RLG2B	1310	1320	1330	1340	1350	1360	1370	1380	1390	1400
RLG2C	1410	1420	1430	1440	1450	1460	1470	1480	1490	1500
RLG2D	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600
RLG2E	1610	1620	1630	1640	1650	1660	1670	1680	1690	1700
RLG2F	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800
RLG2G	1810	1820	1830	1840	1850	1860	1870	1880	1890	1900
RLG2H	1910	1920	1930	1940	1950	1960	1970	1980	1990	2000
RLG2I	2010	2020	2030	2040	2050	2060	2070	2080	2090	2100
RLG2J	2110	2120	2130	2140	2150	2160	2170	2180	2190	2200
RLG2K	2210	2220	2230	2240	2250	2260	2270	2280	2290	2300
RLG2L	2310	2320	2330	2340	2350	2360	2370	2380	2390	2400
RLG2M	2410	2420	2430	2440	2450	2460	2470	2480	2490	2500
RLG2N	2510	2520	2530	2540	2550	2560	2570	2580	2590	2600
RLG2O	2610	2620	2630	2640	2650	2660	2670	2680	2690	2700
RLG2P	2710	2720	2730	2740	2750	2760	2770	2780	2790	2800
RLG2Q	2810	2820	2830	2840	2850	2860	2870	2880	2890	2900
RLG2R	2910	2920	2930	2940	2950	2960	2970	2980	2990	3000
RLG2S	3010	3020	3030	3040	3050	3060	3070	3080	3090	3100
RLG2T	3110	3120	3130	3140	3150	3160	3170	3180	3190	3200
RLG2U	3210	3220	3230	3240	3250	3260	3270	3280	3290	3300
RLG2V	3310	3320	3330	3340	3350	3360	3370	3380	3390	3400
RLG2W	3410	3420	3430	3440	3450	3460	3470	3480	3490	3500
RLG2X	3510	3520	3530	3540	3550	3560	3570	3580	3590	3600
RLG2Y	3610	3620	3630	3640	3650	3660	3670	3680	3690	3700
RLG2Z	3710	3720	3730	3740	3750	3760	3770	3780	3790	3800
RLG2A	3810	3820	3830	3840	3850	3860	3870	3880	3890	3900
RLG2B	3910	3920	3930	3940	3950	3960	3970	3980	3990	4000
RLG2C	4010	4020	4030	4040	4050	4060	4070	4080	4090	4100
RLG2D	4110	4120	4130	4140	4150	4160	4170	4180	4190	4200
RLG2E	4210	4220	4230	4240	4250	4260	4270	4280	4290	4300
RLG2F	4310	4320	4330	4340	4350	4360	4370	4380	4390	4400
RLG2G	4410	4420	4430	4440	4450	4460	4470	4480	4490	4500
RLG2H	4510	4520	4530	4540	4550	4560	4570	4580	4590	4600
RLG2I	4610	4620	4630	4640	4650	4660	4670	4680	4690	4700
RLG2J	4710	4720	4730	4740	4750	4760	4770	4780	4790	4800
RLG2K	4810	4820	4830	4840	4850	4860	4870	4880	4890	4900
RLG2L	4910	4920	4930	4940	4950	4960	4970	4980	4990	5000
RLG2M	5010	5020	5030	5040	5050	5060	5070	5080	5090	5100</

RIG2A 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
 CTTAAAAAATTTGGTCAAACTGGAGGAGCTCTATAT-CACAGTG-----GTT-----GAT-----CCAGGTGGAAAGG-----CGA----- 1437
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1475
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1417
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1411
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1432
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1437
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1466
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1420
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1442
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1449
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1423
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1398
 CTTGAAAAGTTTGGTCAAACTGGAGGAGCTCTATATTTGGAGATGCACTCTGGGTTTATAGATGATTAATCTCAATCAGATGCGAGCGGTTCTTTACACCTT 1441

XXXXXXXXXXXXXXXXXXXXXXXX
 1510 1520

RIG2A 1510 1520
 TCTGCATTAGAAATTCGGTCTCTTTA -TTA -SEQ ID NO: 27
 RIG2B -TTA -SEQ ID NO: 28
 RIG2C -TTA -SEQ ID NO: 29
 RIG2D -TTA -SEQ ID NO: 30
 RIG2E -TTA -SEQ ID NO: 31
 RIG2F -TTA -SEQ ID NO: 32
 RIG2G -SEQ ID NO: 33
 RIG2H -SEQ ID NO: 34
 RIG2I -SEQ ID NO: 35
 RIG2J -SEQ ID NO: 36
 RIG2K -SEQ ID NO: 37
 RIG2L -SEQ ID NO: 38
 RIG2M -SEQ ID NO: 39

SEQ ID NO:

100 90 80 70 60 50 40 30 20 10
 CETT-----LKEVVEKKEKNTVEAVIGKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 98-41
 RIG2A protein GKTTHMIRLKKVVKERKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARTEDRKMFVNSG--KKIIVITIDVWQFVDI NDIGLSPFNQ 98-41
 RIG2B protein GKTTHMIRLKKVVKERKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARTEDRKMFVNSG--KKIIVITIDVWQFVDI NDIGLSPFNQ 100-42
 RIG2C protein NTRK--AKAEVAKKEEFGVIEAVIGESDPIAIQAVADYLGTELKSTKTRAKELRGFKAKSDGNTKFLIILDDVWQSVLEDIGLSPFNQ 98-43
 RIG2D protein EVAK--XK-----RK--FGYIEAVTIEISDPIAIQAVADYLGTELKSTKTRAKELRGFKAKSDGNTKFLIILDDVWQSVLEDIGLSPFNQ 90-44
 RIG2E protein GRND--AKVEEVAKENRNTNVEAVIGKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 99-45
 RIG2F protein LEDTHMIRLKKVVKERKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 100-46
 RIG2G protein GRIDD--EELKEVVEKKEKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 97-47
 RIG2H protein -----KEVVEKKEKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 89-48
 RIG2I protein CKKS-----MKVEVVEKKEKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 94-49
 RIG2J protein ERGR-----GKKTFTNITVQVIGKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 89-50
 RIG2K protein LEDTHMIRLKKVVKERKNTFIEAVVGEKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 100-51
 RIG2L protein -----FSTVVEAVIGKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 82-52
 RIG2M protein AEE-----AAEKKLFNIVGAVIGKTDPIAIQAVADYLGTELKSTKPARADKLREMFKAESDGGKNTFVILDDVWQSVLEDIGLSPFNQ 92-53

110 100 90 80 70 60 50 40 30 20 10
 VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 196
 RIG2A protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 196
 RIG2B protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 195
 RIG2C protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 193
 RIG2D protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 185
 RIG2E protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 193
 RIG2F protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 195
 RIG2G protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 197
 RIG2H protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 189
 RIG2I protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 194
 RIG2J protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 189
 RIG2K protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 195
 RIG2L protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 177
 RIG2M protein VDFKVLITSRDSHUCTVHGVANSIILNGLLLEAEASLFFQFVETS--E---PELQKIGEDIVRKCCGLPIAIKTHACTLNRKRDAMKDALSRLEHYD 187

[illegible]

	410	420	430	440	450	460	470	480	490
RUG2A protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2B protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2C protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2D protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2E protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2F protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2G protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2H protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2I protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2J protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2K protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2L protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								
RUG2M protein	VNLRVILHIECSLAFHFDSCSSIGNLNLNLEVLSPFNLSFANLSTIGLRIKRLDITNCTGLRIENGVLRLNVLKLEELYIGANG-FG								

SEQ ID NO:

[illegible]

	110	120	130	140	150	160	170	180	190	200	
AC15-2A	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2B	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2C	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2D	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2E	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2F	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2G	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2H	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2I	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2J	CCCATCTCTGGAATACCCCGCATGGAACATTC	AAAGCCGCTTCA	TA	CA	TAT	-ATTGTG	-TTGTGCTTTGTATTTT	TTATTTTATTTT	CCCGTGAAGCGTG	194	
AC15-2K	TCTCTGTTGGAAGTAAGTT	-AGTTCGACATCTT	-AAATTAATTAATTTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	CCCGTGAAGCGTG	195	
AC15-2L	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2M	ATCTCTGTTGGAAGTAAGTT	-GCATCTTTATTTT	-TG	-TATTATCTCTGTTGCA	TAGCA	TGCTT	-TAGCA	TCTTTTATTA	TATTTATTT	-----	GAAGCGTG
AC15-2N	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2O	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2P	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2Q	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2R	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2S	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2T	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2U	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2V	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2W	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2X	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2Y	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG
AC15-2Z	-TCT	-ATAA	-TGCACATCTTAATTA	AAAGAGATTTAA	TATTAAT	TGTTGCA	TAGCA	TGCTT	TATTA	-----	GAAGCGTG

[illegible]

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2O

SEQ ID NO:

AC15-2A	810	820	779
AC15-2B	TAAGTACTTGTTTTCACCTCTCACGG - 56		777
AC15-2C	TAAGTACTTGTTTTCACCTCTCACGG - 57		777
AC15-2D	TAGTACTTGTTTTCACCTCTCACGG - 58		788
AC15-2E	TAGTACTTGTTTTCACCTCTCACGG - 59		721
AC15-2G	TAAGTACTTGTTTTCACCTCTCACGG - 60		781
AC15-2H	TAAGTACTTGTTTTCACCTCTCACGG - 61		738
AC15-2I	TAAGTACTTGTTTTCACCTCTCACGG - 62		722
AC15-2J	TAAGTACTTGTTTTCACCTCTCACGG - 63		784
AC15-2K	TAAGTACTTGTTTTCACCTCTCACGG - 64		699
AC15-2L	TAAGTACTTGTTTTCACCTCTCACGG - 65		778
AC15-2M	TAAGTACTTGTTTTCACCTCTCACGG - 66		763
AC15-2N	TAAGTACTTGTTTTCACCTCTCACGG - 67		

()

SEQ ID NO:68

RLG3 (real RLG3)

[Strand]

```
1  AATGGCAAAA GAAGTCGGAG CAAGAGCTAA GTTAGAGCAT CTATTGACG TCATTATCAT GSTAGATGTC
71  ACTCAAGCAC CCAACAAGAA CACAATTCAA AGTAGTATTT CAGAACAGTT GGGATTAAAA CTGCAAGAAG
141 AGAGCTTGTG GSTAAGAGCA GCTAGGGTAA GTGCGAGSTT AAAAATGCTT ACAAGGGTGC TGGTGATATT
211 AGACGATATA TGGTCAAGGC TTGACATGGA GGAAC TTGGG ATTCCCTTTG GATCAGATAG ACAACACCAC
281 GGCTGCAAAA TCTTGTTGAC TTCAGAAGT ATTAGTGCTT GTAACCAGAT GAGAGCTGAT AGAATCTTTA
351 AAATACGAGA AATGCCACTG AATGAAGCAT GGCTTCCTTT CGAAAGAACA GCTAAAAAAG CTCGGAATCT
421 GCATCAAGTA GCAAGAGATA TCGTGGAGGA GTGTGGTGGG C
```


RLG4
SEQ ID NO: 69

```
1  GAATTCGGTG  TTGGTAAGAC  AACTCTTGCC  TCTTCTGTTT  ATGATGAAAT  CTCTAGCAAG  TTTGATGGTT
71  GCTGCTTTCT  AAAAATATCT  GGGAGGAATC  AAGTAATAAA  GACGGTATAG  AAAGATTGCA  AGAAAAAATC
141  ATTTGTGATG  TTTTGAAACA  AGAGCAAGTG  GCGGTAGGGA  GAGTTGAAGA  AGGAAAGCGC  ATGATAAAGG
211  ATAGGTTACA  ACATAGAAAG  GTATTGATTG  TGCTTGATGA  TGTGGACAAC  GTTGAGCAGC  TAGCTAGAAC
281  AGTTGGCTGG  ATCACATGAT  TGSTTTGGTG  AAGGTAGCCG  CATAATAATC  ACAACTAGAG  ATGAACATGT
351  ATTAATTGCA  CACAAAGTAG  ATGTGATACA  CAATATAAGC  TTGTTAAACA  ACGATGAAGC  TATGCATCTC
421  TTCTGCAAGC  AAGCACCACG  GGGTCACAAA  CGTATACAAG  ATTATGAGCA  ACTTTTAAAA  CATGTGGTTT
491  CTTATGCTGG  TGGGCTTCCA  CTAGCACTGT  CGAC
```

SEQ. ID NO: 70
RLG1-E169
[Strand]

```

1 ATCGTAACCG TTCGTACGAG ANCGCTGTCC CTCCTTCATC TTTTGTGATA TGTCATATTC TCATNNATNN
71 TGCCACATAT AATTTTGTGG TTATTTTAAA TTAATTTTAA TTCCACATGT CATTTTATGA GTTTTCTTAT
141 TTTATTGAGT TTCACATAAT ATTTAAATGT AATAACAATA AATGCATATT TATTTTTCCT TAAATAAACG
211 CATATAATAT ATAGATTAAA ATCATATAAT ACATAGGTTA AACTCATATA ATACATATGT TCATCCCCAG
281 TTTATTATA TGCTCATCC TTAATTTAAT TATTATTAT TTATTAGAGT AGATGATCTT TGATATATTA
351 AAAATTTAAT TGTTCAAAA TTAAAAATTA TTAATAATCC CACAATTGTA ATAAAAATTA AAAAAATGNN
421 CCCACCATTA GTCCATCACT TTTTCAGCTC ATCAATATCG TGAGTATTCT CCTTGGTTTC CACCTTAATC
491 AATATTTCGA GCGAATGACA GACTCCTACG GCGTTCTGTA ATTTGGGTTT CGACACTGTT CATTTGAAGGA
561 GATAATAAAT CAAATGGAGC TGCTCCATG TTCAATGCTG ATGAAAGGTG AATTGTATGT GAAGANAATG
631 TCAGCGATCN ATCTCCATCC GGAACCCACC ACATTATCAG TGTAACCCCA AACCTACTCA AACGGYGAA
701 GTAGRRAKAC WRKAAAGTCA TGAAGAATAG ATTAATTTTG TCCTCATGGG CTGACTGAGG AGCGGGTTTA
771 GTTCATCACT TTCTTTTGAN CAAAGAATTA TCGGTCCATC GAATTTTAC ATCGACAAG AGTPTCACT
841 TCGCAATGTT TGTTTAAACA ATTTTAAATC TTTTAACTT TTGTTGAAA CTCTCAATT GCAACTTGCA
911 ACTTGCAACT TTGGGCCCCA CAAATTTGTG GTGGGGGTTA ATTTAATCCA CATATTCACT GTAAACAATA
981 ATTCAAATCG ATCTCTGTT ATCCAATCA TCAACATCTC TTGATAATTG AATCAATCA CGCTTCATCC
1051 ATTTCAATCCA CATCTATCT ATATCTCTG CTCTTATCAT ATTTAAACGAT GGCTGAAATC GTTCTTCTG
1121 CCTTCTTGAG AGTGGTGTG GAAAGGCTGG CATYTGAAAG CTGTGAAGAG ATTTGTTCCT CCAAAAGAA
1191 TGAATCTGAG CTTAAGAAAT TGAAGGAGAC ATTAGACCAA ATCCAAGATC TGCTTAACGA TGCTTCCAG
1261 AAGGAAGTAA CTAATGAAGC CGTTAAAGA TGCTGAATG ATCTCCAACA TTTGGCTTAT GACATAGACG
1331 ACCTACTTGA TGATTTTGA ACTGAAGCTG TTCAACGTTA GTTGACCGAG GAGGGTGGAG CCTCTCCAG
1401 TATGGTAAGA AAATTAATCC CAAGTTGTTG CACAAGTTTC TCACAAAGTA ATAGGATGCA TGCCAAGTTA
1471 GATGATATTS CCACAGGTT ACAAGAATG GTAGAGGCAA AAAATAATCT TGGTTAAGT GTGATAACAT
1541 ATGAAAAGCC AAAAATGAA AGGTATGAGG CGTCTTGGT AGATGAAAGC GGTACTGTG GACGTGAAGA
1611 TGATAAGAAA AAATTCCTGG AGAAGCTGTT GGGGGATAAA GATGAATCAG GGAATCAAAA CTTCAGCATC
1681 GTGCCCCATG TTGGTATGGG TGGAGTTGGT AAAACAATC TAGCTAGACT TTTGTATGAT GAAAAGAAAG
1751 TGAAGGATCA CTTCGAATC AGGGCTTGGG TTTGTGTTTC TGATGAGTTC AGTGTTCCTA ATATAAGCAG
1821 AGTTATTAT CAATCTGTGA CTGGGGAATA GAAGGAGTTT GAAGACTTAA ATCTGCTTCA AGAAGCTCTT
1891 AAAGAGAAAT TTAGGAACCA GCTATTCTTA ATAGTTTGG ATGATGTGTG GTCTGAAAGC TATGGTGATT
1961 GGGAGAAAT AGTGGGCCCC TTCTTGGGG GGTCTCCCTG AAGTAGAATA ATCATGACAA CTGGGAAGGA
2031 GCAATTCCTC AGAAGCTGG GCTTTCTCA TCAAGACCTC CTGGAGGGTC TATCAACGA TGATGCTTTC
2101 TCTTTGTGTT CTCACACGCG ATTTGGGTGA CCAAACTTTG ATTCACATCC AACACTAAGG CCACATGGAG
2171 AACTGTTTGT GAAGAAATGT GATGGCTTAC CTCTAGCTTT AAGAACACTT GGAAGGTTAT TAAGGACAAA
2241 AACAGAGCAG GAACAAATGA AGGAGCTGTT GGATAGTCAG ATATGGAGGT TAGGAAAGAG CGATGAGATT
2311 GTTCCGGCTC TTAGACTAAG CTACAATGAT CTTCCTGCCW CTTTGAAGCT RTTTRTTGCA TAYTGCTCCT
2381 TGTTTCCCAA GGACTATGAG TTTGACAAGG AGGAGTTGAT TCTATGTGG ATGGCAGAAG GGTTTTGGCA
2451 CCAACCAACT AYAAACAAGT CAAAGCAAGC KTTGGGTCTT GAATATTTTR AAGAGTTRIT GTCAAGRTCR
2521 TTTTTCACAC ATGCTCCTAA TRRCAATCS TTGTTGTGTA TGCTAGACCT AATGAATGAT TTGGCTACAT
2591 TTGTGTCTGG AGAATTTTT TCAAGGTTAG ACATAGAGAT GAAGAAGGAA GGTTCACAAA RGTTCGAGCC ATTTAGAGGA
2661 RAAGCACCG CATATGTCAT TTGTATGTGA GRATTACATA GGTTCACAAA TTTAGGATGS AATCTTTGGA
2731 GCTAAAAAT TTGAGAATTT TTTAGCATTT TCTGTGGGG TGGTAGAAGA TTGGAAGATG TTTTACTTAT
2801 CAAACAAGGT CTGGAATGAC WTACTTCARG ATTTACCATT GTTAAAGGTC CTRAKTTTGA TTRRTCTTAY
2871 AATAASYRAG GTACCARAAK TCGTSGGTAG TATGAASCAC TTGCGGTATC TTTAATCTATC WGRAACTTWA
2941 ATCACHCACT TACCAGAAWA TKCTTGCAAT CTTTATAATT TACARACCTT GATTGTNTCT GGCTGTGAMT
3011 ATTTAGTTAA KTTGCCCAAR ACCTTCTCAA ASCTTAAAAA TTTCASCAT TTTGACATGA GGGTACTTCC
3081 KAAKTTRAAJ AACATGCCCT TARGGATTGG TGARTTGAAA ARTCTACAAA CTCTCTTYYG TAACATTGGC
3151 ATAGCAATTA CCGAGCTTAA GAAGTTGCAH AAYCTCCATG GGAARNTTG TATTGGCGGG CTGGGAAAAA
3221 TGGAAAAATG NGTGGGATGC ACGTTAAGCG AACTTGTCTC A: AAAAAGGT TWAATGARTT ANAACTGGR
3291 WTKGGGGGTT ATRAATTAAA TGTTTTCCGA AATGGGAACA CTGAAAAAAA NAAGGTCTCT AATGAATTGA
3361 ATGCTCACTA ATGGTAVTCY AAMWAARRRY YWTAARMKAT TWKXKAWRRK GKGTYYATRR TKTTMYRAAW
3431 WAGRGTRTFR KARGTAGGTT TCATCCAATC ACCCAAGTGG GAAAAATAGAT GATATTTTCA GGCCTACTCG
3501 ATGAGATGTT GAGAGGTATG ATAGGGTNYC TTGGGGCGGT AGAAGAAATA AGCATCCATT CTGTGAATGA
3571 AATAAGATA T YTGTTGGAAT CAGAAGCAGA GGCAAGTAAG GTTCTTATGA ATTTAAAGAA TTTGGATTTA
3641 GGTGAATGTT AAAATTTGGT GAGTTTAGGG GAGAAAAAGG AGGATAATCA TAATATTAAT AGTGGGACGA
3711 GCTTAACACT TTTTAGAGG TTGAATGTAT GGAGATGTAA CAGCTTGAGG CATTCAGGT GTCCAGATAG
3781 CATGGAGAA T TTGTATATG ACATGTGTGA TTCAATNACA TCCGTCTCTT TCCCAACAGG AGGAGGACAG
3851 AAGATCAAGT CACTTACCAT CACTGATTGC AAGAAGCTTT CGGAAGAGGA GTTGGGAGGA CGAGAGAGGA
3921 CAAGAGTGGT TATAAATCA AAAATGCAGA TGCTTGAATC AGTAGATATA CGTAATTTGC CAAATCTGAA
3991 ATCTATCACT GAATTGAGTT GCTTCATTTA CCTGAACAGA TTATATATAT CAAACTGTCC GAGTRTGGAG
4061 TCATTTCCTG ACCATGAGTT GCCAAATCTC ACCTCCTTAA CAGATCGAAG GAGAGGACAG CGATTTTCCT

```

RLG1-E169
[Strand]

4131 ACGAACGGTT ACGATTGAC TGGCCGTCGT TTT

SEQ ID NO: 70

Further Characterization of RG2 Family Members:

Further sequencing of cloned RG2 polynucleotide sequences, as discussed above, identified additional RG2 species, listed below. Additionally, further sequencing of the 5' sections of RG2 sequences listed above resulted in modified and/or new sequence information, also listed below. The AC15 sequences found in the 3' sections of RG2 family have not changed.

Listed below are: four full length species, RG2A, RG2B, RG2C and RG2S; two near complete, but with a gap in the largest intron, RG2D and RG2J; three nearly complete RG2 gene sequences, RG2K, RG2N, and RG2O. The deduced translation products (polypeptides) encoded by these RG2 species are listed below. The polynucleotide sequences do not contain any gaps (as with some of the polynucleotide sequences), because all of the gaps in the sequences are in introns, *i.e.*, there are no gaps in exon, or coding, sequences.

They include: an RG2A polynucleotide sequence (SEQ ID NO:87) and its deduced polypeptide sequence (SEQ ID NO:88); an RG2B polynucleotide sequence (SEQ ID NO:89) and its deduced polypeptide sequence (SEQ ID NO:90); an RG2C polynucleotide sequence (SEQ ID NO:91) and its deduced polypeptide sequence (SEQ ID NO:92); an RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94), and its deduced polypeptide sequence (SEQ ID NO:95); an RG2E polynucleotide sequence (SEQ ID NO:96) and its deduced polypeptide sequence (SEQ ID NO:97); an RG2F polynucleotide sequence (SEQ ID NO:98) and its deduced polypeptide sequence (SEQ ID NO:99); an RG2G polynucleotide sequence (SEQ ID NO:100) and its deduced polypeptide sequence (SEQ ID NO:101); an RG2H polynucleotide sequence (SEQ ID NO:102) and its deduced polypeptide sequence (SEQ ID NO:103); an RG2I polynucleotide sequence (SEQ ID NO:104) and its deduced polypeptide sequence (SEQ ID NO:105); an RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107), and its deduced polypeptide sequence (SEQ ID NO:108); an RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110), and its deduced polypeptide sequence (SEQ ID NO:111); an RG2L polynucleotide sequence (SEQ ID NO:112) and its deduced polypeptide sequence (SEQ ID NO:113); an RG2M polynucleotide sequence (SEQ ID NO:114) and its deduced polypeptide sequence (SEQ ID NO:115); an RG2N polynucleotide sequence (SEQ ID NO:116) and its deduced polypeptide sequence (SEQ ID NO:117); an RG2O

polynucleotide sequence (SEQ ID NO:118) and its deduced polypeptide sequence (SEQ ID NO:119); an RG2P polynucleotide sequence (SEQ ID NO:120) and its deduced polypeptide sequence (SEQ ID NO:121); an RG2Q polynucleotide sequence (SEQ ID NO:122) and its deduced polypeptide sequence (SEQ ID NO:123); RG2S polynucleotide sequence (SEQ ID NO:124) and its deduced polypeptide sequence (SEQ ID NO:125); an RG2T polynucleotide sequence (SEQ ID NO:126) and its deduced polypeptide sequence (SEQ ID NO:127); an RG2U polynucleotide sequence (SEQ ID NO:128) and its deduced polypeptide sequence (SEQ ID NO:129); and RG2V polynucleotide sequence (SEQ ID NO:130) and its deduced polypeptide sequence (SEQ ID NO:131); and, an RG2W polynucleotide sequence (SEQ ID NO:132) and its deduced polypeptide sequence (SEQ ID NO:133).

Characterization of New RG Family Groups and RG Species:

Further BAC insert characterization and sequencing, as discussed above, identified new RG polynucleotide sequences. The new sequences were characterized as belonging to new RG families; designated RG5 and RG7. These RG polynucleotides sequences, and their predicted translation products (the polypeptides which are encoded by these sequences) are summarized and listed below.

Identified and listed below is an RG5 family member, designated as the RG5 polynucleotide sequence set forth in SEQ ID NO:134, and its deduced polypeptide sequence (SEQ ID NO:135). This sequence contains an NBS region sequence.

Also identified and listed below is an RG7 family member, designated as the RG7 polynucleotide sequence set forth in SEQ ID NO:136. No deduced polypeptide sequence is given for the new RG7 family member as this sequence appears to be a pseudogene.

RG2A polynucleotide sequence (SEQ ID NO:87)

AAAGTTCATATCCAAGCTTGCCCTCCAACCTCTAGCTCCTTCAATGGCACC
TCCTTCTCTTCAAAAGCACACAAGAACACTTTCAAGCTCAACCACACTCA
CAC.AAGCTCTAGAACGAGGGTTAGGGCACATTTAGGGTTTTGCTCTCTGG
AAATGGTGTCTAAAAGTGAGGCCATAATGTTTCCTTATATAAGGCTCACTC
CCACAATTAGGCTTTCAATCTGAACGTANTACGCCAGTGTA CACTATGG
TACGCCCAACGTACTCGGTAGTCTCCGCGTCAANAATACTCATGAGTA

CGCGCAACGTACTTTCCCTTACGCCCAGCGTACTCAAAAGCCAAACATTC
TTTTCAAGGACTAATTTTGACAACTTGAGGAAAGAAAAGGATCAAAGANA
TATACTTGAATTCCGGGATGTTACAATGAAGTTGANACCTTGGCTAAAAA
ATTAAATTGGTTGTGGAAGCCGTTGGCTGAGCAAGCAACAAGGGTAAAT
5 TCGTAATCTACAAATGGTGTTATTTTCTATTTCTTCTTATTATTTTACTT
GATTTACGGGTAGTTTTTTTTTCTTACAAAAAATATTAAAGTTGATAAAG
TATAGCCACTAAAATTGACTTTTTTCCAAAACATAATGTCAAATGGTGCGT
ATATGTATCATGTTGTATTANATAATGAATATGATGATNCTGTTCTATTT
AANCCGAAAAAATTATCTAATGATTTTATATTGGAAAACAAAGTTGTGAT
10 TTTTNGCATAATATAATCAAATCCNCTTTTGTNTGGGAGGTGGATAAATG
TGGTAAATTTANAACAAGTGTTTTNACNTTGAAGGGTNTGGAAAGGTTGA
AAAAAGTTAAATGATAAAATGTTTACACAAATGTTGTATCCGACTGAAT
ATNATGTTTAAGGATNATTGTATTAAATTGTTGATATATAGTAAGCATAA
ATATTTAGAATTGTGACTTAAATTTATAAGTTATNCNAACTGGATTGAAA
15 CATTTTTGATATANATTAGGAATGAAAATGAGCAACCCTAACATACTTAT
CTTTGGTAGTTTGGTTATTATATTTTTATTANAATATAGAANCATCCCTT
TATTTTAAACCCATATTGTGGACGGACTTGAATAAATGGGAAAAATGTAC
CTTGCTATTTAGCACAAAAAAATTATAAAAATGTACATTGCTATTTAGCA
CAAACAAAAAATACTTATCCTTTTTGCATTAGGTCACAAAGAAATA
20 TAAATGGGAAATGTGTTGCTATTTAATGCACTAAAAGAACTATTTTGC
CTTTATTAAACCGGGTAAACCAATAGAAAAATGGAAGTACATTGTCATTT
AGCATGAAAAAAATACTTTCCATTTTTTGCATCCGGTCACAATAATAG
AAAAATGAAAGTACGTTGCTATTTAGCGAACTAACTTCCTTTTTTCTTT
TTGGCATCGTATCATAAAATATAGACTAAAATACGTTAGTTTTACATTTT
25 TAATACATTGAAATGTCTAATCCACATGTTATTCTATAAAAAGGGAAATG
TAATTTACTTATTCTTTGATTCTTTGGCTTCTTTTTAGTACCCAAAACAT
CCCTCTATCCATCTATTCCAATAAATAATGAAACTATATTCCTTCCA
TTGTAGGGATGTTATAAATTTTGTAAATGTTTTTATGCAAAAAAGTGTTT
TTTGTTAACTAGATTAACGAGATTCATTTTTCAGCATTTTAGGAGAAGTT
30 CATCCATCTTTTGGATATGAAGTGCAAGCCAAGTTCTTTAACATGGAATA
TGAGGTCCCTATATGCTCAAAAAATAGCAAATGAGAAATTTTTTAAATTG
GATCCCCATAAAAGAAAATTTGTTAATGGTTGTTTTAATATTGGTCAATG
TGTCCACCGGATGAGCATAATACTAGTTTATAAGGGGTAAAGGTGGGTTT
GGTGGGCCCATTTATCTTTATTATTTCTAAAAGTCAGAATTAAGTAAAAA
35 AAATTATAAGATAAATACCATAAGGATAAAAAATCATTTTATTTGGACCA
AAGACCAAAGTTGTTAAGGGGCTGTTTGTTTTTTTTGTGAAGAGCTGTGC
AACCCTTTTGTCTGCGCCGCACAGACAACGTGCAGACATATGCCCTCGC
AGAGTGTTTGTTTTTTGAAGTGCGCAGACCAAAAAAACGTCTGCGCGAG
GTCATCCTGGCGCATATATGTGTCACTGTCTTCAAAGGTCTTCAGACCTC
40 ATTTTAACCAAAAAAAGACCACCGGTTTTTTTTTTTTTTTTNTTC
TTTCTCTTGTAGCTGAAAATGCATTTTAAATCTTTATGACATGAAATTAA
GTTTGAAAAATTAATTTATTTCAACAGCTGTAGACGTTAAAAACAAACAG
TCTTCTTGTTGCAGACTGTGGACATTTGGTCCACCTCTTCTACCGCAGAG

ACTTGCAGATGTGGTCCGCAGACTGCAGACATTTTGGCTTCAAATAAACA
AACATCACCTAATTTGACTACACCACACGGACCTCCAATGTAACAAAAA
AAGGTTGAAACAAAGTTGCCTATTTCTCCATATCCAGGGGCCATTTATGT
AAGAGTTATCTAAATTTTAGTTTCGGTAGATCAGTTCTCACATTTTAACCG
5 GGTAAAGTGTATGTGTGTACGCGCGCACCTGAAAGGTTTGAANGTAACTT
CCAAACTGAANCAANAATCGATATGAAGTATCAAGTTAGAGGTTCAATTG
GTGAAGGAATCAGCTGGAGGTTGGGGAATCGAGCTTCCACTATTAAGGTA
AAATCCATAACCCCTAAATGTTGGTACGCTCATATATCAAATTGCGTGTTT
TGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGGTATAT
10 GACATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTTTACGT
AAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGTCTATC
TATGTATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAATTCGAA
AAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTTTAGCG
ACATCTAATATTAAATAGAATGTATCTGATATTGAATTAATGTCCTTAAT
15 GTGAACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTTCTAAT
CAATAAATTTTAAATTTCTGTTTATGCTTCTAAGACAATAAAAAATCCATG
ATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAAATTAG
GATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGATGCTTT
TGCTTTTCCCTCTTTTCTTGTAGTCTATTATTCTGGAGAGTTTGAGAG
20 AGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTATTCTC
TTTTCTTAATTATGTATTAACCTACAAGCATTTTTTACACGATCCATGGT
TTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGCCCTTG
ATG.ATTCAATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAGTGGTG
AATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATGATGAT
25 GAG.ATAGAGATATGTTAAACTGGCTAGAAAATTGTTTAAATTTGAAATT
TAGGTTGTTGAATTTGAAAGATACCAAGCTAATACTAATTAGTTATGCT
AAATAGTTATAAAGAACAACAACTCGTAGTTTTTTTTTCATGATTTTCA
ACCTCTTCGTACCAAACTAAATTATAACAAAATTGAATATCATTCTCTGC
AATCAATTTTAACTTTTGTATTATCATCATGTCTAAAATTGCCACAAGT
30 TTATTTTCATAGTCATATTGGATTATGAAAGGACTATTTTACCAATTAC
ATCTTTACTTTATGGCCAAAGCTAATACAATCCGACTAACTAAAGGATT
CTAGGATGCATATAGTTTGCTCCCCGATTATAGATTTCTATCTAATTTGT
CTATTGTACTAATTTAGGTGCCACCACAAGTAAATTCCTGAAATGGATGT
CGTTAATGCCATTCTTAAACCAGTTGTCTGAGACTCTCATGGTACCCGTTA
35 AGAAACACATAGGGTACCTCATTTCTGCAGGCAATATATGAGGGAAATG
GGT.ATCAAAATGAGGGGATTGAATGCTACAAGACTTGGTGTCTGAAGAGCA
CGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAAGTCAGGG
GTTGGTTTGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAATTTCCCT
AGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGGTCGGAAA
40 GAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTGATGAGAGAACACT
CTATCATCATTTTGAATGATCATTCCATTCTTTAGGAAGAATTGATTCC
ACG.AAAGCATCCACCTCAATACCATCAACCGATCATCATGATGAGTTCCA
GTC.AAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGATCCTAACC

ACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGGGAAGACG
ACAATGATGCATCGGCTCAAAAAGGTTGTGAAAGAAAAGAAAATGTTTAA
TTTTATAATTGAGGCGGTTGTAGGGGAAAAAACAGACCCCATTGCTATTC
AATCAGCTGTAGCAGATTACCTAGGTATAGAGCTCAATGAAAAAATAAA
5 CCAGCAAGAACTGAGAAGCTTCGGAAATGGTTTGTGGACAATTCTGGTGG
TAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTGGATCTGA
ATGATATTGGTTTAAGTCCTTTACCAAATCAAGGTGTCGACTTCAAGGTG
TTGTTGACATCACGAGACAAAGATGTTTGCCTGAGATGGGAGCTGAAGT
TAATTCAACTTTTAATGTGAAAATGTTAATAGAAACAGAAGCACAAAGTT
10 TATTCCACCAATTTATAGAAATTTCCGATGATGTTGATCCTGAGCTCCAT
AATATAGGAGTGAATATTGTAAGGAAGTGTGGGGGTCTACCCATTGCCAT
AAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCATGGAAGA
ATGCACTTCTTCGTTTAGAGCACTATGACATTGAAAATATTGTTAATGGA
GTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTAAATCCAC
15 CTTTTTGCTTTGTGGAATGTATCCCGAAGACTTTGATATTCTTACCGAGG
AGTTGGTGAGGTATGGATGGGGGTGAAATTATTTAAAAAAGTGTATACT
ATAGGAGAAGCAAGAACCAGGCTCAACACATGCATTGAGCGGCTCATTCA
TACAAATTTGTTGATGGAAGTTGATGATGTTAGGTGCATCAAGATGCATG
ATCTTGTTTCGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGAGCATGCT
20 TCCATTGTCAACCATAGTAATACACTAGAGTGGCATGCAGATAATATGCA
CGACTCTTGTAAGACTTTTCAATTAACATGCAAGGGTATGTCTAAGTTTC
CTACAGACCTGAAGTTTCCAAACCTCTCCATTTTGAACTTATGCATGAA
GATATATCATTGAGGTTTCCCAAAAACCTTTATGAAGAAATGGAGAAGCT
TGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCCTCATCAC
25 CTCAATGTTCCGTCAACCTTCGCGTGTTCATCTACATAAATGCTCGTTA
GTGATGTTTGACTGCTCTTGATTGGAAATCTGTGCAATCTAGAAGTGCT
TAGCTTTGCTGATTCTGCCATTGACCGGTTGCCTTCCACAATCGGAAAGT
TGAAGAAGCTAAGGCTACTGGATTTGACGAATTGTTATGGTGTTTCGTATA
GATAATGGTGTCTTAAAAAAATTGGTCAAACTGGAGGAGCTCTATATGAC
30 AGTGGTTGATCGAGGTCGAAAGGCGATTAGCCTCACAGATGATAACTGCA
AGGAGATGGCAGAGCGTTCAAAAGATATTTATGCATTAGAACTTGAGTTC
TTTGAAAACGATGCTCAACCAAGAATATGTCATTTGAGAAGCTACAACG
ATTCCAGATCTCAGTGGGGCGCTATTTATATGGAGATTCCATAAAGAGTA
GGCACTCGTATGAAAACACATTGAAGTTGGTTCTTGAAAAAGGTGAATTA
35 TTGGAAGCTCGAATGAACGAGTTGTTTAAGAAAACAGAGGTGTTATGTTT
AAGTGTGGGAGATATGAATGATCTTGAAGATATTGAGGTAAAGTCATCCT
CACAACTTCTTCAATCTTCTTCGTTCAACAATTTAAGAGTCCTTGTCGTT
TCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTGTTGCAAACAC
TTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGATAATATGGAAG
40 AACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTACATTCCCCAAG
CTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGGGTTTGTGCGA
TAATGTCAAAATAATTGAGCTACCACAACCTCATGGAGTTGGAACCTTGACG
ACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTTTGAAACATTT

AGTTTGTGAAGGAAGAGGTAAATATAAATTTTAAATGCTAATACATTAC
AAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAATTTGATTGTA
TGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTATCTTGCAGGT
TCTGATTCCCTAAGTTAGAGAACTGCATGTTAGTAGTATGTGGAATCTGA
5 AGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGTTAAGTTCAGA
GAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGTTTCCGCACAA
GCCCATATCTCTGCTGCATCATCTTGAAGAGCTTAAAGTCAAGAATTGTG
GTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGTTGGTGCAACT
GGAGATGAATACAACAACAGTGGTGTAGAATTATTAAAGTGATCAGTTG
10 TGATAAGCTTGTGAATCTCTTTCACACAATCCCATGTCTATACTGCATC
ATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCATTGAATCGTTATTC
AACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAGACAACAGCAT
CAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTAAGAGAGGTGT
GGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTCATGGCTTTCAA
15 TCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAAGTTTAGAAATGTATT
CACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTGGAGATTTCAA
TAGATGACTGCGGAGAAAACAGGGGAAATGACGAATCGGAAGAGAGTAGC
CATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTGTCTTAATTAATGAT
TAAGCTCCTGCTTTTTGAATAAAAAAGGGACAAACCATTTTCATGACTTAA
20 TGTAGCAATACAAGTCATGTATAAGAGTGACCAACTCTTTTTTATTTATA
AAATGACTACAAAATATTTTTTTTCATTAGAGATCATGTATAAATGTGAC
TAATTTTTTCATCACCTAACTTTAGTTGATAAATCTTTATAAATGTCACTA
GTTACTTTTTCAGTAAAATAACAAATTTAATAAATTATCAACAAAAAGCAT
CAACTAAAAAATCCCACAACCCGTAATAATTTAAAATAAAAGGATTTAA
25 CATCTAATACGAACAATTTTTTTTCTAAACATGATTTGGACCAAATATCA
CCAGCAACTCAAGTTTGAATCGATTTCAGCTTAAACTTGACCAGCATAA
TTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATATAAGTTCGTTTCATC
TTTTTCTTGATCTTGATAGCAAGTTGAATGATTTTCTTCTTCAAAATTG
ATAAAAATCTACATTATAAAGAGACTAGCTTGAAAAAAAATGGTCTAGGT
30 GGGTCTTGGGTTCTGGTAGATGAAGATGGAAGGGGAGAGTAGATTTCAAA
GACACAACACATCCTTCATTTTATTTATTATTATTATTATTTTTTG
ATATCTTGCTCATATTTGTTACAGATATGTGAGGTCTATTAATCTTTTTA
AATATATAAAAAAATAAATAACATAAATGAGAAAATTAAATAAAGAATAA
ATTAATAAGGGCACAATAGTCTTTTTAGGTAAGACAAGGACCAAACACGC
35 AACAAAAATAAACAGTAGGGACCATCCGATTTAAAAAAAATAATTAGGGA
CCAAAAACATAAATTCCCCCAAACCATAGGGACCATTCATGTAATTTACT
CTTACTTTTCGTTTTGTTCATATTTGGGTAAGTATTTTTTTTGTACACAT
CTAGGTAACGAACCTGTTGAAGTGTTCCTTATAGGATGTGACCTACTAC
AACCGATCATAATAGTCATATGTGAACACTTCCAACAACCTTTATTACTTA
40 GGTGTGTACAAAAAACAATAGTTACCATGATGTGAACATACTGAAAAAT
TAATTACCTTAGCAAGTTATTTCCCATTTAGGTTGTATGGAAACAGTTC
CGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCCTTC
AATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGATT

CTTGTTTGAAAGTAAGTTGCATCTTTATTTTGTATTATCTTGTTGCATA
GGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAACATA
TTTTTAATCTGTTGGCATTTCATCATTTGCAACTGTTTCTTGAAAAA
AAATACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGAG
5 AATTGTAAATGGACATGGAATCATAAATCATTAACACAGTTCAGTAAACA
AGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAA
GAGACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATC
CTGTCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAG
TTAAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGT
10 AGAGAATTGGTAACAACCTACCATAACCAACAACAACCTATTATACTTCC
CAACCTCCAGGAATTGATTCTATGGAATATGGACAACATGAGTCATGTGT
GGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATCA
GAATCCCCATTCCACAACCTCACAACCATAAAAATTATGTATTGCAAAAG
CATTAAGTACTTGTTTTCGCCTCTCATGGCAGAACTTCTTTCCAACCTAA
15 AGCATATCAAGATAAGAGAGTGTGATGGTATTGGAGAAGTTGTTTCAAAC
AGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAAC
CACCCTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCCTGGAGA
ATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAA
ATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGA
20 GGTATGCTTTGTACATATTCAATTATTTATTTAATTTCTTTTATTTG
CAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAAT
TACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCT
AGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGAT
GGGTAATATAGGCAATTTAAGTTTATTTCTGTAAAGCAGTATTTAGCA
25 AGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTC
ATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGTCAT
CAGGTGACAGATATTGTAGAATAGAACAATATATAATATCACCCAAAAC
ATTTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGTTTTCATNGA
ATTNGCATTCGTATATTTTAGGTGTAAAGTGATTTTNTCTTCAATAAAT
30 CCCGAAATTAATTAACCAACCAACCAACCAACCAACCAACCAACCAAC
AGCACTGGTATCACTTAGTATATAAAAAGCTTGATTTTGAATTAACCTTC
TTATACAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCA
TGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTCTTGAGGCTTATGCC
AATACGCTAGAGAGATGAGAATAGAATTCTGCAATGCATTGTCAAGTGTA
35 ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT
AAGTGATTGCAAAGGGATGAAGGAGGTATTTGAACTCAATTAAGGAGGA
GCAGCAACAAAAACAACAAGAGTGGTGCAGGTGAGGAAGGAATTCCAAGA
GTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATTGGAAATCAG
CTTTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCC
40 TGAGACAGCTCCAAGAGTTAAAGATAACATTTTGCTACGGAATGAAAGTG
ATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGTAAACAACAACAAC
AACACAATAACGAAGGGGGCATCATCATCATCTTCTTCATCTTCTA
AGGAGGTTGTGGTCTTTCCTCGTCTCAAATCCATTGAACTAAATGATGTA

CCAGAGCTGGTAGGATTCTTCTTGGGGAAGAATGAGTTCCGGTTGCCTTC
ATTGGAAGAAGTTACCATCAAGTATTGCTCAAAAATGATGGTGGTTTGCAG
CTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACACAGAATTAGGC
AGACATGCTCTTGATCAAGAATCTGGCCTTAACTTTCATCAGGTATATAT
5 ATTTCTTTAATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAG
TAAATTTACTTCAAACACATTACACTGGTTTCAGTCTAAGTTTATGTTG
TTCTAGGAAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTT
CAGTGGAAAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGG
CTTTTATAGTACCTGGAATCGTGTGTGGGAGGAGCATTATTATTCTGATTT
10 GCTTGTTCCTTATCATTTTTTCTTAGCCTCTGGAACAGCTAGAAACCCT
TTTAACTTTTGATTTTCAATGACAAAATTTTCTGTACTACATTGA
TTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCT
TTTGATTGTTATTTTCATATCATGTTAGTCACCTGAATCAAGCTTTTCTA
TTTTCAACCAGGGCAAAGGTCAAAGTAACCTACTTTATGAGATCAAAA
15 ACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAAATTGGTAC
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT
GGCGTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTG
ACACCTTGGGCCCTGTAACCTCAGAAGGGACAACCTGTTCTTTTCATAAC
20 TTGATCGAATTATATATGGAATTTAATGATGCTGTTAAAAAGATTATTCC
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTCATGTGACTT
ATTGTAATTGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG
AGAAATGGAAATAGTGGAAATTGGTTTTGATGAATCGTCACAAACAACCTAC
CACTACTCTTGTCAATCTTCCAAACCTCAGAGAAATGAAGTTATGGTATC
25 TAAATTGCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG
TTTCCAAACCTAACAAGAGTCGATATATGGGGATGTGATAGGTTAGAACA
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAC
GCATATGGAAGTGCAGTCAGATAGAGGTCGTGATTGTTGAGGATGCAGAT
GTTTGTGTAGAAGAAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAA
30 GGAGATACTTGTGTTACCTCGTCTAAAGTCCTTGATATTAAACACCTTC
CAWGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTA
TTGGATACYTTGGAAATCTACRAATGCCAGCAATAACCACCTTCACCAA
GGGAAATTCRCCTACTCCACAGCTAAAAGAAATTGAAACAMATTTTGGCT
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC
35 AAACAACAGGTAAACCAGATCTTTGTTGCTTNNATAATTCTTAAACNACA
TNTGAAAAGCTTCATGCAAGTTTTTTTTNGTTATATNGTCAAAAACCGCAA
CCTACATTTTCAGCTTTANATTTATGTACTTTATGCAGGATTTCAAACAA
GACTCTGATTAATGTGAAGTGAATATTAAAGGTAAATTATATTTTCATGT
TCCTAGTNGCCTATTAATTAAAGGCCTTTTAGTTCGNGATTTTTGGATGT
40 ATTCCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA
TATGAAGGACATTAAAGAACATGGATGCTCTGAAGATGTTGGGAACACA

RG2A deduced polypeptide sequence (SEQ ID NO:88)

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVN
RNISNQLEVPAQVRGWFEVVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDI
DSVMREHSIITWNHDHSIPLGRIDSTKASTSIPSTDHHDDEFQSREQTFTEALNALDPNHK
5 SHMIALWGMGGVGKTTMMHRLKKVVKEKKMFNFIEAVVGEKTDPIAIQSAVADY
LGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLSPLPNQGV
DFKVLLTSRKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIG
VNIVRKCGGLPIAKTMACTLRGKSKDAWKNALLRLEHYDIENIVNGVFKMSYDNL
QDEETKSTFLLCGMYPEDFDILTEELVRYGWGLKLFKKVYTIGEARTRLNTCIERLI
10 HTNLLMEVDDVRCIKMHDLVRAFLDMYSKVEHASIVNHSNTLEWHADNMHDSC
KRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFPKNFYEEMEKLEVISYDKMKY
PLLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGKLG
KLRLLDLTNCYGVRIDNGVLKKLVKLEELYMTVVDRGRKAISLTDNCKEMAERS
KDIYALELEFFENDAQPKNMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLK
15 GELLEARMNELFKKTEVLCLSVGDMNDLEDIEVKSSSQLLQSSSFNNLRVLVSKC
AELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEEEETITFPKLKFLSLCGLP
KLSGLCDNVKIHLPQLMELELDDIPGFTSIYPMKKFETFSLLKEEVLIPKLEKLHVSS
MWNLKEIWPCEFNMSSEEVKFREIKVSNCDKLVNLFPHKPISLLHHLEELKVKNCGSI
ESLFIHLDCVGATGDEYNNSGVRIIKVISCDKLVNLFPHNPMISILHHLEEELEVEN
20 GSIESLFNIDLDCAGAIGQEDNSISLRNIKVENLGKLREVWRIKGGDNRPLVHGFQS
VESIRVTCKCKFRNVFTPTTTFNFGALLEISIDDCGENRGNDSEESSHEQEIEILS
EKETLQEATDSISNVVFPSCLMHSFHNLOKLILNRVKGEVVFEIESESPTSRELVT
HHNQQQPIILPNLQELILWNMDNMSSHVWKCSNWNKFFTLPKQQSESFPHNLTITKI
MYCKSIKYLFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTT
25 LFPSLDSLTLFLENLKCIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSW
SLCQYAREMRIEFCNALSSVIPCYAAGQMQLQVLTVSDCKGMKEVFETQLRRSSN
KNNKSGAGEEGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLQQLKITFC
YGMKVIVKKEEDEYGEQ.TTTTTITKGASSSSSSSSKEVVVFPRLKSIELNDVPELV
GFFLGKNEFRLPSLEEVTIKYCSKMMVFAAGGSTAPQLKYIHTELGRHALDQESGL
30 NFHQTSFQSLYGDITLGPVTSEGTTCFHNLIELYMEFNDAVKKIIPSELLQLQKLEK
IHVTYCNWVEEVFETALEAAGRNGNSGIGFDESSQTTTTTLVNLPLNREMKLWYL
NCLRYIWKSNQWTAFEFPNLTRVDIWGCDRLEHVFTSSMVGSLQLQELRIWNCSQ
IEVVTVQDADVCVEEDKEKESDGKTNKEILVLPRLKSLILKHLPLKGFSLGKEDFSF
PLDITLEIYKCPAITTFTKGNSTTPQLKEIETHFGFFYAAGEKDINSSIIKIKQQDFKQ
35 DSD.CEVNIK

RG2B polynucleotide sequence (SEQ ID NO:89)

TTTTTTAAGATCAGGGATTCAAATTCAGCCCTAGTGATTACAATTGTGTC
TAAACTTTCCCATACCTTCACATTATTGTAAGTATACTTTCTCAGTTTCT
40 CTCTTGGAAGCTTCCTTGGTATTTAACTCGTGTTCTAATATTAACTCT
GATAGTTATTTTGGCCAATCTACTATCTGCATGTCCGGTTATTGAATCCG
AAGGCACTGGAATCTTGGATTCCATTCCGTTGTGTGTTTGGTTGCCAAAT

GAACGGAATTGAATTATGTAAGATTCCTTCAAAATCCATGTTTAGGTATA
TCGTTGTTTCTTGGGATGGATGGTAAAGAACGGAATTTCTCCTGTTCAATT
TTTTAATGAAAGACCAAATTGACCTTATAAACCTGTTAAAAAAATTACAT
TCCAGTTTTCTTAACAACTGAAAATGGTAAAGGAGTGTGATTGAATTCC
5 AATCTGTTTCCTGTCCAAAACACGTGACGGAATATTACAATTCCTTCAAA
TTTCATTTTCTTAAATTGTTATTCCCTTTCTTACAAAAACAAGGTAAACG
AAACACCCGCTTACTTAATCATACTCCTACATGATGTAAATGAAAAGGGT
ATAAATGGTATTTTATTCACAGGGATGAGTCACCATGGTCATGAAAGAAT
CATTAACCGCCCTTACCCAATTCATGTTTGCCCCTAAAATATGATTTAAA
10 GTAATATTGGCTTATGGGATTCAAGTTGACTTTTTTGTGGCGAAGAAATA
ATGAAAATCTTCATTTCTAAAGTGTCTTCTACCACTGACATTTTCTAAGA
AAGAACTTGCTAGAAGAAGGTGGGTTGTTTAGTCTTTTACTCTTTAAAT
GTGAAGACTGTTGAGTTATTATTATTATTTTGCCAACTATGGACAACCTG
TTTAGTTTTTTTTTTTCCCAATATCCATTTATATGCGATTTATTTCTGA
15 AATAATTTTATCAAAACGCAGGAAACAATGTAGAATAATACTGGTATAAT
TAATTATATAAAGTTATTAGGCTGAAATCTTGAGGCTACTATAATTTAAT
TATCATAATTTGAAAATCATCAAATTGTATTCCATGTATATTTATGTTAT
CAGATAATTAATAATATGTGAGCCACACAAATCCACATCATCAGACACCC
CACCTTATTGTCGGCTACCTCACCCTTGATGATCCCGACATCTTCCCA
20 ACCCCACCGACGACTTGGGGTCTCCTTAATATATCAATTATTTTCTGTAA
GTATTTATTTGTGTAAATGTGTAATGTCATTTTACCTTTTTTCTAATATA
TACAGAAACATAAATTTTAAATGAAATTCAACTGCGTTTCATTCTTGAT
TAAAAAAAAGACTGTACTGTTGTCAATATTTTACTTATAACCTGATTAA
TTAATTAAGCGTAATTGCATAATTTGCATTAGGTTGTAATTTTGTGTTT
25 TATAGGGAGGGTGAGGGTCACCGGAATCAAAGCACTTATGTAAAAGCAG
GGAAATACAAAAAATTTACTCGAAACAAATTTTATTCAATTTAAGTGAGA
TAATAATGTTCTGATTAGATTATGAGAACTAGGAGATTTAAGTGATATAT
CCCATTTAAAAGAAATTGCATTATTAATTTTGGATCTCTTGATGATGACA
AAATTAACCTCGTGACAGGTTATATATCATATACAAAATGAGTGGCTATGC
30 TTTCGCTTTCCAAAAAGCAATTATAGTTATACTACACCTACAAATTTTAA
AAGGGGTTAAACATATCAAAATACTTGATAAGTAATTATATAAATATGCA
TTTAACCCTCTAAAGAAAATGCTACTAAGCTTGGACCATCTCAGAATTAC
AATCATACCCTTCCCCTCAAAAAAGATTTCGTATATATCATGTCATTTGGC
ATTCATTTCTTTTTCACAATTCATAGTTCTATTCTCAAAAAATTCGAGTT
35 CTCGTATTTGTAAGGAAGATCAGAAGAGACTGTTACACAGGTA CTCTCT
TTTATTTATTGATTCACATTCATATATGTTATTGTTTTCTTGCTTAATGG
TTTCGTCAGTCTAACTGCGCTTGCTGATTTAAATTTCTTCACTTTCTTCC
ACGGATTTTTTAAATATTAGTTTTGTGAATGAACAATTGGTGAAGGAAAG
AAACATGGGAGTCTTTTCTAAAGTAAACCTAGATACTTAGGTTATAAGGG
40 TATATGCTAAAAATGAACTATGCCCATTCACCTTTGCCTTTTCTTTTACTT
TTTAGTTTTAGAATCCAAGTTTTTCATATGTATCTCGATGTGTGAGAAGA
ATAGGCATTAGAAAGGTAAAGGACGTACATAAAATTGATTAATTAGTGAA
TGTTCTTTGATATCATTATTTTTACTCTCATAAAAAGCATATAGATCAAA

CACAAATTGCTACTTGTTAGTGTAACAACCTTCGACTTAATAATGTTAATA
ATCAAAGATTCTCTTGATTTCAACTATTTTCTAACCGAACAAGCTCACTAA
AAACTCATATTGCTTTGAGTCTGAGTGGTTTATATTTGGGGTTTTACATT
TAATTTTTTGTGCATGAATGTGAAAATAGACTGCTTATTGATTCTTTGTG
5 TTTCAATTGAGTTGATTTTCATTATTACTACCTTACAAATTGCTCAGTGAT
AGATTTCCATTAATTTGCTAATTCGGTTGCTTCTAAATATGTAGGAGCTA
CTAAAAGCAAAAATATCGAGCAATGTCCGACCCAACGGGGATTGCTGGTG
CCATTATTAACCCAATTGCTCAGACGGCCTTGGTTCCCGTTACGGACCAT
GTAGGCTACATGATTTCCCTGCAGAAAATATGTGAGGGTCATGCAGATGAA
10 AATGACAGAGTTGAATACCTCAAGAATCAGTGTAGAGGAACACATTAGCC
GGAACACAAGAAATCATCTTCAGATTCCATCTCAAACTAAGGAATGGTTG
GACCAAGTAGAAGGGATCAGAGCAAAATGTGGAAAACTTCCGATTGATGT
CATCACTTGTTGTAGTCTCAGGATCAGGCACAAGCTTGGACAGAAAGCCT
TCAAAGATAACTGAGCAGATTGAAAGTCTAACGAGACAACTCTCCCTGATC
15 AGTTGGACTGATGATCCAGTTCCTCTAGGAAGAGTTGGTTCCATGAATGC
ATCCACCTCTGCATCATTAAAGTGATGATTTCCCATCAAGAGAGAAAACCTT
TTACACAAGCACTAAAAGCACTCGAACCCAACCAAAAATTCACATGGTA
GCCTTGTTGTTGGGATGGGTGGAGTGGGGAAGACTAGAATGATGCAAAGGCT
GAAGAAGGCTGCTGAAGAAAAGAAATTGTTTAATTATATTGTTGGGGCAG
20 TTATAGGGGAAAAGACGGACCCCTTTGCCATTCAAGAAGCTATAGCAGAT
TACCTCGGTATACAACCTCAATGAAAAAACTAAGCCAGCAAGAGCTGATAA
GCTTCGTGAATGGTTCAAAAAGAATTCAGATGGAGGTAAGACTAAGTTCC
TCATAGTACTTGACGATGTTTGGCAATTAGTTGATCTTGAAGATATTGGG
TTAAGTCCTTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGACATC
25 ACGAGACTCACAAAGTTTGCATATGATGGGGGTTGAAGCTAATTCAATTA
TTAACGTGGGCCTTCTAACTGAAGCAGAAGCTCAAAGTCTGTTCCAACAA
TTTGTAGAACTTCTGAGCCCAGCTCCAGAAGATAGGAGAGGATATCGT
AAGGAAGTGTTGCGGTCTACCTATTGCCATAAAAACCATGGCATGTACTC
TTAGAAATAAAAAGAAAGGATGCATGGAAGGATGCACTTTCGCGCATAGAG
30 CACTATGACATTACAATGTTGCGCCCAAAGTCTTTGAAACGAGCTACCA
CAATCTCCAAGAAGAGGAGACTAAATCCACTTTTTTAATGTGTGGTTTGT
TTCCCGAAGACTTCGATATTCCTACTGAGGAGTTGATGAGGTATGGATGG
GGCTTGAAGCTATTTGATAGAGTTTATACGATTAGAGAAGCAAGAACCAG
GCTCAACACCTGCATTGAGCGACTGGTGCAGACAAATTTGTTAATTGAAA
35 GTGATGATGTTGGGTGTGTCAAGATGCATGATCTGGTCCGTGCTTTTGT
TTGGGTATGTTTTCTGAAGTCGAGCATGCTTCTATTGTCAACCATGGTAA
TATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCAAAA
GAATTTCAATTAACATGCAAGGGTATGATTGAGATTCCAGTAGACCTCAAG
TTTCCTAAACTAACGATTTTGAAGCTTATGCATGGAGATAAGTCGCTAAG
40 GTTTCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCATGTTATATCAT
ACGATAAAATGAAGTACCATTGCTTCCTTTGGCACCTCGATGCTCCACC
AACATTCGGGTGCTTCATCTCACTGAATGTTCAATTAAGATGTTTGATTG
CTCTTCTATCGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCAAATT

CTCACATTGAATGGTTACCTTCCACAGTCAGAAATTTAAAGAAGCTAAGG
TTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAACAGGGTGTCTT
GAAAAGTTTTGTCAAACCTTGAAGAATTTTATATTGGAGATGCATCTGGGT
TTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTTACAACCTTTCT
5 GCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATATGTC
ATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGCTCTTTTGATG
AAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCAATTGGTG
ACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGGTTATTTTTGAA
AACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAGATG
10 TTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAATTTA
AAAGTTCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAAAC
CAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTGAAT
GTGAGAATATGGAAGAACTCATACATACTGGAATTGGGGGTGTGGAGAA
GAGACAATTACTTTCCCTAAGCTGAAGTTTTATCTTTGAGTCAACTACC
15 GAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACCACATC
TCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTTATCCG
CAGAACAAAGTTGCGAACATCTAGTTTGTGAAGGAAGGGGTAGATATATG
TTCTTTATGTTAATAACAATTTAAATAATATTTCAACCAAATTTTCATAA
TATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCTATT
20 AAGGGATGATTATTTTGCAGGTTGTGATTCTTAAGTTGGAGACACTTCAA
ATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAGTGG
AGGTGAGAAAGTTAAGTTGAGAGCGATTAAAGTGAGTAGCTGTGATAAGC
TTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTTGAA
GAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACATTGA
25 CTTGGATTGTGTCCGTGCAATTGGAGAAGAAGACAACAAGAGCCTCTTAA
GAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGGATA
AAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTTGAAAG
CATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTATCA
CCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGTTGC
30 GGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCATTTCACTTTC
TTAATTAATTAAGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGTGGG
ATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCATGAA
ACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAAAAA
TATGGCTTAAATTTTTTTTATATTTATGTATCAACATGATTTTTTCATTAG
35 AGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATCAGAACTAATT
CTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAGTG
AAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCTTAAC
AAAAAAACTATTTGGTTCAGAAAAACCGTAATTCAAGATAACTAAAATA
AAAATATTTGACATTCATAAGAGCATTTTTTTTTCTAAATATGATTGCA
40 AATGAATAAACTTAAATTTATACAGAAAAATTCTTTTATATATGTTATAC
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG
GTATCACAAAGGGATATATAATAAAATATTATTTTCTGTAGTCATTTGTA
ATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTAA

ACTTTCATAATAAAAATTTATAATTATTATTATTTTAAATAAATTTAATTA
ATTAAGAGATATATCAAAAATTTAAAGTTATTATAACTTCAAATTTAACA
TATAATTAGAAAATATATGATCATAACTTTCTGCAACTCTTCTTTGTAT
TAAAATGACCAGAGAAGCTCTTAGTATATTTCTAATCAAAGTCTCAAAMC
5 TAATGAAGCATATAATTTGTGAAAATCAATTAGCATTAGGTTTTAAGAGT
CACCAAATTCAAAGAATAATCCAATGCTTTCATTACCACTATGGAGAAAA
TATTTTCTTAGTTTTAAATGAAATGAAAACAAACATTCAAACATAATTGTTG
CTTATTAACCAAAGACCCATTACTTAGCCAAGAGTTTAACAAAAA
TTACATTTCATGTATCATTATTCATGACTAGATATATATGAACATGAAGGG
10 AGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCAGGGAAT
TCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACCAAAG
AGAAGTTTAGCCTAGCATGGCTAAACTCAAGAACTAAAATAAGGATTAG
AAGTACCAAACATGTAGTAAGAATCACAGTAAAGATGATGTTGTTCTTG
ATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCAAAGG
15 AGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCACCAACCT
CCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTGAAGGACC
CTATGTGGGTGCCTTGCGCGGGTGGAGCTGCATACGAAAGGTCTTTGGTC
TTTGTGAGGGTGATGTTGTGCGGGATAGCTTGTGCGATGCTTCCGCGCGG
TTCACGCACATGTGCACAGGTGATGCATGGTGTGTGCGTTCTTGAGTTTT
20 GAGCCTCCGATGCTTAGTCCACTTGGCCCAATTTCGAGTCCAATCAGCTTA
TAACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTGTCCTTCT
CCAATCATCCATAACTTCACAGAATCGCCCGTTCATCTTAATCCCGGAT
GCACAATTATTCTCCCGTCTTCATTTAAGCAAGATACCACCTTCTTCAT
GCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTATTTA
25 GTCCACAATCCTTGTTGTCTCCAAATTTAATTATCTCATTTAGTTCCCG
TTCCGCTAGTTTTCCTTAAAATTTGCAATTAAGCTCAGAGAAATATTAAGT
ACCCGAAATGGTCATAAAATAACAAAAGGAAAATATGCATGAAGATTAA
CTAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTAAATA
AAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAGTCCACCCA
30 CCCTTCATTCTTGTACCAATATGGGATGGAAACATCATTAAATTAAGCCA
AAAAGCTAACATATAAGGGTTTTAGTGACAAAGGTAAGTACTAAAGATGAA
AAT.AATCCATTTTTCTTGTATATACACAACACACACATAGGGGCGAGACGT
AGGATTTCAAAGTACAGATTGTTGGTGGCACATAAGTGTTGCTGGTGACA
TTTTTTTTTTTTTTTTTACGTAGTGGCACAACAGTAGGAAAAACGAAAAAT
35 TCGAAATTTTTTACAATTTGTCTAAAAAAAACAGTGGTTGTTGGTGCCAC
TATGGACACCAAAGTTGAACTGCCCCACGCGCGCACACACACACACA
CATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAAAGAAAGAGAGAGA
GAGAGTTTGGGATGTGATACTTCTTTTAGGAAAATGGAGTTATATCTTTG
ATATTGTATTTTTTTAATGTAAATTTATATATTTAATCATTTTAGTTTATA
40 AGTTTTATTTATTTTGATATGAAAAAAAAGTCTTTTATACATTGGATTT
AACATAAAAATCCAACAATATTAATCAAAAAGACCAMACATGTGGACAMW
TATGTATATAAWTAATTCACAATAGTCTTTAGGAATAGNATTATATATAT
AATTAATTCTCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACCT

TNGCCACAATTCTTTGKTTACTTWGACACTTYCCTCTCTCTAATTATATA
TATATATATATATATATATATATATATATACACACACACACACACACTAG
ATGTGTGCCCCGCGCAAAGCAGTGACGTNNNGGAGAANACTTTCTTAAGCA
TAAATAATTATTATATTTTTTTATTGGGTATTATATAATAAAAAAATTACAA
5 CTTTTAAATAAAAATATTTATGTTTATACTTTATATTTATATTGCTTGTAT
ACTATTAATATAATAAAATTAATATTTATGTCTAATTTATGAAATGTAAAT
TAATTTAAATACATGAATTTAATATTTTAAATTTTCAGTTTGCTTCAA
ATTGAGTTTCTTAATTATTTTTTTAATTCANGTATTCAAACCTTTGGTA
AGTATTAAGAATTATTTATGCATAATTGATTTATACAAAAAATTTGTA
10 ACTTATACATCTTAAATTCAGATATACTAACATGTTTTACAATATAT
AT
TAAAGCGCAAAGGTCATAGGAATAGAATATTTTCTATTATTCTACGTTTT
GCCACAAAAGTTTGAACACTTTGCCACTTTTGTCCCTCCTTAACCTTTT
CAATGTTTTGCGACAAAAGTTCCAAAACCTTTGCCACTTTGATCATTCTC
15 AACTTTTCACCGCAATTAGTTTGTGGAGTTGGCAGTTTGTATCCCCCTAA
CTTCGATATTCTCTACTGCTAGCCAAAAAGGGTTCCAGAGTTTCACACTT
TTGGTCCCTGACAGTAACCAAATGTGAGATGTCAAATTTTGGCCACATTA
GTTTGTGGAGTTGTCCCTTTTGGTCCCCCACATTGATATTCTANTATA
CGACCTTATTTTTNTCAAATAACAACACGTATATTTAATTACCAATTATA
20 GAAATAGATATCAAATAAAGTATTTGTAACACTGTGTAAGAACGGTGCTA
CTATAGGTAAAAATAAACATTTCAAAGTACGATATCCTAATTGAAAAAG
AGTTTTAAAAAAATAACGACTAGGGGCGAGTTTTTTTTACAAGTTGTAT
CAAATCATATCAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAAT
GTAATTTATTCTTTGATTTTGATAATTTTTAATATTTTGTGTGATCTAT
25 GTATTTAAAGTAAACAACAAGAACATAATCCAAAACCCTAAATTGCAA
GTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGT
CGCTCTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAA
AAGTTGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGT
CAAAATTTTGATTTTGTGATGGATTTGAGTAGAAGTTTGGGCAGAACGG
30 GAATGATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATA
TATGTAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATC
TTTTTAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACC
AACAACTCTTAAAACTTGATTAATCAATTGTTTTCTTCATCTTGATAAC
AAGTGGAATGATTTTCTACTTAGATTAACCTGAAAAAAAGGTCCATGTG
35 CGTCTGGTGGATCTGGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAG
ACACAAACACGTCACCATATCTCTTATTTTATTTTAAATTTGCTTTTGGT
GTAATTTCTTTTTCTTATTTCTTTCTTTGATCTCCAGATGGTATGT
GGTGTGGATAATTTACACCTAGAGATTGGGAACGATGGGAAGGGGTCTGT
GATTTATGGCTGGCCGAGTTTTACTTATTAACCTCAATTTCAACCTAAAT
40 CTGATTCTTGTGTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGT
TGCATAGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATC
CAACTATTTTTTAGCTGTTGGCATTTTCCATCATTTGCAACTGTTTCTTG
AAAAAAAATACCTAAAATAAAAATAACCATTTTCAAATCCAAAATTATA

AGAGAGAATTGTAAATGGACATGGAATCATAAATCATTAACACAGTTCAG
TAAACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCA
GAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATCTTGTATT
CCCATCCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGG
5 ATAATTATGAAGGAGTGGAGGTGGTATTTGAGATAGAGAGTGAGAGTCCA
ACATGTAGAGAATTGGTAACAACCTCGCAATAACCAACAACAGCCTATTAT
ACTTCCCTACCTCCAGGATTTGTATCTAAGGAATATGGACAACACGAGTC
ATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAA
CAATCAGAATCCCCATTCCACAACCTCACAACCATAAATATTCTTAAATG
10 CAAAAGCATTAAAGTACTTGTTCGCTCTCATGGCAGAACTTCTTTCCA
ACCTAAAGGATATCCGGATAAGTGAGTGTGATGGTATTAAAGAAGTTGTT
TCAAACAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCA
CACAACCACCACTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCC
TGGAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGC
15 AATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCA
ATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCTTTTT
TATTTGCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGAT
AATAATTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGA
AACTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCT
20 TTTGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTAT
TTAGCAAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAAT
CTGGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGG
GGACATCAGGTGACAGATATTGTAGAATAGAACAATATATAATATTACCC
AAAATATTTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGATTT
25 CATTGAATTTGCATTCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCA
ATAAATCCCGAAATTAATTAAAAAAGAAAAAACAAGTAAATTTTTGA
TATGGAGAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAAT
TAAGTTTCTTATATAAAAGCTGTGTATATAGTTTAATTAGTTTACATCA
TTTTTCCATGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTCTTGGAG
30 TTTATGCCAATACGCTAGAGAGATARAATAGKTGGATGCTATGCATTGT
CAAGTGTGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTG
CTGAGAATAGAGTCTTGTGATGGCATGAAGGAGGTATTTGAAACTCAATT
AGGGACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGCGAGGAAGGAA
TTCCAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTA
35 AGTATTGGAAATTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACT
TGAAAGCCTGAGACAGCTCCAAGAGTTAAAGATAAAATTTTGCTACGGAA
TGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACA
ACAACAACAACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTC
TTCTTCTTCTAAGAAGGTTGTGGTCTTCTTCTTGTCTAAAGTCCATTGTAT
40 TGGTCAATCTACCAGAGCTGGTAGGATTCTTCTTGGGGATGAATGAGTTC
CGGTTGCCTTCATTAGATAAACTTAAGATCAAGAAATGCCCAAAAATGAT
GGTGTTTACAGCTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACA
CAAGATTAGGCAACATACTCTTGATCAAGAATCTGGCCTTAACCTTCAT

CAGGTATATATATATTTCTTTAATTGGCATCATCTAATTAAGAAAGATAT
CATTCCTGCCAAGTAAATTTACTTCAAACACATTCACTGGTTTCAGTC
TAAGTTTATGTTGTTCTAAGAAGGCCAAAATGGGAAAGCAAGATAGGGAA
AAATAGTGTATTTCAGTGGAAAGGGTATTTTAGGCATTTTCTGTCAAAAG
5 TTGTTATTGCAGGCTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATT
ATTATTCTGATTTGCTTGTTTCTTTATCATTTTTTCTTAGCCTCTCGAAC
AGCTAGAAACCCTTTTAATCTTTTGATTTTCAATGACGAAATTTTCCCT
GTTACTCCATTTGATTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCT
CATCTGTTACTTCTTTTGATTGTTATTTTCATATCATGTTGTCCTTTGAA
10 TCAAGCTTTTCCATTTTCAACCAGGGCAAAAGGTCAAAAGTAACCTACTT
TATGAGATCAAAAACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAAT
AGTTACAATTACCATTGTGATTAATAATTATAATATCTTGTATTAATTCA
TAAAAATTGGTACAGCACATATATGACATTTCAAAGGTTTTTGTGTTGACA
TATATATGCCTCTGGCGTTTTCTTTATTGGACTTGCAGACCTCATTCCAA
15 AGTTTATACGGTGACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTTG
GTCTTTTTCATAACTTTATCGAATTAGATGTGGAAGGTAATCATGATGTTA
AAAAGATTATTCCATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAG
ATT.AATGTAAGGTGGTGTAAGGGGTAGAGGAGGTATTTGAAACTGCATT
GGAAGCAGCAGGGAGAAATGGAAATAGTGAATTTGGTTTTGATGAATCGT
20 CAC.AAACAACCTACCACTACTCTTGTCATCTTCCAAACCTTAGAGAAATG
AACTTATGGGGTCTAGATTGTCTGAGGTATATATGGAAGAGCAATCAGTG
GAC.AGCATTTGAGTTTCCAAACCTAACAAGAGTTGATATCTATAAATGTA
AAAGGTTAGAACATGTATTTACTAGTTCCATGGTTGGTAGTCTATCGCAA
CTCCAAGAGCTACATATATCCAACCTGCAGTGAGATGGAGGAGGTGATTGT
25 TAAGGATGCAGATGATTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATG
GGGAGACGAATAAGGAGATACTTGTGTTACCTCGTCTAAACTCCTTGATA
TTA.AGAGAACTTCCATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTT
TTC.ATTCCCATTATTGGATACTTTAAGAATTGAGGAATGCCCAGCAATAA
CCACCTTCACCAAGGGAAATTCCGCTACTCCACAGCTAAAAGAAATTGAA
30 ACACATTTTGGCTCGTTTTGTGCTGCAGGGGAAAAAGACATCAACTCTCT
TAT.AAAGATCAAACAACAGGTAAATCAGATCTTTGTTGCTTTAATAATTC
TTAAACTACATTTGAAAAGCTTCATGCAAGTTTTTTTTTGTATATTGTCA
AAAACCGCAACCTACATTTTACGCTTTATATTTATGTACTTTATGCAGGA
GTTCAAACAAGACTCTGATTAATGTGAAGTAAATACTAAAGGTAAATTAT
35 ATTTTCATGTTCTAGTTGCCTATTAATTAATTGCCTTTTAGTTTCATGAT
TTTTGGATGCATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCAT
TGTTTGGTTGAATGTTGACTCTATGTCTTGATGAATATTCAAGGGAAGAA
TTGTTTCATCATATGAAGGACATTAAAGAAGAACATGGATGCTATGAAGAT
GTGGGAAAACAA

40

RG2B deduced polypeptide sequence (SEQ ID NO:90)

MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEE
HISRNTRNHLQIPSQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITE
QIESLTRQLSLISWTDDPVPLGRVGS MNASTSASLSDDFPSREKTFTQALKALEPNQK
5 FHMVALCGMGGVGKTRMMQRLKKAEEKKLFNYIVGAVIGEKTDPFAIQEAIADY
LGIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQ
GVDFKVLLTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGE
DIVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQ
EEETKSTFLMCGLPEDFDIPTEELMRYGWGLKLFDRVYTIREARTLNTCIERLVQ
10 TNLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPGWPDENDMIHVHSC
KRISLTCKGMIEIPVDLKFPKL TILKLMHGDKSLRFPQDFYEGMEKLVHVISYDKMKY
PLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSHIEWLPSTVRNLK
KLRLLDLRFCDGLRIEQGVLSFKLEEFYIGDASGFIDDNCNEMAERSYNLSALEF
AFFNKAAEVKNMSFENLERFKISVGCSDENINMSSHSEYENMLQLVTNKGDVLD SK
15 LNGLFLKTEVLFSLVHGMNDLEDVEVKSTHPTQSSSFCNLKVLHISKVELRYLFKL
NLANTLSRLEHLEVCECENMEELIHTGIGGCGETITFPKLKFLSLSQLPKLSSLCHN
VNIIGLPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEGVVIPKLETLOIDDMENLEEIW
PCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNIDLD
CVGAIGEEDNKSLLRSINVENLGLKREVWRIKGADNSHLINGFQAVESIKIEKCKRFR
20 NIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSCLMH
SFHNLRLVLTLDNYEGVEVVFEIESESPTCRELVTTRNNQQQPIILPYLQDLYLRNMD
NTSHVWKCSNWNKFFTLPKQQSESPFHNLTTINILKCKSIKYLFSPLMAELLSNLKDI
RISECDGIKEVVS NRDEDEEMTTFTSTHTTTTLFPSLDSLTLFLENLKICGGGGAK
DEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEIVGCYALSSVIPCYAA
25 GQMQL

RG2C polynucleotide sequence (SEQ ID NO:91)

ATAATATTACACAAAGGTAACGTCATTAATTAATTACGATACGAGACAGA
CTTTTTCACCTCGGACATNAACGGTCTATTCCTAACTTNANNTAATTNAAT
30 GAATTTAGGATGTGCTAATATGCATGTAANATTCGCTACCGTCATCTTTC
AAATGACCATATTTTTATGTATTTATAATGAATCAATGAAAAACCGGATT
TCT.ATTTAAAATTCTTAAAACTTCATCTTTAAGCCAGGGTGAATACAAT
TGCTAGATCCACTGTTAATTTCCATCGAATTATGCCTGATCAATTGTTGG
CTGCCTACGATGCAGGTGCTACCACAAGAATATGGCCATGGAACTGCTA
35 ATGAAATTATAAAACAAGTTGTTCCAGTTCTCATGGTTCCTATTAACGAT
TACCTACGCTACCTCGTTTCCTGCAGAAAGTACATCAGTGACATGGATTT
GAAAATGAAGGAATTA AAAAGAAGCAAAAGACAATGTTGAAGAGCACAAAGA
ATCATAACATTAGTAATCGTCTTGAGGTTCAGCAGCTCAAGTCCAGAGC
TGGTTGGAAGATGTAGAAAAGATCAATGCAAAAGTGGAAGTGTTCCTAA
40 AGATGTCGGCTGTTGCTTCAATCTAAAGATTAGGTACAGGGCCGGAAGGG
ATGCCTTCAATATAATTGAGGAGATCGACAGTGT CATGAGACGACACTCT
CTG.ATCACTTGGACCGATCATCCCATTCTTTGGGAAGAGTTGATTCCGT

GATGGCATCCACCTCTACGCTTTCAACTGAACACAATGACTTCCAGTCAA
GAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACTTGAGGCCAACCACATG
ATAGCCTTATGTGGAATGGGGGGAGTGGGGAAGACCCACATGATGCAAAG
GCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTTGGTTATATCATCGAGG
5 CGGTTATAGGGGAAATATCGGACCCCATGCTATTCAGCAAGTTGTAGCA
GATTACCTATGCATAGAACTGAAAGAAAGCGATAAGAAAACAAGAGCTGA
GAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGATGGAGGTAACACTAAGT
TCCTCATAATATTGGATGATGTCTGGCAGTCCGTTGATCTAGAAGATATT
GGTTTAAGCCCTTCTCCCAATCAAGGTGTCGACTTCAAGGTCTTGTTGAC
10 TTCACGAGACGAACATGTTTGCTCAGTGATGGGGGTGAAGCTAATTCAA
TTATTAACGTGGGACTTCTAATTGAAGCAGAAGCACAAAGATTGTTCCAG
CAATTTGTAGAACTTCTGAGCCCGAGCTCCACAAGATAGGAGAAGATAT
TGTTAGGAGGTGTTGCGGTCTACCCATTGCCATCAAAACCATGGCGTGTA
CTCTAAGAAATAAAAAGAAAGGATGCATGGAAGGATGCACTTTCTCGTTTA
15 CAACACCATGACATTGGTAATGTTGCTACTGCAGTTTTTAGAACCAGCTA
TGAGAATCTCCCGGACAAGGAGACAAAATCTGTTTTTTTATGATGTGTGGTT
TGTTTCCCGAAGACTTCAATATTCTACCGAGGAGTTGATGAGGTATGGA
TGGGGCTTAAAGTTATTTGATAGAGTTTATACAATTATAGAAGCAAGAAA
CAGGCTCAACACCTGCATTGACCGACTGGTGCAGACAAATTTACTAATTG
20 GAAGTGATAATGGTGTACATGTCAAGATGCATGATCTGGTCCGTGCTTTT
GTTTTGGGTATGTATTCTGAAGTCGAGCAAGCTTCAATTGTCAACCATGG
TAATATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCA
AAAGAATTTCAATTAACATGCAAGGGTATGATTGAGTTTCCAGTAGACCTC
AAGTTTCCTAACTAACGATTTTGAACTTATGCATGGAGATAAATCGCT
25 AAAGTTTCCTCAAGAATTTTATGAAGGAATGGAAAAGCTCCGGGTATAT
CATACCATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCAATGCTCC
ACCAACATTCGGGTGCTTCATCTCACGGAATGTTCAATTAAGATGTTTGA
TTGCTCGTGATTGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCTA
ATTCTTGCAATTGAGTGGTTACCTTCCACGGTCAGAAATTTAAAAAAGCTA
30 AGGTTACTTGATTTGAGATTGTGTTATGGTCTCCGTATAGAACAGGGTGT
CTTGAAAAGTTTGGTCAAACCTGAAGAATTTTATATTGGAAATGCATATG
GGTTTATAGATGATAACTGCAAGGAGATGGCAGAGCGTTCTTACAACCTT
TCTGCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTAAAAAATAT
GTCATTTGAGAATCTTGAACGATTTAAGATCTCAGTGGGATGCTCTTTTG
35 ATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCGATTG
GTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGGTATTATTTT
GAAAACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAG
ATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAAT
TTAAAAGTCCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAA
40 ACTCAATGTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTA
AATGCAAGAATATGGAAGAACTCATACATACTGGGATTGGGGGTGTGGA
GAAGAGACAATTACTTTCCCAAGCTGAAGTTTTTATCTTTGAGTCAACT
ACCGAAGTTATCAGGTTTGTGCCATAATGTCAACATAATTGGGCTACCAC

ATCTCGTAGACTTGAACTTAAGGGCATTCCAGGTTTCACAGTCATTTAT
CCGCAGAACAAGTTGCGAACATCTAGTTTGTGAAGGAAGAGGTAGATAT
ATGTTCTTTATGTTAATACAATTTAAACAATATTTTCAACCAAATTTTCA
TAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCT
5 ATTAAGGGATGATAATTTTGCAGGTTGTGATTCCCTAAGTTGGAGACACTT
CAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAG
TGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGATA
AGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTT
GAAGAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACAT
10 TGACTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCT
TAAGAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGG
ATAAAAGGTGCAGATAACTCTCATCTCATCAATGGTTTTCAAGCTGTTGA
AAGCATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTA
TCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGT
15 TGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCATTTCACT
TTCTTAATTAATTANGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGT
GGGATGACTAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCAT
GAAACGCTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAA
AAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTTCATT
20 AGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAATAA
TTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAG
TGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCTTA
ACAAAAAAACTATTTGGTTCAGAAAACTGTAATTCAAGATAACTAAAA
TAAAAATATTTGACATTCCTAAGAGCATTTTTTTCTAAATATGATTGCA
25 AATGAATAAAACTTAAATTTATACAGAAAAGATTTTATATATGTTATAC
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG
GTATCACAAAGGGATATATAATAAAATATTATTTTTCTGTAGTCATTTAT
AATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTA
AACTTTCATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATTATT
30 AATTAAGAGATATATCAAAAATTTAAAGTTATTATAACTTCAAATTTAAC
ATATAATTAAAAAATATATGATCATAACTTTCCGCAACTCTTCTTTTGTA
TTAAATGACCAGAGAAGCTCTTAGTATATTTTCTAAATCAAAGTCACAA
AACTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTTTAA
GAGTCACCAAATTCAAAGAGTAATCCAATGCTTTCATTACCACTATGGAG
35 AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTAATT
GTTGCTTATTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAACCAAAA
AAAATTACATTCATGTATCATTATTAATGACTAGATATATATGAATATGA
AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCATG
GAATTCCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACC
40 AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAAGGA
TTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTT
CTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCA
AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCACCA

ACCTCCCTTAAATAAACTCAAAGCAAAAATGACAAAATTGCCCTGAAG
GACCCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATATGAAAGGTCTTT
GGTCTTTGTGAGGGTGTGTTGTGCGGGTTAGCTTGTGCGCATGCTTCCGC
GCGGTTGCGGCACATGTGCACAGGTGATGCATGGTGTGTACGTTCTTGAC
5 TTTTGAGCCTCCGATGCTTAGTCCACTTGGCCCAATTCGAGTCCAATCAA
CTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTTGCC
TTCTCCAAATCATCCATAACTTCACAGAATCGCCCGTTCATCTTAATCCC
GAATGAACAATTATTCTCCCGTCTTCATTTTAAGCAAGATACCACCTTCT
TCATGCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTA
10 TTTAGTCCACAGTCCTTGTTGTCCTCCAAATTTAATTATCTCATTTAGTT
CCCGTTCGCTAGTTTCCTTAAAATTTGCAATTAAGCTCACAGAAATATT
AAGTACCCGAAATGGTCATAAAAATAACAGAAAGGAAAATATGCATGAAGA
TTAACTAAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTA
AATAAAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAAGTCCA
15 CCCACCCTTCATTCTTGTACCAATATGGGATGGAAACATCATTAAATTAA
GCCAAAAAACTAACATATAAGGGGTGAGTGACAAAGGTAAGTACTAAAGA
TGAAAAAAATCCATTTTTCTTGTATATACACAACACACACATAGGGGCAG
ACGTAGGATTTTCATAGTACAGATTGTTGGTGGCACATAAGTGTTGCTAGT
GACATTTTTTTTTCTTTTACGTAGTGGCACAACAGTARAAAAAACRAAA
20 AATTCGAAATTTTTACAATGTGCCTAAAAAAAACAGTGGTTGTTGGTGC
CACTATGGACACCAAAGTTGAACTGCCCCTGCGCGCGCACACACACACAC
ACATAAAGTTTG
GGATGTGATACTTCTTTTGGGAAAATGGAGTTATATCTTTGATATTGTAT
TTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAAGTTTTATT
25 TATTTKGATATGAAAAAAAAGTCTTTTATACATTGGATTTAACATAAAA
ATCCAACAATATTAATCAAAAAGACCAAACATGTGGACAATTATGTATAT
AATTAATTCACAATAGTCTTTAGGAATAGNATTATATATATAATTAATTC
TCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACNTTTGCCACAN
TTCTTTGNNTACTTNGACACTTTYCTCTMWNNANWMWWTWATATATATAT
30 ATATATATATATAHAHAHAHAVACACACACACTAGATGTGTGCCMGGCA
AAGCAGTGACGTNNNGGAGAANACTTTCTTAAGCATAAATAATTATTATA
TTTTTTATTGGGTATTATATAATAAAAAATTACAACCTTTAAATAAAATA
TTTATGTTTATACTTTATATTTATATTGCTTGTATACTATTAATATAATA
AATTAATATTTATGTCTAATTTATGAAATGTAAATTAATTTAAATACATG
35 AATTTAATATTTTTAAAATTTTCAGTTTGCTTCAAATTGAGTTTCTTAAT
TATTGACCAAACATGTGGACAATTATGTATATAATTAATTCACAATAGTC
TTTAGGAATAGTATTATATATATAATTAATTCCTCAATGGTCTTAGGAATA
GTAAGTTCTTATATTTCAAACCTTTTGCCACAATTCTTTGCTTACTTTGAC
ACTTTTCCTTCCTAACTTTACATATATATATATATTTAAAGCGCAAAGGTC
40 ATAGGAATATAATATTTTCTATTATCTACGTTTTGCCACAAAAGTTTGA
ACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTTCAATGTTTTGCGACA
AAAGTCCAAAACCTTTGCCACTTTGATCATTCCTCAACTTTTCACCGCAT
TAGTTTGTGGAGTTGGCAGTTTTGGTCCCTCTAACTTCGATATTCTCTAC

TGCTAGCCAAAAAGGGTTCAGAGTTTCACACTTTTGGTCCCTGACAGTA
ACCAAATGTGAGATGTCAAATTTTGGCCACATTAGTTTGTGGAGTTGTCC
CTTTTGGTCCCCCACATTTCGATATTCTACTATACGATCTTATTTTCTC
AAATAACAACACGTATATTTAATTACTAATGATAGAAATAGATATCAAAT
5 AAAGTATTTGTAACACTGTGTAGAGTTTTTTTTTACAAGTTTGTATCAAA
TCATATCAAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAATGTAA
TTTATTCTTTGATTTTGATAATTTTAATATTTTGTTGTGATCTATGTAT
TAAAAGTAAACAACAAAGAACATAATCCAAAACCTAAATTGCAAGTCT
CGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGTCGCT
10 CTCTCACTGCTTACAACCCCTTGTTGCTACTCATTACAATAACGAAAAGT
TGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGTCAAA
TTTTTGATTTAGTTGATGGATTTGAGTAGAAGTTTGGGCAGAACGGGAAT
GATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATATATG
TAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTGATCTTTT
15 TAGAACTTAGTTTTCTGAAACACCCGTGATTTGGATCAAATATCACCAACA
ACTCTTAAAACTTGATTAATCAATTGTTTACTTCATCTTGATAACAAGT
GGAATGATTTTCTACTTGAAAAAAAAGGTCCATGTGCGTCTGGTGGATCT
GGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAGACACAAACACGTCA
CCATATCTTTTATTTTATTTTAAATTTTCTTTTTTCCTATTTCTTTCTTT
20 CTTGATCTCCAGATGGTATGTGGTGTGGATAATTTACACATAGAGATTGG
GAACGACTGTGATTTAGAGAGGACGTGGCTTGGGGTTGAGGATGGTTTAT
GGCTGGCCGAGTTTCATTTATATAAAACAAACAAATATATAAAACAAGGGG
TAAATGGCCATCTTATATGTATTTAACCGTCCTCTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTGTAATTTAAGAAGGGGTATACCAGTGTCAGC
25 CTCTTATTCCCAACCAGTCAAATAGGGACTTAGGTTGTTTGGAAACAGTT
CCGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCCCTT
CAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGAT
TCTTGTTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGTTGCAT
AGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATCCAAC
30 ATTTTAAATCTGTTGACGTTTCCATCATTTGCAACTGTTTCTTGAAAAA
AAAATACCTAAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGA
GAATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAAC
AAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAA
AGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTTGATTCCCAT
35 CCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGGATAAT
TATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAG
TAGAGAATTGGTAACAACCTCACAATAACCAACAACAGCCTATTATACTTC
CCTACCTCCAGGAATTGTATCTAAGGAATATGGACAACACGAGTCATGTG
TGG.AAGTGCAGCAACTGGAATAAATCTTCACTCTTCCAAAACAACAATC
40 AGAATCACCATTCCACAACCTCACAACCATAGAAATGAGATGGTGTGTCATG
GCTTTAGGTACTTGTTTTCGCCTCTCATGGCAGAACTTCTTTCCAACCTA
AAGAAAGTCAAGATACTTGGGTGTGATGGTATTAAAGAAGTTGTTTCAAA
CAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACAAAA

CCACCAACTTGTTCCCTCATCTTGATTCTCTCACTCTAAACCAACTGAAG
AATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGA
AATATCTTTCAATAATACCACTGCAACGACTGCTGTTCTTGATCAATTTG
AGGTATGCTTTGTACATATTCAATTATTTATTTAATTCCTTTTTTTATTT
5 GCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAA
TTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTC
TAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGA
TGGGTAATATAGGCAATTTAAGTTTTATTTCTGTTAAAGCAGTATTTAGC
AAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGT
10 CATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGGTTA
TCAGGTGACAGATATTGTAGAATAGAACAATATGTAATATTACCCAAAAC
TATTTTTTCTAAGGTTGCTCTGTTAAATATGTGCTTTCTTGATTTCATTG
AATTTGCATTCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAA
TCCCGAAATTAATTAACAAAAAAGTAAATTTTGTATATGGA
15 GAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTT
TCTTATATAAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTTC
CATGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTCTTGGAGCTTATG
CCAATACGCTAGAGAGATAAAAAATAGGCAACTGCCATGCATTGTCAAGTG
TGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGA
20 GTAATGGCTTGCAATGGGATGAAGGAGGTATTTGAAACTCAATTAGGGAC
GAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTCCAA
GAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTAAGTATT
GGAAATTGTGGGGGTTTGAACATATATTCACATTCTCTGCACTTGAAAG
CCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTGCTACAGAATGAAAG
25 TGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACA
ACAACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTTAAGAAGGTGGT
GGTCTTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGG
TAGGATTCTTCTTGGGGATGAATGAGTTCGGGTGCCTTCATTAGATAAA
CTTATCATCGAGAAATGCCCAAAAATGATGGTGTGTACAGCTGGTGGGTC
30 CACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTC
TTGATCAAGAATCTGGCCTTAACCTTCATCAGGTACATATATATTCCTTT
AATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTTA
CTTCAAACACATTCACACTAGTTTCAGTCCAAGTTTATGTTGTTCTAGGA
AGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGAGTATTTCAAGTGAA
35 AGGGTATTTTAGGTATTTTCTGTCAAAAATTGTTATTGCAGGCTTTTATG
TACCTGGAAGAGCATGATTATTCTCGATTTGCTTGTTTCTTTATCATTTT
TCTTAGCCTAGCATGATTTTCAATGAAATCTTCCCTGTACTCCATTG
ATTGTTGTTCTTCATGGTTCTAAGTGAGTTAGTGGCTCATCTGTTACTTC
TTTTGATTGTTATTTTCATAGCATGTTGTCACCTGAATCAAGCTTTTCCA
40 TTTTCAACAAGGACAAAAGGTCAAACTAACCTACTTTATGAGATCAAAA
ATAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATACTTACAATTACC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT

GGCGTTTTCTTTATTGGACATGCAGACTTCATTCCAAAGTTTATACGGTG
ACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAAC
TTTATCGAATTAGATGTGAAATCTAATCATGATGTTAAAAAGATTATTCC
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGTAAAGATTAATGTAATGT
5 GGTGTAAGGGTAGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGG
AGAAATGGAAATAGTGGAATTGGTTTTGATGAATCGTCACAAACAACCTAC
CACTACTCTTGTCAATCTTCCAAACCTTGGAGAAATGAAGTTACGGGGTC
TCGATTGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG
TTTCCAAACCTAACAAGAGTTGAAATTTATGAATGTAATTCATTAGAACA
10 TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG
AGATTGGTTTGTGCAACCATATGGAGGTCGTGCATGTTTCAGGATGCAGAT
GTTTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAA
GGAGATACTTGTGTTACCTCATCTAAAGTCATTGAAATTACTACTTCTTC
AAAGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCCATTA
15 TTGGATACTTTGGAAATCTACGAATGCCAGCAATAACCACCTTCACCAA
GGGAAATTCCGCTACTCCACAGCTAAAAGAAATGGAAACAAATTTTGGCT
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC
AAACAACAGGTAAACCAGATCTTTGTTGCTTTAATAATTCTTAAACTACA
TTTGAAGAGCTTCATGCAAGTTTTTTTTGTTATATTGTCAAAAACCGCAA
20 CCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGATTTCAAACAA
GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT
TCCTAGTTGCCTATTAATTAAGGCCTTTTAGTTCGTGATTTTGGATGT
ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA
25 TATGAAGGACATTAAAGAACATGGTGCTAT

RG2C deduced polypeptide sequence (SEQ ID NO:92)

MAMETANEIHKQVVPVLMVPINDYLRYLVSCRKYISDMDLKMKEAKDNVEEH
KNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAFNI
30 IEEIDSVMRRHSLITWTDHPIPLGRVDSVMASTSTLSTEHNDFQSREVRFSEALKALE
ANHMIALCGMGGVGKTHMMQRLKKVAKEKRKFGYHIEAVIGEISDPIAIQQVVADY
LCIELKESDKKTRAELRQGFKAKSDGGNTKFLIILDDVWQSVLEDIGLSPSPNQG
VDFKVLTSRDEHVCVMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIGEDI
VRRCCGLPIAKTMACTLRNKRKDAWKDALSRHQHDIGNVATAVFRTSYENLPD
35 KETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTHIARNRLNTCIDRLVQT
NLLIGSDNGVHVKMHDLVRAFLGMYSEVEQASIVNHGNMPGWPDENMIVHSC
KRISLTCKGMIEFPVDLKFPLTILKLMHGDKSLKFPQEFYEGMEKLRVISYHKMKY
PLLPLAPQCSTNIRVLHLTECSLKMFDSCIGNLSNLEVLFSFANSIEWLPSTVRNLK
KLRLDLRLCYGLRIEQGVLSLVKLEEFYIGNAYGFIDDNCKEMAERSYNLSALEF
40 AFFNKAIEVKNMSFENLERFKISVGCSDGNINMSSHSEYENMLRLVTNKGDVLDK
LNLFLKTEVFLSVHGMNDLEDVEVKSTHPTQSSFCNLKVLIIISKVELRYLFLK
NVANTLSRLEHLEVCKCKNMEELIHTGIGGCGETITFPKLKFLSLSQLPKLSGLCH

NVNIIGLPHLVDLKLGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEI.
WPCELSGGEKV KLR EIKVSSCDKL VNLFP RNPMSLLHHLEELTV ENC GSIESLFNID
LDCVGAIGEEDNKSLLRSINVENLGK LREVWR IKGADNSHLINGFQAVESIKIEKCK
RFRNIFT PITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSC
5 LMHSFHNLRVLTLDNYEGVEVVFEIESESPTSRELVTTHNNQQQP IILPYLQELYLR
NMDNTSHVWKCSNWNKFFTL PKQQSES PFHNLTTIEMRWCHGFRYLFSP LMAELL
SNLKKVKILGCDGIKEVVS NRDD EDEEMTTFTSTHKTNLFP HLD SLTLNQLKNLK
CIGGGGAKDEGSNEISFNNTTATTA VLDQFELSEAGGVSWSLCQYAREIKIGNCHAL
SSVIPCYAAGQMQLQVLRVMACNGMKEVFETQLGTSSNKNNEKSGCEE GIPRVN
10 NNVMILPNLKILSIGNCGGLEHIFTSALES LRQLQELTIKGCYRMKVIVKKEEDEY G
EQQTTTTTTTGASSSSSSSKKV VVFPCLKSIVLVNLP ELVGFFLGMNEFRLPSLDKLI
EKCPKMMVFTAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTLGPAT
SEGTTWSFHNFIELDVKSNDVKKIIPSELLQLQLVKINVMWCKRVEEVFETALE
AAGRNGNSGIGFDESSQTTTTTLVNL PNLGEMKLRGLDCLRYIWKSNQWTA FEFPN
15 LTRVEIYECNSLEHVFTSSMVGSLLQLQELEIGLCNHMEVVHVQDADVSVEEDKEK
ESDGKMNKEILVLP HLKSLKLLLLQSLKGFSLGKEDFSFPLD TLEIYECPAITTTFK
GNS.ATPQLKEMETNFGFFYAAGEKDINSSIIKIKQQDFKQDSD.

RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94)

20 ACGACCACTATAGGGCGAATTGGGCCCCGACGTCGCATGCTCCCGGCCGCC
ATGGCCGCGGGATGTAAAACGACGGCCAGT CGAATCGTAACCGTTCGTAC
GAGAATCGCTGTCTCTCCTTCAACCATTTAATGTATATGAGCTAAATTG
AAACATCTACTATCATGTTTAAATTTATAAACTTTTCCTTTAGATTAC
TTGTCTGGATGTGTTTAATAAAACCCAATTTCCCACATGCGTAGAGATCA
25 TAGATGTAAC TATTGTTAATCAATTTTGCCTGCCAAGTTTAAATAATTAT
ACTTGGATATTAACAAAAC TTTATCTAACGACCAAGGTAATATTA AAAAT
AGGTTATTATTCTTCATGCTAATTA AAAGATGGGTTGCAAAAGTGAGACC
ATG.AAAACATTAACACGTTGATATTTTCAACTTTTATTCTTTCATATTCA
CCATATTTTTTTACTTTTCGTATTGATTAATCATCTTTCAATCACAGGCTCC
30 TTGGCAAAAAGTCAGATCTATTAACAAATACTTCCATGTGGTTGCAAATT
ACAAGGATTTCAACATAATTACCAAAACATAGCATTATCATAAGATCGAA
TAATAATCAAATTCTTCTATAATATTACACAAAGGTAACGTCATTAATTA
ATTACGATACGAGACAGACTTTTTCACTCGTGACATCAACGGTCTATTCT
AACTTTACTTAATTAAATGAATCTAGGATGTGCTCATATGCATGTAATAT
35 TTGCTACCGTCATCTTTCAAATGACCATATTTTTATGTATTTATAATGAA
TCA.ATGAAAAACCGGATTTCTATTTAAATTTCTTAAAACTTCATCTTTTA
AGCCAGGGTGAATACAATTGTAGATCCACTGTTAATTTCCATCGATTATG
CGTGATCAATTGTTGGCTGCATACGATGCAGGTGCTACCACAAGAATATG
GCC.ATGGAAACTGCTAATGAAATTATAAAACAAGTTGTTCCAGTTCTCAT
40 GGTTCCATTATAACGATTACCTACGCTACGTCGTTTCCTGCAGAAAGTACA
TCAGTGACATGGATTTGAAAATGAAGGAATTA AAAAGAAGCAAAAGACAAT
GTTGAAGAGCACAAGAATCATAACATTAGTAATCGTCTTGAGGTTCCAGC

AGCTCAAGTCCAGAGCTGGTTGGAAGATGTAGAAAAGATCAATGCAAAAG
TGGAAACTGTTCCCTAAAGATGTCTGGCTGTTGCTTCAATCTAAAGATTAGG
TACAGGGCCGGAAGGGATGCCTTCAATATAATTGAGGAGATCGACAGTGT
CATGAGACGACACTCTCTGATCACTTGGACCGATCATCCCATTCTTTGG
5 GAAGAGTTGATTCCGTGATGGCATCCACCTCTACGCTTTCAACTGAACAC
AATGACTTCCAGTCAAGAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACT
TGAGGCCAACCACATGATAGCATTATGTGGAATGGGGAGAGTGGGGAAGA
CCCACATGATGCAAAGGCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTT
GGTTATATCATCGAGGCAGTTATAGGGGAAATATCGGACCCCATTTGCTAT
10 TCAGCAAGTTGTAGCAGATTACCTATGCATAGAGCTGAAAGAAAAGCGATA
AGAAAACAAGAGCTGAGAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGAT
GGAGGTAACACTAAGTTCCTCATAATATTGGATGATGTCTGGCAGTCCGT
TGATCTAGAAGATATTGGTTTAAGCCCTTCTCCCAATCAAGGTGTCGACT
TCAAGGTCTTGTTGACTTCACGAGACGAACATGTTTGCTCAGTGATGGGG
15 GTTGAAGCTAATTCAATTATTAACGTGGGACTTCTAATTGAAGCAGAAGC
ACAAGATTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCACA
AGATAGGAGAAGATATTGTTAGGAGGTGTTGCGGTCTACCCATTGCCATC
AAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGGAAGGA
TGCACCTTCTCGTTTACAACACCATGACATTGGTAATGTTGCTACTGCAG
20 TTTTGTAGAACAGCTATGAGAATCTCCCGGACAAGGAGACAAAATCTGTT
TTTTTGATGTGTGGTTTGTTCCTCGAAGACTTCAATATTCTACCGAGGA
GTTGATGAGGTATGGATGGGGCTTAAAGTTATTTGATAGAGTTTATACAA
TTATAGAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
GCAAATTTACTAATTGGAAGTGATAATGGTGTACACGTCAAGATGCATGA
25 TCTGGTCCGTGCTTTTGTTCCTGAGTATGTATTCTGAAGTCGAGCAAGCTT
CAATTGTCAACCATGGTAATATGCCTGGGTGGCCTGATGAAAATGATATG
ATCGTGCACCTCTTGCAAAAGAATTTTCAATTAACATGCAAGGGTATGATTGA
GATTCCAGTAGACCTCAAGTTTCCTAAACTAACGATTTTGAACTTATGC
ATGGAGATAAGTCTCTAAAGTTTCCTCAAGAATTTTATGAAGGAATGGAA
30 AAGCTCCAGGTTATATCATACGATAAAATGAAGTACCCATTGCTTCCTTT
GGCACCTCAATGCTCCACCAACATTCGGGTGCTTCATCTCACTGAATGTT
CATTAAAGATGTTTGATTGCTCTTCTATCGGAAATCTATCGAATCTGGAA
GTGCTGAGCTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAG
AAATTTAAAGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCC
35 GTATAGAACAGGGTGTCTTGAAAAGTTTGGTCAAACCTTGAAGAATTTTAT
ATTGGAAATGCATATGGGTTTATAGATGATAACTGCAAGGACATGGCAGA
GCGTTCTTACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGG
CTGAAGTGAAAAATATGTCAATTTGAGAATCTTGAACGATTCAAGATCTCA
GTGGGGTGCTCTTTTGATGGAAATATCAGTATGAGTAGCCACTCATACGA
40 AAACATGTTGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAAC
TTAATGGGTATTTTTGAAAACAGAGGTGCTTTTTTTAAGTGTGCATGGC
ATGAATGATCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTC
CTCTTCATTCTGCAATTTAAAAGTCCGTATTATTTCAAAGTGTGTAGAGT

TGAGATACCTTTTCAAACCTCCATGTTGCAAACACTTTGTCAAGCCTTGAG
CATCTAGAAGTTTGTGGATGCGAAAATATGGAAGAACTCATACATACTGG
GATTGGGGGTTGTGGAGAAGAGACAATTACTTTCCCAAGCTGAAGTCTT
TATCTTTGAGTCAACTACCGAAGTTATCAGGTTTGTGCCATAATGTCAAC
5 ATAATTGGGCTACCACATCTCGTAGACTTGAACTTAAGGGCATTCCAGG
TTTCACAGTCATTTATCCGCAGAACAGTTGCGAACATCTAGTTTGTGTA
AGGAAGAGGTAGATATATGTTCTTTATGTTAATACAATTTAAATAATATT
TTCAACCAAAAATTTTCATAATATATCTGTAATTTGATTGTATGATGTGTTA
TTGTTTATATGTGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCC
10 TAAGTTGGAGACACTTCAAATTGATGGCATGGAGAAGTTAGAAGAAATAT
GGCCTTGTGAGCTTAGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAA
GTGAGTAGCTGTGATAAGCTTGTGAATCTATTTCCGCACAATCCCATGTC
TCTGTTGCATCATCTTGAAGAGCTTAAAGTCAAAAATTGTCGTTCCATTG
AGTCGTTATTCAACATCGACTTGGATTGTGTCAAGTCAATTGGAGAAGAA
15 GACAACAAGAGCATCTTAAGAAGAATCAAAGTGAAGAATTTAGGGAAGCT
AAGAGAGGTGTGGAGGATAAAAAGGTGCAGATAACTCTCGTCCCCTCATCC
ATGGCTTTCCAGCTGTTGAAAGCATAAGTATCTGGGGATGTAAGCGGTTT
AGAAATATATTACACCTATCACCGCCAATTTTGATCTGGTGGCACTTTT
GGAGATTACATAGGAAATTACAGAGAAAATCATGAATCGGAAGAGCAGG
20 TAACGCTTTCAATTTCACTTTCTTACTTAATTAAGGACTAAGCTCTTGTT
TTTTGAATAATAAAGAGGTGGGATGACTAACTTGGGCATCACAATTGTA
ACAAAATGTTACAAACCATGAACGTACAAACCATTTCTTGAATTAAGGTT
TCAATACAAGTCATTTACAAATATGGCTTAAGTTTTTTTATATTTATGTA
TCAACATTATTTTTTATTAGAGGTCATTATTATAATAGTAAGTTTAAAGC
25 AATTTAAATTAGCACTAATTTTTTCATCATCTAACTTTAGCTAATAAATCG
TTATAAATGTCAATAGCTAAAATAAAAATATTTGACATTTCACTGAGAGCA
ATTTTTTCTAAACATGATTGCAAATGATTAAACTTAAATTTAAACTAAA
AAGATTTTTATATATGTTATACAAAATTTACAAATTGAAATTGGATATGT
TAATTAACAGTTTATAATTATTGTATTACAAAGCGATATATAATAAAATA
30 TTATTTTTCTGTAGTCATGTATAATTGTATATGTAAATGATTTTTTAAGA
TGGTAGAAGTGGAAGTACTCAATCTCACTTAACTCATTGTCACACCAGT
TTTATATCCGTTTCTCTCTCTCTCTCTTGCCTCCATCTTTTTTCAAC
TCATAACACATAAAAATAACATATTTTCCAACACATTTAAGTCACTACCA
CATCATTATTTTTTAATTTAATTAAATTAGAAAATATAAAAATTAAATAAAA
35 CATAACATTTTTTTATTAATAAAGGCACTAATACAAATAAAAAGATACACGG
TAAATAAAAAAACGATAATTAGAAAAAAAACATAATAAAAAAAGACAACA
TTA.AAAATAWAAAGCGACAACATAAATTAATAATGATCAAGAAAATTCT
AAAACCTCCACCATATTTTTCTGCAATTTGTCAATTTATGTTCAAACACCA
TTCGCAGAATCCCTCCTATCAAGTGATCATGTTGATTGAGAAAAAAGTGT
40 ATGCTCTCTCATGTATCTCCAAGTCCAACAAGTTAGCTTTCATTTCTTC
ATTTTCTCATGTAAGACGCAAATTTTCATCCCGATATTGTTTTCTATCTT
CCACCTCTACTTTATTACAGTGTGGATGAAGGAGAGGACAGCGATTCTC
GTACGAACGGTTACGATTGCGACTGGCCGTCGTTTTACAATCCCGCGGCCA

TGGCGGCCGGGAGCATGCGACGTCGGGCCCATTTCGCCCTATAGTGGTCGT
AATACA (SEQ ID NO:93)

Sequence gap

5 TGAGCCTCCGATGCTTAGTCCACTTGGCACAGTTCAAGTCCAATCAACTT
ATAACCCATTTTTCTTCAAGTTGTCTTCAAGTTAAGCCCAATTTGCCTTC
TCCAAATCATCCATAACTTCATGGAATCGCCCCTTCATCTTAATCCCGAA
TGCACAATTATTCTCCCATCTTCATTTTAAGCAAGAGGCCACCTTCTTCA
TGCTTCATCCATCAATAGTCTGTTGGAATAGTGTCTAAGGCTGCAACTAT
ATTAGACAAGTATTTGACCCGGTTGTGCATGGTCCTTTTGGGTTGCCTTC
10 ACCATAGCAACTTGATAGGATGATTTATTAAGAGAGAGTAAATATTATTA
ATATATTATGAGAATAATATAATGAATAATATATTTGTTATTTGATTAAT
ATAAGTCATAGAATTAATTAGAATTAATTTGGTGACTTAAAGAGATTAAT
TAAATAAAGGGGTATAAACTGTCAATTGTTTGATAGTTAAGCTTTAGACT
GTAAATCCATTTGGATATGGTATGGACGAATCCTAAGGGATTTAGGATAG
15 CTAAAATCGTCCATATGAGTTATCTAAGAAGGATTTGGATAGCCTTAAGA
GAAGATTATCTGATAGGGACTTATCTGTAATCCTTAAGGAGTCTACAAGT
ATAAATAGACCCTATGGCTGATGGAATTCGACACATCTCCTAAAGTAAGA
GAGCCTTGGCCGAATTCCTCCCCTCACCTCTCTCCTAAATCATTCTTCTT
GCT.ATTGGTGTTTGTAAAGCCATTAGAGGAGTGACATTTGTGACTCTAGAA
20 TCTCCAAGACCTCAAGATCAACAAGGAATTCAAAGGTATGATTCTAGATC
TGTTTCAATGTTGTTATTTGTCCTAATTAGTCATTAGAAGACTTGGATTCT
AAAGCATGTTTATTAGAAAGCCTAGATCYGAGCAATAGGGTTTTGCATGC
GCACATAGGAAAAGTTCTTATGGCTAAAACCCATCATAGTCCACTTCATGT
ATC.ATCTCTACTAGTTATTTAGTCCATAATCCTTGTTGTCCTCCAAGTTT
25 AATTACCTCCCTTAGTTCCTGTTCTGCTAGTTTCCTTAAAATTTGCTATT
AAGATCACAGAACTAGAGAGTACCCAAAATGGTTATAAAAATAACAAAAAG
GAA.ATATGCATGAAGATTAATAAATTATAAATGTAATATGCTAAAATA
AACTATAAAAAAAAAGTAAATAAAATGAACTATCACACTCCGACCACCC
TTATAGGCTTGTACTGCACCCACCCTTCATTCTTGTTACCAATATGGGAT
30 GGAAACATTATTCATTAAGCCAAAAAACTAACATTTAAGGGGTGAGTGAC
AAAGGTAAGTACTAAAGACAACAATAATCCATTTTTCTTGACATACACA
ACACACACATAGGGGCGGACGTAGGATTTGTAGTATGTGTTGTGGGTGAC
ACATTTTTTCTTTTACGTAGTGACACAATAGTAGAGAAAACGAGAAATTC
CAATTTTTTACATTGTGTTTCAAAAAAATATACAGGGGTTGCTGGTGCTAC
35 TCTGGGCACCAAAGTGGAACCGCCCCTGCACACACACACACATAGAGGGA
GAGAGAGAGGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATT
TGGGATGTGATACTTCTTTTGGGAAAAATGGAGCAATATCTTTAATATTGT
ATTTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAACTTTTA
GTTTTTTTTATTTTAATCTGTATATTTAATCATTTTCAGTTTATAAGTTTT
40 ATTTATTTTGGTATACCAGAAAAAAAAGTCTTTTATGTGTTGGATTTAAC
ATA.ATAATCTAACAATATTAATCAAAAAGACCAACATGTGGACAATTAT
GTATATAATTAATTCTCAATGGTCTTAGTGTAACGATATAAATTTCAAAA
CAATTTTTCACATTAACAAAAAACACTTTCAGTCATAATTGTTATAAATTA

TCATTGTATCACAAAATCAGTTCATAACATCACATCCCAAGATCAATAAA
GTGTAAATACTCCTCATGTGTGTACTAATCAAGCCGACGCCTTCCCGCGA
TTCTCACTGGTACCTGAAACACGTAACATAACAACCTGTAAGCATAAAATGC
TTAGTGAGTTCCCCAAAATACCACATACCACATATATGCCTTTCCAGGCC
5 ATA ACTCTGTAGGATCTTCCGACCCAAGTGTCTCAGGGGACTTCCGTCCC
GAATCCCGGTAGACCTTCCGGTCCTACCCGTATTGACCTTCCGGTCCGTA
TCATACATAACATACATAACACATACATATCACATAACAACATATAGCAC
ATACATCTCATAACATAAAAGACCTTCCGGTCACATAAAGGTACCCTTCC
AGGTACAGTATAGTGAGAACTCACCTCGTATGATGTCTAATACCTCAC
10 GTGCTCGATATCCCTGAATCTCGAAACAATGACCTAGCCCCGCCTACTCA
CATAAAGTAATTATTTCAAATCATTACGGCTCTCAAGGCTAGACTACAT
CCCTTTCTATAAATCCACAGAAGGGTAAAAGACCATTTTACCCCTCCTTG
ACCCAAAAGTCCAAATGTTGATCAAAACCCCAAAAGTCAACGAAAGACAA
TGGTCAACTTTGACCCTACTCGTGGAGTGCACAAAGGTGACTCGGCAAGT
15 ACATGCGGGTCCTCTGAATCCTTTCAGTCTCTCTTGGCTCGTCGAGTCTT
TCTTCCACCCGACGAGTTACACCTGTCATGAATCGCGGGGCAACCCCGAC
TCGACTTGTCGAGTCCGCTCATGGACTCAACGAGTTCATTCCATGCTCAC
ACTCAAATGACCTCCTGAGGTGAGATCTGTTCCCTCTAATCCATAGATCTG
ACCTTCCCAAGCTCAATAAACACGTAAAGGTTTGAACCTTGATACTCATGC
20 AACGTCCAAATGATTCTACTTGATGATTTAGCCCCAAATACAACATCCTA
AGTCCATACGACCTTATTTTTCTCAAATAACAACACATATATTTAATTAC
CAATGACAGTAATAGATATCATATAAAGTATTTGTAACACTTTGTAAGAA
CCTTGCTACTATAGGTAAAAAGAAACATTTCAAAGTACATGCCCTAATTA
GAAAAAAAGTTATAAAAAAATAATGACTAGGGGCGTGTTTTTTTACTAG
25 TTTGTATCAAATTATATCAAAATTTAAGGTGGAAAAGAATGACGACCACA
TTAACCAGAAATGTAATTATTTTTTTATTTGGTAATTTTTAATATTTGTT
GTGATCTATGTATTTAAAAGTAAATATCAAACAAGAACATAATCCAAACC
CTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGA
TGGCGTTACGTCGCTCTCTCACTTCTTACAACCCATTGTTGCTACTAATT
30 AACTAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGAAATTGA
ACGAATCTCGTCAAATTTTTATTTTGTGATGGATTTGAGTGGAAGTTT
AGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACATGGGTGAAGA
TAAATGGAGTTGTGCGCGTTGTATTATAGATCTCTTAGGGGTTTGATTCT
TGAGTTATTACTGTATACGTAGCCTCTTTACAACGACCATTCTTCCAAGT
35 ACCATTTGATCTTTTTAGAATCCAGTTGTCTGAAACACCCTGATTTGGAT
CAAATATCACCAACAACCTCTTAAGAACTGGACTAATTAATTGTTTTCTTG
ATCTTGATAACAAGAGGAAACACGTCACCATATCTTTTATTTTAAATTTG
CTTTTGGTGTATTTTCTTTCTTCCCATTTCTTTCTTGATCTGTTCCAGAT
GGTATTTGGTGTGGATAATTTACACCTGGAGATTGTGAACGATGGGAAGG
40 GGTATGTGATTTACAGAGGATGTGGCTTGTGGTTGAGGATGGTTTATGGC
TGGCCGAGTCTAATTTATATTTATATAAACAATAAATATATAAAACAAG
GGTAAAATATGTATTTAAGCGTCCTCTTTTAATGGTGACAATTTTTACAG
TTTACTCTCTTTGTTTTTTAATTGTGATGCCACGATCGAACTCATTCAT

CCCCCCCCCTTTTTTTTTTAAAATAAAAAATTAAGAAGGGGTACCACCAT
ATACCCGTGTCAGCTTCTTATTCCCAAGCAGTCAAATAGGGACTTAGGTT
GTATGGAAACAGTTCCGTGACTTGATGGCAGATAAATTTAGTAACTTA
ACCCTTCAATTAACCTACCTTTTTCTTATTAACTCAATTTCAAGCTAAAT
5 TCTGATTCTTGTTTGAAAATAAGTTGCATCTTTATTTTGCATATTATCT
TGTTGCATAGGATCCTTAGCATCTTTTAATAGTTTATTTGAAGCTGAAAG
ATCCAACCTAGTTTTGATCTGTTGGCATTTCATCATTTTCAAGCTGTTTC
TTGAAAAAAAATACCTAAAATCAAATAAACCATTTTCAAATCCAAAATTA
TAAGAGAGAATTGTTAATGGACGTGGAATCATAAATCATTAACACAGTTC
10 AGTACACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTAT
CAGAGAAAGAGACATTACAAGAAGTCACTGATACTAATATTTCTAATGAT
GTTGTATTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAA
ACTTAAATTGGAAAATTATGAAGGAGTGGAGGTGGTGGTTTGAGATAGAGA
GTGAGAGTCCAACATGTAGAGAATTGGTAACAACCTCACAATAACCAACAA
15 CAGCCTATTATACTTCCCAACCTCCAGGAATTGTATCTAAGGAATATGGA
CAACACGAGTCATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTC
TTCCAAAACAACAATCAGAATCACCATTCCACAACCTCACAACCATAGAA
ATGAGATGGTGTGTCATGGCTTTAGGTACTTGTTTTCGCCTCTCATGGCAGA
ACTTCTTTCCAACCTAAAGAAAGTCAAGATACTTGGGTGTGATGGTATTG
20 AAGAAGTTGTTTCAAACAGAGATGATGAGGATGAAGAAATGACTACATTT
ACATCTACCCACACAACCACCAACTTGTTCCCTCATCTTGATTCTCTCAC
TCTAAAATACATGCACTGTCTGAAGTGTATTGGTGGAGGTGGTGCCAAGG
ATGAGGGGAGCAATGAAATATCTTTCAATAATACCACTACAACCTACCGAT
CAATTTAAGGTATGTTTGTACATATTTAATTATATATTTAATTTCTTGT
25 TAATTTCTTTTCTTTGCAATATTCTATGCGAACTCAAGAATGGGATTG
GAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCTTTTATTTGTT
ATTTATCATTTTCATATCAAGTACCTATAACATTTCTTTTTTATTTTTCT
AATTAGAAGAGGTCCACATGTCTAATTAGGTTTTCCATTCTATGTGTAAC
CTCTATTCTCTCTGTAATCAAGCATCTTAGATTATTTATCCATTTTCATA
30 ATTGTTGTTTATTTTTACAGTTTTTTTTTTTTTATTTAATTTTAATAATTTAA
TTTTAATTTATTTATTTTTTTTTTTTTGGTAATTGCAACCTGTCATATAT
TCAAGTCTTAATGTAACATAATAATACATTTTATACCCACTATACTAAGA
TAATAATTACCTAAAGGGATGGATGCCATGACACTGCTACACTTCAGNAA
CTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTT
35 TGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTT
AGCTAGTAGTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTCAAAATCT
GGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGG
TCATCAGGTGACAGATATTGTAGAATAGAACAATATGTAATATTACCCAA
AACTATTTTTTCTAAGGTTGCTCTGTTAAATATGTGCTTTCTTGATTTC
40 TTGAATTTGCATTCGTATATTTTAGGTGGTAAACTGATTGTCTCTTCAAT
AAATCCTGAAATTAATTAACAAAAAACAACAAAGTACATTTTGTATT
GGAGAGCACTGGTATCATTTAGTATAGAAAAAACTAGATTTTGAATTAY
CTTCTTATATAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTT

TTCTATGTGTTGTTGCAGTTGTCTGAAGCAGGTGGTGTGTTGTTGGAGCTT
ATGCCAATACTCTAGAGAGATAGAGATATATAGGTGTGATGCACTGTCAA
GTGTAATTCCATGTTACGCAGCAGGACAAATGCAAAAGCTGCAAGTGCTG
ACAGTCAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAACTCAATTAGG
5 GACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTC
CAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTGGAA
ATCTACGGTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGA
AAGCCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTACTACTCTTGTC
AATCTTCCAAACCTCAAAGAAATGAGGTTGGAGTGGCTAAGTAATCTGAG
10 GTATATATGGAAGAGCAATCAGTGGACAGCATTTGAGTTTCCAAACCTAA
CAAGAGTTGAAATTTGTGAATGTAATTCATTAGAACATGTATTTACTAGT
TCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTACATATATTTAACTG
CAGTCTGATGGAGGAGGTAATTGTTAAGGATGCAGATGTTTCTGTAGAAG
AAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAAGGAGATACTTGTG
15 TTACCTCATCTAAAGTCCTTGAAATTACAACCTCTTCGAAGTCTTAAGGG
GTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTATTGGATACTTTAG
AAATCAAAAGATGCCCAACAATAACCACCTTCACCAAAGGAAATTCCGCT
ACTCCACAATAAAAGAAATACAAACAAATTTTGGCTTCTTTTATGCTGC
AGGGGAAAAAGACATCAACTCTCTTATAAAGATCAAACAACAGGTAAATC
20 AGATCTTTGTTGCTTTAATAATCTTAAACTACATTTGAAAAGCTTCATG
CAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTACATTCAGCTTTAT
ATTTATGTACTTTATGCAGGATTTCAAACAAGACTCAGATTAATGTGAAG
TGAATATTAAAGGTAAATTATATTTTCATGTTCTAGTTGCCTATTAATT
AATGGCCTTTTAGTTCATGATTTTTGGATGTATTCTTCATGATGATGTGA
25 ATCTTCTAATACCCCATTCATTGTTTGGTTGAATGTTGACTCTATGTCAG
GATGAATATTCAAGGGAAGAATTGTTCAATCAWATGAAGGACATTAAAGAA
CATGGATGCTATGAAGATGTTGGGAAAACATATGTATCAAGTGGCAARCT
GCTTAATGATCTAAGTTTGTGTTGGTTGANGATGTTGATTTTAATATTTCAA
ATTCATTGGTTATATGGGCTTATCAATAGTGTTAATGGGATAATGAGTGA
30 CTTAACCTAAATTATGTTGTTGGTAAATGTTGGACAAGTATGGAAAATTA
GGAATGACTTGTGAAAAAAAATAAAAAAAA (SEQ ID NO:94)

RG2D deduced polypeptide sequence (SEQ ID NO:95)

MAMETANEIKQVVPVLMVPINDYLRYVVSCRKYISDMDLKMKEAKDNVEE
35 HKNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAF
NIIIEIDSVMRRHSLITWTDHPIPLGRVDSVMASTSTLSTEHNDFQSREVRVSEALKA
LEANHMIALCGMGRVGKTHMMQRLKKVAKERKFGYIIEAVIGEISDPIAIQVVA
DYLIELKESDKKTRAEKLRQGFKAKSDGGNTKFLIILDDVWQSVLEDIGLSPSPN
QGVDFKVLTSRDEHVC SVMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIG
40 EDIVRRCCGLPIAJKTMACTLRNKRKDAWKDALSLQHHDIGNVATAVFRTSYENL
PDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTHIERNRLNTCIERLV
QANLLIGSDNGVHV KMHDLVRAFLVGMYSVEQASIVNHGNMPGWPDENDMIVH

SCKRISLTCKGMIEIPVDLKF PKLTILKLMHGD KSLKFPQEFYEGMEKLQVISYDKM
 KYPLLPLAPQCSTNIRVLHLTECSLKMFD CSSIGNLSNLEVLSFANSRIEWLPSTVRN
 LKKLRLLDLRFCDGLRIEQGVLSLVKLEEFYIGNAYGFIDDNCKDMAERSYNLSA
 LEFAFFNNKAEVKNMSFENLERFKISVGC SFDGNISMSSH SYENMLQLVTNKG DVL
 5 DSKLNGFLFKTEVLF LSVHGMNDLEDVEVKSTHPTQSSSFCNLKVRIISKCVELRYL
 FKLHVANTLSSLEHLEVCGCENMEELIHTGIGGC GEETITFPKLKSLSLSQLPKLSGL
 CHNVNIIGLPHLVDLKLKGIPGFTVIYPQNK LRTSSLLKEEVVIPKLET LQIDGMENL
 EEIWPCELSGGEKVKLREIKVSSCDKL VNLFPHPNMSLLHHLEELKVKNCRSIESLF
 NIDLDCVSAIGEEDNKSILRRIKVKNL GKLREVWRIKGADNSRPLIHGFPAVESISIW
 10 GCKRFRNIFT PITANFDLVALLEI HIGNYRENHESEEQIEILSEKETLQEVTD TNISND
 VVLFPSCLMHSFHNLHKLKLENYEGVEV VFEIESESPTCRELVTTHNNQQQPILPN
 LQELYL RNMDNTSHVWKCSNWNKFFTL PKQQSESPFHNLT TIEMRWCHGFRYLF S
 PLMAELLSNLKKVKILGCDGIEEVVSNR DDEDEEMTTFTSTHTTTNLFP HLDSTL K
 YMHCLKCIGGGGAKDEGSNEISFNNT TTTTDDQFKLSEAGGVCWSLCQYSREIEIYRC
 15 DALSSVIPCYAAGQMQLQVLT VSSCNGLKEVFETQLGTSSNKNNEKSGCEE GIPR
 VNNNVIMLPNLKILEIYGCGGLEHIFTF SALESRLQLQELTIKGY YTLVNLPNLKEM
 RLEWLSNLRYTWKSNQWTA FEFPNLTRVEICECNSLEHVFTSSMVG SLLQLQELHIF
 NCSLMEEVIVKDADV SVEEDKEKESDGKT NKEILVPLHLKSLKLQLL RSLKGFSLGK
 EDFSFPLLD TLEIKRCPTTTTFTKGNSATPQLKEIQTNFGFFYA AGEKDINSLIKIKQQ
 20 DFKQDSD.CEVNIK

RG2E polynucleotide sequence (SEQ ID NO:96)

TGGGAAGACACAATGATGCAAAGGTTGAAGAAGGTTGCTAAAGAAAATAGAAT
 GTTCAATTATATGGTTGAGGCAGTTATAGGGGAAAAGACAGACCCACTTGCTAT
 25 TCAACAAGCTGTAGCGGATTACCTTTGTATAGAGTTAAAAGAAAGCACTAAACC
 AGCAAGAGCTGATAAGCTTCGTGAATGGTTTAAGGCCAACTCTGGAGAAGGTA
 AGAATAAGTTCCTTGTAATATTTGATGATGTTTGGCAGTCCGTTGATCTGGAAG
 ACATTGGTTTAAGTCATTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGA
 CTTACAGAGACGAACATGTTTGCACAGTAATGGGGGTTGAAGCTAATTCAATTC
 30 TTAATGTGGGACTTCTAGTAGAAGCAGAAGCACAAAGTTTGTTCCAGCAATTTG
 TAGAAACTTTTGAGCCCGAGCTCCATAAGATAGGAGAAGATATCGTAAGGAAG
 TGTTGTGGTTTACCTATTGCCATTAAAACCATGGCATGTACTCTAAGAAATAAA
 AGAAAGGATGCATGGAAGGATGCACTTTTGCATTTAGAGTACCATGACATTAGC
 AGTGTTGCGCCCAAAGTCTTTGAAACGAGCTACCATAATCTCCACAACAAGGAG
 35 ACTAAATCTGTGTTTTTGATGTGTGGTTTTTTTCTGAAGACTTCAATATTCCAA
 TCGAGGAGTTGATGAGGTATGGATGGGGCTTAAAGATATTTGATAGAGTTTATA
 CTATTAGACAAGCAAGAATCAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
 ACA AATTTGTTAATAGAAAGTGATGATGGTGTGCACGTCAAGATGCATGATCTG
 GTCCGTGCTTTCGTTTTGGTTATGTTTTCTGAAGTTGAACATGCTTCAATTATCA
 40 ACCATGGTAATATGCTTGGATGGCCTGAAAATTATATGACCAACTCTTGCAAAA
 CAATTTTCATTAACATGCAAGAGTATGTCTGAATTTCCGGGAGATCTCAAGTTTC
 CAAACCTAACGATTTTGAAACTCATGCATGGAGATAAGTTGCTAAGATATCCTC

AAGACTTTTATGAAGGAATGGAAAAGCTCTGGGTTATATCATATGATGAAATGA
AGTATCCATTGCTTCCCTCGTTACCTCAATGCTCCATCAACCTTCGAGTGCTTCA
CCTCCATCGATGCTCATTAAATGATGTTTGATTGCTCTTGATTGGAAATATGTTG
AATCTGGAAGTGCTTAGCTTTGTAAATCTGGCATTGAATGGTTACCTTCCACA
5 ATAGGAAATTTAAAGAAGCTAAGGTTACTTGATCTGAGAGATTGTTATGGTCTT
CGTATAGAAAAAGGTGTCTTGAAAAATTTGGTGAAAATTGGAGGAATTTATATT
GGTAGAGCAGATATTTTATAGAT

RG2E deduced polypeptide sequence (SEQ ID NO:97)

10 WEDTMMQRLKKVAKENRMFNYMVEAVIGEKTDP LAIQQAVADYLCIELKESTKP
ARADKLREWFKANS GEGKNKFLVIFDDVWQSV DLEDIGLSHFPNQGVDFKVLLTS
RDEHVCTVMGVEANSILNVGLLVEAEAQSLFQQFVETFEPELHKIGEDIVRKCCGL
PIAKTMACTLRNKRKDAWKDALLHLEYHDISSVAPKVFETSYHNLHNKETKSVFL
MCGFFPEDFNIPIEELMRYGWGLKIFDRVYTIRQARIRLNTCIERLVQTNLLIESDDG
15 VHVKMHDLVRAFLVMFSEVEHASIINHGNMLGWPENYMTNSCKTISLTCKSMSE
FPGDLKFPNLTILKLMHGDKLLRYPQDFYEGMEKLWVISYDEMKYPLLPSLPQCSI
NLRVLHLHRCSLMMFDCSCIGNMLNLEVL SFVKSGIEWLPSTIGNLKKLRLLDLRD
CYGLRIEKGVLKNLVKIGGIYIGRADIL.

RG2F polynucleotide sequence (SEQ ID NO:98)

CTGTGGAAGACACAATGATGCAAAGGCTGAAAAAGGTTGTGCATGAAAAGAAA
ATGTTTAACTTTATTGTTGAAGCAGTTATAGGGGAAAAGACAGACCCCGTTGCC
ATTCAGGATGCTATAGCAGATTACCTAGGTGTAGAGCTCAATGAAAAATCTAAG
CAAGCAAGAGCTGATAAGCTCCGTCAAGGATTCAAGGACAAATCAGATGGAGG
25 CAAAAATAAGTTCTTTGTAATACTTGACGATGTTTGGCAGTCTGTTGATCTGGA
AGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGCGTCGACTTCAAGGTCTTGTT
GACATCACGAGACAGACATGTTTGCACAGTGATGGGGGTTGAAGCCAAATTAA
TTCTAAACGTGGGACTTCTAATTGAAGCTGAAGCACAAAGTTTGTTCACCAAT
TTGTTGTCACTTCTGAGCCCGAGCTCCATAAGATAGGAGAAGATATTGTAAAGA
30 AGTGTTCGGTCTGCCAATTGCCATCAAACCATGGCATGTACTCTACGACATA
AAAGAAAGGATGCATGGAAGGATGCACTTTCACGTTTAGAGCACCATGACATT
CAAAGTGTTGTGCCTAAAGTATTTGAAACGAGCTACAACAATCTCAAAGACAA
GGAGACTAAATCCGTATTTTTGATGTGTGGTTTGTTTCCTGAAGACTTGATAT
ACCTATCGAGGAGTTGATGAGGTATGGATGGGGCTTAAGATTATTTGATAGAGT
35 TAATACTATTACACAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGG
TGCACACAAATTTGTTAATTGAAAGTGTTGATGGTGTGCATGTCAAGATGCATG
ATCTGGTTCGTGCTTTTGT TTTGGGAATGTTTTCTGAAGTGGAGCATGCTTCAAT
TGTCAACCATGGTAATATGCCCGAGTGGACTGAAAATGATATGACTGACTCTTG
CAAACAAATTTCAATTAACATGCAAGAGTATGTTGGAGTTTCCTGGAGACCTCAA
40 GTTTCCAAACCTAAAGATTTTGAAACTTATGCATGGAGGTAAGTCACTAAGGTA
TCCTCAAGACTTTTATCAAGGAATGGAAAAGCTGGAGGTTATATCATACGATGA
AATGAAGTATCCATTGCTTCCCTCGTTGCCTCAATGTTCCACCATCCTTCGAGTG

CTTCATCTCCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTCAATCGGTAATC.
TTTTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAGCATTGAATTGTTACCTTC
CGTAATTGGAAATTTGAAGAAGTTGCGGCTGCTAGATTTGACAAACTGTTATGG
TGTTTCGTATAGAAAAGGATGTCTTGAAAAATTTGGTGAAACTTGAAGAGCTTTA
5 TATTAGGAATGGTCTACCAGTTTACAGAGGAT

RG2F deduced polypeptide sequence (SEQ ID NO:99)

VEDTMMQRLKKVVHEKKMFNFIVEAVIGEKTDPVAIQDAIADYLGVELNEKSKQA
RADKLRQGFKDKSDGGKNKFFVILDDVWQSVLEDIGLSPFPNQGVDFKVLLTSRD
10 RHVCTVMGVEAKLILNVGLLIEAEAQSLFHQFVVTSEPELHKIGEDIVKKCFGLPIAI
KTMACTLRHKRKAWDALSRLEHHDIQSVVPKVFETSYNNLKDKETKSVFLMCG
LPEDLDIPIELMRYGWGLRFLFDRVNTITQARNRLNTCIERLVHTNLLIESVDGVH
VKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDMTDSCKQISLTCKSMLEFP
GDLKFPNLKILKLMHGGKSLRYPQDFYQGMKLEVISYDEMKYPLLPSLPQCSTILR
15 VLHLHECSLRMFDCSSIGNLFNMEVLSFANSSIPELLSVIGNLKKLRLDLTNCYGV
RIEKDVLKNLVKLEELYIRNGLPVYRG

RG2G polynucleotide sequence (SEQ ID NO:100)

GAAGACACGATGATGAAGAACTGAAGGAGGTCGTGGGACAAAAGAAATCATTC
20 AATATTATTATTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCAATTCAG
CAAGCTGTAGCAGATTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGC
AAGAGCTGATAAGCTTCGTAAACGGTTTGAAGCCGATGGAGGAAAGAATAAGT
TCCTTGTAATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTT
AAGTCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAGA
25 TTCACATGTTTGCACCTCTGATGGGAGCTGAAGCAAATTCAATTCTTAATATAAA
AGTTTTTAAAGATGTAGAAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGC
GGGTGATGATGACCTGGATCCTGCTTTCATGGGATAGCAGATAGTATTGCAAG
TAGATGTCAAGGTTTGCCCATTCATCAAAACCATTGCCTTAAGTCTTAAAGG
TAGAAGCAAGTCTGCATGGGACGTTGCACTTCTCGTCTGGAGAATCATAAGAT
30 TGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATTAGCTACGACAATCTCCA
AGATGAGGTTACTAAATCTATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTT
GATATTCCTACTGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATA
GAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCG
GCTTAGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGTGTCAAGAT
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAACACGC
TTCAATTGTCAACCATGGTAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCAT
CTACTCTTGTAAGAATTTTCATTAACATGCAAGGGTATGTCTCAGTTTCCCAA
AGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTATGCATGGAGATAAGTC
ACTGAGCTTTCCTGAAAACCTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATC
40 ATATGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACCAA
CGTTCGAGTGCTTCATCTTCATTACTGTTTCATTAAGGATGTTTGATTGCTCTTCA
ATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTGAA

TGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACA
AATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTTGGTCAAACCTT
GAAGAGCTTTATATGGGTGTTAATCGTCCGTATGGACAGGCCGTTAGCTTGACA
GATGAAAA

5

RG2G deduced polypeptide sequence (SEQ ID NO:101)

RHDDEELKEVVGQKKSFNIIIQVVIGEKTNPPIAQAVADYLSIELKENTKEARADKL
RKRFEADGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTL
MGAEANSILNIKVLKDVEGQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGLPIAI
10 KTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCAL
FPEDFDIPTTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVK
MHDVVRDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSQFPKDL
KFPNLSILKLMHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNVRVLH
LHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRID
15 NGVLKNLVKLEELYMGVNRPYGQAVSLTDE

RG2H polynucleotide sequence (SEQ ID NO:102)

TGAAGGAGGTTGTGGAACGAAAGAAAATGTTCAGTATTATTGTTCAAGTG
GTCATAGGAGAGAAGACAAACCCTATTGCTATTCAGCAAGCTGTAGCAGA
20 TTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATA
AGCTTCGTAAATGGTTCGAGGCCGATGGAGGAAAGAATAAGTTCCTTGTA
ATACTTGACGATGTATGGCAGTTTGTTCGATCTTGAAGATATTGGTTTAA
TCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAG
ATTCACATGTTTGCACCTCTGATGGGAGCCGAAGCCAATTCAATTCTCAAT
25 ATA-AAAGTTTTAACAGCTGTAGAAGGACAAAGTTTGTTCGCCAGTTTGC
TAA-AAATGCGGGTGATGATGACCTGGATCCTGCTTCAATAGGATAGCAG
ATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATTCGCATCAAAACCATT
GCCTTAAGTCTTAAAGGTAGAAGCAAGCCTGCGTGGGACCATGCGCTTTC
TCGTTTGGAGAACCATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTT
30 TTA-AAATTAGCTATGACAATCTCCAAGATGAGATTACTAAATCTATTTTT
TTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTACTGAGGAGTT
GATGAGGTATGGATGGGGCTTGAAATTATTTATAGAAGCAAAAACATAAA
GAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTTAGGGAGACA
AATTTGTTATTTGGAAGCGATGACATTGGATGCGTCAAGATGCACGATGT
35 GGTGCGTGATTTTGTTTTGCATATATTCTCAGAAAGTCCAGCACGCTTCAA
TTGTCAACCATGGTAACGTGTGAGAGTGGCTAGAGGAAAATCATAGCATC
TACTCTTGTA-AAAGAAATTTTCAATTAACATGCAAGGGTATGTCTGAGTTTCC
CAAAGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTATGCATGGAG
ATAAGTCGCTGAGCTTTCCTGAAAACCTTTTATGGAAAGATGGAAAAGGTT
40 CAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCCCTCATCACT
TGAATGCTCCACTAACGTTTCGAGTGCTTCATCTCCATTATTGTTCAATTA
GGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTC

AGCTTTGCTAATTCTAACATTGAATGGTTACCATCTACAATTGGAAATTT
GAAGAAGCTAAGGCTACTAGATTTGACAAATTGTAAAGGTCTTCGTATAG
ATAATGGTGTCTTAAAAAATTTGGTCAAACCTTGAAGAGCTTTATATGGGT
GTTAATCATCCGTATGGAC

5

RG2H deduced polypeptide sequence (SEQ ID NO:103)

KEVVERKKMFSIIVQVVIGEKTNP IAIQQA VADYLSIELKENTKEARADKLRKWFEA
DGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTLMGAEAN
SILNKKVLTAVEGQSLFRQFAKNAGDDDLDPAFNRIADSIASRCQGLPIAIKTIALSLK
10 GRSKPAWDHALSRLENHKIGSEEVVREVFKISYDNLQDEITKSIFLLCALFPEDFDIP
TEELMRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVVR
DFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLSI
LKL.MHGDKSLSFPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNVRVLHLHYCSL
RMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRIDNGVLKN
15 LVKLEELYMGVNHYPYG

RG2I polynucleotide sequence (SEQ ID NO:104)

AAGAAGAGCTGAAGGAGGTTGTGGAACAAAAGAAAACGTTCAATATTATT
GTTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCTATTCAAGCAAGC
20 TGTAGCAGATTCCCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAA
GAGCTGATAAGCTTCGTAAATGGTTCGAGGCTGATGGAGGAAAGAATAAG
TTCCTCGTNATACTTGACGATGTATGGCNGTTTGTGATCTTGAAGATAT
TG GTTTAAGTCCTCATCCAAATAAAGGTGTCANCTTCAAGGTCTTGTGTA
CGTCAAGAGATTCACATGTTTGC ACTCTGATGGGAGCTGAAGCCAATTCA
25 ATTCTCAATATAAAAAGTTTTAAAAGATGTAGAAGGAAAAAGTTTGTTCGG
CCAGTTTGCTAAAAATGCGGGTGATGATGACCTGGATCCTGCTTTCATTG
GGATAGCAGATAGTATTGCAAGTAGATGTCAAGGTTTGCCCAT TGCCATC
AAAACCATTGCCCTTAAGTCTTAAAGGTAGAAGCAAGTCTGCATGGGACGT
TGC.ACTTTCTCGTCTGGAGAATCATAAGATTGGTAGTGAAGAAGTTGTGC
30 GTG.AAGTTTTTTAAAATTAGCTATGACAATCTCCAAGATGAGGTTACTAAA
TCT.ATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTAC
TGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATAGAAGCAA
AAACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTT
AGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGCGTCAAGAT
35 GCACGATGTGGTGCGTGATTTTGT TTTGCATATATTCTCAGAAGTCCAGC
ACGCTTCAATTGTCAACCATGGTAATGTGTCAGAGTGGCTAGAGGAAAAT
CATAGCATCTACTCTTGTA AAAAGAATTTCAATTAACATGCAAGGGTATGTC
TGAGTTTCCCAAAGACCTCAAATTTCCAAACCTTTCAATTTTGAAACTTA
TGC.ATGGAGATAAGTCGCTGAGCTTTCTGAAAACCTTTTATGGAAAGATG
40 GAAAAGGTTCAAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCC
CTC.ATCACTTGAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCAATTAAGGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATG

GAAGTGCTCAGCTTTGCTAATTCTGGCATTGAATGGTTACCATCTACAAT
TGGAAATTTGAAGAAGCTAAGGCTACTGGATCTGACAGATTGTGGAGGTC
TTCATATAGATAATGGCGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTT
TATATGGGTGCTAATCGTCTGTTTGGAAAGTGCCAT

5

RG2I deduced polypeptide sequence (SEQ ID NO:105)

EELKEVVEQKKTFNIIVQVVIGEKTNPQIAIQQAVADSLSELKENTKEARADKLRKWF
EADGGKNKFLVILDDVW?FVDLEDIGLSPHPNKGV?FKVLLTSRDSHVCTLMGAEA
NSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPAFIGIADSIASRCQGLPIAKTIALSL
10 KGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCALFPEDFDI
PTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDDV
RDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLS
ILKLMHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSLEECSTNLRVHLHECSL
RMFDCSSIGNLLNMEVLSFANSIGIEWLPSTIGNLKKLRLLDLTDCGGLHIDNGVLKN
15 LVKLEELYMGANRLFGKCH

RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107)

ATGTCCGACCCAACAGGGATTGTTGGTGCCATTATTAACCCAATTGCTCA
AACGGCCTTGGTTCCCCTTACAGACCATGTAGGCTACATGATTTCCCTGCA
20 GAAAATATGTGAGGGACATGCAAATGAAAATGACAGAGTTAAATACCTCA
AGAATCAGTGCAGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCA
GATTCCATCTCAAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAG
CGAATGTTGCAAACCTTTCCAATTGATGTCATCAGTTGTTGTAGTCTCAGG
ATCAGGCACAAGCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATCGA
25 AAGTCTAACGAGACAAAATTCGCTGATTATCTGGACTGATGAACCTGTTC
CCCTGGGAAGAGTTGGTTCCATGATTGCATCCACCTCTGCAGCATCAAGT
GATCATCATGATGTCTTCCCTTCAAGAGAGCAAATTTTTAGGAAAGCACT
AGAAGCACTTGAACCCGTCCAAAAATCCCACATAATAGCCTTATGGGGGA
TGGGCGGAGTGGGGAAGACCACGATGATGAAGAAGCTGAAAGAGGTCGTG
30 GAACAAAAGAAAACGTGCAATATTATTGTTCAAGTGGTCATAGGAGAGAA
GACAAACCCTATTGCTATCCAGCAAGCTGTAGCAGATTACCTCTCTATAG
AGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTAAACGG
TTCGAAGCCGATGGAGGAAAGAATAAGTTCCTTGTAACTTGACGATGT
ATGGCAGTTTTTTCGATCTTGAAGATATTGGTTTAAGTCCTCTGCCAAATA
35 AAGGTGTCAACTTCAAGGTCTTGTGACGTCAAGAGATTCACATGTTTGC
ACTCTGATGGGAGCTGAAGCCAATTCTATTCTCAATATAAAAGTTTTAAA
AGATGTAGAAGGAAAAAGTTTGTTCGCCAGTTTGCTAAAAATGCGGGTG
ATGATGACCTGGATCCTGCTTTCATTGGGATAGCAGATAGTATTGCAAGT
AGATGTCAAGGTTTGCCCATTCATCAAAACCATTGCCTTAAGTCTTAA
40 AGGTAGAAGCAAGTCTGCATGGGACGTGCACTTTCTCGTCTGGAGAATC
ATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATTAGCTAT
GACAATCTCCAAGATGAGGTTACTAAATCTATTTTTTTACTCTGTGCTTT

ATTCCTGAAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGT
GGGGCTTGAAATTATTTATAGAAGCAAAAACATAAGAGAAGCAAGAAAC
AGGCTCAACAACCTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGG
AAGTCATGACTTTGGGTGCGTCAAGATGCACGATGTGGTGCGTGATTTTG
5 TTTTGCATATGTTTTCAGAAGTCAAGCATGCTTCAATTGTCAACCATGGT
AACATGTCAGAGTGGCCAGAGAAAAATGATACCAGCAACTCTTGTA AAAAG
AATTCATTAACATGCAAGGGTATGTCTAAGTTTCCTAAAGACATCAACT
ATCCAAACCTTTTGATTTTGAACTTATGCATGGAGATAAGTCGCTGTGC
TTTCCTGAAAACCTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATA
10 TGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTA
ACGTTTCGAGTGCTTCATCTCCATTATTGTTCAATTAAGGATGTTTGATTGC
TCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTC
TAACATTGAATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGC
TACTAGATTTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTA
15 AAAAATTTGGTCAAACCTTGAAGAGCTTTATATGGGTGTTAATCGTCCGTA
TGGACAGGCCGTTAGCTTGACAGATGAAAACCTGCAATGAAATGGTAGAAG
GTTCCAAAAA ACTTCTTGCACTAGAATATGAGTTGTTTAAATACAATGCT
CAAGTGAAGAATATATCCTTCGAGAATCTTAAACGATTCAAGATCTCAGT
GGGATGTTCTTTACATGGATCTTTCAGTAAAAGCAGGCACTCATAACGAAA
20 ACACGTTGAAGTTGGCCATTGACAAAGGCCGAACATTGGAATCCC GAATG
AACGGGTTGTTTGAGAAAACGGAGGTTCTTTGTTTAAAGTGTGGGGGATAT
GTATCATCTTTCAGATGTTAAGGTGAAGTCCTCTTCGTTCTACAATTTAA
GAGTCCTTGTCGTTTTAGAGTGTGCAGAGTTGAAACACCTCTTCACACTT
GGTGTGCAAATACTTTGTCAAAGCTTGAGCATCTTAAAGTCTACAAATG
25 CGATAATATGGAAGAACTCATACATACCGGGGGTAGTGAAGGAGATACAA
TTACATTCCCCAAGCTGAAGCTTTTATATTTGCATGGGCTGCCAAACCTA
TTGGGTTTGTGTCTTAATGTCAACGCAATTGAGCTACCAAAACTTGTGCA
AATGAAGCTTTACAGCATTCCGGGTTTCACAAGCATTATCCGCGGAACA
AGTTGGAAGCATCTAGTTTGTGAAAGAAGAGGTACATATACATATAGTT
30 TATGTTAATACATTTTAAACAATCTTTCAACTAAAAGTTTCAGAATATA
TCTGTATTTTGATTGTATGATGTGTTAGTGTGTTGGATGTGGCTATTAAAG
GATAATTATTTGGCAGGTTGTGATTCCCTAAGTTGGATATACTTGAAATTC
ATGACATGGAGAATTTAAAGGAAATATGGCCTAGTGAGCTTAGTAGAGGT
GAGAAAGTTAAGTTGAGAAAGATTAAAGTGAGAAATTGTGATAAACTTGT
35 GAATCTATTTCCACACAATCCCATGTCTCTGCTGCATCATCTTGAAGAGC
TTATAGTCGAGAAATGTGGTTCCATTGAAGAGTTGTTCAACATCGACTTG
GATTGTGCCAGTGTAATTGGAGAAGAAGACAACAACAGCAGCTTAAGAAA
CATCAATGTGGAGAATTCAATGAAGCTAAGAGAGGTGTGGAGGATAAAAAG
GTGCAGATAACTCTCGTCCCCTCTTTCGTGGCTTTCAGTTGTTGAAAAG
40 ATAATCATTACGAGATGTAAGAGGTTTACAAATGTATTCACACCTATCAC
CACAAATTTTGATCTGGGGGCACTTTTGGAGATTTCAAGTTGATTGTAGAG
GAAATGATGAATCAGACCAAAGTAACCAAGAGCAAGAGCAGGTATGGATT
TCAATTTTACTCTTTTACTTAATTAATGATTAAGCCCCTGCTTTTAAATA

AAAAGGGGACAAACCATTCTTGACTTAATGTTGCAATACAAGTCATGTA
TAAGAGTGATTAACCTTTTTTTTATTTATAAAATAACTACAAAACATGTTT
TTTCATTATAGATCATGTATAAATGTGACTAATTTTTTTTCATCGCCTAAC
TTTTGTTGATAAATCATTAGAAATGTCATAATTACTTTTTAGTATTTAT
5 AAAATAACTACAAAACATGTTTTTTCATTATAGATCATGTATATATCAAC
TAAAAATATTATTCCCTTACACAAAAAAGGTTCAAGAAAGCCTGTA
TTTCGAAATAACTAAAAAGAAATATTTGATATTCATAAGAGAAATTTT
TTTCTAAACATGATCGCAAAATGATTAAACTTAAATTAAACTAAAAAGA
TTTTTATATATGTTATNCAAAATTAAAATTTGAAATTAAGTTTATAATTC
10 TNGTNTCACAAAGGGATATATATAGTAAATATTATTTTTTTTGCAGTCAT
GCATAGTTGTATTTTTTAAATGATTTATTAACGTGGTAGGAGTGGAACCA
CTCAATCTAGTAGACCCACTATCACATGTCACATCAGCTTTACATCTATT
TTTCTTTCTCCTTTTTTTCATCTTTTTTAAACTCATAACACNTAAAANTANC
ATATTTTCCAACACACTNAACTCATTTGTCACATTATTATTTTTTAATTTAA
15 TTAATTNGAAAATTAAAATTAANTAAANCNTAACATTTTTTTAATTTAAA
AATATTAATCCAAATAAAAANTNCACGATAAATTAAAAANGTTTANTTTG
GAAAAAANCC (SEQ ID NO:106)
Sequence gap
ATAACCCTTTCAAGGGTCAACTCAAGTCCAAGTTAAAGTCAAGGTCAAAA
20 CCTTGGTTAAAGTCAACTTTGGTCAAAGTCAACATCTACTTGACTCACCT
CACCGAGTTGGTCCACCAACTTGTCTGAGTCCCTTAATCCACAACTTCAA
GAACCTCGATCCTACTCGTCGAGTCTTTCAAGAACTCTTCGAGTTTCCAT
TACACAGAATCGGGACCTTTTGCTCATGACTCGCCGAGTTCATCCTTGAA
CTTGTCGAGTCTAGCTTCATACGAGTTCGAGTGTTTAGTCCTTGACTCGT
25 CGAGTTCTTCCTTGAACTCGTCGAGTCCATCTTCGTATAGTTGGGACATT
GCCTTGAACTCACCGAGTTCATCATTGAACTCATCGAGTCCTTCGATCTT
CAAGTCCATAATCCTGTCCATCTTGTTGAGTCCTCTTCTAGACTCAACCA
GATTCCTCAGAAACAGAAAAGGTTAGGGAACCATTACCTGACTCGCCGAG
TCCCAAGAACGAATCCCCGAGTCCCCCAATGTCCATGACCATAACAATCGA
30 TTTTCGTTGGGCTCATTGCATCCAAAGCATAGATCTAACCTCCTAGGGTC
CATATTACACGTAAAGCTACGAACCTTGACGTCCATGCATGGGGGATTG
CTCAAATGGCATTAAAATGGGGTTTATCTGATGCATGGGACTCCCATGGC
CATAAAGTTAACACCTTTATGCCATGGGAATCCTCAATGGTTCCATATCT
GAAGTTAACTCTACAATATGTTCTAAACCCGAAGGTGGCTTAGAAATG
35 CCCCCAAATGGCAAGATTCAAGCCTTAAAGGAGATCTAACAAATGATAAG
TCAAGGTTCAAGCTTTTTACCTTGAATAAGCTGGAAATGAAGCAAAATCT
CTGGATCCACTTGCTTCTTCAAGAACCCCAAGCTTCCACTTCTTCCTTC
AAGTTTCAAACAACCTTTAAACACTCAAAAATGGCTCAAGAACACTCAAAA
AGCTTTAGGGTTTCGAGTTAGGGCTTTTTGGAAGCGAGAGGGACGATGGG
40 GGCTGAAATGAGGCTAGAAAAAGTGTTTAAATAGGGGGCAAACCCTAAAT
ATTAGGGTTTCATCCAGGCAGCCCTACTCGTCTGAGTCGGGCTCCCGACTC
GTCGAGTAGGTCACTTAAAACCCGCGTCCATAATCCAGTCTACTCGACGA
GTTGGGCCTCCAACCTCGTCGATTCCGAGTGCAAAACGTTCAATTACTTAA

ATTTAAATATGTACCAGGAACCGGGTGTACAGTTGAGACTTTATACCTC
CATAAGATAGATCTAGGTGCACATAGCCTGGATCCACAAGCTCCATGTCA
ACAAGCGACTCTTCAAGAAGTTTCATTCTTCCTCCTTAAGCACCAAAAAAC
ACACAAAATCACCATGAAGCTCAAGAAATACTCAAATAGAGGATAGGGTT
5 TCGTTCGTAGGGTTAGAGAGGATGGAGGCTAGAGGAAATGAGGGATAGAG
GCGAGTTAAGGTCTTTAAATAGGGTCCAAGACCCTAAATTAGGGTTTTAA
TCTGGCCAGACGAACGCAGGGTGTCCCAAATGCATATGTGTCCAAATTC
TCGTGTGCGCCATGCGTACCTCCCTTGTACGCCATGTGTACCGGGTTTGG
TCCAAACCCTTCTAACTTCAAATGATCATAACTTGCACCCCTTATCTGTT
10 TTCGATGTTCTTTATATCCACGGAAAGGTAACAAGAAGCCCTATACTTCT
ATAAACTTTATTTAATCTGAAAACCAACCGAAATTAAATCCAAAATTCAT
AAAAGTCCCGAACCAACACATTTACCGATACCCTTGGGCTCCAAAACACA
AATTGAAAACCCGGATCATCCAAACTACATCATCCACCTCCAAATGAGCC
CAAACCTCAATTATTCAAGGGTTCTAAGCCTGTTAATGCCCACTCCTCGAT
15 TACCACCCCGCAATGGGAAACGATTCAAAACAGGGCGTTACATAATTTGT
TGTGGTTTTGTATTTTTTATTTCCGGTGAAGGTGAAAGATCCAACCTATTT
TTAATCTGTTGGCATTTTCCATCATTTGCAACTGTTTCTTGAAAAAAA
TACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGAGAAT
TGTAAATGGACATGGAATCTTAAATCATTAACACAGTTCAGTACACAAGT
20 TGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAAGAG
ACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATCCTG
TCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAGTTA
AAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGA
GAATTGGTAACAACCTCACCATAACCAACAACAGCCTGTTATATTTCCCAA
25 CCTCCAGCATTTGGATCTAAGGGGTATGGACAACATGATTCGCGTGTGGA
AGTGCAGCAACTGGAATAAATTCCTCACTCTTCCAAAACAACAATCAGAA
TCCCCATTCCACAACCTCACAACCATAAATATTGATTTTTGCAGAAGCAT
TAAGTACTTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGA
AAGTCAATATAAAATGGTGTATGGTATTGAAGAAGTTGTTTCAAACAGA
30 GATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAACCAC
CATCTTGTTCCCTCATCTTGATTCTCTCACTCTAAGTTTCCTGGAGAATC
TGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATA
TCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGAGGT
ATGCTTTGTTTCATATTCAATTATTTATTTAATTTCCCTTTTTTATTTGCAA
35 TATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAATTAC
CTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCTAGT
AAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGG
TAATATAGGCAATTTAAGTTTTATTCTGTAAAGCAGTATTTAGCAAGT
ACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATT
40 GTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAG
GTGACAGATATTGTAGAATAGAACAATATATAATATTACCCAAAACCTATT
TTTTCTAAGGTTTTTCTGTAAATATGTGCTTTCTTGATTTTCATTGAATT
TGCATTCCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCC

GAAATTAATTAATAAAAAAACAACAAAGTAAATTTTGGATATGGAGA
 GCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTC
 TTATATAAAAGCTGTGTATATAGTTTAATTAGTTTACATCATTTTTCCA
 TGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTTGGAGCTTATGCC
 5 AATACGCTAGAGAGATAAGTATAGAATTCTGCAATGCATTGTCAAGTGTG
 ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT
 CAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAACTCAATTAAGGAGGA
 GCAGCAACAAAAACAACGAGAAGAGTGGTTGTGATGAAGGAAATGGTGGA
 ATTCCAAGAGTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATT
 10 GGAAATCAGCTTTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCAC
 TTGAAAGCCTGAGACAGCTCGAAGAGTTAACGATAATGAATTGCTGGTCA
 ATGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAC
 AACACAACAACGAAGGGGACTTCTTCTTCTTCTTCTTCTTCTTCTTCTT
 CTTCTTCTTCTTCTTCTTCTCCTCCTTCTTCTTCTAAGAAGGTTGTGGTC
 15 TTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGGTAGG
 ATTCTTCTTGGGGATGAATGAGTTCGGTTGCCTTCATTAGATGAACTTA
 TCATCGAGAAATGCCCAAAAATGATGGTGTTCACAGCTGGTGGGTCCACA
 GCTCCCCAACTCAAGTATATACACACAAGATTAGGCCAAACATACTATTGA
 TCAAGAATCTGGCCTTAACTTTCATCAGGTATATATGTTTCTTTAATTGG
 20 CATCATCTAATTAAGAAAGATATCATTCTGCCAAGTAAATTTACTTCAA
 ACACATTACACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGGAAGGCCA
 AAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCAGTGGAAGGGTA
 TTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTLAGTACCTG
 GAATCGTGTGTGGGAGGAGCATTATTATTCTGATTTGCTTGTTTCTTTAT
 25 CATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATCTTTTGAT
 TTTAAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTGTTCTTCA
 TGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTGATTGTTATT
 TTCATAGCATGTTAGTCACTGAATCAAGCTTTTTTCATTTTCAACCAGGG
 CAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAAACAGCAACCCATC
 30 GGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGATTAATA
 ATTATAATATCCTGTATTAATTCATAAAAATTGGTACAGCACATATATGA
 CATTTCAAAGGTTTTTGTGTGACATATATATGCCTCTGGCGTTTTCTTTA
 TTGGACTTGCAGACCTCATTCCAAAGTTTATACGGTGACACCTTGGGCCC
 TGCTACTTCAGAAGGGACAACCTTGGTCTTTTCATAACTTGATTGAATTAG
 35 ATGTGAAATTTAATAAGGATGTTAAAAAGATTATCCATCCAGTGAGTTG
 CTGCAACTGCAAAAGCTGGAAAAGATAAATATAAACAGTTGTGTTGGGGT
 AGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGGAGAAATGGAATA
 GTGGAATTGTTTTGATGAATCGTCACAAACAACCTACCACTACTCTTGTC
 AATCTTCCAAACCTTAGAGAAATGAACTTATGGGGTCTAGATTGTCTGAG
 40 GTATATATGGAAGAGCAATCAGTGGACAGCATTGAGTTTCCAAAACATAA
 CAAGAGTTGAAATTAGTAATTGCAACAGTTTAGAACATGTATTTACTAGT
 TCCATGGTTGGTAGTCTATCGCAACTCCAAGAGCTACATATAAGTCAGTG
 CA-
 AACTTATGGAGGAGGTGATTGTTAAGGATGCAGATGTTTCTGTAGAAG

AAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAAGGAGATACTTGCG
TTACCTAGTCTAAAGTCCCTGAAATTAGAAAGCTTACCATCTCTTGAGGG
GTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTATTGGATACTTTAA
GAATTGAGGAATGCCCAGCAATAACCACCTTCACCAAGGGAAATTCCGCT
5 ACTCCACAACATAAGAGAAATAGAAACAAGATTTGGCTCGGTTTATGCAGG
GGAAGACATCAAATCCTCTATTATAAAGATCAAACAACAGGTAAATCAGA
TCATTGTTGGTTTAATAATTCTTAAACTACATTTGAAAAGTTTCATGTAA
GTTTTTTATTATTGTCAAAAGCCGCAACCTATATTTTCAACTTTATATTT
ATGTACTTTATGCAGGATTTCAAAAAAGCCCAGGACTCTATTTAATGTGA
10 AGTAAATACTAGAAGAGGTAAATTCTATTTACATGTCTCCTGATTGCCTA
TTAATTAATGGCCTTTCAGTTCATGGTTTTTGGATGTATTCTTCATGATG
ACGTGAATGTTTAAATACCCCACTAGTTAATTGTTAGGTTGAATGTTGAT
GACCAAAGGACTATATGTCTGGGAAGAATATTCAAGGAAAGAATTGTTTCAT
CATATGAAGGGCATTAAATTAAGAAGAACATGGATGCTATGAAGATGTTG
15 GGAAATATATGAATCAAATAACAAGCTACTCACTTATCTAAGTTTGTG
GTTGAGGATGTTGATTTTAATATTTCAAATTCATTGGTATCATTATATGG
GTTTATCAGTAGTGTTAATGGGATAATGAGCAACTTAACCTTAAATTATG
CTGTTGGTAAATGTTGGACTCAAGTATGGAAAATTAGGAATAACTTGTGA
AAAATATATGCAAAAGTAGGATTGAGATTTTCAATGAAAAAAATTATGAA
20 ACTATACTACTATAGTATATAAATAAATTCAACTTACTGTTGGGTATATT
GGAAGCACATATCATGAAAGTAAGTAGAAGCAGAATTTGTTCCCATCTTC
ATCTACTTATAGTTTCCATTTCTTACTTGTAATAATCTGATTAACTTTA
GAGTTATTTCTATTTTTTACCAACCAAAATTTTCATATAAAGGCCACAAG
T (SEQ ID NO:107)

25

RG2J deduced polypeptide sequence (SEQ ID NO:108)

MSDPTGIVGAIINPIAQTALVPLTDHVGYMISCRKYVRDMQMKMTELNTSRISAEHH
ISRNTRNHLQIPSQIKDWLDQVEGIRANVANFPIDVISCCSLRIRHKLQKAFKITEQI
ESLTRQNSLIWTDEPVPLGRVGSMIASTSAASSDHHDFPSREQIFRKALEALEPVQ
30 KSHIILWGMGGVGKTTMMKKLKEVVEQKKTENIIVQVVIGEKTNPPIAQAVADY
LSIELKENTKEARADKLKRFEADGGKNKFLVILDDVWQFFDLEDIGLSPLPNKGV
NFKVLLTSRDSHVCTLMGAEANSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPFI
GIADSIASRCQGLPIAIKTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYD
NLQDEVTKSIFLLCALFPEDFDIPIELVRYGWGLKLFIEAKTIREARNRLNNCTERL
35 RETNLLFGSHDFGCVKMHDVVRDFVLHMFSEVKHASIVNHGNMSEWPEKNDTSN
SCKRISLTCKGMSKFPKDINYPNLLILKLMHGDKSLCFPENFYGKMEKVQVISYDKL
MYPLLPSSLECSTNVRVLHLHYCSLRMFDCCSIGNLLNMEVLSFANSNIEWLPSTIG
NLKKLRLDLTNCKGLRIDNGVLKLNVLKLEELYMGVNRPYQAVSLTDENCNEM
VEGSKKLLALEYELFKYNAQVKNISFENLKRKISVGC SLHGSFSKSRHSYENTLKL
40 AIDKGELLESRMNGLFEKTEVLCLSVGDMYHLSVVKVSSSFYNLRVLVSECAEL
KHLFTLGAVANTLSKLEHLKVYKCDNMEELIHTGGSEGDITITPKLKL LYLHGLPNL
LGLCLNVNAIELPKLVQMKLYSIPGFTSIYPRNKLEASSLLKEEVVIPEELIVEKCGSI
EELFNIDLDCAVIGEEDNSSLRNINVENSMKLEVVRIKGADNSRPLFRGFQVVE

KIITRCKRFTNVFTPIITNFDLGALLEISVDCRGNDESDQSNQEQEQIEILSEKETLQE
ATDSISNVVFPSCLMHSFHNLQKLILNRVKGEVVFIEIESPTSRELVTTHHNQQQP
VIFPNLQHLDLRGMDNMIRVWKCSNWNKFFTLPKQQSESPFHNLTINIDFCRSIKY
LFSPLMAELLSNLKKVNIKWCYGIEEVVSNRDEDEEMTTFTSTHTTTILFPHLDSL
5 TLSFLENLKCIGGGGAKDEGSNEISFNNTTATTA VLDQFELSEAGGVSWSLCQYAR
EISIEFCNALSSVIPCYAAGQMQLQVLTVSSCNGLKEVFETQLRRSSNKNNEKSGC
DEGNGGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLRQLEELTIMNCWSMK
VIVKKEEDEYGEQQT TTTTGTSSSSSSSSSSSSSSSSSSSSSKKVVFPCLSIVLVNLP
ELVGFFLGMNEFRLPSLDELHIEKCPKMMVFTAGGSTAPQLKYIHTRLGKHTIDQES
10 GLNFHQDIYMPLAFSLDLQTSFQSLYGDTLGPATSEGTTWSFHNLIELDVKFNKD
VKKIIPSELLQLQKLEKININSCVGEVVFETALEAAGRNGNSGIGFDESSQTTTTTL
VNLPLREMNWGLDCLRYIWKSQWTAFEFPLKTRVEISNCNSLEHVFTSSMVGS
LSQLQELHISQCKLMEEVIVKDA DVSV EEDKEKESDGKMNKEILALPSLKSLESL
PSLEGFSLGKEDFSFPLD TLRIEECPAITTFTK GNSATPQLREIETRFGSVYAGEDIKS
15 SIIKIKQQDFKKAQDSI.CEVNTR

RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110)

TGGGATTCCATATATAAAAACATATATTTTTATAAAGTGGGATTCCATTG
TTTATATAGATTTTTATTCACCAATAGACAATAGATTAAAAAAGATATA
20 AAAACATGTCGGCTTTTGACTAAAAATATAGATTTTTATGAATAGAATAT
TCAATTTGCTTAACTCGTTTAAAAAAAATGAAAAAGATGTCGATATAAAA
TCTCATATGGGCCTTCTTTACCATTCAAATAGTAAAATAGTAAAAGATAC
TTGTTTGGGGCATGAACTGACCATAGTCAAACCCATACAAAATCAAACGA
ATCCACATGGATGATGACGATGGGGTCGCAGTAAATGTGTTTTGGTCCT
25 TTTTTTTCGAGAGAACAGAAGCTTCTGCTCTTCATCTTCTTTAGATTTTG
GGGATTTTCTGGTTTCAGGGGTTTGTGAGTGGAAACTAAATTGAAGCAAA
AAAGTATGGTATAATTGGTTGCTAGTGAAATTGATGCTTTCTATTACTAT
CATCTTTAAAATTGTCAAAACATTATGTATTAAATTATGAGATCGAAAGT
GGTCTATGGGCCAAAGGTAATACAAGCTTACTCAATGAAATGAATCTAGG
30 ATGCATCATGCATGTATTGGTTAGATTAAAGATTTTCATCAAATTTCTT
TATCAAATTGTTGTATACCATGTTATGTAGGTGCTACCACAAGCCATAAC
ATCGAGCAATGGAGTGTATTACTGGCATCTTTAGCAACCCGTTTGCTCAG
TGTCTCATCGCTCCTGTGAAAGAACACCTTTGCCTTCTGATTTTCTATAC
ACAATATGTAGGGGATATGCTTACTGCAATGACGGAGTTGAATGCTGCAA
35 AAGACATTGTTGAAGAGCGGAAGAATCAAAACGTAGAAAAATGTTTTGAG
GTTCCAAACCATGTCAACCGTTGGTTGGAAGATGTTCAAACAATCAACAG
AAAAGTGGAAACGTGTTCTTAACGATAATTGCAATTGGTTCAATCTATGTA
ATAGGTACATGCTCGCAGTGAAAGCCTTGGAGATAACTCAGGAGATCGAT
CATGCCATGAAACAACCTCTCTCGGATAGAATGGACTGATGATTCAGTTCC
40 TTTGGGAAGAAATGATTCCACAAAGGCATCCACCTCTACACCATCAAGTG
ATTACAATGACTTCGAGTCAAGAGAACACACTTTTAGGAAAGCACTTGAA
GCACTTGGATCCAACCACACATCCACATGGTAGCCTTATGGGGGATGGG

TGGAGTTGGGAAGACCACGATGATGAAGAGGCTGAAAAATATTATTAAAG
AAAAGAGGACGTTTCATTATATTGTTTTGGTGGTTATAAAGGAAAATATG
GATCTCATTTCATCCAGGATGCTGTAGCAGATTATCTGGATATGAAGCT
AACAGAAAGCAATGAATCAGAAAGAGCCGATAAACTTCGTGAAGGGTTTC
5 AGGCCAAATCAGATGGAGGTAAGAATAGGTTCCCTCATAATACTGGATGAT
GTATGGCAATCTGTTAATATGGAAGATATTGGTTTAAGTCCTTTTCCGAA
TCAAGGTGTCGACTTCAAGGTCTTGTGACCTCGGAAAACAAAGATGTTT
GTGCAAAAATGGGAGTTGAAGCTAATTTAATTTTCGACGTGAAATTCTTA
ACAGAAGAAGAAGCACAAAGTTTGTTTTATCAATTTGTAAAAGTTTCTGA
10 TACCCACCTTGATAAGATTGGAAGCTATTGTAAGAACTGTGGTGGTC
TACCCATTGCCATCAAACCATAGCCAATACTCTTAAAAATAGAAACAAG
GATGTATGGAAGGATGCACCTTCTCGTATAGAGCATCATGACATTGAGAC
AATTGCACATGTTGTTTTTCAAATGAGCTACGACAATCTCCAAAACGAAG
AAGCTCAATCCATTTTTTTGCTTTGTGGATTGTTTCCTGAAGACTTTGAT
15 ATTCCTACTGAGGAATTGGTGAGGTATGGATGGGGATTGAGAGTATTTAA
TGGAGTGTATACTATAGGAGAAGCAAGACACAGGTTGAACGCCTACATCG
AGCTGCTCAAGGATTCTAATTTATTGATTGAAAGTGATGATGTTCACTGC
ATC.AAGATGCATGATTTAGTTTCGTGCTTTTGTGTTGGATACGTTTAATAG
ATTCAAGCATTCTTTGATTGTAAACCATGGTAATGGTGGTATGTTAGGGT
20 GGCCTGAAAATGATATGAGTGCCTCATCTTGCAAAAGAATTTCAATTAATA
TGCAAGGGCATGTCCGATTTTCTAGAGACGTAAAGTTTCCAAATCTCTT
GATTTTGAAACTTATGCATGCAGATAAGTCTTTGAAGTTTCCCTCAAGACT
TTTATGGAGAAATGAAGAAGCTTCAGGTTATATCATACGATCACATGAAG
TATCCCTTGCTTCCAACATCACCTCAATGCTCCACCAACCTTCGTGTGCT
25 TCATCTTCATCAATGCTCATTGATGTTTGATTGCTCTTCTATTGGAAATC
TGTTGAATCTGGAAGTGCTCAGCTTTGCTAATTCTGGTATTGAGTGGTTG
CCTTCCACAATCGGAAATTTGAAGGAGCTAAGGGTACTAGATTTGACAAA
TTGTGATGGTCTTCGTATAGATAATGGTGTCTTAAAGAAATTGGTGAAAC
TTG.AAGAGCTTTATATGAGAGTTGGTGGTCGATATCAAAGGCCATTAGC
30 TTC.ACTGATGAAAACCTGCAATGAAATGGCAGAGCGTTCAAAAAATCTTTC
TGC.ATTAGAATTTGAGTTCTTCAAAAACAATGCTCAACCAAAGAATATGT
CATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGTTATTTAAG
GGAGATTTCCGTAAGATCTTTCACCTCTTTTGAAAACACGTTGCGGTTGGT
CACCAACAGAACTGAAGTTCTTGAATCTAGGCTTAATGAGTTGTTTGAGA
35 AAACAGATGTTCTTTATTTAAGTGTGGGAGATATGAATGATCTTGAAGAT
GTTGAGGTAAAGTTGGCACATCTTCCTAAATCCTCTTCCTTCCACAATTT
AAGAGTCCTTATCATTTCTGAGTGTATAGAGTTGAGATACCTTTTCACAC
TTG.ATGTTGCAAACACTTTGTCAAAGCTTGAGCATCTTCAAGTTTACGAA
TGCGATAATATGGAAGAAATCATACATACAGAGGGTAGAGGAGAAGTGAC
40 AATTACATTCCCAAAGCTGAAGTTTTTATCATTGTGTGGGCTACCAAATC
TGTTGGGTTTGTGTGGTAATGTGCACATAATTAATCTACCACAACCTCACA
GAGTTGAAACTTAATGGCATTCCAGGTTTCACAAGCATATATCCTGAAAA
AGATGTTGAAACATCTAGTTTGTGTAATAAAGAGGTAAATGTGTTTTATG

TTAATACAATACAATCTTTTCAATTAACCGTTTCAAAAATATATTGTATGA
TTTATTTTTGTTTGGATGGGGTTATTAATGGGTGATTATTTCTCAGGTTG
TAATTCCTAATTTGGAGAACTTGATATTAGTTATATGAAGGATTTGAAA
GAGATATGGCCTTGTGAATTAGGGATGAGTCAGGAAGTTGATGTTTCTAC
5 GTTGAGAGTGATTAAAGTAAGCAGTTGTGATAATCTTGTGAATCTATTCC
CGTGCAATCCTATGCCATTGATACATCACCTTGAAGAGCTTCAAGTGATA
TTTTGTGGTTCCATTGAAGTGTTATTCAACATTGAGTTGGATTCTATTGG
TCAAATTGGAGAAGGCATCAACAATAGCAGCTTGAGAATCATCCAATTGC
AGAACTTAGGGAAGCTAAGTGAGGTGTGGAGGATAAAAGGTGCGGATAAC
10 TCTAGTCTTCTCATCAGTGGCTTTCAAGGTGTTGAAAGCATTATCGTTAA
CAAATGCAAGATGTTTAGAAATGTATTACACCTACCACCACCAATTTTG
ATCTGGGGGCACCTTATGGAGATTCCGATACAAGATTGTGGAGAAAAGAGG
AGAAACAACGAATTGGTAGAGAGTAGCCAAGAGCAAGAGCAGGTATGGCT
TTCAATTTCACTTTCTTACTTAATGAAGGATTAAGCTCCTGCTTTTTGAA
15 TAAAAAGTGGATGAATGACTAAATTCGGGAATGCCACCCGGAAAGTTATC
AACCATTTAGCTACACCATTTTTTGAACATAATGTTGCAATAAATGCATAA
TATAATTAATAAATGGTCATTGATAAATGTAAACCAACCTTTTTTATTTA
TTAAAATGTCTACAATAAATGATTTTCTTTATTATATATCATTTTATAAC
AATAAGCTTAAAGATGTTTAAATAGCCAATGTCAGTTATAGATCGTAACT
20 AATTTTTTATTAAGTATTTTAGTTAAGATATCACTCATTATTATTTTAA
TAGAAAAAGACAAGATTGGCTAATCCTCATAAGAATTTGGAAGATTTAA
GCAAAATATAGAGCTTTTCCAAACATAGCCAATAGTTTCTTTTGCAGGTC
CCATCTACGAAATTATCAATAGATTGCGATTTTTTTTTTGGCACCCGGGA
AATTTCCATTAATTAATAAATAAGTTCAAGCCATTTTGTAAGTTGGCACCTG
25 CAAAATGGTAGTTTGCACCTGCGGAAATCACCTTTCACCATTTTCGCATCT
ATGACTTGTGAAAATGTTAATTTGTGAAATGGTCATGTGCACCTCATGAG
AAATACGAAATGGTCAGTAATATGACTTTTTTATATAAATATGATGGTGG
CATATATTTATAGGAAAATATAGCTGCACGATATTAATTAATAGTGAAAT
TAGTTAACTGTATACGATAAGTATACAAAATTTATATGTATGAAGTATAC
30 TCAATTTAGGACGACTCGGGCAATGAAATCATCATTTAATAGGAGCAATG
AAATCATTTTCGAAAAATGTTTACAAATGAATAAAATATTAAATTAACT
TAAACATTTTGTAGTAGTTTGAAATTTACAACTGAAATTTGTTGTAT
TTATTAACATTTATAAATGTTGTACTATGATTTTTTCCTTGTTTGCAAAT
ATTCCTTAAAAATCCACCTAAAATCAAAATAATTAATCTTTTTCAAGTTG
35 AAAAATGAAAATCGTATGATATAACCGTGTATGGATGTGGAATTATATAT
CAGTTACTAATTACATTTTTTGTGTTGGGATATATGTGCGCAGATTGATATT
GCAATCCCATTCACCTCTCACACACTCTTCCAAAACCTCCGTAAACTTGC
TTTGGAAGATATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTCCAA
CAAGTAGAGAATTGATAACAATTCACCATAATCAACAACCACTACTTCCC
40 AACCTTGAGTTATTGGATATAAGTTTTATGGACAGCATGAGTCATGTATG
GAAGTGCAACTGGAATAAATTCCTTCATTCTTCAAAAACAACAGTCAGAAT
CCCCATTCTGTAATCTCACAACCATAATCAATATTGCCAAAGCATT
AAGTACTTGTTTTCAACTCTCATGGCAAACTTCTTCCAACCTAAAGAA

GGTCGAGGTAAGAGAGTGTCATGGTATTGAAGAAGTTGTTTCGAACAGAG
ATGATGAAGATGAGGAAAAGACTACATTTACATCTACATCTTCTGAAAAA
AGCACTAATTTGTTCCCTCGTCTTGAATCTCTCGCTCTTTATCAACTTCC
AAATCTCAAGTGTATTGGTGGTGGTGGTCTGCCAACAGTGGGAACAATG
5 AAATATCTCTTGATAATCCACTACTACTACTTCTTTTGTGATCAATCT
AAGGTATGTTTTTTTTTTNGTTNCCCTT (SEQ ID NO:109)
Sequence gap
CCTCCCTAATAATACATGTTATGCACACTATACTAACATATTAGACACGT
AAAGGATAAATGCTATGCCTCATATAATACGTTATATTTATAATCTTTAA
10 ACAATCAAATTTATTAAACAAATAACTAAGTGTGAGCAAAGGCAGGTACC
CGACTAAATTGCCCAAACCAGTCTGGTGGTTCGTGGAATGTTGGGCCAG
GTCGTTAAACGTCTACACACCGGTTCTTTAAATCACAGATCCGCTTCTC
ATACTGTGAACCCGGTTTTAATTTTAAAAGAAAATTCATTATAAAGTAA
ATGACTTAAACCATTACAAACAACAAAATTTACCATTACAATGTTGGAC
15 TATCATTATTTGCAACATAAACTGAAAATACACATATTTCTTCTGATA
TCAGCATGAGTGGCTGGTTGGCTAACCCAAAATCCATGCATTGTAGATG
TGTGTTACAACACATAGTATCAATGAAAGGCATATTTTTAGGCTAGAATT
TAACAATCTGTAATAATATCCCTAAAATAATATCATCATCAACCAACT
AATATAAAACCATTTGGGTTTCGTCAATTTTAGGTACAAAACATAGATTTTC
20 TAAGCTTGTTGTATTTAAACATATGCTTTCTAAACTTAATTGATTTTGCA
TTCCAAAATTTTAGGTTGTAAAGTGGTATGTCATTTGTTGTCTTTTCAAC
ATTAAATTGTACAAAACCAAACTACATAATTGATGTAGATATCATAACA
ATTGTGTTATTTAGTATATAAAAACTAAATTTTGAATTGAATTTCTTATA
CAAAGTTGTGTCTATGTATACATGTTTATGTAGGTAATAGACAATTAGT
25 CTCTGTTAAGTATATGGAGTTTAATTTTTAGACTAATTTTTCATGTGTTG
CAGTTTTATCAGGCAGGTGGCGTTTTTTGGACGTTATGCCAATACTCCAG
AGAGATAAATATAAGGGAGTGTTATGCATTGTCAAGTGTAATTCATGTT
ATGCAGCAGGACAGATGCAAAATGTTCAAGTGCTGAATATATACAGGTGC
AACTCAATGAAGGAGTTATTTGAACTCAAGGGATGAACAACAACATGG
30 TGACAGTGGTTGTGATGAAGGAAATGGTTGTATACCAGCAATCCAAGAC
TAAATAACGTTATTATGCTACCCAATCTAAAGATATTGAAGATTGAAGAT
TGTGGTCATCTGGAACATGTATTCACATTCTCTGCACTTGGAAGCCTGAG
ACAGCTCGAAGAGTTAACGATAGAGAAATGCAAGGCAATGAAAGTGATAG
TGAAGGAAGAAGATGAATATGGAGAGCAAACAACAAAGGCATCTTCGAAG
35 GAGGTTGTGGTCTTTCCTCGTCTCAAGTCCATTGAACTGGAAAATCTACA
AGAGCTCATGGGTTTCTACTTAGGGAAGAATGAGATTCAGTGGCCTTCAT
TGGATAAGGTTATGATCAAGAATTGCCCAGAAATGATGGTGTTCACCT
GGTGAGTCCACAGTTCCCAAGCGCAAGTATATAAATACAAGCTTTGGCAT
ATATGGGATGGAGGAGGTACTTGAACTCAAGGGATGAACAACAATAATG
40 ATGACAATTGTTGTGATGATGGAATGGTGGAAATCCAAGACTAAATAAC
GTTATTATGTTTCAAATATAAAGATATTGCAAATCAGCAATTGTGGCAG
TTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGATGCAGCTCA
AAGAGTTAACAATAGCGGATTGCAAGGCAATGAAAGTGATTGTGAAGGAG

GAATATGATGTAGAGCAAACAAGGGTATTGAAGGCTGTGGTATTTTCTTG
TCTAAAGTCCATTACACTATGCCATCTACCAGAGTTGGTGGGTTTCTTCT
TGGGGAAGAATGAGTTCTGGTGGCCTTCATTGGATAAGGTTACCATCATT
GATTGCCACAAATGATGGGGTTCACACCTGGTGGGTCAACAACCTCCCA
5 CCTCAAGTACATACTCAAGCTTAGGCAAACATACTCTTGAATGTGGCC
TTAATTTCAAGTCACAACACTACTGCATATCATCAGGTATAATTATTATTCT
TTNACACCATCTAATTATGGAATCATGACGCTAATTACAGTATTAAACAC
(SEQ ID NO:110)

10 **RG2K deduced polypeptide sequence (SEQ ID NO:111)**

MECITGIFSNPFAQCLIAPVKEHLCLLIFYTQYVGDMLTAMTELNAKDIVEERK
NQNVKCFEVPNHVNRWLEDVQTINRKVERVLNDNCNWFNLCNRYMLAVKAL
EITQEIDHAMKQLSRIEWTDDSVPLGRNDSTKASTSTPSSDYNDFESREHTFRKAL
EALGSNHTSHMVALWGMGGVGKTTMMKRLKNIIEKRTFHYIVLVVIKENMDL
15 ISIQDAVADYLDMKLTESNESERADKLREGFQAKSDGGKNRFLIILDDVWQSVN
MEDIGLSPFPNQGVDFKVLITSENKDVCAKMGVEANLIFDVKFLTEEEAQSIFY
QFVKVSDTHLDKIGKAIVRNCGGLPIAKTIANLKNRNDVWKDALSRIEHH
IETIAHVVFQMSYDNLQNEEAQSIFLLCGLFPEDFDIPTEELVRYGWGLRVFNGV
YTIGEARHRLNAYIELLKDSNLLIESDDVHCIMHDLVRAFVLDTFNRFKHSLIV
20 NHGNGGMLGWPENDMSASSCKRISLICKGMSDFPRDVKFPNLLILKLMHADKS
LKFPQDFYGMKKLQVISYDHMKYPLLPTSPQCSTNLRVLHLHQCSLMFDCSSI
GNLLNLEVLFSFANSIEWLPSTIGNLKELRVLDLTNCDGLRIDNGVLKKLVKLEELY
MRVGGRYQKAISFTDENCNEMAERSKNLSALEFEFFKNNAPKNMSFENLERFKIS
VGCFYFGDFGKIFHSFENTLRLVTNRTEVLESRLNELFEKTDVLYLSVGDMDLED
25 VEVKLAHLPKSSSFHNLRLVLIISECIELRYLFTLDVANTLSKLEHLQVYECDNMEEII
HTEGRGEVTITFPKLKFLSLCGLPNLLGLCGNVHIINLPQLTELKLNIGIPGFTSIYPEK
DVETSSLLNKEVVIPNLEKLDISYMKDLKEIWPCELGMSQEVVDVSTLRVIKVSSCDN
LVNLFPCNPMPLIHHLEELQVIFCGSIEVLFNIELDSIGQIGEGINSSLRRIQLQNLGK
LSEVWRIKGADNSSLLISGFQGVESIIVNKCKMFRNVFTPTTTNFDLGALMEIRIQDC
30 GEKRRNNELVESSQEQQ

RG2L polynucleotide sequence (SEQ ID NO:112)

GGAAGACACAATGATGCAAAGACTGAAGAAGGTTGCCAAAGAAAATAGAA
TGTTCAAGTTACATGGTCGAGGCAGTTATAGGGGAAAAGACAGACCCAATT
35 GCTATTCAACAAGCTGTAGCCGATTACCTTCGTATACAGTTCAAAGAAAG
CACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCCACT
CTGNAGACGGTAAGAATAAGTTCCTCGTAATATTTGATGACGTCTGGCAG
TCCGTTGATCTGGAAGATATTGGNTTAAGTCCTTTTCCAAATCAAGGTGT
CGACTTCAAGGTCTTGTTGACTTCACGAGACGAACACGTTTGACAATGA
40 TGGGGGTTGAAGCTAATTCAGTTATTAATGTGGGACTTCTAACTGAAGTA
GAAGCACAAAGTCTGTTCCAGCAATTTGTAGAACTTTTGAGCCCGAGCT
CTGTAAGATAGGAGAAGTTATCGTAAGAAAGTGTGCGGTCTACCTATTG

CCATCAAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGG
AAGGATGCACTTTCACGTATAGAGCACTATGACATTCGTAGTGTTCGCC
TAAAGTCTTTGAAACAAGCTATCACAATCTCCAAGACAGGGAGACTAAAT
CCGTGTTTTTGGTGTGTGGTTTGTTCCTGAAGACTTCAATATTCCTACC
5 GAGGAGTTGATGAGGTATGGATGGGGCTTAAAGCTATTTGACAGAGTTTA
TACAATTAGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTTG
TGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATG
CATGATCTGGTGCCTGCTTTTGTTCCTGAAGTCGAGCA
TGCTTCAATTGTCAACCATGGTAATATGCATGGGTGGACTAAAAATGATA
10 TGAACGACTCTTGCAAAACAGTTTCTTTAACATGCGAGAGTGTGTCTGAG
TTTCCAGGAGACCTCAAGTTTCCAAACCTAAAGCTTTTGAACTTATGCA
TGGAGATAAGATGCTAAGGTTTCTCAAGACTTTTATGAAGGAATGGAAA
AGCTCCAGGTAATATCATACCATAAAATGAAGTATCCATTGCTTCCCTCG
TCACCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTTCATCGGTGTTT
15 ATTACGGATGCTTGATTGCTCTTGATCGGAAATTTGACGAATCTGGAAG
TGTTGAGCTTCGCTAATTCTGGCATTGAACGGATACCTTCAGCAATCGGA
AATTTGAAGAAGCTTAGGCAACTTGATCTGAGAGGTCGTTATGGTCTTTG
TATAGAACAGGGTGTCTTGAAAAATTTGGTCGAACTTGAAGAACTTTATA
TTGGAAATGCATCTGCGTTTAGAGATTATAACTGCAATGAGATGGCAG

20

RG2L deduced polypeptide sequence (SEQ ID NO:113)

EDTMMQRLKKVAKENRMFSYMVEAVIGEKTDPPIAQQAVADYLRIQFKESTKPAR
ADKLREWFKAHS?DGKNKFLVIFDDVWQSVLDLEDIGLSPFPNQGVDFKVLLTSRDE
HVCTMMGVEANSVINVGLLTEVEAQSLFQQFVETFEPELCKIGEIVVRKCCGLPIAI
25 KTMACTLRNKRKDAWKDALSRIEHYDIRSVAPKVFETSYHNLQDRETKSVFLMCG
LFPEDFNIPTEELMRYGWGLKLFDRVYTIREARLNTCIERLVQTNLLIESDDVGC
VKMHDLVRAFVLGMYSEVEHASIVNHGNUMHGWTKNDMNDSCKTVSLTCEVSSEF
PGDLKFPNLKLLKLMHGDKMLRFSQDFYEGMEKLQVISYHKMKYPLLPSSPQCST
NLRVLHLHRCSLRMLDCSCIGNLTNLEVLFSFANSGERIPSAIGNLKKLRQLDLRGR
30 YGLCIEQGVKLNLELELYIGNASAFRDYCNEMA

30

RG2M polynucleotide sequence (SEQ ID NO:114)

GGGGAAGACACAATAGATGCAAAGGCTGAAGAAGTTGCCAAAGAAAAGAG
AATGTTCAAGTTATATCATTGAGGCGTTATAGGGGAAAAGACAGACCCCA
35 TTTCCATTCAAGGAAGCTATATCATATTACCTTGGTGTAGAGCTCAATGCA
AATACTAAGTCAGTAAGAGCTGATATGCTTCGTCAAGGGTTCAAGGCCAA
ATCTGATGTAGGTAAGGATAAATTCTTAATAATACTCGACGATGTATGGC
AGTCTGTTGATTTGGAAGATATTGGATTAAGTCCATTTCCAAATCAAGGT
GTTAACTTCAAGGTCCTGTAAACATCACGAGACCGACATATTTGCACTGT
40 GATGGGGGTTGAAGGTCATTCGATTTTAAATGTGGGACTTCTCACAGAAG
CAGAATCAAAAAGATTGTTCTGGCAGTTTGTAGAAGGTTCTGATCCTGAG
CTCCATAAGATAGGAGAAGATATTGTAAGTAAGTGTTGTGGTCTACCCAT

40

TGCCATTAAAACCATGGCATGTACACTTAGAGATAAAAGTACGGATGCAT
GGAAGGATGCACTGTCTCGTTTAGAGCATCATGACATTGAAAATGTTGCC
TCTAAAGTTTTTAGAGCGAGCTATGACCATCTCCAAGACGAGGAGACTAA
ATCCACTTTTTTCTATGTGGATTGTTTCCAGAAGATTCCAATATTCTTA
5 TGGAGGAGTTGGTGAGGTATGGGTGGGGATTGAAATTATTTAAAAAAGTG
TATACCATAAGAGAAGCAAGAACTAGGCTCAACACTTGCAATTGAGCGGCT
CATCTATACCAATTTGTTGATAAAAGTTGATGATGTTTCAGTGCATCAAGA
TGCATGATCTCATCCGTTCTTTTGTGTTTGGATATGTTTTCTAAAGTTGAG
CATGCTTCGATTGTCAACCATGGTAATACGCTAGAGTGGCCTGCAGATNA
10 TNTGCACGACTCTTGTAAGGGCTTTCATTAACATGCAAGGGTANATGTG
AGTTTTGTGGAGACCTNAANTTCCAACCCTAATGATTTTAAACTTATG
CATGGAGATAAATCGCTAAGGTTT

RG2M deduced polypeptide sequence (SEQ ID NO:115)

15 GEDTIDAKAEVAKERMFSYIIEAVIGEKTDPISIQEAISSYYLGVELNANTKSVRAD
MLRQGFKAQSDVVGKDKFLILDDVWQSVLEDIGLSPFPNQGVNFKVLLTSRDRHI
CTVMGVEGHSIFNVGLLTAESKRLFWQFVEGSDPELHKIGEDIVSKCCGLPIAIKT
MACTLRDKSTDAWKDALSRLEHHDIENTVASKVFRASYDHLQDEETKSTFFLCGLFP
EDSNIPMEELVRYGWGLKLFKKVYTIREARLNTCIERLIYTNLLIKVDDVQCIKM
20 HDLIRSFVLDMFSKVEHASIVNHGNTLEWPAAD??HDSCKGLSLTCKG?CEFCGDL?F
PTLMILKLMHGDKSLRF

RG2N polynucleotide sequence (SEQ ID NO:116)

AGGTAAATCCATAACCTAAATGTTGGTACGCTCATATATCAAATTGCG
25 TGTTTTGTTGAATGAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGG
TATATGACATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTT
TACRTAAGTTAGGATTCGTA CTTC AACCAAATGTAATAGTTTTTGTGAGT
CTATCTATGTATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAAT
TCGAAAAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTT
30 TAGCGACATCTAATATTAAATAGAATGTATCTGATATTGAATTAATGTCC
TTAATGTGAACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTT
CTAATCAATAAATTTTAATTTCTGTTTATGCTTCTAAGACAATAAAAAAT
CCATGATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAA
ATTAGGATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGAT
35 GCTTTTGCTTTTCCCTCTTTTCTTGTAGTCTATTATTCTGGAGAGTTT
GAGAGAGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTA
TTCTCTTTTCTTAATTATGTATTAACCTACAAGCATTTTTTACACGATCC
ATGGTTTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGC
CCTTGATGATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAG
40 TGGTGAATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATG
ATGATGAGATAGAGATATGTTAAACTGGCTAGAAAATTGTTTTAATTTG
AAATTTAGGTKGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTT

ATGCTAAWTAGTTATAAAGAACAACAAACTCTTAGTTTTTTTTTTCATGA
TTTTCAACCTCTTTGTACCAAATAAATTATAGCAAAATTGAATATCATT
CTCTGCAATCAATCTTAACTTTTGTTATTATCATCATGTCTAAAATTGCC
ACAAGTTTATTTTCAAAGTCATATTGGATTATGAAAGGACTATTTTTACC
5 AATTACATCTTTACTTTATGGGCCAAAGCTAATACAATCCGACTAAACTA
AAGGAATATGGGATGCATATAGTTTGCTTCCCGATTATAGATTCTATCT
AATTTGTCTATTGTACTAATTTAGGTGCCACCACAAGTAAATTTGTTAAA
TGGATATCGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTA
CCCGTTAAGAAACACATAGGGTACCTCATTTCCCTGCAGGCAATATATGAG
10 GGAAATGGGTATCAAAATGAGGGGATTGAATGCTACTAGACTTGGTGTCTG
AAGAGCATGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCCAA
GGCAGGGGTTGGTATGAAGAAGTAGGAAAGATCAATGCAAAAGTGGA
TTTTCTAGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGG
TCGGAAAGAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTCTATGAGA
15 GAACACTCTATCATCATCTGGAATGATCATTCCATTCTTCTAGGAAGAAT
TGATTCCACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATG
AGTTCCAGTCAAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGAT
CCTAACCACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGG
GAAGACGACAATGATGCATCGGCTGAAAAAGGTTGTGAAAGAAAAGAAAA
20 TGTTTAATTTTATTGTTGAGGCGTTGTAGGGGAAAAAACAGACCCCAT
GCTATTCAATCAGCTGTGGCAGATTACCTAGGTATAGAGCTCAATGAAAA
AACTAAACCAGCAAGAAGCTGAGAAGCTTCGTAAATGGTTTGTGGACAATT
CTGCTGGTAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTA
GATCTGAATGATATTGGTTTAAAGTCCTTTACCAAATCAAGGTGTGCACTT
25 CAAGGTGTTGTTGACATCACGAGACAAAGATGTTTGCACTGAGATGGGAG
CTGAAGTTAATTCAACTTTTAATGTGAAAATGTTAATAGAAACAGAAAGCA
CAAAGTTTATTCCACCAATTTGTAGAAATTTTCGGATGATGTTGATCGTGA
GCTCCATAATATAGGAGTGAATATTGTAAGGAAGTGTGGCGGTCTACCCA
TTGTCATCAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCA
30 TGGAAGAATGCACTTCTTCGTTTAGTGAACTACAACATTGAAAATATAGT
GAATGGAGTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTA
AATCCACCTTTTTGCTTTGTGGAATGTTTCCCGAAGACTTTAATATTCTT
ACCGAGGAGTTGGTGAGGTATGGATGGGGGTTGAAATTATTTAAAAAAGT
GTATACTATAGGAGAAGCAAGAATCAGGCTCAACACATGCATTGAGCGGC
35 TCATTACATAAAATTTGTTGATTGAAGTTGATGATGTTAGGTGCATCAAG
ATGCATGATCTTGTCCGTGCTTTTGTGTTGGATATGTATTCTAAAGTCGA
GCATGCTTCCATTGTCAACCATGGTAATACTAGAGTGGCATGTGGATA
ATATGCACAACTCTTGTAAGAACTTTCATTAAACATGCAAGGGTATGTCT
AAGTTTCCTACAGACCTCAAGTTTCCAAACCTCTCGATTTTGAACTTAT
40 GCATGAAGATATATCATTGAGGTTTCCCAAAAACCTTTATGAAGAAATGG
AGAAGCTTGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCC
TCATCACCAGCAATGCTCCGTCAACCTTTGCGTGTTTCATCTCCATAAATG
CTCGTTAGTGATGTTTGACTGCTCTTGTATTGGAAATCTGTGCAATCTAG

AAGTGCTTAGCTTTGCTGATTCTGCCATTGACCTGTTGCCTTCCACAATC
GGAATTTTGAAGAAGCTAAGGCTACTGGATTTGACAAATTGTTATGGTCT
TTGTATAGCTAATGGTGTCTTTAAAAAATTGGTCAAACCTGAAGAGCTCT
ATATGACAGTGGTTAATGGAGGAGTTCGAAAGGCGATCAGCCTCACTGAG
5 GATAACTGCAATGAGATGGCAGAACGTTCAAAAGACCTTTCTGCATTAGA
ACTTGAGTTCTTTGAAAACAATGCTCAGCCAAAGAATATGTCATTTGAGA
AGCTACAACGATTCCAGATCTCAGTGGGGTGCTATTTATATGGAGCTTCC
ATAAAGAGCAGGCACTCGTATGAAAACACATTGAAGTTGGTTATTGACAA
AGGTGAATTATTTGAATCTTGAATGAACGGCCTGTTTAAGAAAACAGAGG
10 TGTTATGTTTAAGTGTGGGAGATATGAATGATCTTGAAGATRTTGAGGTT
AAGTCATCCTCACAACYTCTTCAATCTTCTTCGTTCAACAATTTAAGAGT
CCTTGTCGTTTCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTG
TTGCAAACTTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGAT
AATATGGAAGAACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTAC
15 ATCCCCAAGCTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGG
GTTTGTGCGATAATGTCAAATAATTGAGCTACCACAACTCATGGAGTTG
GAACTTGACGACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTT
TGAAACATTTAGTTTGTGAAGGAAGAGGTAAATATAAATTTTAAATGCT
AATACATTACAAAGGATCTTTTCAGTTAAATCTTTCAAATATATTGTAA
20 TTTGATTGTATGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTA
TCTTGCAGGTTCTGATTCCCTAAGTTAGAGAACTGCATGTTAGTAGTATG
TGGAACTCTGAAGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGT
TAAGTTCAGAGAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGT
TTCCGCACAAGCCCATATCTCTGCTGCGTCATCTTGAAGAGCTTAAAGTC
25 AAGAATTGTGGTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGC
TGGTGCAACTGGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAG
TGATCAGTTGTGATAAGCTTGTGAATCTCTTCCACACAATCCCATGTCT
ATACTGCATCATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGA
ATCGTTATTCAACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAG
30 ACAACAGAAGCAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTA
AGAGAGGTGTGGAGGATAAAAGGTGGAGATAACTCTCGTCCCCCTTGTTCA
TGGCTTTCAATCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAGGTTTA
GAAATGTATTACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTG
GAGATTTCAATAGATGACTGCGGAGAAAACAGGGAAAATGACGAATCGGA
35 AGAGAGTAGCCATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTTTCKT
ACTTAATTAATGATTAAGCTCCTGCTTTTTRAATAAAAAAGGGACAAACC
ATTTTCATGACTTAATGTAGCAATACAAGTCATGTATAAGAGTGACCAACT
CTTTTTTATTTATAAAATGACTACAAAATATTTTTTTTTCATTAGAGATCA
TGTATAAATGTGACTAATTTTTCATCACCTAACTTTAGTTGATAAATCTT
40 TATAAATGTCAGTAGTTACTTTTCAGTAAAATAACAAATTTAATAAATTA
TCAACAAAAAGCATCAACTAAAAAATCCCAACCCGTAATAATTTAAA
ATAAAAGGATTTAACATCTAATACGAACAATTTTTTTTCTAAACATGATT
TGGACCAAATATCACCAGCAACTCAAGTTTGGAATCGATTCAGCTTAAAA

CTTGACCARCATAATTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATAT
AAGTTCGTTTCATCTTTTTCTTGATCTTGATAGCAAGTTGAATSATTTT
CTTCTTCAAAATTGATAAAAATCTACATTATAAAGAGACTAGCTTGAAAA
AAAATGGTCTAGGTGGGTCTTGGGTCTGGTAGATGAAGATGGAAGGGAGA
5 GTAGATTTCAAAGACACAAACACATCTTCATTTTATTTATTTATTTATTA
TTATTATTTTTTGATATCTTGCTCATATTTGTTACAGATATGTGAGGTCT
ATTAATCTTTTTAAATATATAAAAAATAAATACATAAATGAGAAAATTAA
ATAAAGAATAAATTAATAAGGGCACAAATAGTCTTTTTGGTAAGACAAGG
ACCAAAAGCGCAACAAAAGTAAACAGTAGGGACCATCCGATTTAAAAAAT
10 TAATTAGGGACCAAAAACATAAATTCCTCCCAAACCATAGGGACCATTCGT
GTAATTTACTCTTGCTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTT
TTGTACATATCTAGGTAACGAACTTGTTGAAAGTGTTACATCTACGATG
TGACCTACTACAACCGATCATAATGGTCATATATGAACACTTCCAACAAG
TTTGTTATCTAGGTGTGTACAAAAAACGATAGTTACCATGATGTGAACA
15 TACCAAAAAATTAATTACCTTAGCAAGTTATTTTCCCATTTAGGTTGTAT
GGAAACAGTTCCTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAAA
CTTAACCCCTTCAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAAGCT
AAATTCTGATTCTTGTTGAAAGTAAGTTGCATCTTTATGTTTGTATTAT
CTTGTTGCATAGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAA
20 AGATCCAACCTATTTTTAATCTGTTGGCATTTCCTCATCTTTGCAACTGTT
TCTTGAAAAAAA::TACCTAAAATCAAAATAACCATTTTCATATCCAAAA
TTATAAGAGAGAATTGTTAACGGACATGGAATCATAAATCATTAAACACAG
TTCAGTACACAGGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTC
TATCAGAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATATT
25 GTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAAACTTAA
CTTGAACAGAGTTGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGA
GTCCAACAAGTAGAGAATTGGTAACAACCTCACCATAACCAACAACAACCT
ATTATACTTCCCAACCTCCAGGAATTGATTCTATGGAATATGGACAACAT
GAGTCATGTGTGGAAGTGCGGCAACTGGAATAAATTCTTCACTCTTCCAA
30 AAGAACAATCAGAATCCCCATTCCACAACCTCAGTAACATACATATTTAT
GAATGCAAAAGCATTAAAGTACTTGTTTTCACCTCTCATGGCAGAACTTCT
TTCCAACCTAAAGCATATCGAGATAAGAGAGTGTGATGGTATTGAAGAAG
TTGTTTTCAAAAAGAGATGGTGAGGATGAAGACATGACTACATCTAC:::
:::GCACACAACCACCACTTTTTCCCTCATCTTGATTCTCTCACTCTAA
35 GCAACTGAAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGG
GGAGCAATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTT
GATCAATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCC
TTGTTAATTTCTTTTTCTTTGCAATATTCTATGAAAAAATCACCAAA
TCACAAATAAGAGATTTAACTTTTATTTACACCCATGCGGACTCAAGA
40 ATGGGATTTGGAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCA
TTT.ATTTGTTATTTATCATTTTCATATCATTTACTGATAACATTTCTTT
TTACTTTTCTAATTAGAAAAGGTCCACATGTCTAATTAGGTTTTCCATTC
TATGTGAATCCTCTATTCTGTCTGTAATCAAGCATCTTAGATTATTTATC

CATTTTCATAATTGTGTTTATATTGACAGTTTTTTTTCTTTTATAGTTGT
AATTGCAACCTGTCATATWTTMWWKKCWWWATKYWMWWARTAATACATTT
TATACCCWCTATACTAAGATA

5 **RG2N deduced polypeptide sequence (SEQ ID NO:117)**

LGKTTMMHRLKKVVKEKKMFNFIVEAVVGEKTDPIAIQSAVADYLGIELNEKTKPA
RTEKLRKWFVDNSAGKKILVILDDVWQFVDLNDIGLSPLPNQGVDFKVLTSRDKD
VCTEMGAENVSTFNVKMLIETEAQSLFHQFVEISDDVDRELHNIGVNIVRKCGGLPI
VIKTMACTLRGKSKDAWKNALLRLVNYNIENIVNGVFKMSYDNLQDEETKSTFLL
10 CGMPEDFNIPTEELVRYGWGLKLFKKVYTIGEARIRLNTCIERLIHTNLLIEVDDVR
CIKMHDLVRAFVLDMYSKVEHASIVNHGNTLEWHVDNMHNSCKRLSLTCKGMSK
FPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKYPLLPSSPQCSVNL
CVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDLLPSTIGILKKLRLLDLTNCYGL
CIANGVFKKLVKLEELYMTVVNGGVRKAISL

15

RG2O polynucleotide sequence (SEQ ID NO:118)

TTGTAAAACGACGGCCAGTCGAATCGTAACCGTTCGTACGAGAATCGCTG
TCCTCTCCTTCATTTGAATCATGATATTTGAATATCGATACTTTTGACTG
TAGCTTTTGGGTCGATTTTTTAGCAAGATACATAACTGGCCAAACCCATT
20 GGCTATTTTAGCCCAAATATGAAATGGACTGGATTGTTTTTTCCTTTC
TAACACGCACACATCTGGCGATCAGTATCACTCCATTATGAAGACCTAGT
CAAATTCATTAACGTTCAAGTCGTTCCCTTCAAAGTTTCAAAGTTCCAATT
CCAATTCCCTCTTTTTTTTTTCTTTCCTCGATTCTGATTGTAATCCGAT
TCTGCGACGAAGGAGAGCTTGGTCAGAGGGCTGTGATTCTTGAGTCTTGA
25 CCTCCGAATCTAGCTGGATTATTTTCGACACACCAGACCACGTATCAGGT
TGCTCATCCCGAAATACTGCTTTGCAAACGTTGTATCATCGCCTAGGAA
ATTAAAGTTTCTTTTTTGGCTCTGTTACTGAATCAGTAGCTTTGCAACTTG
CTCATTATAAGCTGATCCATATTTTACATATCTTTTGAAGAATAATAGGT
ACTGACTTTACCTTTCTGATGAGAGCGATTTAAGAGATACCTCTGTAAAA
30 TCCATTTTTGTGAAGGGATCTGGGTTAGTTTTTAAAGGATTGCTACAAC
AGTATCCCACAAACGATCTATTTCCCATTTNACTCATCCGCTCAAGATCT
ATCCACCTTTATATATGTTAATTGGGAGTCTTCCATGGTGCAATGAATCT
AGGATGCATTTAGAAGCCCAATCCATTACAAGTTTTTCATCCAATTTTCATG
TGACAAGTTGTTGGTTACTATGTAGGTACTTCCACAATTAAGAATTTCCA
35 GCAATGGATGTTGTTAATGCCATTCTTAAACCAGTTGCCGAGACACTTAT
GGAACCTGTTAAGAAACATCTAGGCTACATCATTTCCAGCACAAAACATG
TGAGGGATATGAGTAACAAAATGAGGGAGTTGAACGCTGCAAGACATGCT
GAAGAAGACCACTTGGACAGGAACATAAGAAGTCTGTTGAGATTTCAAA
TCAAGTTAGGAGTTGGTTAGAAGAAGTAGAAAAGATCGATGCAAAAAGTAA
40 AAGCCCTTCCTAGTGATGTCACCGCTTGTGTCAGTCTCAAGATCAAACAT
GAAGTCGGAAGGGAAGCCTTGAAGCTAATTGTGGAGATTGAAAGTGCCAC
AAGACAACACTCTTTGATCACCTGGACTGATCATCCCATTCTCTGGGAA

AAGTTGATTCCATGAAGGCATCGATGTCCACAGCATCAACCGATTACAAT
GACTTTCAGTCAAGAGAAAAAACTTTTACTCAAGCATTGAAAGCACTTGA
ACCAAACAACGCTTCCCACATGATAGCGTTATGTGGGATGGGTGGAGTGG
5 GGAAGACCACAATGATGCAAAGACTAAAAAAAGTTGCTAAACAAAATAGA
ATGTTTCAGTTATATGGTTGAGGCAGTTATAGGGGAAAAGACGGACCCAAT
TGCTATTCAACAAGCTGTAGCGGATTACCTTCGTATAGAGTTAAAAGAAA
GCACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCAAC
TCTGGAGAAGGTAAGAATAAATTCCTTGTAATACTTGATGACGTCTGGCA
GTCTGTTGATCTAGAAGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGTG
10 TCGACTTCAAGGTCTTATTGACTTCACGAGACGAACATGTTTGCACAGTA
ATGGGAGTTGGATCTAATTCAATTCTTAATGTGGGACTTCTAATAGAAGC
AGAAGCACAAAGTTTGTTCACAAATTTGTAGAACTTCTGAGCCCGAGC
TCCATAAGATAGGAGAAGATATTGTAAGGAAGTGTGCGGTCTACCTATT
GCCATCAAAACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCTTG
15 GAAGGATGCACTTTCGCGTATAGAGCACTATGACCTTCGCAATGTTGCGC
CTAAAGTCTTTGAAACGAGCTACCACAATCTCCATGACAAAGAGACTAAA
TCAGTGTTTTTGATGTGTGGTTTGTTCGGAAGACTTCAATATTCCTAC
TGAGGAGTTGATGAGGTATGGATGGGGATTAAAGATATTTGATAGAGTCT
ATACATTTATAGAAGCAAGAAACAGGATCAACACCTGCATTGAGCGACTG
20 GTGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGAT
GCATGATCTGGTCCGTGCTTTTGTTTTAGGTATGTATTCTGAAGTAGAGC
ATGCTTCAGTTGTCAACCATGGTAATATACCTGGATGGACTGAAAATGAT
CCGACTGACTCTTGTAAGCAATTCATTAAACATGCGAGAGTATGTCTGG
AAACATTCCAGGAGACTTCAAGTTTCCAAACCTAACGATTTTGAACTTA
25 TGCATGGAGATAAGTCGCTAAGATTTCCACAAGACTTTTATGAAGGAATG
GAAAAGCTCCAGGTTATATCATACGATAAAATGAAGTATCCAATGCTTCC
CTTGTCTCCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCAATTAAGATGTTTGATTGCTCTTGTATTGGAAATATGGCGAATGTG
GAAGTGTTGAGCTTTGCTAATTCTGGCATTGAAATGTTACCTTCCACTAT
30 CGGAAATTTAAAGAAGCTAAGGTTACTTGATTTAACAGATTGTCATGGTC
TTCATATAACACACGGTGTCTTTAACAATTTGGTCAAACCTGAAGAGTTG
TATATGGGATTTTCTGATCGACCTGATCAAACCTCGTGGTAATATTAGCAT
GACAGATGTCAGCTACAATGAATTAGCAGAACGTTCAAAAGGCCTTTCTG
CATTAGAGTTCCAGTTCTTTGAAAACAATGCCCAACCAATAATATGTCG
35 TTTGGGAAACTTAAACGATTCAAGATCTCAATGGGATGCACTTTATATGG
AGGATCAGATTACTTTAAGAAAACGTATGCTGTCCAAAACACATTGAAGT
TGGTTACTAACAAAGGTGAAGTATTGGACTCTAGAATGAACGAGTTGTTT
GTTGAAACAGAAATGCTTTGTTTAAAGTGTGATGATATGAATGATCTTGG
TGATGTTTGTGTGAAGTCCTCACGTTCTCCTCAACCTTCTGTGTTCAAAA
40 TTCTAAGAGTCTTTGTCTGTTTCCAAGTGTGTTGAGTTGAGATACCTTTTC
ACAATTGGTGTAGCCAAGGATTTGTCAAATCTTGAGCATCTTGAAGTTGA
TTCATGTAATAATATGGAACAACTCATATGTATTGAGAATGCTGGAAAAG
AGACAATTACATTCCTAAAGCTGAAGATTTTATCTTTGAGTGGGCTACCA

AAGCTTTCGGGTTTGTGCCAAAATGTCAACAACTTGAGCTACCACAACT
CATAGAGTTGAACTTAAGGGCATTCCAGGGTTCACATGCATTTATCCGC
AAAACAAGTTGGAAACATCTAGTTTGTGAAGGAAGAGGTAGATATATGT
TTTATGTTAATACAAGTTAAAAAATCTTTTAACTAAAAGTTTCAGTATA
5 TATATCTATATGTCTATAATTTGATTATATGATGTATTAGTGTGTTGGATG
TGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGA
CACTTCAAATTGATGAGATGGAGAATTTAAAGGAAATATGGCATTATAAA
GTTAGTAATGGTGAGAGAGTTAAGTTGAGAAAGATTGAAGTGAGTAACTG
TGATAAGCTTGTGAATCTATTTCCACACAACCCCATGTCTCTGCTGCATC
10 ATCTTGAAGAGCTTGAAGTCAAGAAATGTGGTTCATTGAATCGTTATTC
AACATCGACTTGGATTGTGTTGATGCCATAGGAGAAGAAGACAACATGAG
GAGCTTAAGAAACATTAAAGTGAAGAATTCATGGAAGTTAAGAGAAGTGT
GGTGTATAAAAGGTGAAAATAACTCTTGCCCCCTTGTTTCTGGCTTCAA
GCTGTTGAAAGCATAAGCATTGAAAGTTGTAAGAGGTTTAGAAATGTATT
15 CACACCTACCACCACCAATTTTAATATGGGGGCACTTTTGGAGATATCAA
TAGATGACTGTGGAGAATACATGGAAAATGAAAAATCGGAAAAGAGTAGC
CAAGAGCAAGAGCAGGTATGGATTTCAATTTCACTTTCTTACTTACTTAA
GGATTAAGCTTCTGTTTTTTTGAATAAAAAAGGGACATCTTCTAATAATG
CACATCTTAAATTAAAAAGTATTTAATTGTTGCATAGCAGCGTATAACAT
20 CTTCTAATAATTTATCTGAAGGTGAAAGATCCAACCTACTTCTAATTTGTT
AAC.AATTTCAATCATTTGCAAATGTTCCCTTAAAAAATTAATTACCTGAAA
TCAA.AACAATCTTCTTCAAATCCAAAATTATGAGACAGAATTGAGAAGGG
ATGTGAAATTATAAACCATTAAACACAATTCCATGCTCACGTTACTAATTA
CATTTCTTGTTGGGATATATATGTACAGACTGATATTTTGTGAGAGGAAG
25 TGA.AATTACAAGAAGTCACTGATACTATTTCTAATGTTGTATTACATCG
TGTCTCATACACTCTTTTATAACAACCTCCGTAAACTCAACTTGGAGAA
GTATGGAGGAGTTGAGGTTGTGTTTGAAGATAGAGAGTTCAACAAGTAGAG
AATTGGTAACAACATACCATAAACAACAACAACAACAACCTATATTT
CCC.AACCTTGAGGAATTATATCTATATTATATGGACAACATGAGTCATGT
30 ATGGAAGTGCAACAACCTGGAATAAATTTTACAACAATCAGAATCCCCAT
TCC.ACAACCTCACAACCATACACATGTCCGATTGCAAAAGCATTAAAGTAC
TTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGAGAATCAA
TATTGACGAGTGTGATGGTATTGAAGAAATTGTTTCAAAAAGAGATGATG
TGG.ATGAAGAA
35

RG2O deduced polypeptide sequence (SEQ ID NO:119)

MDVVNAILKPVAETLMPEVKKHLGYIISSTKHVRDMSNKMRELNAARHAEEDHLD
RNIRTRLEISNQVRSWLEEEVEKIDAKVKALPSDVTACCSLKIKHEVGREALKLIVEIE
SATRQHSLITWTDHPIPLGKVDSMKASMSTASTDYNDFQSREKTFQALKALEPNN
40 ASHMIALCGMGGVGKTTMMQRLKKVAKQNRMFSYMVEAVIGEKTDPPIAQQAVA
DYLRIELKESTKPARADKLREWFKANSLEGKNKFLVILDDVWQSVLEDIGLSPFP
NQGVDKVLTSRDEHVCTVMGVGSNSILNVGLLIEAEAQSLFQQFVETSEPELHKI

GEDIVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDLRNVAPKVFETSYHN
LHDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKIFDRVYTFIEARNRINTCIERL
VQTNLLIESDDVGCVKMHDLVRAFVLGMYSEVEHASVVNHGNIPGWTENDPTDSC
KAISLTCEMSGNIPGDFKFPNLTILKLMHGDKSLRFPQDFYEGMEKLQVISYDKMK
5 YPMLPLSPQCSTNLRVLHLHECSLKMFDCCSIGNMANVEVLSFANSNGIEMLPSTIGN
LKKLRLLDLTDCHGLHITHGVFNNLVKLEELYMGFSDRPDQTRGNISMTDVSYNE
LAERSKGLSALEFQFFENNAQPNMNSFGKLKRFKISMGTLYGGSDYFKKTYAVQ
NTLKLVTNKGELLSRMNELFVETEMLCLSVDDMNDLGDVCVKSSRSPQPSVFKIL
RVFVVSCKVELRYLFTIGVAKDLNLEHLEVDSCNNMEQLICIENAGKETITFLKIKI
10 LSLSGPLKLSGLCQNVNKLLELPQLIELKLKGIPGFTCIYPQNKLETSSLLKEEVVIPKL
ETLQIDEMENLKEIWHYKVSNGERVKLKRIEVSNCCKLVNLFPHNPMSSLHHLEEL
EVKKCGSIESLFNIDLDCVDAIGEEDNMRLRNKVKNSWKLREVWCIGENNSCPL
VSGFQAVESISIESCKRFRNVFTPTTTNFMGALLEISIDDCGEYMEKSEKSSQEQ
EQTDILSEEVKLQEVTDITISNVVFTSLIHSFYNNLRKLNLEKYGGVEVVFEIESSTS
15 RELVTYHKQQQQQPIFPNLEELYLYMDNMShVWKCNNWNKFLQQSESPFHN
LTTIHMSDCKSIKYLFSPLMAELLSNLKRINIDECDGI

RG2P polynucleotide sequence (SEQ ID NO:120)

CCCATTGCTATTCAGGAAGCAGTAGCAGATTACCTCNGTATAGAGCTCAA
20 AGAAAAAACTAAATCNGCAAGAGCTGATATGCTTCGTAAAATGTTAGTTG
CCAAGTCCGATGGTGGTAAAAATAAGTTCCTAGTAATACTTGACGATGTA
TGGCAGTTTGTGATTTAGAAGATATCGGTTTAAGTCCTTTGCCAAATCA
AGGTGTTAACTTCAAGGTCTTGCTAACATCACGGGATGTAGATGTTTGCA
CTATGATGGGAGTCGAAGCCAATTCAATTCTCAACATGAAAATCTTACTA
25 GATGAAGAAGCACAAAGTTTGTTCATGGAGTTTGTACAAATTCGAGTGA
TGTTGATCCCAAGCTTCATAAGATAGGAGAAGATATTGTAAGAAAGTGT
GTGGTTTGCCTATTGCCATCAAAACCATGGCCCTTACTCTTAGAAATAAA
AGCAAGGATGCATGGAGTGATGCACCTTCTCGTTTAGAGCATCATGACCT
TCACAATTTTGTGAATGAAGTTTTTGAATTAGCTACGACTATCTTCAAG
30 ACCAGGAGACTAAATATATCTTTTTGCTTTGTGGATTGTTTCCCGAAGAC
TACAATATTCCTCCTGAGGAGTTAATGAGGTATGGATGGGGCTTAAATTT
ATTTAAAAAAGTGTATACTATAAGAGAAGCAAGAGCCAGACTCAACACCT
GCATTGAGCGGCTTATCCATACCAATTTGTTGATGGAAGGAGATGTTGTT
GGGTGTGTAAAGATGCATGATCTAGCACTTGCTTTTGTATGGATATGTT
35 TTCTAAAGTGCAGGATGCTTCAATTGTCAACCATGGTAGCATGTCAGGGT
GGCCTGAAAATGATGTGAGTGGCTCTTGCCAAAGAATTCATTAACATGC
AAGGGTATGTCTGGGTTTCTATAGACCTCAACTTTCCAAACCTCACAAT
TTTAAACTTATGCATGGAGATAAGTTTCTCAAGTTTCTCCTCCAGACTTTT
ATGAACAAATGGAAAAGCTTCAAGTTGTATCGTTTCATGAAATGAAATAT
40 CCGTTTCTTCCCTCGTCTCCTCAATATTGCTCCACCAACCTTCGAGTTCT
TCATCTCCATCAATGCTCATTGATGTTTGATTGCTCTTGATTGGAAATC
TGTTTAATCTGGAAGTGTTGAGCTTTGCTAATTCTGGCATTGAATGGTTA

CCTTCCAGAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACAGA
TTGTTTTGGTCTTCGTATAGATAAGGGTGTCTTAAAAAATTTGGTCAAAC
TTGAAGAGGTTTATATGAGAGTTGCTGTTTGAAGCAAAAAAGCCGGAAT
AGAAAAGCCATTAGCTTCACAGATGATAACTGCAATGAGATGGCAGAGCG
5 TTC

RG2P deduced polypeptide sequence (SEQ ID NO:121)

PIAIQEAVADYL?IELKEKTKSARADMLRKMLVAKSDGGKNKFLVILDDVWQFVDL
EDIGLSPLPNQGVNFKVLLTSRDVDVCTMMGVEANSILNMKILLDEEAQSLFMEFV
10 QISSDVDPKLHKIGEDIVRKCCGLPIAKTMALTLRNKSKDAWSDALSRLHHDLHN
FVNEVFGISYDYLQDQETKYIFLLCGLFPEDYNIPPEELMRYGWGLNLFKKVYTIRE
ARARLNTCIERLIHTNLLMEGDVVGCVKMHDALALAFVMDMFSKVQDASIVNHGS
MSGWPENDVSGSCQRISLTCKGMSGFPIDLNFPNLTKLMHGDKFLKFPDFYEQ
MEKLQVVSFHEMKYPFLPSSPQYCSTNLRVLHLHQCSLMFDCSCIGNLNFNLEVLSE
15 ANSGIEWLPSRIGNLKKLRLLDLTDCFGLRIDKGVKLNLVKLEEVYMRVAVRSKKA
GNRKAISFTDDNCNEMAERS

RG2Q polynucleotide sequence (SEQ ID NO:122)

TGGGGAAGACACAGTGATAGAAAAAAGAAATGTTGTGGAAAAGAGGA
20 AAATGTTTGATTATGCTGTTGTGGCGGTTATAGGGGAAAAGACGGACCCT
ATTGCTCTTCAGAAAACCTGTTGCGGATTACTTGCATATTGAGCTAAATGA
AAGCACTAACTAGCAAGAGCAGATAAACTTTGCAAATGGTTCAAGGACA
ACTCGGATGGAGGTAAGAAAAAGTTCTCTCGTAATACTCGACGATGTTTGG
CAATCTGTTGATTTGGAAGATATTGGTTTAAGTACTCCTTTTCCAAATCA
25 AGGTGTCAACTTCAAGGTTTTGTTGACATCACGAAAGAGAGAAATTTGCA
CAATGATGGGAGTTGAAGCTGATTAAATTCTCAATGTCAAAGTCTTAGAA
GAAGAAGAAGCACAAAAGTTGTTCTCCTCCAGTTTGTAGAAATTGGTGACCA
ATACCACGAGCTTCATCAGATAGGGGTACATATAGTAAAGAAGTGTTATG
GTTTACCCATTGCCATTAAACCATTGGCTCTTACTTTAAGAAATAAAAGA
30 AAGGATTCATGGAAGGACGCACTCTCTCGTTTAGAGGACCATGACACTGA
AAATGTTGCAAATGCAGTTTTTCGAGATGAACTACCGCAATCTACAAGATG
AGGAGACCAAAGCCATTTTTTTGCTTTGCGGTTTGTTCCTCGAAGACTTT
GATATTCTACTGAGGAGTTGGTGAGGTATGGATGGGGCTTAAATCTATT
TAAAAAAGTGTATACCATAAGAAAGGCAAGAACGAGATCGCATACATGTA
35 TTGAGCGACTCTTGATTCAAATTTGTTGATTGAAAGTAACGATATTCGG
TGCGTCAAGATACACGATCTGGTGCGGCTTTTGTGTTTGGATATGTATTG
TAAAGTTGAGCATGCTTCAATTGTCAACCATGGTAATATGCGGACCGAAT
ATAATATGGCTGACTCTTGCAAAACAATTCATTAACATACAAGAGTATG
TCTGGGTTTGAGTTTCCAGGAGACCTCAAGTTTCCAAACCTAACAGTTTT
40 GAAACTTATGCANGGAGATAAGTCTCTAAGGTTTCTCAAGACTTTTATC
AATCAATGGAAAACTTCGGGTTATATCATATGATAAAATGAAGTATCCA
TTGCTTCCCTCATCACCTCAATGCTCCACTAACATCCGAGTGCTTCGTCT

CCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTGTATTGGAAAGCTAT
TGAATTTGGAAGTCCTCAGCTTTTTTAATTCTAACATTGAATGGTTACCT
TCCACAATCAGAAATTTAAAAAAGCTAAGGCTACTAGATTTGAGATATTG
TGATCGTCTTCGTATAGAACAAAGGTGTCTTGAAAAATTTGGTCAAACCTTG
5 AAGAACTTTATACTGGATATACATCAGCGTTTACAGA

RG2Q deduced polypeptide sequence (SEQ ID NO:123)

GEDTVIEKKKNVVEKRKMFDYAVVAVIGEKTDPIALQKTVADYLHIELNESTKLAR
ADKLCKWFKDNSDGGKKKFLVILDDVWQSVLEDIGLSTFPNQGVNFKVLLTSR
10 KREICTMMGVEADLILNVKLEEEEAQKLFQFVEIGDQYHELHQIGVHIVKKCYG
LPIAIKTMALTLRNKRKDSWKDALSRLEDHDTENVANAVFEMNYRNLQDEETKAI
FLLCGLFPEDFDIPTEELVRYGWGLNLFKKVYTIRKARTRSHTCIERLLDSNLLIESN
DIRCVKIHDLVRAFVLDMYCKVEHASIVNHGMRTEYNMADSKTISLTYKSMMSG
FEFPGDLKFPNLTVLKLM?GDKSLRFPQDFYQSMEKLRVISYDKMKYPLLPSSPQCS
15 TNIRVLRLHECSLRMFDCSCIGKLLNLEVLFFNSNIEWLPSTIRNLKKLRLDLLRYC
DRLRIEQGVLKNLVKLEELYTGYSAFTE

RG2S polynucleotide sequence (SEQ ID NO:124)

ATTTGGGGTTTTACATTTAATTTTTTGTGCATGAATGTGAAAATAGACTG
20 CTTATTGATTCTTTGTGTTTCATTGAGTTGATTTTCATTATTACTACCTT
ACAAATTGCTCAGTGATAGATTTCCATTAATTTGCTAATTCGGTTGCTTC
TAAATATGTAGGAGCTACTAAAAGCAAAAATATCGAGCAATGTCGGACCC
AACGGGGATTGCTGGTGCCATTATTAACCCAATTGCTCAGAGGGCCTTGG
TTCCCGTTACAGACCATGTAGGCTACATGATTTCTGCAGAAAATATGTG
25 AGGGTCATGCAGACGAAAATGACAGAGTTGAATACCTCAAGAATCAGTGT
AGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCAGATTCCATCTC
AAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAGCAAAATGTGGAA
AACTTTCCGATTGATGTCATCACTTGTTGTAGTCTCAGGATCAGGCACAA
GCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATTGAAAGTCTAACAA
30 GACAGCTCTCCCTGATCAGTTGGACTGATGATCCAGTTCCTCTAGGAAGA
GTTGGTTCCATGAATGCATCCACCTCTGCATCATCAAGTGATGATTTCCC
ATCAAGAGAGAAAACCTTTACACAAGCACTAAAAGCACTCGAACCCAACC
AACAAATTCCACATGGTAGCCTTGTGTGGGATGGGTGGAGTAGGGAAGACT
AGAATGATGCAAAGGCTGAAGAAGGCCGCTGAAGAAAAGAAATTGTTTAA
35 TTATATTGTTAGGGCAGTTATAGGGGAAAAGACGGACCCCTTTGCCATT
AAGAAGCTATAGCAGATTACCTCGGTATACAACCTCAATGAAAAAACTAAG
CCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAAAAGAATTCAGATGG
AGGTAAGACTAAGTTCCTCATAGTACTTGACGATGTTTGGCAATTAGTTG
ATCTTGAAGATATTGGGTAAAGTCCTTTTCAAATCAAGGTGTCGACTTC
40 AAGGTCTTGTTGACATCACGAGACTCACAAGTTTGCACTATGATGGGGGT
TGAAGCTAATTCAATTATTAACGTGGGCCTTCTAACTGAAGCAGAAGCTC
AAAGTCTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCAGAAG

ATAGGAGAGGATATCGTAAGGAAGTGTTGCGGTCTACCTATTGCCATAAA
AACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCATGGAAGGATG
CACTTTCGCGCATAGAGCACTATGACATTCACAATGTTGCGCCCAAAGTC
TTTGAAACGAGCTACCACAATCTCCAAGAAGAGGAGACTAAATCCACTTT
5 TTTAATGTGTGGTTTGTTCCTCGAAGACTTCGATATTCTACTGAGGAGT
TGATGAGGTATGGATGGGGCTTGAAGCTATTTGATAGAGTTTATACGATT
AGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTGGTGCAGAC
AAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATGCATGATC
TGGTCCGTGCTTTTGTTCCTGAGTATGTTTCTGAAGTCGAGCATGCTTCT
10 ATTGTCAACCATGGTAATATGCCCCGAGTGGACTGAAAATGATATAACTGA
CTCTTGCAAAAGAATTTTCATTAACATGCAAGAGTATGTCTAAGTTTCCAG
GAGATTTCAAGTTTCCAAACCTAATGATTTTGAAACTTATGCATGGAGAT
AAGTCGCTAAGGTTTCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCA
TGTTATATCATACGATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTC
15 GATGCTCCACCAACATTTCGGGTGCTTCATCTCACTAAATGTTTCAATAAG
ATGTTTGATTGCTCTTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAG
CTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAGAAATTTAA
AGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAA
CAGGGTGTCTTGAAAAGTTTAGTCAAACCTGAAGAATTTTATATTGAAA
20 TGCATCTGGGTTTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTG
ACAACCTTTCTGCATTAGAATTCGCGTTCCTTAATAACAAGGCTGAAGTG
AAAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGACG
CTCTTTTGATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGT
TGC.AATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGG
25 TTATTTTGAACAAAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGA
TCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCAT
TCTGCAATTTAAAAGTTCTTATTATTTCAAAGTGTGTAGAGTTGAGATAC
CTTTTCAAACCTCAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGA
AGTTTGTGAATGCGAGAATATGGAAGAACTCATACATACTGGAATTTGTG
30 GAGAAGAGACAATTACTTCCCTAAGCTGAAGTTTTTATCTTTGAGTCAA
CTACCGAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACC
ACATCTCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTT
ATCCGCAGAACAAAGTTGCGAACATCTAGTTTGTGTTGAAGGAAGAGGTAGAT
ATATGTTCTTTATGTTAATACAATTTAAATAATATTTTCAACCAAATTTT
35 CAT.AATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGG
CTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGACAC
TTC.AAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTAACCT
AGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGA
TAAGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATC
40 TTG.AAGAGCTTAAAGTCAAGAATTGCGGTTCCATTGAATCGTTATTCAAC
ATTGACTTGGATTGTGTGCGGTGCAATTGGAGAAGAAGACAACAAGAGCCT
CTT.AAGAAGCATCAACATGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGA
GGATAAAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTTCAAGCTGTT

GAAAGCATAAAGATTGAAAAATGTAAGAGGTTTAGCAATATATTCACACC
TATCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAG
GTTGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTC AATTTAA
CTTTCTTAAGTAATTAAGGACTAACCTCCTGTTTTTTGAATAATAAAGAG
5 GTGGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACC
ATGAAACGTTCAAACCATTCTTGAATTAAGGTTTCAATACAAGTCATT
AAAAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTCA
TTAGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACT
AATTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTT
10 AGTGAAATAAGCAACGGATTTAATAAGTTAACAACCTAAATGTCATTTC
TAACAAAAAACTATTTGGTTCAGAAGAACCGTAATTCAAGATAACTAA
AATAAAAAATATTTGACATTCCTAAGAGCATTTTTTTTTTCTAAATATGAT
TGCAAATGAATAAACTTAAATTTATACAGAAAAGATTTTTATATATGTT
ATACAAAATTTACAAATTGAACTGGATATGTTAATTAACGGTTTATAAT
15 TCTGGTATCACAAAGGGATATATAAATAAATATTATTTCTGTAGTCATT
TATAATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAG
TTAACTTTTCATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATT
ATTAAATTAAGAGATGTATCAAAAATTTAAAGTTATTATAACTTCAAATTT
AACATATAATTAGAAAATATATGATCATAACTTTCCGCAACTCTTCTTTT
20 GTATTAAAATGCCAGAGAAGCTCTTAGTAYATTTTCTAAATCAAAGTCA
CAAACCTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTT
TAAGAGTCACCAAATTC AAAGAGTAATCCAATGCTTTCATTACCACTATG
GAGAAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTA
ATTGTTGCTTACTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAAACCA
25 AAAAAAATTACATTCATGTATCATTATTCATGACTAGATATATATGAACA
TGAAGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTC
ATGGAATTCCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCA
ACC.AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAA
GGATTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTT
30 GTTCTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAAT
GCA.AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCA
CCAACCTCCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTG
AAGGACCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATACGAAAGGTC
TTTGGTCTTTGTGAGGGTGATGCTGTGCGGGTTAGCTTGTCGCATGCTTC
35 CGCGCGGTTGCGGCACATGTGCACAAGTGATGCATGGTGTGTACGTTCTT
GAGTTTTGAGCCTCCGATGCTTAGTCCATTTGGCCCAATTCGAGTCCAAT
CAGCTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTATCTTCAAGTT
AAGCCCAAATTGCCTTCTCAAATCATCCATAACTTCACAAAATCGCCCG
TTC.ATCTTAATCCCGAATGCACAATTATTCTCCTGTCTTCTTTTAAAGCA
40 AGATACCACCTTCTTCATGCTTCATCCATCAATAGTACACTTCATGTATC
ATCTCTACTAGTTATTTAGTCCACAATCCTTATTGTCCTCCAAATTTAAT
TATCTCATTTAGTTCCCGTTCCTAGTTTCCTTAAATTTGCAATTAAG
CTC.ACACAAATATTAAGTACCTGAAATGGTCATAAAATAACAAAAGGAA

AATATGCATGAAGATTAACATAAATGATGAACGAAATATGCTAAAATAGAC
TATAAAATGAAGTAAATAAAATGAAATTATCGCACTCCGACCACCCTTAT
AGGCTTGTAGTCCATCCACCCTTCATTCTTGTACCAATATGGGATGGAA
ACATCATTAATTAAGCCAAAAAACTAACATATAAGGGGTGAGTGACAAAG
5 GTAAGTACTAAAGATGAAAATAATCCATTTTTYTTGTATATACACAACAC
ACACATAGGGGCAGACGTAGGATTTTCATAGTACAGATTGTTGGTGGCACA
TAAGTGTGCTGGTGACACTTTTTTTTTCTTTTACGTAGTGGCACAACAG
TAG.AAAAAACGARAAATTCGAAATTTTTTACAATGTGTSTAAAAAAAAYA
GTGGTTGTTGGTGCCACTATGGACACCAAAGTTGAACTGCCCCCTGCGCGC
10 RCACACACACACACATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
ARAGWAWGRRRGAKAKARMCSMSYTTGGGATGTGATACTTCTTTTAGGAA
AATGGAGTTATATCTTTGATATTGTATTTTTTTAATGTAATTTATATATT
TAATCATTTTTAGTTTATAAGTTTATTTATTTTGATATGAAAAAAAAGT
CTTTTATACATTGGATTTAACATAAAAAATCCAACAATATTAATCAAAAAG
15 ACCAMACATGTGGACAMWTATGTATATAAWTAATTCACAATAGTCTTTAG
GAATAGNATTATATATATAATTAATTCTCAATGGTCTTAGGAATAGTAAG
TTCTTATATTTCAAACCTTNGCCACAATTCTTTGKTTACTTWGACACTTY
CCTCTCTCTAATTATATATATATATATATATATATATATATATATACACA
CACACACACACACACTAGATGTGTGCCCGCGCAAAGCAGTGACGTNNNGG
20 AGAANACTTTCTTAAGCATAAATAATTATTATTTTTTTATTGGGTATTA
TATAATAAAAAATTACAACCTTTTAAATAAAATATTTATGTTTATACTTTA
TATTTATATTGCTTGTATACTATTAATATAATAAATTAATATTTATGTCT
AATTTATGAAATGTAAATTAATTTAAATACATGAATTTAATATTTTTAAA
ATTTTCAGTTTGCTTCAAATTGAGTTTCTTAATTATTTTTTTTAATTCAN
25 GTATTCAAACCTTTGGTAAGTATTAAGAATTATTTATGCACAATTGATT
TATACAAAAAATTTGTAACCTTATACATCTTAAAATTCAAGATATAACTA
ACATGTTTTACAATATATATATATATANATATATATATATATATATATAT
ATATATATATATATATAGTAAAGCGCANAGGTCATAGGNANAGANTATTT
TCT.ATTATTCTACGTTTTGCCACAAAAGTTTGAACACTTTGCCACTTTTT
30 GTCCCTCCTTAACCTTTTCAATGTTTTGCGACAAAAGTTCCAAAACCTTG
CCACTTTGATCATTCTCAACTTTTCACCGCATTAGTTTGTGGAGTTGGC
AGTTTTGGTCCCCCTAACTTCGATATTTTCTCCTGCTAGCCAAAAAGGT
TCCAGAGTTTCACANTTTTGGTCCCTGACAATAACCAAATGTGAGATGTC
AAATTTTTGCCACATTAGTTTGTGGAGTTGTCCCTTTTGGTCCCCCACA
35 TTCGATATTCTACTATACGACCTTATTTTTCTCAAATAACAACACGTATA
TTT.AATTACCAATGATAGAAATAGATATCAAATAAAGTATTTGTAACACC
GTGTAAGAACGGTGCTACTATAGGTAAAAATAAACATTTCAAAGTACGAT
GTCCTAATTGGAAGAGAGTTTTAAAAAATAACAACCTAGGGGCGAGTTT
TTTTTACAAGTTTGTATCAAATCATATCAAAATTTAAGGTGGAACGGTGA
40 CCACATTAACCAGAAATGTAATTTATTCTTTGATTTTGATAATTTTTAAT
ATTTTGTGTGATCTATGTATTTAAAGTAAACAACAAGAACATAATCC
AAAACCCTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCGTCAC
TTACGATGGCGTTACGTGCTCTCTCACTTCTTACAACCCTTTGTTGCTA

CTCATTACAATAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGG
AATTGAACAAATCTCGTCAAATTTTTGATTTTGTGATGGATTTGAGTAG
AAGTTTGGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACTTGAT
TCTGAGTTATTACTATATATGTAGCCTCTTTACAACGACCAAGGTTTCTT
5 CCAGGTACCATTTGATCTTTTTAGAACCCAGTTGTCTGAAACACCCTGAT
TTGGATCAAATATCACCAACAACCTCTTAAAACTTGATTAATCAATTGTT
TTCTTCATCTTGATAACAAGTGGAATGATTTTCTACTTAGATTAACCTGA
AAAAAAAGGTCCATGTGCGTCTGGTGGATCTGGTAAATGAAGATGGAAGG
GAGAGCTGACTTTAAAGACACAAACACGTCACCATATCTTTATTTTATT
10 TTAAATTTGCTTTTTTCCTATTTCTTTCTTTCTTGATCTCCAGATGGTAT
GTGGTGTGGATAATTTACACATAGAGATTGGGAACGACTGTGTTTTAGAG
AGGACGTGGCTTGGGGTTGAGGATGGTTTATGGCTGGCCGAGTTTCATTT
ATATAAACAAACAAATATATAAAACAAGGGGTAAAATGGCCATCTTATAT
GTATTTAACCGTCCTTTTTTATTTTTTTTTTATTTTTTAAATTTAAGAAGG
15 GGTATACCAGTGTGAGCCTCTTATTCCCAACCAGGCAACCAGTCAAATAG
GGACTTAGGTTGTTTGGAAACAGTTCCGTGAGACCGTGACTTGGATGGTA
GATAAATTTAGTAACTTAACCCTTCAATTAACCTACCTTTTTCTTATTA
ACTCAATTTCAACCTAAATTCTGATTCTTGTTTGAAAATAAGTTGCATCT
TTATGTTTGTATTATCCTGTTGCATAGGATCCTTAGCATCTTTTAATAAT
20 TTATTTGAAGGTGAAAGATCCAACCTATTTTTTAGCTGTTGGCATTTTCCA
TCATTTGCAACTGTTTCTTGAAAAAAAATACCTAAAATCAAAATAACCA
TTTTCAAATCCAAAATTATAAGAGAGAATTGTTAATGGACGTGGAATCGT
AAATCATTAACACAGTTTCAAGTACACAAGTTGCTAATTACATTTCTTGCTG
TGCAGATTGAAATTCTATCAGAGAAAGAGACATTACAAGAAGTCACTGAT
25 ACTAATATTTCTAATGATGTTGTATTATTCCCATCCTGTCTCATGCACTC
TTTTCATAACCTCCATAAACTTAAATTGGAGAGAGTTAAAGGAGTGGAGG
TGGTGTTTGAGATAGAGAGTGAGAGTCCAACAAGTAGAGAATTGGTAACA
ACTCACCATAACCAACAACATCCTATTATACTTCCCAACCTCCAGGAATT
GGATCTAAGTTTTATGGACAACATGAGTCATGTGTGGAAGTGCAGCAACT
30 GGAATAAATTCTTCACTCTTCCAAAACAACAATCAGAATCCCCATTCCAC
AACCTCACAACCATAACACATGTTTCAAGCTGCAGAAGCATTAAAGTACTTGTT
TTCGCCTCTCATGGCAGAACTTCTTTCCAACCTAAAGGATATCTGGATAA
GTGGGTGTAATGGTATTAAAGAAGTTGTTTCAAAGAGAGATGATGAGGAT
GAAGAAATGACTACATTTACATCTACCCACACAACCACCATCTTGTTCCC
35 TCATCTTGATTCTCTCACTCTAAGACTACTGGAGAATCTGAAGTGTATTG
GTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATATCTTTCAATAAT
ACCCTGCAACTACTGCTGTTCTTGATCAATTTGAGGTATGCTTTGTACA
TATTCAATTATTTATTTAATTTCTTTTCTTTGCAATATTCTATAAAT
AATACATTTTATACCCACTATACTAAGATAATAATTACCTAGAGGGGATGG
40 ATGCTATGACACAGCTGCTACACTTCAGAACTCTAGTAAGGGCAGTTAT
GGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGGTAATATAGGCAA
TTTAAAGTTTATTTCTGTTAAAGCAGTATTTAGCAAGTACTGGCCAGTAG
GAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATTGTACCCAAGAAT

TTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAGGTGACAGATAT
TGTAGAATAGAACAAATATATAATATTACCCAAAACATTTTTTCTAAGGT
TATTCTGTAAATATGTGCTTCTTGATTTCATTGAATTTGCATTCCCTAT
ATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCCGAAATTAATTA
5 AAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGAGCACTGGTATCA
TTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTCTTATATAAAAGC
TGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCATGTGGTGTGCA
GTTGTCTGAAGCAGGTGGTGTCTTGGAGTTTATGCCAATACGCTAGAG
AGATAGAGATATCTAAGTGTAATGTATTGTCAAGTGTGATTCCATGTTAT
10 GCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGAGTAACGGGTTGTGA
TGGCATGAAGGAGGTATTTGAAACTCAATTAGGGACGAGCAGCAACAAAA
ACAGAAAGGGTGGTGGTGAAGGAAATGGTGGAAATCCAAGAGTAAAT
AAC.AATGTTATTATGCTTCCCAATCTAAAGACATTGAAAATCTACATGTG
CGGGGGTTTTGGAACATATATTACATTCTCTGCACTTGAAAGCCTGACAC
15 AGCTCCAAGAGTTAAAGATAGTGGGTTGCTACGGAATGAAAGTGATTGTG
AAG.AAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACAACAAC
AACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTTCTAAGAAGGTTG
TGGTCTTTCCCCGTCTAAAGTCCATTGAACTATTCAATCTACCAGAGCTG
GTAGGATTCTTCTTGGGGATGAATGAGTTCCGGTTGCCTTCATTGGAAGA
20 AGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCGAGCTGGTGGGT
CCACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACT
CTTGATCAAGAATCTGGCCTTAACCTTCATCAGGTATATATATATTCCTT
TAATTGGCATGATCTAATTAAGAAAGATATCATTCCTGCCAAGTAAATTT
ACTTCAAACACATTACACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGG
25 AAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCAGTGGA
AAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTTTA
GTACCTGGAATCGTGTGTGGGAGGAGCGTTATTATTCTGATTTGCTTGTT
TCTTTATCATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATC
TTTTGATTTTAAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTG
30 TTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGAT
TGTTATTTTCATATCATGTTGTCTTTGAATCAAGCTTTTCCATTTTCAA
CCAGGGCAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAAACAGCAA
CCC.ATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGA
TTA.ATAATTATAATATCTTGTATTAATTCATTAATAATTGGTACAGCACAT
35 ATATGACATTTTAAAGGTTTGTGTTTGTGTTWGACATATATATGCCTCTGGC
GTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTGACA
CCTCGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTG
ATCGAATTAGATATGGAATTAAATTATGATGTTAAAAAGATTATCCATC
CAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTGATGTGAGTAGTT
40 GTT.ATTGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGGAGA
AATGGAAATAGTGGAATTGGTTTTGATGAATCGTCACAACTACTACTAC
TACTACTCTTTTCAATCTTCGAAACCTCAGAGAAATGAAGTTGCATTTTC
TACGTGGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTTGAG

TTTCCAAACCTAACAAGAGTTCATATAAGTAGGTGTAGAAGGTTAGAACA
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG
ATATTAGTTGGTGCAACCATATGGAGGAGGTGATTGTTAAGGATGCAGAT
GTTTCTGTTGAAGAAGACAAAGAGAGAGAATCTGATGGCAAGACGAATAA
5 GGAGATACTTGTGTTACCTCGTCTAAAATCCTTGAAATTAAAATGCCTTC
CATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCTTA
TTGGATACTTTAGAAATCTACAAATGCCCAGCAATAACGACCTTCACCAA
GGGAAATTCTGCTACTCCACAGCTAAAAGAAATAGAAACAAGATTTGGCT
CGTTTTATGCAGGGGAAGACATCAACTCCTCTATTATAAAAAGATCAAAC
10 AACAGGTAAATCAGATCTTTGTTGCTTTAATAATTCTTAACTACATTTG
AAAAGCTTCATGCAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTA
CATTTTCAGCTTTATATTTATGTACTTTATGCAGGAGTTCAAACAAAAC
CTGATTAATGTGAAGTGAATATTAAAGGTAAATTATATTTTCATGTTCT
AGTTGCCTATTAATTAATGGCCTTTTAGTTTCRTGATTTTTGGATGTAGTY
15 WTCATGATGATGTGAATCTTCTAATACCCCATTCATTGTTTGGTTGAATG
TTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCATATG
AAGGACATTAAAGAACATGGATGCTATGAAGATGTTGGAARAC

RG2S deduced polypeptide sequence (SEQ ID NO:125)

20 MSDPTGIAGAIINPIAQRALVPVTDHVGVMISCRKYVRVMQTKMTELNTSRISVEEH
ISRNTRNHLQIPSIKDWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITEQI
ESLTRQLSLISWTD DDPVPLGRVGS MNASTSASSDDFPSREKTFTQALKALEPNQQF
HMYALCGMGGVGKTRMMQRLKKAEEKKLFNYIVRAVIGEKTDPFAIQEAIADYL
GIQLNEKTKPARADKLREWFKN SDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQG
25 VDFKVL LSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGED
IVRCCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQE
EETKSTFLMCGLFPEDFDIPEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQT
NLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDITDSCKRIS
LTCKSMSKFP GDFKFPNLMILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKYPLL
30 PLAPRCSTNIRVLHLTKCSLKMFD CSCIGNLSNLEVLSFANSRIEWLPSTVRNLKKLR
LLDLRFCDGLRIEQGV LKSLVKLEEFYIGNASGFIDN CNEMAERSDNL SALEFAFF
NNKAEVKNMSFENLERFKISVGRSFDGNINMSSH SYENMLQLVTNKGDVLD SKLN
GLFLKTKVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFKLN
ANTLSRLEHLEVCECENMEELIHTGICGEETITFPKLKFLSLSQLPKLSSLCHNVNIG
35 LPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEIWPCELS
GGEKVKLREIKVSSCDKL VNLFP RNPMSLLHHLEELKVKNCGSIESLFNIDLDCVGA
IGEEDNKSLLRSINMENLGKLREVWRIGADNSHLINGFQAVESIKIECKRFSNIFT
PITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEVTD TNISNDV VLFPSCLMH
SFHNLHKLKLERVKGEVVFEIESESPTSRELVTTHHNQQHPHILPNLQELDSL FMD
40 NM SHVWKCSNWNKFFTL PKQQSES PFHNL TIHMFSCRSIKYLFSP LMAELLSNLK
DIWISGCNGIKEV VSKRDEDEEMTTFTSTHTTTILFPHLDSLTLRLLENLKCIGGGG
AKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEISKCNVLSSVIPCY

AAGQMQLQVLRVTGCDGMKEVFETQLGTSSNKNRKGGGDEGNNGGIPRVNNNVI
MLPNLKTLLKIYMCGGLEHIFTFSALESLTQLQELKIVGCYGMKVIVKKEEDEYGEQ
QTTTTTTTKGASSSSSSSSKVVVFPRLKSIELFNLPELVGFFLGMNEFRLPSLEEVT
IKYCSKMMVFAAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTS GPA
5 TSEGTTWSFHNLIELDMELNYDVKKIIPSELLQLQKLEKIHVSSCYWVEEVFETAL
EAAGRNGNSGIGFDESSQTTTTTTLFNLRLNREMKLHFLRGLRYTWKSNQWTAFEF
PNLTRVHISRCRRLEHVFTSSMVGSLLQLQELDISWCNHMEEVIVKDADVSVEEDK
ERESDGKTNKEILVLPRLKSLKLKCLPCLKGFSLGKEDFSFPLDLEIYKCPAITTFT
KGN SATPQLKEIETRFGSFYAGEDINSSIIKRSNNRSSNKT LINVK.ILK

10

RG2T polynucleotide sequence (SEQ ID NO:126)

GGAAGACGACAATGGTGCAACGGTTGAAGAAGGTTGTGAAAGATAAGAAG
ATGTTCCATTATATTGTCGAGGTGGTTGTAGGGGCAAACACTGACCCCAT
TGCTATCCAGGATACTGTTGCAGATTACCTCAGCATAGAACTGAAAGGAA
15 ATACGAGAGATGCAAGGGCTTATAAGCTTCGTGAATGCTTTAAGGCCCTC
TCTGGTGGAGGTAAGATGAAGTTCCTAGTAATTCTTGACGATGTATGGAG
CCCTGTTGATCTGGATGATATCGGTTTAAGTCTTTGCCAAATCAAGGTG
TTGACTTCAAGGTCTTGCTGACATCACGCAACAGTGATATCTGCATGATG
ATGGGAGCTAGTTTAATTTTCAACCTCAATATGTTAACAGACGAGGAAGC
20 ACATAATTTTTTCCGTCGATACGCAGAAATTTCTTATGATGCTGATCCCCG
AGCTTATTAAGATAGGAGAAGCTATTGTAGAGAAATGTGGTGGTTTACCC
ATTGCCATCAAACTATGGCCGTTACTCTTAGAAATAAACGCAAAGATGC
ATGGAAAGATGCACTTTCTCGTTTAGAGCACCGTGACACTCATAATGTTG
TGGCTGATGTTCTTAAATTGAGCTACAGCAATATCCAAGACGAGGAGACT
25 CGGTCGATTTTTTTGCTATGTGGTTTGTTCCTGAAGACTTTGATATTCC
TACCGAAGACTTAGTGAGGTATGGATGGGGATTGAAAATATTTACCAGAG
TGTATACTATGAGACATGCAAGAAAAAGGTTGGACACGTGCATTGAGCGG
CTTATGCATGCCAACATGTTGATAAAAAGTGATAATGTTGGATTTGTCAA
GATGCATGATCTGGTTCGTGCTTTTGTGTTTGGGCATGTTATCTGAAGTCG
30 AGCATGCATCAATTGTCAACCATGGGGATATGCCAGGGTGGTTTGAAACT
GCAAATGATAAGAACAGCTTGTGCAAAAGAATTCATTAACATGCAAAGG
TATGTCTGCGATTCTGAAGACCTCACGTTTCCAAACCTCTCGATCCTGA
AATTAATGGATGGAGACGAGTCACTGAGGTTTCTGAAGGCTTTTATGGA
GAAATGGAAAACCTTCAGGTTATATCATATGATAACATGAAGCAGCCATT
35 TCTTCCACAATCACTTCAATGCTCCAATGTTTCGAGTGCTTCATCTCCATC
ACTGCTCATTAATGTTTGATTGCTCTTCTATTGGAAATCTTTTGAATCTC
GAGGTGCTCAGCATTGCTAATTCTGCCATTAAATTGTTACCCTCCACTAT
TGGAGATCTGAAGAAGCTAAGGCTCCTGGATTTGACAAATTGTGTTGGTC
TCTGTATAGCTAATGGCGTCTTTAGAAATTTGGTCAAACCTGAAGAGCTT
40 TATATGAGAGTTGATGATCGAGATTCGTTTTTTGTGAAAGCTGATGACAG
CAAGACCATTACCT

RG2T deduced polypeptide sequence (SEQ ID NO:127)

KTMTMVQRLKKVVKDKKMFHYIVEVVVGANTDPIAIQDTVADYLSIELKGNTRDAR
AYKLRECFKALSGGGKMKFLVILDDVWSPVDLDDIGLSSLPNQGVDFKVLTSRNS
DICMMMGLASLIFNLNMLTDEEAHNFFRRYAEISYDADPELIKIGEAVEKCGGLPIAI
5 KTMAVTLRNKRKDAWKDALSRLEHRDTHNVVADVCLKSYSNIQDEETRSIFLLCG
LFPEDFDIPTEDLVRYGWGLKIFTRVYTMRHARKRLDTCIERLMHANMLIKSDNVG
FVKMHDLVRAFLVGLMLSEVEHASIVNHGDMPGWFETANDKNSLCKRISLTCKGMS
AIPEDLTFPNLSILKLMGDESRLFPEGFYGEMENLQVISYDNMKQPFLPQSLQCSN
VRVLHLHHCSLMFDCSSIGNLLNLEVLSIANSIAIKLLPSTIGDLKKLRLLDLTNCVGL
10 CIANGVFRNLVKLEELYMRVDDRDSFFVKADDSKTIT

RG2U polynucleotide sequence (SEQ ID NO:128)

GCCTTGTGTGGGATGGGTGGAGTGGGAAAGACCACTGTGATGAAGAAGCT
GAAGGAGGTTGTGGTAGGAAAGAACTGTTAATCATTATGTTGAGGCGG
15 TTATAGGGGAAAAGACAGACCCCATGCTATTCAACAAGCTGTTGCCGAG
TACCTTGGTATAAGTCTAACCGAAACCACTAAACCAGCAAGAACTGATAA
GCTCCGTACATGGTTTGCAAACAACCTCAAATGGAGGAAAGAAGAAGTTC
TGGTAATACTAGACGATGTATGGCAACCAGTTGATTTGGAAGATATTGGT
TTAAGTCGTTTTCCAAATCAAGATGTTGACTTCAAGGTCTTGATTACATC
20 ACGGGACCAATCAGTTTGCCTGAGATGGGAGTTAAAGCTGATTAGTTC
TCAAGGTGAGTGTCTGGAGGAAGCGGAAGCACACAGTTTGTTCCTCCAA
TTTTTAGAACCTTCTGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA
AGAAATTGTAAAGAAGTGTGCGAGTACCCATTGCTATCAAAACCATGG
CCTGAACTCTTAGAAGTAAAGTAAGGATACATGGAAGAATGCCCTTTCT
25 CGTTTACAACACCATGACATTAACACAATTGCGTCTACTGTTTTCCAAAC
TAGCTATGACAATCTCGAAGACGAGGTGACTAAAGCTACTTTTTTGCTTT
GTGGTTTATTTCCGGAGGACTTCAATATTCTACCGAGGACCTATTGAGG
TATGGATGGGGATTGAAGTTATTCAAGGAAGTAGATACTATACGAGAAGC
AAGATCCAAGTTGAAAGCCTGCATTGAGCGGCTCATGCATACCAATTTGT
30 TGATCGAAGGTGATGATGTTAGGTACGTTAAGATGCATGATCTGGTGCGT
GCTTTTGTTTTGGATATGTTTTCTAAAGCCGAGCATGCATCTATTGTCAA
CCATGGTAGTAGTAAGCCAAGGTGGCCTGAAACTGAAAGTGATGTGAGCT
CCTCTTGCAAAAAGAATTCATTAAACATGCAAGGGTNTG

RG2U deduced polypeptide sequence (SEQ ID NO:129)

ALCGMGGVGKTTVMKKLKEVVVGKKLFNHYVEAVIGEKTDPIAIQQAVA EYLGIS
LTETTKPARTDKLRTWFA NNSNGGKKKFLVILDDVWQPVDLEDIGLSRFPNQDVD
FKVLITSRDQSVCTEMGVKADLV LKVSVEEA EAHSLFLQFLEPSDDVDPELNKIGE
EIVKKCCRLPIAIKTMA.TLR SKSKDTWK NALSRLQHHDINTIASTVFQTSYDNLEDE
40 VTKATFLLCGLFPEDFNIPTEDLLRYGWGLKLFKEVD TIREARSKLKACIERLMHTN

LLIEGDDVRYVKMHDLVRAFVLDMFSKAEHASIVNHGSSKPRWPETESDVSSSCKR.
ISLTCKG?

RG2V polynucleotide sequence (SEQ ID NO:130)

5 CTGTGGAAGACACGAATGATSAAGAAGCTGAAGGAGGTCGTGGAACAAAA
GAAAATGTTCAATATTATTGTTCAAGTGGTCATAGGAGAGAAGACAAACC
CTATTGCTATTCAAGCTGTAGCAGATTACCTCTCTATTGAGCTGAAA
GAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTNAATGGTTCGAGGA
CGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGATGATGTATGGCAGT
10 TTGTCGATCTTGAAGATATTGGTTTAAGTCCTCTGCCAAATAAAGGTGTC
AACTTCAAGGTCTTGTTGACGTTAAGAGATTCACATGTTTGCACCTCTGAT
GGGAGCTGAAGCCAATTCAATTCTCAATATAAAAGTTTTAAAAGATGTTN
AAGGACAAAGTTTTGTTCCGCCAGTTTGCTAAAAATGCAGGTGATGATGAC
CTGGATCCTGCTTTCAATGGGATAGCAGATAGTATTGCAAGTAGATGTCA
15 AGGTTTGCCCATTTGCCATCAAACCATTCCTTAAGTCTTAAAGGTAGAA
GCAAGCCTGCGTGGGACCATGCGCTTTCTCGTTTGGAGAACCATAAGATT
GGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTATGACAATCT
CCAAGATGAGGTTACTAAATCTATTTTTWTACTTTGTGCTTTATTTCTTG
AAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGTGGGGCTTG
20 AAATTATTTATAGAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAA
CACCTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGGAAGTGATG
ACATTGGATGCGTCAAGATGCACGATGTGGTGCGTGATTTTGTTTGGTAT
ATATTCTCAGAAGTCCAGCACGCTTCAATTGTCAACCATGGTAATGTGTC
AGAGTGGCTAGAGGAAAATCATAGCATCTACTCTTGTAAGAATTTTCAT
25 TAACATGCAAGGGTATGTCTGAGTTTCCCAAAGACCTCAAATTTCCAAAC
CTTTCAATTTTGAACTTATGCATGGAGATAAGTCGNTGAGCTTTCCTGA
AGACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATATGATAAAT
TGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTAACGTTCTGA
GTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGCTCTTCAAT
30 TGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTG
AATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGAT
TTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTT
GGTCAAACCTGAAGAGCTTTATATGGGTGTAAATGTCCGTATGGACCAGG
CCGT
35

RG2V deduced polypeptide sequence (SEQ ID NO:131)

LWKTRM?KKLKEVVEQKKMFNIIQVQVIGECTNPVIAIQQAVADYLSIELKENTKEAR
ADKLR?WFEDDGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTLRDSH
VCTLMGAEANSILNIKVLKDV?GQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGL
40 PIAIKTIALSLKGRSKPAWDHALSRLNHNKIGSEEVVREVFKISYDNLQDEVTKSIF?L
CALFPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIG

CVKMHDVVRDFVWYIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEF
PKDLKFPNLSILKLMHGDKS?SFPEDFYGKMEKVQVISYDKLMYPLLPSSECTNV
RVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLDLTNCKG
LRIDNGVLKNLVKLEELYMGVNVVRMDQAV

5

RG2W polynucleotide sequence (SEQ ID NO:132)

TTGGGAAAGAGACAATGATGAAGAATTGAAAGAGGTTGTGGTTGAAAAGA
AAATGTTTAATCATTATGTGGAGGCGTTATAGGGGAGAAGACGGACCCC
ATTGCTATT CAGCAAGCCGTTGCAGAGTACCTTGGTATAATTCTAACAGA
10 AACCCTAAGGCAGCAAGAACCGATAAGCTACGTGCATGGCTTTCTGACA
ATTCAGATGGAGGAAGAAAGAAGTTCCTAGTAATACTAGACGATGTATGG
CATCCGTTTGATATGGAAGATATTGGTTTAAGTCGTTCCCAAATCAAGG
TGTCGACTTCAAGGTCTTGATTACATCACGGGACCAAGCTGTTTGCACTG
AGATGGGAGTTAAAGCTGATTCAAGTTATCAAGGTGAGTGTCTAGAGGAA
15 GCTGAAGCACAAAGCTTATTCTGCCAACTTTGGGAACCTTCTGATGATGT
CGATCCTGAGCTCCATCAGATTGGAGAAGAAATTGTAAGGAAGTGTTGTG
GTTTACCCATTGCAATAAAAACCATGGCCTGCACTCTTAGAAGTAAAAGC
AAGGATACATGGAAGAATGCACTTTCTCGTTTACAACACCATGACATTAA
CACAGTCGCGCCTACTGTTTTTCAAACCAGCTATGACAATCTCCAAGATG
20 AGGTGACTGGAGATACTTTTTTGCTATGTGGTTTGTTCGGAGGACTTC
GATATTCCTACTGAAGACTTATTGAAGTATGGATGGGGCTTAAATATT
CAAGGGAGTGGATTCTGTAAGAGAAGCAAGATACCAGTTGAACGCCTGCA
TTGAGCGGCTCGTGCATACCAATTTGTTGATTGAAAGTGATGTTGTTGGG
TGCGTCAAGTTGCACGATCTGGTGCCTTTATTTTGGATATGTTTTG
25 TAAAGCGGAGCATGCTTCGATTGTCAACCATGGTAGTAGTAAGCCTGGGT
GGCCTGAAACTGAAAATGATGTGATCAGGACCTCCTGCAAAAGAATCTCA
TTAACATGCAAGGGTATGATTGAGTTTTCTAGTGACCTCAAGTTTCCAAA
TGTCTTGATTTTAAACTTATGCATGGAGATAAGTCGCTAAGGTTT

30 **RG2W deduced polypeptide sequence (SEQ ID NO:133)**

WERDNDEELKEVVVEKKMFNHYVEAVIGEKTDP IAIQQA VAEYLG IILTETTKAAR
TDKLRWLSDNSDGRKKFLVILDDVWHPVDMEDIGLSRFPNQGVDFKVLITSRD
QAVCTEMGVKADSVIKVSVLEEAEASLFCQLWEP SDDVDPELHQIGEEIVRKCCG
LPIAJKTMACTLRSKSKDTWKNALSRLQHHDINTVAPT VFQTSYDNLQDEVTGDTF
35 LLCGLFPEDFDIPTEDLLKYGWGLKLFKGVDSVREARYQLNACIERLVHTNLLIESD
VVGCVKLHDLVRAFILDMFCKAEHASIVNHGSSKPGWPETENDVIRT SCKRISLTCK
GMIEFSSDLKFPNVLILKLMHGDKSLRF

RG5 polynucleotide sequence (SEQ ID NO:134)

40 GGGGGGGTGGGGAAGNCGACTCTAGCCCAGAAGNTCTATAATGACCATAA
AATAAAAGGAAGCTTTAGTAAACAAGCATGGATCTGTGTTTCTCAACAAT

ATTCTGATATTTTCAGTTTTGAAAGAAGTCCTTCGGAACATCGGTGTTGAT
TATAAGCATGATGAAACTGTTGGAGAACTTAGCAGAAGGCTTGCAATAGC
TGTCGAAAATGCAAGTTTCTTTCTTGTGTTGGATGATATTTGGCAACATG
AGGTGTGGACTAATTTACTCAGAGCCCCATTAAACACTGCAGCTACAGGA
5 ATAATTCTAGTAACAACTCGTAATGATACAGTTGCACGAGCAATTGGGGT
GGAAGATATTCATCGAGTAGAATTGATGTCAGATGAAGTAGGATGGAAAT
TGCTTTTGAAGAGTATGAACATTAGCAAAGAAAGTGAAGTAGAAAACCTA
CGAGTTTTAGGGGTTGACATTGTTCTGTTTGTGTGGTGGCCTCCCCCTAGC
CTT

10

RG5 deduced polypeptide sequence (SEQ ID NO:135)

GGVGKTTLAQK?YNDHKIKGSFSKQAWICVSQQYSDISVLKEVLRNIGVDYKHDET
VGELSRRLAIAVENASFLLVLDLWQHEVWTNLLRAPLNTAATGIILVTTRNDTVA
RAIGVEDIHRVELMSDEVGWKLLLKSMNISKESSEVENLRVLGVLDIVRLCGGLPLAL

15

RG7 polynucleotide sequence (SEQ ID NO:136)

GGTGGGGTTGGGAAGACAACGGGCACAAGGAGGCGACTGCCAATACTTCC
GACTTTTATTCATAGAGATGACGAGTCTTATTTTCCTACTACTATAGGGA
GGATATTTGGTTGCGCGAGACGATTCATTGCGCGAAGGGATTCTATCCTT
20 CTTTTTTTCCGCGAAGACTTCGTTCCGGAGGACGGGCTATATTCCCTTTA
ATATTAGTCTAGCCCAGTCTAGGCCAACCATATGGCGATGCGGTAGACCT
CCCAGAGATAGATACTTGATCTTAGAGGATTCACACGTTCAATGGTGGAA
ACTTAAGGAACCGGCTAAGAGTGACTAAACGGAAAAACCCTATTCAATCC
ATAGCCTCATCCGGTCGAGGCATTAAACAATCCATCCCAATCCTCTTTCC
25 TTTGGTCTACTCTAATGATGTGCCCGTTTCGTTGGTGGGAATATCTCTTTAT
ACCGACGATTTATATGGGGATTGCCACTAGCGTTG

30

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.
5
2. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising an leucine rich region (LRR).
10
3. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising a nucleotide binding site (NBS).
4. The nucleic acid construct of claim 1, wherein the polynucleotide is a full length gene.
15
5. The nucleic acid construct of claim 1, wherein the further encodes a fusion protein.
6. The nucleic acid construct of claim 1, wherein the RG1 polypeptide is encoded by an RG1 polynucleotide sequence.
20
7. The nucleic acid construct of claim 6, wherein the RG1 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
25
8. The nucleic acid construct of claim 1, wherein the RG2 polypeptide is encoded by an RG2 polynucleotide sequence.
30
9. The nucleic acid construct of claim 8, wherein the RG2 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 (RG2A);

SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

10. The nucleic acid construct of claim 1, wherein the RG3 polypeptide is encoded by an RG3 polynucleotide sequence.

11. The nucleic acid construct of claim 10, wherein the RG3 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:68.

12. The nucleic acid construct of claim 1, wherein the RG4 polypeptide is encoded by an RG4 polynucleotide sequence.

13. The nucleic acid construct of claim 12, wherein the RG4 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:69.

14. The nucleic acid construct of claim 1, wherein the RG5 polypeptide is encoded by an RG5 polynucleotide sequence.

15. The nucleic acid construct of claim 14, wherein the RG5 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

16. The nucleic acid construct of claim 1, wherein the RG7 polypeptide is encoded by an RG7 polynucleotide sequence.
17. The nucleic acid construct of claim 16, wherein the RG7 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.
18. The nucleic acid construct of claim 1, further comprising a promoter operably linked to the RG polynucleotide.
19. The nucleic acid construct of claim 18, wherein the promoter is a plant promoter.
20. The nucleic acid construct of of claim 19, wherein the plant promoter is a disease resistance promoter.
21. The nucleic acid construct of claim 19, wherein the plant promoter is a lettuce promoter.
22. The nucleic acid construct of claim 18, wherein the promoter is a constitutive promoter.
23. The nucleic acid construct of claim 18, wherein the promoter is an inducible promoter.
24. The nucleic acid construct of claim 18, wherein the promoter is a tissue-specific promoter.
25. A nucleic acid construct comprising a promoter sequence from an RG gene linked to a heterologous polynucleotide.
26. A transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide.

27. The transgenic plant of claim 26, wherein the plant promoter is a plant promoter.
28. The transgenic plant of claim 26, wherein the plant promoter is a viral promoter.
- 5 29. The transgenic plant of claim 26, wherein the plant promoter is a heterologous promoter.
30. The transgenic plant of claim 26, wherein the plant is lettuce.
- 10 31. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
- 15 32. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:21 (RG2A); SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).
- 20 33. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:68 (RG3) and SEQ ID NO:69 (RG4).
- 25 30

34. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:134 (RG5).

5 35. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:136 (RG7).

36. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO: 13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ
10 ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), and SEQ ID NO:20 (RG1J).

37. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41
15 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ
20 ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID
25 NO:133 (RG2W).

38. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG3 polypeptide with a sequence as set forth by SEQ ID NO:138.

30 39. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG4 polypeptide with a sequence as set forth by SEQ ID NO:139.

40. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135.

5 41. A method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence.

42. The method of claim 41, wherein the plant is a lettuce plant.

10 43. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51
15 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O);
20 SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

25 44. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:138 (RG3); SEQ ID NO:139 (RG4); and SEQ ID NO:135 (RG5).

45. The method of claim 41, wherein the promoter is a tissue-specific promoter or a plant disease resistance promoter.

46. The method of claim 41, wherein the promoter is a constitutive promoter or an inducible promoter.

5 47. A method of detecting RG resistance genes in a nucleic acid sample, the method comprising:

contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and,

wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample.

10

48. The method of claim 47, wherein the RG polynucleotide is an RG1 polynucleotide.

49. The method of claim 47, wherein the RG polynucleotide is an RG2 polynucleotide.

15 50. The method of claim 47, wherein the RG polynucleotide is an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide.

51. The method of claim 47, wherein the RG resistance gene is amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

20

52. The method of claim 51, where the RG resistance gene is amplified by the polymerase chain reaction.

53. The method of claim 47, wherein the RG polynucleotide is labeled.

25

54. An RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet. US CL : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, DIALOG		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Development of Reliable PCR-Based Markers Linked to Downy Mildew Resistance Genes in Lettuce. Theor. Appl. Genet. 1993. Vol. 85, No. 8, pages 985-993, see entire article.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	KESSELI et al. Analysis of a Detailed Genetic Linkage Map of Lactuca sativa (Lettuce) Constructed From RFLP and RAPD Markers. Genetics. April 1994. Vol. 136, No. 4, pages 1435-1446, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	MICHELMORE, RW. Isolation of Disease Resistance Genes from Crop Plants. Current Opinion in Biotechnology. 1995. Vol. 6, No. 2, pages 145-152, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"I"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"A" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 14 MARCH 1998		Date of mailing of the international search report 13 APR 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer PHUONG BUI Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Recent Amplification of Triose Phosphate Isomerase Related Sequences in Lettuce. Genome. 1992. Vol. 35, No. 4, pages 627-635, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	PARAN et al. Identification of Restriction Fragment Length Polymorphism and Random Amplified Polymorphic DNA markers linked to Downy Mildew Resistance Genes in Lettuce, Using Near-Isogenic Lines. Genome. 1991. Vol. 34, No. 6, pages 1021-1027, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 7, 9, 11, 13, 15, 17, 31-40, 43-44
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

these claims are drawn to numerous sequences identified by SEQ ID NOs. However, since no computer readable form was submitted, no meaningful search could be carried out.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A01H 1/00; C07H 21/04; C07K 14/00; C12N 5/04, 5/10; C12P 19/34; C12Q 1/68